var title_f8_10_8352="Related food allergies PI";
var content_f8_10_8352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Risk of clinical reactivity among related fruits and vegetables",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The numeric risks cited here are based upon findings in limited series of patients and may not be generalizable to all populations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Sicherer, SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8352=[""].join("\n");
var outline_f8_10_8352=null;
var title_f8_10_8353="Loxoprofen: International drug information";
var content_f8_10_8353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loxoprofen: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Loxonin (BR, JP, MX, TH);",
"     </li>",
"     <li>",
"      Oxeno (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F3466664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Loxoprofen Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3466665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of pain and inflammation associated with musculoskeletal and joint disorders or operative procedures",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3466668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Immediate release: 60 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, immediate release: 60 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10494 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8353=[""].join("\n");
var outline_f8_10_8353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302639\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466664\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466665\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466666\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466668\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821116\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466669\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_10_8354="Corneal lacerations";
var content_f8_10_8354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two patients with obvious corneal lacerations with uveal prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Full thickness corneal laceration from a fragment of glass. Uveal tissue and aqueous are seen prolapsing through the wound. Subconjunctival hemorrhage is seen superiorly.",
"    <br>",
"     (B) Patient with full thickness corneal laceration. Brown uveal tissue (iris) is seen prolapsing through wound.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8354=[""].join("\n");
var outline_f8_10_8354=null;
var title_f8_10_8355="Steroidogenesis by zone";
var content_f8_10_8355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 652px\">",
"   <div class=\"ttl\">",
"    Steroidogenesis by zone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 632px; height: 409px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Outline of the organization of the major steroid biosynthetic pathways in the adrenal cortex. The top (dark blue) row shows the zona glomerulosa pathway to aldosterone that is angiotensin responsive. The middle (red) row shows the pathway to cortisol that occurs in the zona fasciculata, and the lower (green) row shows the pathways to dehydroepiandrosterone sulfate (DHEA-S) and other 17-ketosteroids that occur in the zona reticularis; these zones are ACTH-responsive. The yellow dotted box surrounds pathways that are common to all adrenocortical zones and the gonads. The white dotted pathways are relatively minor. Compound S (Cmpd S) = 11-deoxycortisol. Corticosterone and 18-hydroxycorticosterone, the successive 11&beta;- and 18-hydroxyl intermediates between deoxycorticosterone (DOC) and aldosterone, are not shown. The steroidogenic enzymes are italicized. Cytochrome P450 enzyme activities are: side chain cleavage; 17&alpha;-hydroxylase/17,20-lyase; 21 hydroxylase (",
"    <em>",
"     21H",
"    </em>",
"    ); aldosterone synthase (aldo synth; 11&beta;-hydroxylase/18-hydroxylase/18-dehydrogenase); type 1 (zona fasciculata) 11&beta;-hydroxylase (",
"    <em>",
"     11&beta;H",
"    </em>",
"    ); and aromatase. Non-P450 enzyme activities are carried out by steroidogenic acute regulatory protein (",
"    <em>",
"     StAR",
"    </em>",
"    ); type 2 &Delta;",
"    <sup>",
"     5",
"    </sup>",
"    -isomerase-3&beta;-hydroxysteroid dehydrogenase (",
"    <em>",
"     3&beta;HSD",
"    </em>",
"    ); type 5 17&beta;-hydroxysteroid dehydrogenase (",
"    <em>",
"     17&beta;HSD",
"    </em>",
"    ); and type 2A1 sulfotransferase (",
"    <em>",
"     SULT",
"    </em>",
"    ). Clinically relevant cofactors are P450 oxidoreductase (",
"    <em>",
"     POR",
"    </em>",
"    ), cytochrome b5 (",
"    <em>",
"     CYb5",
"    </em>",
"    ), and type 2 3'phosphoadenosine-5'phosphosulfate synthase (",
"    <em>",
"     PAPSS",
"    </em>",
"    ).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787. file://jcem.endojournals.org/. Copyright &copy; 2007 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8355=[""].join("\n");
var outline_f8_10_8355=null;
var title_f8_10_8356="Coronary heart disease PI";
var content_f8_10_8356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In people with coronary heart disease, the coronary arteries get clogged with fatty deposits called plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8356=[""].join("\n");
var outline_f8_10_8356=null;
var title_f8_10_8357="Saxagliptin: Patient drug information";
var content_f8_10_8357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Saxagliptin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/26/26022?source=see_link\">",
"     see \"Saxagliptin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7997762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Onglyza&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9608124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Onglyza&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13382868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to saxagliptin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12221 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8357=[""].join("\n");
var outline_f8_10_8357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7997762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9608124\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382868\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030194\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030193\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030198\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030199\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030201\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030196\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030197\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030202\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030203\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/26/26022?source=related_link\">",
"      Saxagliptin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_10_8358="Interferon beta-1a: Drug information";
var content_f8_10_8358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Interferon beta-1a: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/5/38997?source=see_link\">",
"    see \"Interferon beta-1a: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avonex&reg;;",
"     </li>",
"     <li>",
"      Avonex&reg; Pen&trade;;",
"     </li>",
"     <li>",
"      Rebif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avonex&reg;;",
"     </li>",
"     <li>",
"      Rebif&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple sclerosis:",
"     <b>",
"      Note:",
"     </b>",
"     Analgesics and/or antipyretics may help decrease flu-like symptoms on treatment days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. (Avonex&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     30 mcg once weekly; to decrease flu-like symptoms, may initiate once-weekly dosing with 7.5 mcg (week 1) then increase dose in increments of 7.5 mcg  once weekly (weeks 2-4) up to recommended dose (30 mcg once weekly)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     30 mcg once weekly; may consider increasing to 60 mcg once weekly in progressive relapsing MS or secondary progressive MS with recurrent neurologic dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ (Rebif&reg;): Doses should be separated by at least 48 hours:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Target dose 44 mcg 3 times/week:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 8.8 mcg (20 % of final dose) 3 times/week for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Titration: 22 mcg (50% of final dose) 3 times/week for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Final dose: 44 mcg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Target dose 22 mcg 3 times/week:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: 4.4 mcg (20 % of final dose) 3 times/week for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Titration: 11 mcg (50% of final dose) 3 times/week for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Final dose: 22 mcg 3 times/week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14385980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F183463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution in patients with a past or present history of active liver disease or ALT &gt;2.5 x ULN.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F14385978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Autoimmune disorder development: Consider discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Depression or other psychiatric symptoms: Consider discontinuing treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatotoxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     ALT &gt;5 x ULN: Temporarily discontinue therapy or consider dose reduction until ALT normalizes, then may consider retitration of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Symptomatic (eg, jaundice): Discontinue immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Leukopenia: May require temporary discontinuation or dose reduction until resolution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avonex&reg;: 33 mcg [contains albumin (human); provides 30 mcg/mL following reconstitution; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avonex&reg;: 30 mcg/0.5 mL (0.5 mL) [albumin free; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avonex&reg; Pen&trade;:  30 mcg/0.5 mL (0.5 mL) [albumin free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rebif&reg;: 22 mcg/0.5 mL (0.5 mL), 44 mcg/0.5 mL (0.5 mL) [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free, combination package]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rebif&reg;: Titration Pack: 22 mcg/0.5 mL (6s) and 8.8 mcg/0.2 mL (6s) [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15878286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rebif&reg; Rebidose&reg; Autoinjector: FDA approved January 2013; availability anticipated in March 2013.  Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Avonex&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085930.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm085930.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rebif&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089019.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089019.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Avonex&reg;: Must be administered by I.M. injection; rotate injection site; do not inject into area where skin is irritated, red, bruised, scarred, or infected. Two hours after injection, examine site for redness, swelling, or tenderness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rebif&reg;: Administer SubQ at the same time of day on the same 3 days each week (ie, late afternoon/evening Mon, Wed, Fri); rotate injection site; do not inject into area where skin is sore, red, damaged, or infected.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsing forms of multiple sclerosis (MS)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Avonex&reg;: To decrease the number and volume of active brain lesions, decrease overall disease burden, and delay onset of clinically definite MS in patients who have experienced a single demyelinating event.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F183506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avonex&reg; may be confused with Avelox&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions reported as a composite of both commercially-available products. Spectrum and incidence of reactions is generally similar between products, but consult individual product labels for specific incidence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (58% to 70%), fatigue (33% to 41%), fever (20% to 28%), pain (23%), chills (19%), depression (18% to 25%), dizziness (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (23%), abdominal pain (8% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (28% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (20% to 27%), AST increased (10% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (3% to 92%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (25% to 29%), back pain (23% to 25%), weakness (24%), skeletal pain (10% to 15%), rigors (6% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision abnormal (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (14%), upper respiratory tract infection (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (49% to 59%), neutralizing antibodies (significance not known; Avonex&reg; 5%; Rebif&reg; 24%), lymphadenopathy (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5% to 6%), vasodilation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Migraine (5%), somnolence (4% to 5%), malaise (4% to 5%), seizure (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Erythematous rash (5% to 7%), maculopapular rash (4% to 5%), alopecia (4%), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid disorder (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (1% to 5%), toothache (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Micturition frequency (2% to 7%), urinary incontinence (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (2% to 8%), anemia (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubinemia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (8%), injection site bruising (6%), injection site necrosis (1% to 3%), injection site inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (9%), hypertonia (6% to 7%), coordination abnormal (4% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye disorder (4%), xerophthalmia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important and life-threatening): Anaphylaxis, autoimmune hepatitis, cardiomyopathy, CHF, hepatic failure, hepatitis, hyper-/hypothyroidism, idiopathic thrombocytopenia, injection site abscess/cellulitis, menorrhagia, metrorrhagia, pancytopenia, psychiatric disorders (new or worsening; including suicidal ideation), vesicular rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to natural or recombinant interferons, human albumin (only for albumin-containing formulations), or any other component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Rebif&reg;: Pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions, including anaphylaxis, have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disorders: Autoimmune disorders including idiopathic thrombocytopenia, hyper- and hypothyroidism and rarely autoimmune hepatitis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Pancytopenia (rare) and thrombocytopenia have been reported; use with caution in patients with bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Associated with a high incidence of flu-like adverse effects; use of analgesics and/or antipyretics on treatment days may be helpful.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: Rare cases of severe hepatic injury, including hepatic failure, have been reported in patients receiving interferon beta-1a; risk may be increased by ethanol use or concurrent therapy with hepatotoxic drugs. Treatment should be suspended if jaundice or symptoms of hepatic dysfunction occur. Some reports indicate symptoms began after 1-6 months of treatment. Transaminase elevations may be asymptomatic, so monitoring is important.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders: Interferons have been associated with severe psychiatric adverse events (psychosis, mania, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms, avoid use in severe psychiatric disorders and use caution in patients with a history of depression; patients exhibiting symptoms of depression should be closely monitored and discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease, including angina, HF, and/or arrhythmia. Rare cases of new-onset cardiomyopathy and/or HF have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment or in those who abuse alcohol. Dosage adjustment may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic progressive MS: Safety and efficacy have not been established for this use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Some formulations contain albumin, which may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases. Interferon beta-1a formulations that contain albumin are contraindicated in albumin-sensitive patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies in pregnant women. Consideration should be given to discontinue treatment if a woman becomes pregnant, or plans to become pregnant during therapy. Dose-related abortifacient activity was reported in Rhesus monkeys.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential for serious adverse reactions. Because its use has not been evaluated during lactation, a decision should be made to either discontinue breast-feeding or discontinue the drug.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F183447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Avonex Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mcg (1): $1174.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Avonex Pen Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mcg/0.5 mL (1): $4696.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Avonex Prefilled Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mcg/0.5 mL (1): $4696.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rebif Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     22 mcg/0.5 mL (0.5 mL): $392.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     44 mcg/0.5 mL (0.5 mL): $426.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Rebif Titration Pack Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6X8.8 &amp; 6X22 mcg (4.2 mL): $4715.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyroid function tests, CBC with differential, transaminase levels, blood chemistries, symptoms of autoimmune disorders, signs/symptoms of psychiatric disorder (including depression and/or suicidal ideation), signs/symptoms of new onset/worsening cardiovascular disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Avonex&reg;: Frequency of monitoring for patients receiving Avonex&reg; has not been specifically defined; in clinical trials, monitoring was at 6-month intervals. Canadian labeling recommends liver function testing monthly for first 6 months, then every 6 months thereafter or as clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rebif&reg;: CBC and liver function testing at 1-, 3-, and 6 months, then periodically thereafter. Thyroid function every 6 months (in patients with pre-existing abnormalities and/or clinical indications). Canadian labeling recommends liver function testing monthly for first 6 months, then every 6 months thereafter or as clinically indicated.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avonex (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, IE, IL, IT, MT, NL, NO, NZ, PE, PL, PT, PY, RU, SE, SK, TR, UY, VE);",
"     </li>",
"     <li>",
"      Betaferon (HU, LU, ZA);",
"     </li>",
"     <li>",
"      Emaxen (CR, DO, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Rebif (AR, AU, BR, CH, CL, CZ, DE, DK, EE, ES, FR, GB, HK, HU, ID, IE, IL, IN, MX, MY, NL, NZ, PE, PH, PL, SE, SG, TH, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferon beta differs from naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; alters the expression and response to surface antigens and can enhance immune cell activities. Properties of interferon beta that modify biologic responses are mediated by cell surface receptor interactions; mechanism in the treatment of MS is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Avonex&reg;: 12 hours (based on biological response markers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Avonex&reg;: 4 days (based on biological response markers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Avonex&reg;: 10 hours; Rebif&reg;: 69 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Avonex&reg; (I.M.): 3-15 hours; Rebif&reg; (SubQ): 16 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jacobs LD, Beck RW, Simon JH, et al, &ldquo;Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis. CHAMPS Study Group,",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(13):898-904.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Panitch H, Goodin DS, Francis G, et al, &ldquo;Randomized, Comparative Study of Interferon Beta-1a Treatment Regimens in MS: The EVIDENCE Trial. EVIDENCE Study Group. Evidence of Interferon Dose-Response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2002, 59(10):1496-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/10/8358/abstract-text/12451188/pubmed\" id=\"12451188\" target=\"_blank\">",
"        12451188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8565 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-E31ECE9AB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8358=[""].join("\n");
var outline_f8_10_8358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183458\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183459\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183497\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183461\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183462\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14385980\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183463\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14385978\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183440\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183424\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15878286\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874830\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183442\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183441\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183506\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183495\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183445\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183428\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299523\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183433\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183435\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183448\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183466\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183449\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183447\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183437\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183450\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183427\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183444\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8565|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/5/38997?source=related_link\">",
"      Interferon beta-1a: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_10_8359="Photomicrograph of urine sediment with a red cell cast";
var content_f8_10_8359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55778%7ENEPH%2F79440%7ENEPH%2F62064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55778%7ENEPH%2F79440%7ENEPH%2F62064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with a red cell cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 251px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD7AXcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyE23+iiSIA5HOKfaRuI8tgY6A03TZTFZlJCc9KdOWFsxiwe9eK77H3seVpT8i1FfQsrLJgVQkn23Y2MdhrKtd7yncTyfWtuO2Xyj5g+lOUFTIhWniFppYklu1EiRsc7q2LGIEL5w+Vq5SSJ4bgSjLKOcGuz06WC/sVdMBlGCKxrLlirHXgqjqTkp7mPq+jL9sE9uSqnnFU7jTog6yu3Trmty7E7ZRV+bpx3rmNSS7WXEjcZ5FXScpaXJxVKlSvLkvc9A0fTrZ7NXhIXisLVbCMagPMO4KaXQriYQoiMQvGa2zBG75mGc+tcrbpzbbO+MY1aaVivvjS3VI1GKdHaI6F0Yq1E+nZ5ibA65FFws8cGI+o61F09maKLT1KjXc6s0AQu3rUMMYZyZgVB6itPThNtZ3iGR3pNXjIs5JQvI9KfNZ8qB2abkY6XkNncGMvlScVsq9i6botoYjvXK2ENvdRySSMN47VHYBpNR8uIkoOOOlbSop9dUckcTKNk0mnsda2nxT27DdkHp/hWPaSXGnXLRZO0HjNaEjzWbKuSVPpUFwWnuVDdSMZrKDez1R0VYq6cdGdbo2oR38YVwAR296uGNIvvfKG45FcVFHPY3IeFj5fGa2dX1XfoxaM7pAM9a55Uve93ZmilpeXQj1CKV9QUGLzo88GpbyKMSoLgFExxWd4O1a4muNt7GQoPB7Vu+IFS4lBjbp2qpJwmoMUJKpHmXUrRyRW0oEJLKanntw0RkR/mPQVUtbcKcMCeM5pZ2KYK5IU9M1LWuha2Jra1OD5uc5rR+zK8JXb06VLYnz7ZWYL06U4sEU4AArJydxWKNvCFJALevNDBzOVGSDV1VDHC9evWmyvsdQMZWjm1FYgtLQidi2eB+FWX2hCpfcQevoPSnwyh+DjpVK8iOQFkO4HNLWT1CxZCB0IwaRCokxj65pon8mHLEZ6896qw3KNPk5BPY9KEmPlLqsmTvGPSpNi7Tt5HpTGYNnIUDPBzz+NWFiKEYGQRSbEQlFVT6dMHtSBAehwQPzqaZFKN6D0qCykRlYMOnFF9AQkhGz5ScUsLZyrDJFNUCfcobbjvTRCYWG9geeDTt0GTTRiQFdoB6ZqlDYpFK2F5znPrWqSpAbj60xsA5HOKSk0hWK6pkEnPPWmmMbMGlWdHfZg59qUcrhs/8A1qY7EOFH3l5zSSFQAwIqc43nK+wNZrQPdXBRDtwetVHXcViUQm4YiJsH602NW3kEdD0NV7m0uNMkV0clT1q9YlJozJxu7j1qm9LrYaV9SPcgwBk0VHJbyNMSfu0UtBq3U8wku4VnKN096t25iuvlhbg9RWRc6bcPNtKkN0yKuaWo06Ub/wAa9qUY8t4vU+fo1KjnaasjTj0dDzHguO3vWRqk8lpKY5iRzwMV00GoxYaRQo78fzrH1azOuOGhX5h3FY05vm9/Y68TQj7P9x8X5mXJeebAY4FLufStfwxZ6jDGTtZUPNW9A0M6ewaVVPqDXVtdRxRLs4U8YFTWrpLkgrjwmCndVars10OasZLyK/IuB8ueKNVsHui5Q9Txmte7ddwZuCelQXKO9rugJwOSBWSnqpLQ7PZLlcJO5zmm3NxY3widciuvMgntwx4yMiuTsJ9+phZjhgea6nUEU26rA204/Oqr/EtNTLBfBKzurld7uaFOBuFRW2sN5uyZNoPTNZq3E8M/lzcrmrN5cQTRruAV88EUuRdUaqbesXt3NV7iWEYjGUPeqDarNnyJU3I3BzVe2vfs52Sn5D0qDW7yGJVmVgcYpRp+9ZoupVSg53tYu2el2THeXKbucZre0vTtOiieS3wZBzXMzlrvTUubfggdqq6BezxXx3sWRjgjNEqcpxfvbEe0p05RXLv1NK/1FZbloMYbPBxSJldpmODnAJp2t20UkwniUo4PJqpJ5uoJHBAp83px3oik4qwSnKLlfXsbUknkW5aRt6kc1gwapbmVoWyBnIBruvDXh6RYvJ1VSVxxnv7VieJdFtP7REFvEq5PDD/Gs6dWnzODCp7SSXJ+Jc054Xtl8pBvHSnzuryKGGG96543M3h6URzEsh6YrW8OXSaxqGGXaBzUyptXn0NI1k3yPR9jsIbWI2YK43FfyNYsVozXMgZSQD3rUuLeaxnVQ2YjVtJI4gDxnvk1xqTjqtblFGBfsy7Tj6UjTRS7l4UnvWjJDa3xVxIFI64OM1g3umT214HhcPFnoDTg1J6vULllZFjYgOARz9agmnBfdu57gVXvraV3UgspBqeO1Cpk8kjnmrslqUS2s8TOVJIJ7+tWbiIBlkb7tZtpZPMWbOwDoa1Ykke0ZD8+OAamVk9CblDUypwy8rjkCo7J4mDlhg+tWDCrx+WSQ/v3pbbTJt2xgNpPandWswfSwyJhJEwJPBzmpftXlwZlfao6VNc6VLAw2EbCck1LeaTFf6XJEz7XxgHPQ0uaPXYTl1Q2yvLe5Uqp3NjrUkkarGWjHzkdKpeH9DfSI2ErmU55NaYZGk74GeDUyspPld0JO6uUlVFUbB8xxU4QSsFYfNnikmiwQ0fJ/lUgjbKkn6mk2UNOMkdcU1uQWwSOmKfM6IvBGe5pLZkYt8xxnvQtriI1SPeGCgHGeKDg85wtTmPcCQPqaZNkMAoz2zTuBC4DLkEg49KoxuY7rvuP5ZrQnDIFKL25pn2dZcFhgj1qk7FIYQ1yrLJ8ykZHtWfYwNFdPGhyAatss65VOUzipoIDGxcDD9/eja4K6IrmQRglmxz1oqxcWRuYQAcbeaKE49WCZ5bdzLIC6EZ9BXJ3V1LNdMJCVGcGoor24QjDFh6Gu00vQrbULZbmVcOBmvessPrI+flOWY+7T0a3OdsILiaXjdsPBxXcaWkNjblw4A24IPrS20drbRmIbRjrmnJbQzSdyD0wa46tX2m+iPTwuEWHjvdlEar9oZ0j4OfSpkuiAiueQavrp9tCpbaM04afDLyp3H61nzw7HRGFRLVkV2FMQbhmxnHpVrRCTGVcDkdMUg0uZuUJx+dW7WCS2I3Fc1nKStZGiTvcydS0y1hvFldduOpHrSXEiGIHBYDkEVr3scbxkyMGJ7elYs2o21tGRIVx6VUZOS7i5Ywu9ijGba6u9rybT6ZqDX7LyFLwDdj0NTRaZDqU63Vq+wZ5FaUUSxzGOZt0Z45rVz5WmvuMVB1E1Jb7M87a8uby6WFVIxxW02m/agkU0nJ6V0reHbZZzdQOACSTiqMjWouQpfawPXNbPEKXwI5KOBcE/bu9ynDZ3Njbm3Vz5bDArR8G6fJ9vJlQlc8E9K27SzEkY5EiYyD1rc0NYbdtpT71clXEPla7nbHCxi1JdNjM8UCBIcBdrD9a5XS71rG/SRQCAevWuo8d6TebPPtkLx+1cfoulX9zMCVwoPQinh+X2V2zKtUm6qUUepalqrT6XHcRnaQMnFcxZ31vqN+qsf3ue9SgyW1uLeXkd+apyQRWMy3aJ8w5PFc9OEYpr7jss1ZLYq+NtNumkWQoGiU5yORUXg63um1ONliZY+hOK17vxM08I3RhowfSul0HUrS5slkt0QOOCB1q5VakKXLKJzulF1PaJ6l/WUaOx3lxx+BriLq/lKlju2evaur8Qs0mmSYbJ25HNcHZ3UjK0Migjnk9qyw0LxuaXtoyXRJLq8vyDMUiDY57V0lxLLp0iRyS743HDe9cvZT+RqPlsx2HutdNqEMt5HGsSEoMfMa0qr3lfYKcna25e3s0IZ1DKOQfWsq7vGDh4vmxwVq/eyG1sY4WzuI7GrOk2VmLX9+QHYdSO9YKSirstuxYsbeO9tFdDtLdVqO+uE01dj4I7AVUtJn0/WWt8hoG5zT/ABbaG9hH2cliOTUJe+k3oyZN7k+i3UF7KWZf3g6VqXE6xMcMoI5Oa5Pwtpt3a3gefKp3BrU16EtPuDHae2ac4R57J6CXvas0Lq582A7OR2rLZZ3TenQnkCqtpPsuEgZty9+a6a3TyoSQFAPOal/uyn7uxmMlw9rgHDH1qOAS+WBN68kVoyPufDYIPHHFDQrNF8nDKOlHMK5CjDbgcn+dUpbswsVkJGTxVmK3McmXJOR+VMk04TTb8buRTXLfUd0JHF5qA8YPrVmGKID5wSByMU8xiP5RwBUagMcA5BNTe4tyUrIQijIVu3Wk8phkEYAHeotS1FNMtwCQxI7da5y48UyFtwjfaOOlVCE56xQr23OhZkUgHt60jITz1Fc/bXn9oP5iN3xgnpWvbySpIqTEnNU4uJVi1u2oT26mq8821sg4zU82dwXPGDgVUktjuJA+Y9TmkkgQ6K9BcoOvpRUf2fyiCOM+1FDS6FaHmWneHjEo8+Nc/WtB7iO0TyVcIR2q5qNzILLcGCuPzrhrq7MzSGQkEetexBSrO8jzas6WBglBas7mK2W4t/MQgkjnHrTrZZk+VgCOlc/4Q1QmUQtuZemT2rqLydbUhuoasKkZQlys6aFWNamqkSQozqUPTHftU+mWgty2GLBuhrPjvVky205Hb1rQ0+5TPBwPQ1lK6TRurPUhvdSlsZCq53H36VgXmqXbXCs7YXPauo1/TV1G23QECXHX1rlB4d1Fyn2kkR559a0oezau9zmxLq3tBHQ2tr9pgE/mnB6jNch48sY44llhfkdQDXf21nHb6Z5SsSccVxmt+H7yab/WboickU8PNKpe+gY2DqUHFRu2WPCEwGkAqRux+VaL2/mZdXHJyKhs9E+wWQCA4IzzWeLya0nZQpKg4IptKcm4Fwbo0oxmX9Qmks7XdvO3GDzWCYobtGlU4b2reVhrkf2cqVI71XufC1zAqpbPkntThKMNJOzJrKdTVK8S/wCE71ltGjl5K8DNPvNYazvlJ5UHtVjSPDd3Y2BkkXJxk1gawP8ASCNnOaziqdSo7aovnnCku56rpmqRXmmjgNxyDzXI64LiC8DWI27jzjtSaDIRp52PtbHTNXbCbz3KzAMwPpXIoezk2tjaMdLrqZTC4+0xi8GVPJbNafiS3jXR1a1+c45q3dJFLtWQgHPFQQlY5tkhzG3BBp812pLoPlurHEwalEtjJB5f730xV7wbeTWtwUkBCscjNdo2laQswlNuu7qOKS50y0knWSLanHGK1eJhJONtzmhSlGSk3sattHFcJiTncOBXKavodtHcllYKrnjB4rYEwhlQbuQcZFZXjNbm38uYA+SehFc9HmU7J7m0kt2Lp9pp9oSZSGbPGa6Szu4TYn7PghRgV59pQW7uDvmxv4AJrqdI0m6sppE37om5qq0F9p6jTUlpsJdK16WTOHHQ5qsdE1QkHzfkH4VaEf2bUfvArn1rpTMXjGPTpxUSqOFuUJ62OQmsruzmjkYF/XvWpFOzruJIPpV77Tgv9oUbMHk1y1xq0FtqBBOYyeueBTV6mltUNaLU17y5li3MrcjpzWRem7uMO0g2npg9K6KKxt9XszJbSANjpXOXsEkURhQkSoetVSavbqDd9CNIZI4zIz5IGa3fDuoSXqNbtyw7e1c3bXn2eMrejMnQAHrXS+EoyFkn2nHUYHP0qqytFtkX00NOeCUSDAyParVsCoKnAJ52nrUEWpI960QI4qprdy9vJG8XV8EVy2b90LN6M1PswzlySevHAqJ51hnVNp249KyE1i4jZRKOp61syRpcRJLkDIzScXF+8KzW5R1Rpw48tsrn8hRp9tJI28nqOaneP5D86Eduafb3KWUO6VhkGnfSyHdpaHJaxeRf2+tveH5RxzXR6gNMg0ouixtleoFYnjqysdQshfQOFuV54NcxotnrurweRGjeUDgt2xXWqcakFO9rbmLqNPlkv68y14TzcanKyZEG7itPWvEUcGopbxoflPWuk0vw9Fo+kPu/1mMk+9Zt/Y6NLpU80jx/aRyDnkUvawnUu1dbFKTUFyvVGjplzHf2mV/1g7VKnLMBjj2rmfAE7XU8ipygJGR6V2V1bokjHcqvjJ9656sfZzcS1NOzXUpTIWACnminjOTnBHrRU3aK2PONUCPb525PXiuL1F4Ajll2lT6da7iBo42CsQy1R8Q6Ampw7rYqj45A717NGooStLY48bRlWpvk1a6Gf4C8mWVwi5Xv7V1OpWySyBT90dqwPCWmTaHcP5w610kr+fKSuCajESvVcovQrAwlGgoVFZmc1rsdAq/IO1Ty2xkG2JSr470XV55TjI+b2pbe+bdvzx6is7yaudNorRDrWS8tU2ycqOhFaceowSOiyhxIoOOuMfyrOvryTywyLkelQTD7RabkOGPb0qOXm1Zb02L08w8z90+4E8ijzpGIBHPvWVpNhci4Ejtx3Brd1G5gtYw5xuHpRNKL5VqEJNq70F3P5TGZdkQHJboPesqQ2kIkEoDMHOc/XP8AKki8VwtKYnA2HjJ9Ko6y0E0olifk9R2pwpyvaSsT7RNXi72NbSr2wLFYtqS+nrV1bj98rswJHrXn/lkyh4Mqw5Jpk+pXltMpUM/pWrwvM9GYfXFFXmvuPWF1pXjaEldze9c3qNuXkbgbSck1xdprDvfxrdB4nJ4Jrtml3xId4bI4rN4d0GvM1oV4V03EgtnjiXKHGODV4SNDtmtznPYVTexzG7dN3Ws43UlvhEckZ6UuXn2LlPkWp0U4uJYSzLt7iq1j58pCtyQe9bWn/v8ATAZR8/qaihtwkoZeAeKxU7XRSLF1KIbUeZ1A61XO6ayEkYII9KW/i/ebc7h71PDKERUCgKO1Z7K6GMtGimERmYbwOhrR8RyRS+HHRwOBwfSs++tlnTenyuB0FRIsd5ZNaykqGGM1NrtS7Eyjc8208z+e7wOTtbivXNH1QSaNG85AdVwfesH/AIQqPTbZruOfcvXaazIxLdB4InCgE9K6q0oYn4dkYYenyQs9TXvN17J5lsxLKc4FbtluFmu/lwOnrXI+F5JLTVzazEtk8Gu1m+WTGBjsa56y5Xy9De/MjE1a/P2SRTGy++OlcAYHmdt75U8161MbWSzkW4RSCO45rg5BCt80McZ2E8H2rXDVLJpIiUFPcl8JTXKXXkWrE+grtb3QmuY/MaQJPjkDvXNWUL6XdR3Nom8dWAFdJdajJc2vmICrY4ArKvJualEfLJJJHL3WkCO6BunBKelamn6xDbEW2Ag6Z9RVTTLqG7umjvWwQe5p+uaTCyCW2dSUOcg1UnzPlqF6WJYbGRdXMqtmKTkD2rQ1u1YbJhkqvB9hS6LG09ku5sMO9U9fvpVzaxKSrcFvWs7ylO3Ym2uhnXTmYKsOGb0FWxNdwWiq2fw7VlNbtptv9oVtwB5z1ra02SXULdG6oR+taTslfoXYs6HJ9omAkbp2JrM8TTMl2VOQp5FaGUs5cR8ue47Vc1GK2ubJXlUbwOWNZqSjPmtoRJa3OVurGW/gUQEhTgEetd34SVdJ0vY+MhcfWuXizAR5DBgKtTXEzxBgSDjvVVG5pR6E1YqcbG/f3fnQOANyEEHjpXl95oX2jUCpuGRGOSue1d7oF0pDRTDcxPSsTxPusp2kSM46gU6EpQk4rcjkhaz2NDTrSz8P2Si3fDkdR3qRrj7SwYN8zDjmuTiubnUJYRhhyBiuw0zTypTz1wF9O9KpHk1k7s1XKo3RVcyQkLI3Hb1ora1S3jlUEDleAaKzUk1dijK6PJ3h/wBDSR9wJrQ0tWCKyvlh2qYKlxDgrwByKxdSvGsWHltweABXpq8/dRMuWmueWxq6xeYQKB+8I5qhaPcIfNAJz1rnb3XZEbMsbE1LD4maSIKo4HtWqw81HRHN9eoSnZysaeqagEYMynZ9Kt6XqNrdRFFcKfQ1gS67bkESpkYrBclrwTWTlBnIGa0jQ5o2ehhXx0aclKDUl26nqP2u0t7crKwzz1NYE+tCJm8oArnjArOMcmpWIDttlA65qtpcb2TOt0u+MHvUQoxV29WbVcRUk4qCsn1Oz8NanFeOQ7BWPGOlQeJpBBIC+Snr61yd5qCRMs1gjZU87a0I9VOt2ZiYESDjmpdBxlz9C4YqM06V/e6dmZOoBpnBtRk9eBV7TrV12vcsSPQ1FpYewv8AyrpdyueDWvq80UZUYwGrac3pBHPhqC1rVHZroVNUufJiIthub2pvhvV4pLopexAYHBYU+zeKH99KVIPTNV9VFuxWeDAye1SkmuRr5mtRzi/bKW3Q2/E9vbXyQ/ZkXzFOcr6VetInGkqm/wDfAdenNV9CLtCrCMMuME4qPVJ57W4Vo1ITqa5tdKa6HWlBN1bbk1prUkCtb3yjA6GtHTF02SfzpWJXr1rn9YVbm2WZeW71lwapHFF5LEh+lV7HnV46MznWjSly1NujPZG1HS0tNkTIQBxXPy+ILATCPeAenJriLxZ4bFJ4nbaeorSis7C905ZHIWXGc+9c6w0IK7bZak2+WK131O4k+yXFsJY50J7c1QWS3BCmTEo6c1xE8b2MQeK5YjPC5qx5oWzE8uQ45B96aw9loy1LdNbHcW8zSPghiq96axjguN7N8hxn2rndI1zUWtHaOANGByxqi/iKG/YwElHPBFR9Xndj9rBWu99j0K6lhvdLlSC4BIHC5715uJrm1mlhDDcCcH3qqt5Po2pIW3tbuefQCulaz067i+0q212GetXCn7DfVMiLVS6jo0S+CbCSbU/tF3KoPvXV3cU9zqYgt/uDndmvMFuLuy1ZXgZjbjvmtq98UXNk8ctkjSFuuOamtQnOfMuootRTe1v6uWPGNxe2F2sKBiMYyOaxU1WdELSQEOB1xW2+of2pZ/apDi4XG5WHSs+O/aOYfaLYOuew7VdPSPK46otwk/eUjZ8F6sJ2ka5XanfcK6K08q5aU25AA5rz3Wr7dGF09BGX64q3pv8AatjZpJGfMLDJwayqUOb307X6AnryvddTpL7S7e7u96DZN0JHFTR6a1ou6aXfH6GsCx1y7BaKaPbKegPr606TUNUfekqhgB1JxipdOps2X6HX2VxGx2RxnYe4FZ/iFJbCRZo4i8R5PfFc7F4pkRTb7QJBwcetTt4iuVt2hvQSsg4NSqE4yvYlb3TAltStnGSBjpUvh64mtgbYHHOBXOXNxfxSEWSb1PO1ak0HV5IL4nUI2RgehrodJuDsL2i5+V7nokduu5TMRk9yOazvGKvbWqsoYL396p3GvNLOJLeFnVRn2q9c6/Za7pxtbtRDKny4J6VyRjOElJrQU1LZGJoNyki7AxYjpmr+ozSBQqpjFZVpAmnSnypAVJIyeldHpn2SQpJeSoxHRRWtRpS5lsNRly6mp4W08LELiUfPwRWhe2MN3ODJHkeue1Na/hQKkOAnoKrXF+wZEQnOe9cd5Slc5+WblcZf2sdo0Zhtwy55KDpUR1CI3AUNtbvk1rSTGKx3vg+1cbPbNPM0idycgVdNKfxGlPVa9Drnki8sHOR64orI0aaRkMUoAVemaKyfuuwOKi7HAWU6RwkSEAe4rJuwtxfhcZUng1oR2/2q2O0EHsPWoLZ4reZhcDaR0yK9xWTbQprmiovYzdW03LneoOBWAbK4gjcxRfKa7G+uDKd0akxY+9isi+knljIgwAOa2pVJJWZyYnC0pvnV7+RnWNlC1ozTr83Xmq9npTTO8sJ2qp6VHFqMtukkNwhz2p+jaubVmjlXCsc810NVEm0edGWGlKEJaW39TRtpmiUxvjPTIpl9cwi3Ku/JqrPdYmZkwQ3ese6KPMPm4J5ohT5ncuvi3ThyR16HX6NLZLpx5UnHINUdPjMuoyNZ52dcVLpNpaG3VGIOR+dWUH9iS+fCNyntWLdnJLdnbGEpU6cppKMe25Rv/OguQ1wD14zWldMJ40kC7gB0qvqWoG+Ale3bZnrin6VfxzkxxgYHBpNS5U2tiqbgqjgpaS2MjULh71hBCmzb6Vs6HYqloROd7Lzio/LggvTI5XJqWNZZLppYXAXHTFOcrx5Vogo0OWq6lT3pbfI1dG1e3t5mt+Rg8Crd5eJOChCHPrXKNtF2zHiUHk0SXYLhXkwaydBN3RtDF8sWpdzRub+KzYI+Chp8+m2l/ai5h2hx82M9apXNhFcQZdmPpxVaCGa22rHIfLzjFUoq14uzInObk41IXizW/tASaf5BAYrwRVOBbhYtoOE7c1Zi05LdhMJQQwyRVZzO85EOfKzSjbXlLkp6OpvtoSNYuyiTzSSvOCetWL68P9nYaIbcVTuYbmCEyrISOpHtTra782zYBSxAotez3HeMW4JcraNDw/qMradJFCQA3r1FUdP0R0vmmYZLHtVfQnZJJCFZMdBWjb6xNFctvGVz19KUlKLlydSabp1YQlV3R0sxs5dNME0QLY4YjpXORQylWiWQ7c4GKW71CWdgVU+WepFSMyWgWQswU9axhFwXqdk3GTuJNO9rZtC0RZgPvVZ8MalCR5NyF696f5kN5GSjg8dKo2ljEJ3k5RhT92UWpaMTjNTjKLujT1wbiRY8jrwaNE1NGgeO5XDLxyKdbSravnO5DWbfzoszyW8e49TUKPMuRouXuvmuV7jUoReOsKEkHgelb3hnVpBOY2XAH8Jql4eWzmLTSxhJT2NMklhOt7onCKeCPSqmoyvC2xnByVpN6M3Z2EuqbgiqPappblmSSGNRv9cc4rK1O4EPzxuNwHX1rOtdRmndmUkAdTWKpOSubOUYu3UfbeTa3rtcgbieKm1+8t5dNZYRlx09qw9bBuJlIkIPfmtLTjaR2Z8zBPv610Sglab3OeM3JypLRdzW+H84QI1ywODyD6VL8RWhlKPYIpkX722uUNxI8rC0Yxr0FXtKhuXci6bcGP8AFUSpctT2zfyEmqiVNX2tc3dF1R7XTwJYQSwxn1rndat76bVklt02o5zgdKn1CSeHYsI3oDnHpVibXYooImKneg7CiEXF80VuXVjCS5Zu1rGlHKoshHMoVwMfjXO3F3eWrsxVjFngrQt+dXnOH2Lnp0q7c3SQQfZnwy4704x5HZoqTVWPNCVvM1PD3iOOSJUkYhuhzXTRaxaSKOgINef2ZtfNDRhS3oK0ra1myZiuEbrk8VhVowcr7BHmcVzavyOpF3cajcmKGQ+Xn8K0JrP7OnDruA7HvXO6fILNAYZF3N1xV/yZQq3dzM3lnnaDXNKNnpsNxehYsZ5ZFZGjYD+/iircWtW72vkxJhgM5I96Khpt7WD3uxxdu+DgDGB1qnq4iuFZTjeBWgVRrcyKc57iud1XfuMkDAsOSMdRXpU1zSM6j5YN2uVLg3NrAIuSje1NsvLSJnd/mPY0txqsVxbBJOJh2NczqMrIoYSYc9BXZCm5qz0PMr4mFBqpF8y/Ik1aUG6LYGM1YR7O8hMfAYDgmslFlvgckDaOD61PZ6e5lw7bSK6nFKNm9UeVCtOdRyjG6kQ/ZblZdkWXHtVhdMkRlaXHPrV21u0sbkLIN3NXtUBuoPNh+QfSpdWSaXQ2p4OlKEpJtyXQqS2bQQeZHIRjsKJ7iVbVZGfeB1qK3Ek0bQvJ09fWp7LRp5CY5H+T1qXaPxM0ipz/AIEXZ/ma9hqNtcWHlMADisrSzbxalKoIAY8c1Nb6dFayFXPzZqteQRRXgkHy+4rOKjdpdTqqzqqMJzSvFlnVAs1xhT8wq3aXEVvB85w2OKreZELmI8EEda1rqzt7m1GcZIrOTSSTOmjBylOpTtc5y6kW6uWMEm1jx9ahsoG+07boHd6+tB04xXRaEkqDWzJAZ7VHQ/MDW7kopJHn06M6snOa1T26MmcNDHg+mRzUMQeRGLcCpJLeS4gUo/zLTo7eWS24kww6iue6SPTalKWi0sQ2U0jXRhckx1pS5GEtlzU2k2yRREygGQdDRZXMS6owcZ56VnKV27LY3o03CCUnq/6sY+oNdKnI+Reop1jMscO6PADdRWnr0kULEqQY2OCKwp1g8hhEcE9q0h78Voc1a9Ko5KV9Opp20LyhmQgKeTUV1aGLBzw1Q6LNLCo8w7kNP1R7iS5RIRuB6UWalYtzhKipNO5btrjyrUrkHHbvVy3ngvLN0kHI9aZY6YkR824bBx0q/ptrZ3F00e4DdxmsJyjq0dVOM7Wlb0MPTbaS3klkXmPJxV+C9BJWVQAeAfekvydMuvs3DI5wDVybQGWzWaRvlYEginOSdnLqTTjyLlp9DJ1JbpI2aAZU8jHen6c4a23udrd81PZTFYyp+fbUX2m3d2i2AE55p3drWGklLn5t+gwypCrYJy3HFPs7SI5lYnPXk1E8UULAyNlT0q29pKy74GAQjIFDdkNRu9VexDrUTyWm+DORUFnEy2Wed2M1sWsu+28qZQGHU4rNmBhnIjbKHtSjJ25QlTSn7TvoLplpFcyHecuD3q9qdlFaopZQAw5rLa1vILj7QpAQ9QK0pDLfwkS8BRSnunfQdP4WuWz/ADKqSWscGUAyOc1qabMlyUMRGc1lWkAe2cMmSvFQRQS2ymWFmAz92iUVK6vqCnKNtNDoNbglgR5goK45waxNDktHkInAOTzU9lfS3xaGdiRjoayFtXs9Rfn5DyMU6cLRcJPUzqT96M4q6Zt6jZWySiS2AjHtSfY7e5UBmywHUVVSOa9JTdx2rLu4L+ykJD7kz3pxi3pzahUqKmr8l4ljH9n6uBCrMh/GuoaW4v4AkfyIvU1V8PiEWxlukDPjg4qG31JxqTxwLiMnpmom3N6LVFU4KkrX0b0LVrG9vOBOxKhuK257tHhCCXK91zTEshcxNI0iqSMjJoW2tvLwew7CuWUlJ3Zuo20Ftri3RMfKPxorEvLRZLg7GKrnpmir9nF6tk+/0RiabqNzbXX2fbuiIwT6VZ1OTZJ8wCluc4qPS1ayX/SlBJ/ix0rJ8U3k7MHt+VHcV3KKnUsjzXN0MO5zb9OqH3mnqymcDaQMmucu0FzKdrfMvUVpQ69NJbmKRPnxjNYtzBIrGVTjJzXXSjKLtI8bHVaNSKdFXvuaFgVjkWMnp14q3c2k5kR4Thaw4S8koJOG9auXN7dQhU3cetXKEr6GdGvTVJqadulgu4HRw7j5hWpb3lz9nWIx4U98ViNeylcS8seQTVq2vbiUBNwABpSg2tUFGvCE24Nq5YlsJWbzbeXDDnFTWmq3FmwFwQc1PBbyRKZDIDkd+lOu9MW7IMR5xWbnF6S2O6NCrD36Oku19ya8k+3Ijxn5u1L9mSWHy7hwGA4zTLC3kgiKcFhUd/Z3Tr5pOD7Vl15UzqfM4upKN2910KkemSy3BSNvkH8VaUCvEPImlJx0NPsVntIwxIZW9alaLzV80jrxxRObbs9h4fDRguaKal+hFG62yOHYMp7mobVpAJGgfMbdKqXlpNcKYrfIx1pNL+02D+RdIfLP8VVyrlbT1MvbP2ijKLUV1J9EmmW9kEpyvpW7qN9DBZkKh8w9qdYWNpG3mpJlm9ag1ZEWQHjbWEpRnM76VOpQoNX1GQ6hLLbDELfWn6e0clyHdfn71Nb3sUcBQgKccGs6K+IuGJUDB6jvQk3eyG5qLi5yubN7aRXRYHgisPUrZIgqiNjjrir0Gpia42g9Tg1rvYK9uZg4Y4/KoUnSspGs6dPEpuP3nOwyxRRqCCq+/arKTwSMjxuC69KtrZrcowdRx6VnXGm/Z2SSEAANyKpSjL1M5QqwStZo2YJTdSssoOBxUF1stbtGjG01YAmKpNAgB/iBqjqkM80qSY2seNtZR1lbodFRtRuldli78i/wN+XHQn1qWe+1B7dbCIbgOATU+k6XHHA80jgOBmooLhoL1bgYZPaldN2Wtg5W1d6NlWXSL6yhE8g3BuSKdJapPamQJsk65rY1jxNHNEYCoyRxjrVaz1CI23l3UW1exxS56lryWooQgrxuYT2ct0qrI2QDV+XfZxKpbCYq7P5Sy/uTlG6Vm6g8kgMLgeoq1Jyt2HyKmnKO7I7WffI5OWB6U63jWa4K52kHvV6Kz22KSREKRwar3YWKVHXhjwTRzJvQai0k5C6rHdRxhY+V9R3qewkb7LtlA3Edaseefs+AAwqGdwsOQRv6ACou2rNGihaTlclt4JLaJ3X7rdapwgjJZciqU9/ex4AUFM4Namn3iiHMyDcabjKKuyYVIzdl0KlzCijzIvkb6YqpGrXB5YFh0q/fkzbhD1I7GqOlW8kEjNK3eri/dv1Imn7RRS0HRSzWU43jj1FLc3IvZgHwE9B61Zv9k6bIcFu9ZdxaFYd65Vh3qo2er0ZE+eN0tUak8c8MA8vmPHBp2lxK8o3Ahz3ptnPO1ltHzAdvWqy6mARGybGBqLSd0i5ThFpvqdCsVxudYnyO1SFZ4IW8wfOevtUdlPIluLmPlhjAqSaa5ulEmOe4rmd7m1jOeRt3ltw1FLKxSbJHzY5zRWmvQS5ftGBf6tBOvlwyg5FcxPdPBPzlkzzmtm402zjt2aI7ZB0NZMyrGgZiGUd69OioLY+axsq8mnNpehqWz2E8IfCq+OlVJYUu5SkG3jnjvVDUWh+zK9tkYPOKh0i68mbd3+tWqbs5JnPPFxclRmlbq0Wzpr+b8x2heuK0rrRl+yh1bJx0NVBe+fOeRn0p97eSpGUZzjt2pN1G0awWFjGTaujHu7ZiAwPK8GpLPT7ueMvDnGPXrW5plpHdWb78ZNQ6XO9jcy27nCDoav2zs0t0YRwMFKE5u0ZdiO1kuJreS3YfOgrQ0Cd0WWG5OGHc0aeyHUXYkYbn61m68zRXpliB2nrisn77cLWudaboRVe97O3yLE928N+zhyUz605teMlyqD7p4OKXw/ZLfRO02MHpmqE1lHbXkiEk4PFO0G3F7oiVTExgqkHaMmdFqMUn2FZITxjOB2pNIv1MXlyg7ugrI+3XkdsY9rFOmSKNHYfblMtZ+z913OpYxOtF09L6O5slZFusxALk96t30eLXMigmnXMf2jDQkBh0xWZqK3hUxvJ1rGPvWPQqP2SlZN3NTS9PS4ty8RII5GKxtRZ3vTDN8u0/nWppEd5bWv7tu1Os4YdWkl+0MElXgcd6SlyybeqJnTdSlGC0b6FC8jje1VAfmI6g1NY2caQFZSNxHU96o67bTWeVgcEdvWn2TXElmv2hCGAznHWtLe5dMwU17dxlHVL5ECvHYXMjBSw9q3NH1WCe3ZWc7x2NVrCO3ZgZyMk9KrarDb2cwmhTAPXFKXLN8r3Kh7TDx9pFrl6olhv7iK+b5T5RPWrN3MyzI7YKZzin6PeQ3LpHKgUHoSOtGo2a/aiEfIB55qHbms1Y3jzOneMrm5BqUBt1HAfGPSs/UczMHjfDpUN1Y7bdJI2/I1Vkhng2ygkhuorKMI3umdE5ytaSL1+0ps8xu2zGTipfDzQyQlJCGboM0+1uUSyaGRSQ/rWTZxPDctsO2NjmhK8XFkyvGaktbmrPp9sLze2Dir7mykUBhggYx61k7Ga43Fjgd6n3JsJPBX261DTdrs1VuiGIjzTtHaR8A0x4TNchJSI36DNdZpsUMulNPAAsqjnFcPfyPf6t5IJSQNw2aKcueTW1jOpLkXcteVcwXKw3BzA3pV7WbBIrMNCMjHU0alZ3mm20Ut4d6Docc1JFrFvdWjRupXK45FJtu0o7FLltytmPbCaWL93xt60t8BDEHLEt3FOPm2R3L80THnNMuZ4Z02Zxmtd3foD0jZvUhid5YufnbqBWlZxedZskgw2ahsohahcDcpH5UwamI7l4yh56e1KScvhGmoJc7C0kW2udh5bpzUmoSbpo0KlVbvVaSFpN06qSfX0otEku3/evjaeKdl8QuZ/D/VjRisUgi8wOvTOCeazruc3IMcanjqfUVcvFEarukI45FU1lWNg0YJUdfelD+bcc7fDeyLNheJZoFdceoPekksrbUJEZcBic5qa3hhvDwFBzis6+iksNSjWKT5T15ojrLTRk1LKPvq8Tflgm0xESI7kYde1OlecW4fBHripyWm09do3tinWMdxNCYpYm2AY6c1z82l2bbEH2czxI6KST1oq9K4gQRRhU/wB7iip5n0DmPG5bq6uXEPII6ir0mlyGwZnfHGcU02Mt5N59jj1xUd1cX0cbQXKMueMivdbvZQsj5CMVHmlXTaez6Een+QLOSORcsc03RLOK4mcE8A8Vo6HZxSQSZIZscg1X04R2uqvu4TOKHP4kghRt7Kc0rPQuCwt7dZC3BHQmoI1S+t5FyCV6GtTUZLW5jMZcDIrDgt5bGZmQ5j96zg3JXe52YiEaU1GKTh1sV9M+1/bfs0BIJOOa6WTTFhizeYZz3xWbZObycPakCbP0rYvrPUJlXz2DJ0OBSqz95dB4KilTejn27FeCOOKF2yBjpWZLcfaJWVBvHQgDNaj2xtVMUvII4Jqfw7Z2sMzvJ19D3qOdRTlubyozqONJaLqZWj3kdtcGAggk8D0rUFkpvxLKrbW74ou7W2fWI5YgN2ea6+V7ZrQKI1D4/OsqtWzUktzow2HlZ06juovQ564hjYeXGF6cVi3GmG2k8xiVB5HtVjVYrmzu/tEBLJ2FStfvdW5W4hOccNVR5opNPRiqunUbhUjZrYm0SJ2DMWJUHiqfiHz7aRZEBMZ6nFXtK8+ytnyhaNvSteC3W+sS0u0L6HtWbnyT5nsaqk6lBU72Zj6ZetNabUb5jVGAva3zNPlGZuPerek2i2WuY+9A3p0FdB4rt9OntUaEhXAGfXNEpqE+VLRkKM6lNN/FE5rxBaiZEkhk+c84zS2uqCGzjivYir9A2ODUZ0y/LQ3EavJGv8PtW1qNumpWCwR2Ti4XvjFU5RSUXqvyJSm5yqQXK+3RlK400ywrc2/QfNxU9zHb3tkiynDCrduZbTSxBJE4lHUY61gSG5iDefbui5yDiojefXbY2nKFNar4ty/5EcSrEATt6EVBNbmJWdmYZ5Ga39PurC701MsgkXnrg1EyR3MRjAypGM1CqNOzRryRlH3X6GNp880kLq+TGOnFR3F9cS4jQZHStHTy1rLJbTQnb/CcVAJEtp2V485PBHatLrmehnaTgouRZt2nESCeMAdM1Hq8ZhCPGPlJ5rdngkvLNPs0ZZgMk+lZ9nbzaiXgETfL1rFT15mbyXu8iI0iY2AlVw3r7VmSme4nCQ5cHtWjZ2Lx35tXYqrHGDxUl5BJpN0HtU8wLz65qlJJ2W4prmjroWrK2vLaHyw5RWHINSf2bF5qOCDITksRzWtpdncaraNey8FV4UVT0u1lm1F2myqA965vab66otNC390W1C2tr0nyeOo4rU1nTNJi0wsjLuYfLj1qtfW/9r3Bjt4/MKDGR7VWisDZ3CJqwYRj7pzWd1pZ2a6A1dlHyYjprhiCemD1rEntraJVOcMa6HWZLaVytqxUDueKzbWxSclQQW7EnvXTTlZXY5LmNHR1gkADjMY6k1PdaXY3c7GPaCOeKz7gixijGR5h4cL6+1bNhokt7YvcRboSFyCD1rGb5ffvYpuNtTHVooDLbkZ/CqcFr5Ts4bA6gVJaOEnkjuELSoetLcRT306/Zh5aL94DvWy00E5Xs7EFzG8hDuOBmqlopMzjyyQ3AIHStXV9CvUt0dZdqdxWz4Zk0+3tT9s2kgcjFEqqjC8dSHrJ6bficnYW0kd+eSUJ6DtUmo6VLPfxlnIQnj2q1r1yW1DdpyARn9as2E++FnvQwdfu4qnOStMShCS5GtNy1p11No0ot5MOpGQSO1aujXk1xfPtVdmCcGuPcy6rqKJGzlVOBxXpfhfRTHCDOfmA7Vy4jlpxvLdhKrFRbexnroYu53a6nCelFaPiSwkhn3WzMVPYUVhGUpK6lYmMnNc0WeF+D7xYZJIZRt+tbGo+XdDACkHviotM02Izt5qhWboalurOS3kyMlO2BkV7k5RlU5luedh4VKWH9nJXRjy6VLYAzQSHaeq0ttoNzfOs4O1CMsavtBeXpCLGwj7muv0ize1svKz8+OMilVryhG99TOjg6dWTTi1H9TkF0eC2fEh/eDoSa1YLC3ZNuByKvSWDvdjzcNgcnFOn09kXMZ6VhKq5W1PSp0adPSMdDG0rQBBdgxnGOhrcngZEKSENkdqNLZmkG8cL0q9OQGGcHjnNZzqSlLUulThSjaCsjl9XCsoAUnaOtFiIHTDOFJHWty6FvMjKgG/2qGw0uGQEXA7/AIVp7RctmZum/ac6KH2KFpRtOW9adOJ7fBxx25rZuYra0XbH83aue1i9kIJjU4HAyKKbc2OrJUotlq3judQ2q8QWMd/WtPULDybddkSkY6mpPBtzmzJuFB47jpUOuajcJcRi1XdHu5HpWUnJ1OVdCotcnM+olnHstylwpUH+L2qjeWjrG5glIjPXBrs205dQ0aNwFSQjoK5y40S+WCYbsAd6mnVTbu7DnqrEXhJFhjkkulDqO561LqWraK9wqnaOee9cfe6vc6bFLbOwPoR3riJ7l5ZGZmOSa7oYN1ZOcmeRis1hhIqEVd9bn0d4cu7OaApBtZBVy5e3hO4IoYc9K80+EczylklkJXPRjXoevadJJCTBxn0ryq9JUqzg2ejh66r041NriW2o2BlP2mNDk9cU/wAS20MtqHtIkaMjGB2riJZHsyI5gSRXXaTJcXWmsEXgDjNE6Xs2ppm2jdzh7bS2e8aGOFlJPT1rVtpEsB9muICJgfSnand31tdbreMeavRhWLba9eTazuvYA+DkjGM12WnUV+hzyqQpSUe/kdVc3ljJFujizMtYcj2Vy+HPlSE9K1tUu7W8niktbc24Iw2elZOoaKWYTrKNgOc4rKkorfQ1nKXKnFHV+H7e6tXAQK8TLyT6VctdEvNN1CW4tJY3SXnB7ZqTw/AbbTVnRi2R/FUF1qNzFI0vPlA9AelccnKUmolu8noYOt+HdWlv/tEJXfnPHAofS70IgvNqg9TXW2E813amROT2PvXOaguo3M8scpKouSOMVpCrOXuu2gQ0bOn0jT0srHbHcDyyORnvVWCzlNxKoUGFjwRXNWGm3727vBcuyqT8jHmtrwrrdxFJJaXwDEcBu9ZTptXadyfeSbW5n2L33h3VnZoDLbucqR2pfG2pXepwxSR2TKiHLNiu2010nuHRkDR9ia0N1vNvtCinIx0qPbpTU3HVGE6ijL4dTzE6fp1/YxNFIElx83OKoW1gLC7LqzSL6Dmul1fwzawagGQmMMeQOldFpml2NvBkoh46mtpYlRjo20zodWMVz7nnfiNC8UckEZZxgkAV0nhvxTbwaUYLyMpIFxgjrW4BbyTmJYV2Kc8jvTLjTbIyq7W6sR6DjNZyqwnFQmiZyjPSSOI03SrzUdXmu0jXymOQD6Vam0bVre6kls4d3cqeldlp5kinKQw7UI6gcVaTVDYb1lTr3xRLEz5tEKVSa0grnn8lvqjttuwI0xyOppw8OvJEZLZt3+wDXQ3U7am0uPkIHy8U/SI7izUsx6dsdKt1pJaaM15mo67nOWXhu7nytxGIFBxnvWo3hYxRpGZNwY9xXY21yJVG/BB9qts9tCFaXA2msHiajZySxM4u1jCsPDdnp9sHjiHmN3PX8KtpBOz8cKOOKbqOvbWBjiLKpwKk0jxDBdOQy7H5FZS537z1M263LzNXJUtjI3luQ3fPpRVt0TzSynGeaKzuzF1JdGfP11A0zjyHwfY1NM1xbwJvQvj9axLO5mS43JkoDnB5rrba6g1C3EfCyY4FfS1E4WvqjppVI1W2tGXdM1G1kslAjAkHUYqVr1CWbaQcVTtLBbTc0g/E1J9otLkGMD5+2K5JRi27HZF2+IyNT1vy7nbDycfjVKz1S+eX94uIye4rS1HRoVPnqfzPSkt7d7hfKgIPbgV0RlTUdEYSp1XO7lp5GhpN3FOCAuGXrU1yiXIeMkBuxptr4fnsQWfJzTXtHDhtxBHYVg3FyvFnRBvl94ZbaTKvzAnr1qeVWjUxt09cVbg1DygFZc44NXwbO9CjAVu54qJTkneSHpayOWhkje4Ky42jpzWV4jaMtstQGJ447V2NzpVl5pRcbietWrfw9YY3Eqz981oq8INSZlUg5Rcb7mL4M0pxb5uSVBrWnis4nZV+8eMYrQEYjAQfIi+lc7rWpRWkjMq7iDWPNKtO5cbU426I2rZ3ihG1sL6mnz7jBKSxbI6U3wpejW7T5YwSOoxWlNG1nORIvyk4IIrGT5ZOL3BTi9jwHxRHJNqUiqDkHoayrjTXt7dZHIGe1eh/Emxit5/tcSFCeeK85ubl7nG5jx2zX0eGqOpTi47HymZUYU60ufWT1R23gq7t7KNZHbyyeprvrDxXE90inLxdK8cjf/Ro4gCT3rrfC2m3H2hGYNsyODXJiqEHecj1MDiZSUaUY6I9C1C2tLmYTKMo3PNR3eux6RAkcKhk747VpWViQmJVG0jPFZsuiPJM5jAaP0PNeTFwektkevK2yGaRJb392sjjGTnBrX1vw1pt4pkgKxzkHkVmWNsbe52xxEEDvVu+FxA6PKhCH07USb57wdiZR5rXZiW9s0CNbXBDsvAOK3LD+zYrIpcMC2OnpU0s1p9jDOmd3cVW09dNuvNixtlHIOeaUpOSu7lO1rFq3vYpbQxQ5CJ6VHLCpt2KPvU9RUNjaeQZApJU8VJpFncS3Lrhkjzk1Oiu0wukX7CNre1P2de2StTZ8yEvKo981tnTUS3KK2JGHBqnHps8du4nYcnrjiudyTdzmVeEjntL0eb7ZJPZT4RjylWLHQI01YyyS5ZjyB61at82IcJuweSe1Rw3Jd2lEnzDpg1o5zd9TV8zvY6GC3hjdoo8hscDHSslEubC+Z5QZBnrT9K1mO5umQcTKMGm6rHfLqSSK/7ruprJJp2kc8IyU3GXVFjVYzfxBwuGH6VXurW4jso+uMgE1rafIJH8sgAkYNWtYvLW1txFKy5PaoUmmkjJVpQkqaRlNYWiWsUqyMJe/NaUenh4VYd+5rJiRXMcrNmLPY10sFwhtFRMZPSpk2RiJTglZ3KUcUVrAygc1nzWY1DKvhQe9a88JjhLsM89hWYLhVywHHahX3RNKTd5R3M1dNg0648vezbuakmQltrY8s+3WrMoFxGzZyfU0+CaF4RHOwBHFW5N6s6ueVrvVhaRJGygncP5Vj+JblVutisSBjviuiSCMAvE28DtWVq9nZzIJCQHFEGlK7IpTTqXZmRsslqxbHPX2p/h7SoxK9wwbHbNZkVvMNQUOGNuT26V2ZP+hYtlwFGa0qS5VZPc6K8uRWXUzL9LhyyxSMmOARRVtJkFtlgCw65+tFZpvsRGckrJHzzo0yyyFJF2knk1vvpBixcQyDA5IrlESSWbdbAg9eK7nR43fTwJHDNjHNfR4huHvJnPgX7Rcs1t1JEvhcwiOZyNvGB3qLT1jguH+YEHoT2qlewvCx3ZyTUKs8e1lyAawULrQ73Kz1RPr0yLIqxkk1VilmtpEkhJVjVi5iZlE8cRk/WpNNtJLpleddoHUGqTUYakTTlLQ6jSLyW9tisu4MBwarzXscRMcqgn1NXIL23sYyqqOmPrWNqMR1Hc8PEmcgCuOMU5O6sje7S0HLcRK7OwyD29qm07Et2DGpVM9ccVX0TTkaQrdynf/dNdXa2UVvFlFqqs4w0RCvuyjfwKgEiZYjnIrLjvpftCKFOCa0r+5VQY06kevSmWmnSToJlI3IelRF8sfeKuWtalMFgezEferiL8JNuLMCenXrXVeIYbu9sQtspY9CPSsGx8PXhBe5OIwO/FaYdxhG7epnUu/dtobPgNrjTlbyVySM4ropLuact9qiIIPSsHTNRg00ZdwWUdBXYabPa6vaGWF1yByM8muau3zObRL5adnY4bxfbW2o2LruAYAggjp+NeOano0tqS8YLKOeK931zSlLEKcA54rBi0MIT5se9PQjrXdhMUqMdGY4zA08YlffucR4CshqEuyVBkHByK9ds7K3tikQZcjtnqKpaJpVrbiO4hj2sy5CgYA+taMulxtdi6BYSjgc9vpWGJxCqzfRF4Wj7CkoX17mu0IYDDBdo5FVsi3YhTu9RUY3hslj9alIEpGTgVxWsapET4eQSEYzSXtyZ43tyAeOKZeK4CiPJQelQR2sqzCXBx1xVJLcqy3MzTLpbWaS2ukyp45qZNPibURNbkKTzVu+slnYSMo3jn3p0IiMTJHIqzKOOa0c+qKG/2mtheCKa3JVu/XJrp7TU4dqjytpYZ6V57b3l4ur/Z7yHdg8M3P5V3DuvlAbACR1rOtBRsYVIKe5e1K/W2hNwcnHp2qLT9ej1KA+Yu0DgZHWuf1LzfsssWGKsOBWboGqRqxtJxsbPU0lRTg2iFho8up2cqwSWflkh224LgYyfp2rFhso40lhTAY8j2q0q/ZQ0kZLoRnGarafdi7u2xG6HpyOKhXs2ti4RcE7PQNJ0820hkA+f1NajSuwO//Gp/KKKCeQO4NUpmPmALwDxwKlycndk83tHctacpnDeW3zryMVz19E97qkiX0pXacAZrq9NgW2G9Q2SeTTtY0G31X97G/lzYzle9KFRRkYrERhUfNt3M/QgtsDCCJEJxk10JiVIxsGPf0rD0rR5LS4JlYkD8a2jOGZl68YzWc7OWjMMS1Kd4u4kl0xYx4OMYquIUdhtUBuhqrcLPAXkTLZ7Vm6Vc3b3jNPkKDwKajpdFQo+65RZc1ZGtiFO7aT271nSWrHLbiDjgVsanPHcou7gj1rP+zyzthOh71cXZHRRk1Bc2g7RJJBIYjyhPeq2t2UzXyPGTs7gVr6fatYDL5dj3JqvqEsyXgeMbkY8j0pRl710KM71W4DItqL5TL25zTo9RjtF8tgRuOBxUr3APDxEH1AqjJGs5O9TlTkUkr7jSU/jRNPYTyAyQfdfnFFKt1cRRALnI4xRTTn0GnVW1jxK2s5IIwyqASM5rPbWLvTrwHH7rPIq3/arJGIpk+Ze9QXe3UYuF/SvpIp399aGdazhahKzR0kV3FqVqrIQZMcVWkj8oMJxj0z0NcvpxubC5G0NsBrpb/UY7u3iL8EVlOlyStHY0w+J9rG81ZofpuqvYGRWh81MccdKuTajNcw+ZDAVToeKn0mWyNoEdFZgOc9av2t3Bbh1WJNjdsdKwm1dtR1OmKdrXOXF25Yhwc9ge1W9HaeS8yhwK0bqeyUkyRgA89OtQpLCqrLZjGe1U5XVrEqm07uVzUdY4nDtzL1p/9pzN8r/KpPFUoJ2mYbxk1YaQ7gNmQP0rBx6M2sTi1SW4EhYAe9W7e7S3l8lZFwfeucuppWiYxlhgdKp6Msk94WfOV71XsrxbbM5S5ZJWPQoryKF8LgEiqWtvJc2TCD5RisuSYrIeM8Y+lWdGv43n+zzfdfjnvXN7Pl95FWS1OdstNRSTPISec1Po8ktjqnl2rnY/bNXvEOknTrlZgx8mTr9Kzpby00uRZlcFiec11qXtI6a3MlZa9DqvENrcm3jnXOccgVHZjNqjOp3d6zE8WGZFjcrsPFX7efZHuTBVhkjrXK4TjHlkjWLuieO4VVPlcRjBU9vpUJu3lcqr/MOnNVob/wC0XZjm+VT0p8tkkcxMZJRqfKluEVbQ1rNlmH72UA9KtxrEsbtHJuVTgZNcjHLFBdGJWCgcADtVyHUkhuURnBUnp71MqT6CcX3OjhCuoxj8aWJXaUoOQOBmopfKwr7iueQR2p1m7vcZVgVJ61g9rkPZsy9fvfssgib5SR2Nc8beZZhOjN1z1rrPFuhm6VJozyOwrinkvrS/EMiboPWuvD2lH3dwjNOKZ2uhvBqUYaeMeeg5Per8yCTIA2+hBrF8L2jtM8nzKD+FdOyoqEYBJ75rkq+7PQicuWRQiYRjbKoPoSayNQ063N15yAKT3zW7JGrkAk8d6S5tl8pd3YdaUZ2d0UppMr6XtaPZKwOOKvW8cSg4VQetcvO80M++PJjH61Yg1NQnmbio9KqVNvVDnTctUzrFwUI7CmlIvJACjeOtULW5Fxb748DPXmtGONZI9wOOKwatucko8m5Ij7Y8HIz2qWEMpMm4jFLbBfLyVBHqak82G4iI4Uj3qTnk+lix9piZAGOGPeoxFGV3RHPvWfKyRv8AKOO9T6dcIkpTdweuaViHScY3iWw0brg4J9KyL+MxMXXAz6Vo3SpBuZASD2FQl1kiYuOSMfSmtCqT5feWxz6Ss84AHy98mq3iPXRowhMSFmY4rYntIgQYxz3xWbqVpbSsDekEDpmtoOPMnJaHoJxm0aOlXsmo2izT/LnnFWwiykkH5awbDUrVZPIjbg/droYCqgc5GOxrOacXsYVY8juiRGjAyeQOoFLvhPRQrD0qtMqlSyVFaSK7N/s9c1FuplyXVy5JEjkMcbvSise+1MeaRCCCOozRVqErGsaE7bngkG+VmM6jPuKnt3EV3s3DZSuB5nT1qjcqBOMdzX1C97QwadJJ7nVXLWv2bEagvj0rk9R84Bgmc54rai+VFI64pjAM4JAJz3rKH7tnXWp+3ilsHhcTNGTcBhjr710/mRrHlevrjNZtjxKVHCkDgVK3ythSQPrWNV80rmtCHsoKN72C5eCRMTDAzwaYZUhtlMXTsCKiuVBK5Hf+tLtHlrwOlJWsaJu47TL6Q3RV8cdMCrOq659mXaFJP0rHQlbkbTjFXNRjR9hZQSRVyhHmTaMueag0nqdB4a1Cy1W2cMAko4qxGsNpO2F657VymgQot2Nq4/eDoSK7S9RTjjqBXNWioTstmXQlKUby3M9rgeeS3G6mW8kC3Yc8Hs1UtQ+WQ7eOalKK9qNwByKfKrLzNb9DY1e9We3VGcNGOK47XdLWWHfEcrnNRvK671DttB6Zq9oTGQyK53L6GtIQdFc0WZS5aq9m1ozkZr17X5GBwPWvQfBepRXlmkLdcfxVg61Z25l5iXqKt6WiwmLyhtzjpWtZxq09tTnoUatGo1KV4nTXlpHDcK+QOc4qa+uwIUMceQMAkVSvXZohuYnHSnab88G1uQTXBbRN9Due5h65ay/aIpo1YbupFT2GlSSMLiJmZuvNditvFLZt5iK2F4z9Ki0BR5bDAwGxT+sPk06GbitZFe8kvBZLGy4OBjFT6HerbgpdMcgblrcmRWgG4A1yOofLNLgAYOKwg1NcthRammi74s1/yYkazk5AywFWdCEeqaZ51ygz64rjXiSYN5i7uO9dv4fVU0HCjA46VdWEadNKO9yXHlWhoB4La2dVwMLXD2Ooajca4URmaJW4B6V07KNpOOvWpNPtIEYyLEoc96zhJU07q9w5bampgsgLgcdSPWlaRJIyhO7HU1SuXYDaCcc02AkSEDpisLX1I5CO4h2gKB9B61kCOKNmjmTGTxWhqUrhMhiDnrWdqPNojH7wxzW8EzeNzU0pXiDKgynetyN3MTIg+YVg6UxW3QAnFdDYE+b+FYVdzDEaakOp6h9ktzjk45BrnrTV/NaQmTbjuaveLkVZRgYz1xXDagojzsyv0NdFClGcQpRXJzI7DTb+S4uiJCWjJwCa1pgtvMZlkwMAHPSuO00kadGwJDbhzmuhkYzacRKSw29zUVKdpaGko31R1ti6y25YsHGOKdmIK8bEbyMjisHwqx+xuMnAPrWpe8PGe+K5nGzaPNnStUcbmRczNBNIM8KMiuVmupL+7ZJCQoyBXV68i+QTgZPWuAtWK3rYOK7KEU02ejSasmTXVt9nkV0Jzmu48N3fm2qmcghR+dctqqj7GGxyeCazNMuZlmKCRgucYH1q5w9rAudNVFync6jrcNvIYgBg9KpWWovLMwAO0npis68jR0R2UFh3/Gr2mALbggYODzWDhFR0BUowjaxcv4IZwrROI5T3orntSd/tifMenY0VcacktGVGLStc/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing free red cells and a red cell cast that is tightly packed with red cells. It is more common for red cell casts to have fewer red cells trapped within a hyaline or granular cast. Red cell casts are virtually diagnostic of glomerulonephritis or vasculitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phase contrast micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 231px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADnAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrEJU9cIRSsVJHGcikIy3PAApi4IJzyOM0AKwUggZBPHNDKREAO3oaaTj5twxTi4aPIb2AoAApZe/NKuQSCKhuzPZFGkOVY9Ktx8hT1z3oAjCMWGB7ikJUNh8FqTewlbDbVUdaasAY73ck0AORjzgcdjU6MZBg5wO9IkQ5OcY6D1pykYwDzQAryNHkrznpWjpUokjIcGsjdmQAE4/lWhbKY4xzigBl3GjGVSM56VgIpS82xjjuK2ZZFDt8wLHis2UbZWKkZzQBctM+cA3c/lVm8ACqXBIqlp+4XALHNaGqIzKMdKAJ/CrLb6irFv4ucV6Zr1jZ6lZCSXa2F4JPNeKwSzW1wCrEHsa2D4julhCyPweKAK3iOCCBwkfY1D4cuRFMdgzjvVLVLlp/3mCc1e8O2ynEm/APagDU1EiT94wxu7VhzyCI7dvAPHetfWLpQvlY9hWbAoePBXDEjJoAh8+QRo8icn9asmaORFGCCe/pVnWJYprC3WNQGiG0+9RW4QWqk9CM4xQBGiKq/Kc1G+TyBgZpJSoOUPympApJ5PGKAC1iMkmBnkdqtj7NbgLNMAxOMVe0qJVgllzjaCea4+cyaokyxk8MWV/XNAHTS2TRKGj+YN096lngFlaia5cJEo3Fj2pvgfU4b7SJ7S4BNxanbz1PJ/wqt4qge9s2hDnbjp2PBFAGhGlvq2mx3VrIJIyOq1hX9iFuVJHHam+FbmHRNMGn7iQGySa3rmFbhIpoyCpHFAFMxGe1by3CeWuRnvVi0ZDYkOBvx+dQXMbRQ/dyO9UovMZSVb5RQBBPO4lWPcQpPQetdFb3Bh07yTgqR3rCghZm3uOh4xV12YRDcOvbNAFawhnhD3Gw+Vkjd2qW5YXMRGF3EcirdxdSHTY7bdiNeQMVSiUgD5gp65oAisoWE4RlwnbHFWdRkf7PsjByvrTHlG8HJDL1qSWZZck5yKAKlq8ixFc4U+pzVy1JhZgQrEmmWqg7to75xUksjQ7m2Zz1oAbqC+bbjcdoUHhehrGikZWGEwPWrX2tnbayjYOBUnkLkkHnGaAJfMCRAucuOhqNbkMNzcgVKsSPgMcZ4xVfULfyo8xNgjqBQBXuYcszjkHnFZRkbJ/dt/3yatx3DKQMn0xQWGTnOaANa3dZIZNrj8PWq6QBZZJSTlwFA7fWmWp8s9Rg88VZZy6gED2xQBGyqpxkkYzimwgKxAz0odwX29T60qgAAE4NADriI3DLuckDoDU8a4XbnAFVQSG4JwP1qVWPXseKABMh2+nehhuOFOKdb5wS+N/SnmIgFge/SgCHc6jJPtU9lH5mR1GeTUSQtJMFJzXV+HdGjbymu3KRyPgH1oAx49Od5NygbR3xUl/BJbIinPPAArofHOq6TomlGCxmQ3hYLhfmIHr6UvhuzudY8MvcXo3OGJjkIwWFAHEmIqWyoye5qMWwkyxOW/rUurCWK8ZGUjnAqi89xDhip2d80AXYISj5OavuylBuOecVHZ3C3MHy43VTutwfBbGKAJ5YEkBCiqsmlmVD9760+ORoo2bduHXjrV2PUBFFtkG3jpQBS0zTi8JL9FPANaywR2sa4wOOap2tyXlYx8L/AFqG6mJ/1jcntmgBt6FeUAE5GcVXXKnBJJJxUsZGA7ZwabFMqSYcZBPy0ASGOQYzgKcVGVYPh2XHQYqzdqJ4wYycjmqJR1Xr845oAl8r0wxUdu9RAuvzOCFI6HqKljlIXDfpTwAybTyD60AaekTb4Hjz94VylzBLo6yQsr7S37tsnBH4VuJutnymcVpxXEM8bJOgkHGMigDH0DZplrJcFQHn5H0rYtnS+ZFGN5Pes7V4EuYt1uxCjjHYVl6dfyWM22Q5FAG14y8IXWneTewkPC4ywHUUmiTtDoFzNy7Qngegq3rHiO51HTY4kZTtGMe1Zejzy28LIVGH+8vrQAzw9r76r9qjmiwEOBn/ABpzMsRdgflB5q1c3FukhSKERnGflGMmqK4bgZwTQA9b2M0k7gJvJOT0A7VC8cSXQywIxnAqwTuyoTqM0AJDceYCQckdc1Bc/OuV3bvY0OFkYBBtbH61LbxM2VkH1oAhtGZXJc5Harcex5ATwf5VE8W3IXkgdqAjtbqxBUkjI7igC8IYUTcJCMt1BxWhcC0uIFjilUzemap6zpX9qeHrUWk6wzW8u6Qk/fQjH5g1n6xodjNq1q1hqbL9ljWKVYeQD1yfzoAvXOjlVWTaRUE8YhhIIOfeqz6x9i1CK3e6aX5wpDd/etTWSGXK4ORwKAMKKY/x8N7cjNPmn/cHe5Y44pHiB69qrTRtwM8CgCohJIHG4ntSkEE/P+lTrEqkOwOTTTLz1FAF4jLgLxxzUilVO08Ej86bEm2MN2PIp28kg4J7cUARMmHBx1p4UHg89/rTn+mcc801QQ2ScmgBJFOeAQKevPA7U+X7vI4pNwVD3zQA6MYYbcE9qlEnzHPSqUxdFUDjNJGzKuVbPBzmgDf0e0N1MuwZ3nAxXRfECZ9O0iz060AEjDezY6Ad6xvBsxjBJ++G4FP+LU18klrcrERG8BTPbOaAPMdRSeaaHfDPLvkA83BwK9d/4SK40Twt5OmwfaZETj5SQnrkCuSsPFWmy+GbfRrtCt0jbyy8Mxrs/hlbTgX11cQlLOTIBfnPTigDnF1RNftBPNbpFdR48xV6H3qnqV/btYGAQAue9aes29lps9xHaEASMST9TWdaWkDqzs2QoyM9zQBHo8W2EEcd8U6fT7p3LhCATxnuK6aO3s9I0FtQmUPNcFoYMjhCAct+lZNqftFhFJOxLtz8x5oAwZkntZB5kZVeuRVkOk8QDjLYyD61fuEXBV2LRlcYJ4H0rGhJhuXhIxg8E0AWEYwR8Lg+lEyiWISbRVu8jDQIzAYIqpbKpXZ2z0oAWNBIg5AA6U64hQJHkDIPGKQgWrHI+XqDTbmRZIEP8VAEyW5KEIW3GgwSI/C/jiqkd5KCgwR2NX49VjhU+ceOnNAFXym8zdjg9sVr6bo9zduBDE2D3xV7QtHbU9RRlJMPVuOK7yC/0/Tbh7JWVGjAyTxzjpQBzcHhVEjC30qRu3Y1U1nwnNawmW0PmQ4zlTXKeP8Ax9d2+rtBHKFQcBVHAHvXoHwz1eXV9DxcjP7tXH0OQR9Mj9aAOFgidVaGUAAnisi4tAJXAXOeM1v+I2eG/k8tcgE9Ky7YSu7BlJ3c9KAHWNo+0/KFX19qm2gSYGRtpZpGtFAJ5x+VVGcyNuyRnvQBHcsyT5b5i3FXo1VYQ2Mt9KqqpTBkXKnoanEkZXC/doArSwq8ytkgk1K8EkU6tGCVxz71PHtzkYPcVJDceVIDkHccbcUAV9iO5KD5kODVmHa0Jx98VVvX8m9YRJw1Fm7CVsgYPoaAJGZSu7HAqsZiWOB9KazlZHOf3eaCybePXrQBp2d6UR4+uV2/mKwbDw82lyy3OnzSSPM3zLIcjmp4GLSkqxGe9XYbgo3LZAoAadJjN39puFQPw20DjIp13cCSQAdBwAKju7l5MDPHaqx6Ak0ASAbjnHSnuFxzUKPgqN3PfipHYkEe1AENzGohcgYPTisYg56/rW7/AAc4Axgis5lXceD19KANIqPLUZwMc09I1AwvfsRUaur4GccZPOakjJDD5hjOBQA1xjkimAq2MYKt+tSSnccZFFsFD4+UBentQBLLEptsdCeKZ5AiC+Zk4HWrMhUsnIzjNOABiCk5c+/SgDOncF0AXg9KHjVMA5HPfrT5EHmhcZZf1qvfuzsuw/j6UAa/h2cjWFUELGeDWj8TvEsgkstKSFXgdNzFlySenBrn9PLROkinJ71vXOoW0pjeZEaZORuGcGgDT0f4d6EbS11K9LiVkEhTIABPapLvWbazFzbWjsqucbQeB9KxLvWLiZMeaQo6gdKxbpik4cMDmgBdXeSe4LEnaBU9kD5BWq0splUrjOfep7NwFKsdpx3oAk8Uu80ekC4JMEe8ADoDnNW3JktleLPlrgcdqjEkM9s9tecxMch16qexFNgg+xQlftsLRt04OcfSgCLzssE6/XtUAj+1XLyjsfSo3kHmNFbEs7dX9qv6VGY4nL8Y6570AEjt5KxOAdvcVnq4EgHoea0ZJEkDFSOnrWPEXNy244UD86ALNwzTR7QAQeKnis9kCA9O9Nt9khXJOKsTTy5dSoEa4CtnOfXigChcwyQoZBEzoOmKihiimKO64ZTkZHeug02ZGXy2AZHHccisPVN1rdMqfdz0oA7/AOGWoQvPc2zN++6ge1cJ4qu7uHxvdQOGVvPJGe4J4P5Vf8J3X2LUvtSbRIOoz1rstSvNH1WaKe/tUNzH0ccHHpQBz+q/DJdZgS5vppFuScbIl4I7V6D4V0ODQNJS3TAIQBiT0AHSsa48ZRIqpbBegAzVP4la/LZ+EYTC22a6HJBxwOv8xQBl+JvEWiWF8Vt4xOQ3zselaXh7VPDuuIsMLJBdHoD0NeLWu69mMZYNnqM1t6j4T1Hw9p0OphTEH+YAnt70Adx4j0WS0mkZlLJ1B6iuYcICdpxj1rs/BGuf8JR4VliuSGuLYAbj3GOK5fV7REnPJxnoKAKlzN+7AUk4HAojgXyi65LehqNLdjtO/AHQGpbbzUyNy46UATWbBAdwywp/2hY5SyoGPWq5V42IOMYqBmcNz0PpQBYJeaVndeTU9vGMMxUg4xRaMD8xOAOuaZeusLGQN8oX5iScYHNACLbBA4bJyaoywYb5SQPSrgmbHJGMetQ3M80l1LZadJ5N1Hj7XebQwsQRkKoPDXDDkKeEHzN2BAFsxbebeWrvL9qtow0jKoMUTnG2F2znzGBLbQDtAy2MimhstgY96dFbw29rFa2aCG2izsjLFjknLMzHlnY8sx5Jo2kEgc0ANYHAwBzTcZYZ6VKfTPNIRjqRmgCMRg+496JQY1D9qfjYMsR68UeYk8bLwO1ADUIIB4wfaoGtlZidq8nNToi8c4BHQ1JgjjI/OgCIxsiYX0p8KEYJHNJETnmrAxt6/SgCN06+9NQBeTj5Rz705vm5HI9jTWJfgcZ9qAJIpl2NIwByPypitI8gaM4HemuGCBFPWkBYBU/jxQBOVZ5RzyOpFN+0QfaFildEJ6buM06KQW2T/G1VLm0jnlE5Ul15FAFx2jThDhG4yaTaHBwQWH61FFH5iMcDC9M05S6ge/pQBJCkjIwC47ZNDW0jOAE3HrxWpo1sbudY2HXoPWrWrCfS5QWhcWwIHmeWdhP16UAYIt2iXcykt9KrSFi6hQQK7G5hSfThcBQuRzXLTjDsffigB0O1uHHPapTbLIPm49KqiXYdx+92qWKSSQEg8Z6GgCeK3jibKge/rUs8ob5VXC1XRvnwTyKbLLhTk0AQTZVwEPB4psMIE2D3zT02uu/cDg44qzFHuYMTjmgBsKiNgHCgCrPl+cn7vr1FUL1d7sYwUYd6sWkjxQ5Db2X0oAnt0azYlgB1NUdQUXQkl7j0p+oXZkulOTtI5qpkx2F80IYtJwMsTj160AQ6XPtnLDhRWh9oZnYryawNHM0dsxdhh3+UEc4HetrTxwd3fmgB0AJlBboDXY+NdDk8S+BbZ7HLXVquVUdWGOR/KvOLeG+GtySFittt4APBNddoHiG70pwu7KHqp6AUAeY+HvO0nU/9NRhsbJDCu9+JHj6z1jRI4LVSpAyyn1rvb6z8P+I7bffQokrDJkThvzrmF8BeGLctNLNJOBnCscUAUvg1p01h4bv9QuFKRzLtQHv1Of1qPUJPMmLgcE/lU+o+IEtbRLCx+SBRhAnYVnWF3+7xIdzE5yaAK5jd34BIHapPLcocDB7GpG3LLkDgjORWtar/AKMokwepoAwraR45NlxgjoOafOGXhANp5pmpIUuNy885xVmNt8I3dQKAIIlYN8xJBq59neW0eXaTGpCMccZOeP0NUCWViACBXnnjfxX4lT4jWGjeDLa7u5NPtWW8S2j3nfPtZjkgqpRVjwzAhWU57igDv0M6u2mafJ5N1Adt1eYDixU8qqg8NcFcEKeEB3N2Bkjjis4YrW1i8m0jB2JuLHJOWZmPLOx5ZjyTU1vbJZ2VpBBAbWNU3G1MgleJicsXdSyu7H5i4Y5J59AlyjCIuMgAZNADFBBBH51Iq5bPapYEElsHz2pshYcKM4oAikGeApGO9NZc/P6etWJIzjHOTVVgY1I3HBoAcWDAKc8j0qMfKOnB4PrSxgvtJPODSHJwOvtQAsjDchHQdqeHAHaonDbRzim7X9D+VAFpdob1pwI5LZwKhjID9ePeng8tjBFACshkctGdo9KcFbdzx64pYN33Rg+lPmdo2x3I7UAQvGUnJzkU3aNwZsgipEeRYyzqDk8fSmK5YMSvPtQA5gPL3MARSwYbPoTSuCUB9OTRA5XbnAJoAbK3lPgAnPapdqzDAGMVHdDLmQfepLdyDyT70AbnhG5j0/VYJbjJiztye1el6vPa3OlTwfLKJoygUDIORxXk25TGCoqa21e5t/l3kKOnNAHQa7HDpukQ2iODIq85rjIkEhOTmreoXbXTbpX3Enk+oqOLy41yhH0oAoXO0Pt6N796uWqkWuSpJz+lQPKLlihUqB1JHP4VfspvswYDDqwKkGgDNtZlnmYc59ameLfGyj7wNMjgaF2kGAB90U7fK5LhcKTjI70ARIPLTaowO9TCQ4w2R6UwxSOMgcUNEy/NIee1AFolZYyOjY71Hat5KnKn6VBGzebuJBHSrQ+dsgjFAEaxLPKzEEGpriEW9gYgAZD8wpchWwTk+tU72Z8suePWgChZwl328gL+la8cABJHpgYqpB5aKHx83SriSo8ZCj5zzigBs11DDGB3Jxz61UyJJVO7r97FPubduGdQfaq6L5b85xQB0OnsIkbLkKRwM1VnvFknMTSHbnjHFQSTYtwI2xj0rJlkYtuTk59KAL2paesLedt3A85FU8mJldTW/dLtsIRLjle/rWNwxyRwD1FAGl961WQDJPUU6BmVg5PyL0FMeRfsi4OBT7dHuNsK9+9AEF232mXcgwD6VqW8Fva2Ymv3CRqMljVix023s5Ue+mjiXPVziq/xJ/svVNDht9N1O281XG5AwyeOKAH6fLpWrSMmnTpLKgyUI5I+neqWo+cbqUMVjEkpkdIlEas5PLFQACxPU9TWH8K/C2p2Wv8A2q5Di3iy28jAPHSuw154RekkDGc0AYGs3S2Nl5UYBu2XeuR6HGKwP7TvbiIrdp8z4VVQV2V9pcWpCCRMb0PBx27iq/8AZa6Y5lmIeU/dyOBQBXtiIbIRtw/8qVRzk9PWsy+uZPtJIOBVmC5JjDMc0AaDRsQuOTVK5VSxBBGKv2sgkj7596gvYiGL4B+lAFCJQGwAcChm+Y4X6YpxbZ944PvSsSw4A49qAGMTtyB0pd49ajkLiM7FDHP3en603yh7UATMGjJLj5c1IFJywzz6U2S4E8BQnnPXHSpbRcja4OR39aAIElIcnbtI6ip1AkGRnrnPpUVxxLtAPPrSq52EelAD2PPH696SMsMrgc1EwBlBOSDxipZo9jK+4hehzQA8H9xgDJPWoWfYQqjJxQ7liFjxg+lPSIIp5OQeaAJIypHIyajkXBJAxiiIkMwLHHb2qUqGVgp7UAJFJzjBx0p0sRkHU4+tJGgC9eamRj0AzQBAYdke5xnnFRgeYCEGDjrVyTlSoAyexqCWEKQEyG74oAokSI37xWPbrWhaoMf0NQTNIsGJCC3v6Uy2ZsDc340AWp3QED060x5UUfKPlHJ9qbuXeSfmz60+RVaRSmBkdKAGiVm6KSrdMUEsw2kZANSNIqkbcVKG8wADjHpQBmXG5CQeKLeV4wcDI7VZu4S/LEfnVQQqH+9igC55pcqdvfGKbJCzxtkdOaEHlqGYgtnBwaVJDyh4yfWgCvEgKHdwOwqxZSKsjhuBjK4FBdYkGADUYaMuCc5PWgCWRi0hwQQO571AxWSYY4OabzyU4OOmaSJuQSDkdTQBIuFZlYHpWhaRW4UOU564NUGZShGCM+lOEv7gAZzjANAFvV7g3MexBwOABVLTIvMIjYAHuKfEQVGQeaAv2Vg+7DmgCXVI/J2rH0ro/C1jvs5bqUEKils1ycs7Ow8wdehrtvDLm40ye13AbkI/SgDzPSlv/H3jQxB2jtEYgeiIP611fjr4XJFam80K6Zrm1TfJCx+Yj1/Q1zvhHVW+H3ii5i1SEiNyQSR95c9RXqF/8R/DJ0x3hvleeWMqqbTnJHQ0AU/AniFtX8IywXI/0m3GwsB1GODXK6rIzznPPzda0PA1sbTw7c3THabhvlz6Csm+QuzEHigCxYX0kV3GoPy5rW12aO5jBVcnFYmmwIrbpCM4NNspCbllkyygFSrfpQBl3sJaUOVI2gjGf6fhUMROQMHOa3bu281QUzk1s6f4ds4bRbjUZkhTqCxxzQBjWGV+6KnnyY8kfnXd6f4Vsbm3jnt7hXQ8gryKXU/CUE0ZSCdfMA6ZGc0AeZtIJMoQMimt5isBtwMdK1L/AEG90yeTzosrn5WHcVXm28DvjNAFGRCQA/SomkjViD2471ZaYIw3+vXrU3mxHn+lAGbB8pYAZB6VdtRcFm8tSVAqDygvzHgetTW00gDFHYZoAkBLs3mL8w9KhkJEgYA/SpkwFJZssRmosFiTzQA+NTnJzmp5XBjZWGeKrM5Bzk4x2pZBu5yQBQA23GCeDmp8ZqsrkNtzyelWbJWdsLliO3qaAJI7SR+gNTfYXQdOTVHUdRuba3ZraFpdrYOznFWdN1JtRsidrmRfvADoaABYmiY7hnNLFM7yeXHFuYnAAq7okZvrsRAFsdQfSoLuRLXULby4t6SZOUPQe9AGXqFveQO0jttZSNy56VMjzeWGZcsOc1s3FrbC1lkSVppZsDbjJXHOao3uyJcq3QYNAEEri4gA24YcUyPbsKuOfU1JCwK71I57UjMknJIoAaiYyABj1NNc7Qeo96L8MYQbdlD4+Unpmk2v5Kecyl8c4oAjUMJA38I9+tSi4LPtjGD0yaRIyyg5wBU0Uag7iaAI5wVP7znPWqzxqHDKpA71Jdbi/wAjcU0nEQ3t8uKAJYlV/vDntzSXCqAcZye/pUVozb2J+6elEuWfgn25oAVAScYJGKmeMKN3HTjNIjbE3dH9KYfMuOHOB2oAak6KwJU7SME1KIRIo2gDPNV/LJJU/MAe3ap53EIiEZyaALOwRRfOAfeqZdIpArLgHpmnXFw620BmQJKR8yA5wajVo5V3Pk46e1AFwnEZ2LxVWXLN83PoatwyDyM8jHvVRtrPwxzQASAKOBkDpWhoepPYXCMpJHcVQijZHDZJHelyod3zg5oA6fxbomm+MLGP7V+6nT7kin5h/wDWrltL+Gem2Vwst5qDzInIQADNXEu2MeFkIPsaYZZ8EmViexzQBsavq0QjW0tVCRoAAoHArFkG9P1quV2nfIcseaVzISu0ZXHNAD4C5yo6e1XYY8EFwCT1J61RhjZDuBxj9avZJXO4g0AXrGMS6hGmBjIHNcz8Z11eHWYIrbzBbeUvl7env+taMl81tMs+7AXriu50LxFpWt2kf2tIbgKcfMA2DQB5v4O1/XrLS2t9zhWHJNdTpvh/WdSs/t/mcHkDdya7XxZpEN1ock1hAhkijLIkYxvGOnFeWaX8Sr3Tbu3tFgPkxDaY26dfT1oA7fw5r0Wo7tG1dw0w+SORjzn0NYWsWA0/UJY5lHB4b2rn9ekdvES6nEvl+fOrIAMd67XxpiRLOQtlyg3flQByF1EgG5VzkcVWBTA4atG6AVEwevY9qok89T+dAEgPmRFMjOM0W6NH1xQfLZz1GB3prEfwk5oAmlKuBgc96dCipknGFqvGAVzk7unWprcDEiOckigBLWOS7mITbz0A9K3bPw1PclfvDPbir/hHQ4IYft92SuxDkjpgVz154j1bxLqjWGg+ZBbbtq+X95h6k0AdTF4M3cK6GQDpkVA3h66sI7kAbJGjdY37AkcGuT17w/4h8OwpqPmzkIfnkR8la7T4eeMT4iQ6fqW15yhKSgY346g+9AHG+F/J0aN21cgAZDIGGSfWs7T7+S51lm0y3kEGMx7TkE+tdvr+m2VvqMguIQ4B4yM1Y0owyQvbabF5W1dzD7oFAHP2N6bXxFLKVwo4cD3HIqXU00+CZHsiwDMf3bHJX2zW5aafpc1q8sk8QcnByw5NZusaYsLHaBtx1zmgBkErRpI8aDnoKxbrfNNImFznpVpJJUHlRye2TUkccMALSPvlNAEa25SzGQBiqUMJ2OGA61buJ9/AyFNMjwy8E89s0AQ+WQMCngbvlbAPTrVhbUKwYk81K1onD5JNAFWNSBjjFNk3EfKuParoRAQDmrkaQsuKAOeYMFywGetG3em1q2JbJJDkE1XFqI5CAG44zQBRSN1iwQABSEIgDHHHb1qzdbgcDgd+Khe2XzEOSA36UANChsOxw56ClYEnggAVJLDwNoGRVJ1O7kkAd80ATR7426AlvepxADKqvgZGc1EOFBKtj1zT4JELfvCwPRcmgCK8tyjk7txzwKVQxjPygZ71JLLGSMk5qKFj8x5IPGRQA5Q4i2sMgelRnHXGBTtxD5XcV96k3xtH83PNADIJASwOCDTGt3eQ9ADSKEBO0N7U7zAsqqxJLelAEoiWNQAKR5dkqoFzkEmpSyiMKTyf0qEQ7huZj+FACyMHGSBgUQShiRgDtUUiAEr8xHakCxjA5GKALZkGCpUYx2qu9w5G0YHtTgMrwSRnmlNqhw4PWgCvNCbiBo2wpYetTeG9L/sqFgv8TFmyakCiIkkHHQVMZSIhs3UAd14b8QKsawSPgDoetR6vY6W1wbuPRbWa5J3ByTgn1xXDxyeSdxYhjzxVqPUbsRSSozmFGCsx6AkEgfoaANRNNaXUDqOsGNVTlIl6D2xWbq+p/brxSn3B0XNU73UJLhCJJDk1UtIoySdxyOhFAE99+92gYVvaq4sjgfOf0ptyG8xSAWUGk+0Afwv/AJ/CgAw3JA+tTRxloxux68GpVgUw8ketOIRAo7e1AEEYxGTjHapI1O4EjjNPYIQADjBz9aJGVUB6k0Adr4nle2+Hl00aEsYccHpk9axvgSkf2S9cgGbCjJ645z/Suk0qWDWfDLWspGGQo3sK8y0671PwHr0sMiZiz8pI+V1oA9zgEl7ZzxajAqqxZCvZlrxTwXbtY+PIoLQZRbtgpH9zn+lb+ufEd77TDbWUDRXEvyllOeParfgHRzpMb6vqfyXDj92p6gHvQB1er2S3OtW5ZAwDAkHvXnfinR77VPF1zYaVO8UajaEVsbu5yfStnx1rmoRWBuNFYtPkcqMkD2rlNJk8V2uq2muJbSSPOCJA6k557jtQBlxeDPEGj+JIbO4l8y3dlIKtnAJxXseuaAxskS2+cRoFHrwK5XX9YvLWWPUL5fLnIVljIIA9K5uX4qagL8M7IIw3Kr0xQBbv7d7V2Dgrg81T83KjB5969A1hLbWvD0GqQKAJFBOPWuB8sSMVHAzQBMilsAYNXIbcIASMnGTTbCMIDuP0NOnmAztb2OKAGvJmUKv3RxUNzcmJueQaYzjkg8imuoMe4nJxQAC5Z1XmnrdFATn86z4yUbB6A1owwxyoNz7SfUcUAS2l/ngkda1LUJJI5Y5DYIHpXEzF7e8Oxiy7sCtiz1QwyhWGMUAdNcWKtlguMCuau0ukuVA/1QbLZHauh07VYpsrITyOKtXFrDPGyrySM5NAHKzbnUcbRUMieYMdhU12rQzMkm4AGoSpWN2zwP1oAlYmIY4ZAOaYgi2liQpOSTUcQaZflY5P60ksAMRYk7scYoAVQHfKAMpP5VOrRRsA/wAufyqhZMYyFfOM9K0r5YbkqF6gfjQBFIoZt0XQUzA2cY+lNRJI1Ck4SpIwG3bei+9AEaqW6DJz0qV4tgLY5pCwibORxT2BdAxbigCnAzGV965FW1fKYA4FV9481h+vrUqMoi64waABQz88Uwoxb7oANWAcJuXoaaZR79OtAEcEJQnLZp0W6P5D1HrTFdi4x+dKzhpSQTnHegC0w5+bGD2pJnAhC8A5qGM56tROPlGDmgBsrGRBjBx0Nefax8Qf7L+Luk+GnuAukrD9jvst8ouJ9rBj/wBcyIQfTEg7mu+hkEZXAyQc4bkH61Fe6Xp11fxNNp1i/wBpstTmmDWyESObnTSWYY5J3NyfU0APngZZWR1KkHBB7EVKiCNSAO1WbyRp5GlcgvJ8zEDGTVQMTnJoAQErg/lRuXuf0oL4ySai680AWEdxIuP4v1p8qbipUj8TVYPlRjIbt7VLHp11cjdAHdaAJ/ILoCB1FVJlkiGFBIHWp4LhrKTZOC2DgitadIbmAPEuAetAFLR9dk01lGflJ5FdaNQsNUhX7XHFLx91xnH0rgrm1RGOPvA9DU0G4LuViAKAOyVdJ05/OtrKBJOucZxWVq2sPdtjdgVkPK7IQzE596hRRnkkgUAWxcspUckdRXUeHPE+y7jhuANh4z6VxhOGKnI9KkgYq5IHfg0AdP8AF3Tp721hu7UGSILt+TnFeEjSr651DyooJCzHH3TXvOjeJRHCLe6XcvT61ee+0iMGdIAZOxIFAEVrF/ZPgeysJz+9CDINcosfzsQOKva9qj3sqsxIGMAVTgIEZ6kUAMUSZbJBXpnNQOhU4HQ9akkk2njqaI5FPBH40AUmjkWXIzj0qeORZFCDnB65qXHmPhM/jU2l6f5ly2AwxwRjg0AQNamRwcYA5NTmxxnliMcEetdNFpeyPIQk1Ru4HgUllIA6cUAY1vost2M45HNVdQ0a6t7gqUJxXRWGprHuLZBpt3rMTzsWbnjrQBgW8M0LDCkMPUVu6fdsUCueegJrTtJtOu1Tfjd3q1DoUc6ySwMcDkKKAOe1GISy4x82Kz/sjNGyHgHiti8iMMrh8jacE1z8168dy0SAuQe1AE1rE0ERDKDtOOKjkLAgAAHNU5tYjto2klyEU4Ye9bJeGeziuOdrqG6c0AV1tPl8w8HuKiSATyEhyjLx9aBqAunMakqE44qa02+Ywc5HvQBTuZXU+XuXg4qawAaNywG7rUEiLJIxXJINOtvlY9aAI3IaXbjK9/arSbUQqTlf51ANu8kZwal++hUDHpQA8LAOoGB+dQNscjYKiKNkjJJ9qdGoDAnPFAEkaMFCscikkQk4HbgU9/nGOcVDI/llcHJoAkUEL0z70Rrg7sAURsCMEED3pXIGAM+lADZUYOMcZpTGdhJOalIyc9sVIdqxdDntQBRSPnPOMd6njk/4mFgxxgadqI/8mNMplywaMogPT8ahiQRvYR/MQmm6iuWOScXGmd+9AE8pLKMHBxUCjHB6ninxyw+Wpbdlm2rgE8+/pTnxjC0AV3GCcDimgnH3lqZyrcNUXlr6GgCxNEoYfMOvSut8P39raxCGdQeOcdcd8Vz+s6PIjx54Paq0dsy3AYuQy9Oe1AGj4m0ZtP1VtWjZZtHlXMeGzkkZ5pdLZXtvPBCxkcA9KJ3nutOaySTFm7+Y0Z52t7e1R3LrHBHBEpCIOfrQBTu4tzkhhkn60JE64TgjOageXaFOcg859akinJmO4cAUASNbsCGHT2oVAGwSBVpZNyDA49cVHNGVYPjrQBDcwgqZGYenWmKEWMhT2zVldrR89KryKqtlM88GgBkW5j1yfWpxKQNrEYz60yFMklQavxWXng7UO446UAZksh3DOPSrigiHAI9auDRZQNwVjg1DNbPGDuBzigCqw3g7iMfWmKuwY+U+9V752j2Yzjk4qaKVHhTB3MRk+x9KALtjCWcNkYIrqtCtkjG98fU+lczZfeAGeD3roreUbdq5HFAHT2c1uXAYrzmrGo6bDdxNhQHxxXOWOmz3TLtzGueXPauyQbUVc5wMZoA8n1qxktZSmwYQ/MR1rk7iG4FwZB9zr1r1rxXa+fcxCNWIPD4rihpNumrFZZmTLbRngfSgDC0eef7R++OFzwc9K9e8NKZLX5WXYR1B5zXCatoDWamWF90R53Vs+DbxYXCyzbB0HvQBoeJ9NG4tH0J+asOwisbe+PmqPMYYBxyavTwTvrstzcT3L25bdHH0TFZd9Ck2pM3TuAO1AHPa9YtJqzB4k8l26Dpit7RLS2u51trqURQqMdaq69cxW6IkasbhR8w7fWs6znW5WLOUeTjPvQBn6nbGx165S0bdDv8AlPqKtTSsV2qG3kdzXRW2lRpcKZgHCjIPesi/ureDUGVYiR0J9KAKls6xkCThuOc1PdbUjJGAW6e9XLi0jIEqD5WUGsxnEoZQM4PBPagBbdS68kcdDV6KMcgleOc1UVAgCrnJqYDBzzQAs1uyfMrDmoCjFhvI/OrCziN9rA4bpUc20HAHFACwuFJUY4/WoZoONzEBuwpIAC+W6CpZiSD12jnmgCAxgBCSAR0p7IRzkUsirOg7HHFOaIrEGIxQArEhcAj86cj71C5G4DpVaVWOGHFOiVgTnJH8qAEhBBbeRk9TUkgzfWIUgj+ztR/9KNMqGUEkEZq3bXM8Vo9uJZBA53NHuO1j6kdOwoAgVVRVVAAc9aV1K915qGZ0jkVnDYZgg2qTyenT+dTSEcKBjFAEDryM4Az1qMocnkVPt6e3pUf40AdXfSfadAWSVh58LbCfWubspDJOA+WKnlumeK1dVcw6d5GCZCTI2Tjr296ybfAJZBzjrQBemlIB2MDkdMdKpPIzOjMdpAOKaHdXPHNTEDa5kPQ5FADVVptyOEx1BH8sVBdxFI8xkMBjkdxSI7h1aMkcHIPrVgONxB5z60AQWsjpG7SfezwfatKCVJkAYjI9aSKyUru2/L1NJbNZvI6Qzxs6nawB7+lAFfeTLsiHI5IA7Up3l+OlSPbmGUvg88ZB7VKoUqM4yeOKAGwKUx+Zrd069WPQr+eOJjPHG5XcMZIFZce1GxjNdl4XNrLZy28wXbIu0g9waAOD8BeMLxdTS21koYLhsLu6jPGfpmvUr/RLO9G5SEJHBXoa4q2+HVjbeIJtYv7sGwjIaOL1x6n0+nWm654/02PUDbRw3EaxrlZl4H0oAk8R+GJbSEyAGSIcgoORXMR2/lMBye/0r1XwzrFtr2l5V1kI+Vge49a5DxZpqabe/KD5b/Mp9KAMeEbBv7mtnSGLTJyBk+lYbOpC4JrT0iVPPQHIAYUAd6upWlhaQLI4Tc2xQe5rRhAG6XzGZX5GTwPpXDeKxayQ2a+YVkVyVXPvXUaFdx3diIkZiyKAW96ALV+pyN0ZkiIOQo5z2ryrW0ll1Ce1lLLF99WZcMrfWvV/7Qt1Lo8oEifeHeua8RW0V/PBcQmMluGGQDQBxPhzV2s4zp+oyNKpztLHgV02k2cEoMq8AnPFc7r/AIUAubYi52DG7aRg5zWvpDwWZcxzFwF2kZ6GgDrtRWWSwUwoCgGAfSuG1IXEN6ZXChB0Yd67OS9VtBBRW3D071xEl8ly5juAVYN37fWgChriHUZBcthMDbgDGfeqMdn5c8UyN+6Q8Zrc1PAtCF5A6Y71hgzXenSoAyBfTrxQB2Wkzxz7DIRtJx+FZXxHRba4ih09oFRgPlxyT65p3hCBZvLhmk2A/wAR7VBrdlA2qSqzbzbtww70AMsd39n/AL1suRgj0rPlCJMM8cZOK1LiVFyqgAkCo4EBtXKLGZ2IGXGQB34oAroEnKtGR07U6RQOpFZ/2a+0/XlRNkli4yWBwR+FaOxWYlv50AUpmBnVSc4PanT8ncKs7IywUgBj1Y1VheMyMj8hTjNADP8AVnJx9at7g9mSy/MR2pk0KFxgDFNuMRwsB1z2oAqxu2Qq8r/dI6VMLgOwRgRznmmQsNgBGW3bt39KsPDG2GKjPfFADpymVK4z6Uhk+U4xgdTRIkaR5AJNVnIMR2ADvj3oAcrZOMinODzg1FbL8ueoJBz3FTOdxOeCeOaAIQ+DgcEU4fMM5FVrhir89CBmpPn8tBGVC7vmyucjHb9KAHFR1PangcdF/OmkcEDqKCmeQRz70APu5TNJvZs9wCeRRbZLOMDj9agjeN4nkCNlWKcqRkjr1p8EnkWxaQDcfagBZHEcpAwQeme1Slw5VcgA4/H8KqWzMXJZOR0OOKnnx8hx86nIIGaALgQAAEhgvDE9TVIyt55SRUVN2I2DZ3D1PHFKjsiqw5zkYzx+JqN5luUAVA2DnevTg4IoA0opZRLGiEsjdjVW38KW8d9LcFjFCTu2g8Z9au6aEnZUkXDdMipdUt7qGdE/1qHkKzbc0AW7rTi1urIwYbaxHRreXnjB610FvqDSWMxudPNr5fCnfndWKtzFelhg7h39aAJUmDAEHNbunbliHlkZb1rl2zE2CO9a2mXgyo2EsBndxxz0oA6jxSJZtE0p0P8Ao3Amwf8AZ4P86wLHwfpWvRzrLOyXWSBtP3h2yK6vSLiz1LSjp87BM52g8d88fQ1zl3pmqeHtTkvLIF4v+WcaDduwP0oA5Twwup+GvEp09D8sbbX5yCO2K9M8fRh9MhbaN+6uG8L2V/f+MxdXsLKZ5fPfI4UdSP6V2vju5Ajih25GNx9qAPPNzo+Mcd6vWkjLKhA4Jwcmqed77sHHqKsREKQGGcigC/4utZL+xtZrNSbmB/3hBzhPpW/4Q1RLe1Vr2URqo2njGfrWJp14fPbzmOGXYw6ZWqms2aXYaG0cqu7bsJ6+9AHcR6Yk891qkU3ntJ/q+egrN03TdPu5Jrlrt/tkWARvGF+grP0q11aw8N3FvbTxsxXALtzj2rN8N29/pd9NJdQo8MqYI3Z5oA7DxZp0M1lbzySORGNpbPJ44rzu2dY3eOPOM55PWuz1vVFu9MWzCkEjP0rjbS2JlIKkEGgD0nw55dxovkzkHK5H0rjNVskjvXZCOTW3aXK2ViCAQxXArkdTvHeUlVwu6gCO/mZowkbdOpzRYiRIgN/DHOahiRZkKgHr+NaoijjiGRwooAUNLGqCJRlTywPWmSZMu98Lnlie9AuVT/Vg89hVeSQzyc9Ceh7UAR3DN5m9ScD0oWdtvJwB6d6kVgJtgweKJ4F2ZAoAa8mdvJLY4qgtxJHNhj8vpU8TDfhwafqCRiKSQKAVXIHqaAES4ilPlsRnHBpbW3j3FmC4zxgVlRRNJLFIqkEjkGthSIkyV+6cc0AEzFTkcqKSNDIC7H86r3U5LgLjnk1MsqiELjmgBD8p4wBTlbd0PHXNMypPTPrSFgoPymgB8rbhjI54qBuEC+lOIyoNRsQD0NAE8BIU8D6jinY9M1XDrHjJ4JPXtStOoXCck/pQAy4jL43EEjg59KdFuCDPOOlMDbic8j3pyH1zx+tADzntgGoTImeXGfrTXuF3lR/+qs9nlDEbY+vfNAGnIweBNvKtyvvSxRtLGS2DjmiigBtsSpPzZJHenSyO7lVIAxg4HeiigB2wLEC3XgewpqEqWG7PbkUUUAWbGYDlMgr3rolvobmARXSZ7A45FFFAEsH2NbKcO7uAPlyK4u1gdLmaSFiYy3Q0UUAX3cMoXHSn2zeXIWHXoaKKANOAs7Ao5BrY0tr6KXd5oKeh/wA+1FFAG5daxBptsZBGGnI6ha4bU9UuNRmeSTAYjtRRQBXstpiX+916VZWI7uTmiigBL+PyIlZTzTtOj8wq7MC3OQRRRQBcujOi4iJCk9M1BFLLJMBKSAo9aKKAEedpbhiP4eOas2UILbnHNFFADNXugsewZJ6VmW8Ku5Z84H60UUAPSJIJN6jApbudSmAeo7iiigDOwyqXjIyOgpLKB3k3OflPJoooAnkgVvMdJDuU7SMe2at26l7dt5zgZNFFAGSu55CegzijVEAtwxfaucZoooAbArKgLfeHSpW+YYZvfpRRQBBdMo2LGMkdSamjKmHmiigAydxxgCkY9euR2oooAYJMHb3okYBSwHPYUUUAQvKoALMRzjgVG1zGg+ZgPwNFFAFeXVbRYpN8u3aeDtPP6VU/4SbSUXD3WOo/1b/4UUUAYreMtFt7gl744wR/qn/+Jpf+E98OH/mIH/vxJ/8AE0UUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Phase contrast microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scanning electron micrograph showing dysmorphic red cells in urine sediment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning microscopy showing dysmorphic red cells in a patient with glomerular bleeding. Acanthocytes can be recognized as ring forms with vesicle-shaped protrusions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hans K&ouml;hler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8359=[""].join("\n");
var outline_f8_10_8359=null;
var title_f8_10_8360="Eosinophilic fasciitis";
var content_f8_10_8360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eosinophilic fasciitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/10/8360/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8360/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8360/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/10/8360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8360/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/10/8360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8360/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/10/8360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic fasciitis (EF, also called Shulman&rsquo;s syndrome or diffuse fasciitis with eosinophilia) is an uncommon disorder of unknown etiology and poorly understood pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/1\">",
"     1",
"    </a>",
"    ]. EF is characterized in its early phase by limb or trunk erythema and edema and later by collagenous thickening of the dermis and subcutaneous fascia. Eosinophilia is a prominent laboratory finding in the early phase. This topic will review the clinical manifestations, pathology, diagnosis, differential diagnosis, and treatment of EF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EF is characterized by symmetrical induration of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The onset is typically acute, and findings include erythema, swelling, and induration of the extremities that is accompanied by eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/4\">",
"     4",
"    </a>",
"    ]. A subacute course may also occur. The thickening and hide-bound quality of the affected skin is similar to that seen with the scleroderma-spectrum disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cutaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all patients with EF have clinically apparent symmetrical skin involvement. There is a temporal evolution of skin findings. Initially, there may be marked, nonpitting edema of the extremities. With progression of the disease, the swelling resolves and is replaced by symmetrical induration with puckering that gives the skin the texture of orange peel (peau d&rsquo;orange). While the initial edematous phase may be indistinguishable from early sclerodermatous skin changes, the irregular, woody, peau d&rsquo;orange texture of EF is distinct from the smooth, shiny skin surface seen in patients with systemic sclerosis or localized scleroderma (",
"    <a class=\"graphic graphic_picture graphicRef65829 \" href=\"UTD.htm?26/37/27230\">",
"     picture 1",
"    </a>",
"    ). Skin involvement most commonly occurs on the extremities, neck, and trunk. Sclerodactyly, the hallmark of systemic sclerosis, is absent in EF. Moreover, the skin of the hands and feet is generally spared.",
"   </p>",
"   <p>",
"    Elevation of an affected limb, which reduces the distending venous pressure, causes visible indentation along the course of the superficial veins. This physical finding, referred to as the &ldquo;groove sign,&rdquo; is probably due to the relative sparing of the epidermis and superficial dermis by the fibrotic process coupled with the relative immobility of the connective tissue around the remainder of the veins. Thus, the superficial layers of skin can bow inward as the peripheral venous pressure falls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Articular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory arthritis occurs in a substantial minority of patients with EF. In one study of 52 patients, 40 percent had arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ]. However, limited joint mobility may also be the result of thickening and loss of pliability of overlying skin and fascia. Joint contractures may result, sometimes occurring in the absence of typical skin involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/6\">",
"     6",
"    </a>",
"    ]. In the series of 52 patients cited earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ], 56 percent had flexion contractures of the joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Endocrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroiditis has been reported in association with EF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. It is uncertain whether there is a causal relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial and peripheral neuropathies have occurred more often than would be expected by chance. Carpal tunnel syndrome has been a commonly described peripheral neuropathy in association with EF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5,12\">",
"     5,12",
"    </a>",
"    ], occurring in 12 of 52 patients (23 percent) in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ]. In one case, EMG and nerve conduction studies characterized a peripheral neuropathy of the lower extremities as being due to mononeuritis multiplex [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Muscular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle pain and muscle weakness are common symptoms in EF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/14\">",
"     14",
"    </a>",
"    ]. Deep skin and fascial involvement merging into perimyositis may occur. However, inflammatory myositis is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one series, hematologic disorders other than eosinophilia were present in 5 of 52 patients with EF (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ]. Hematologic abnormalities that have been described in association with EF include [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5,15-20\">",
"     5,15-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aplastic anemia",
"     </li>",
"     <li>",
"      Acquired amegakaryocytic thrombocytopenia",
"     </li>",
"     <li>",
"      Myeloproliferative disorders",
"     </li>",
"     <li>",
"      Myelodysplastic syndromes",
"     </li>",
"     <li>",
"      Lymphoma",
"     </li>",
"     <li>",
"      Leukemia",
"     </li>",
"     <li>",
"      Multiple myeloma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of lymphadenopathy is unusual. In a review of 10 patients with EF and enlarged lymph nodes, six had lymphoma, and four had reactive lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/21\">",
"     21",
"    </a>",
"    ]. Skin changes and lymph node enlargement were contemporaneous in the patients with reactive nodes. In those with lymphoma, the adenopathy appeared months (2 to 36 months) after the fasciitis was noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Visceral",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to systemic sclerosis, internal organs are generally not involved in the fibrotic process. In the series of 52 patients, none had evidence of pulmonary, renal, cardiac, or gastrointestinal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A majority of patients with EF have a peripheral blood eosinophilia. Peripheral eosinophilia is transient and may only be found during the acute phase of the disease. In one series, 33 of 52 patients had eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ]. Serum antinuclear antibodies have not been reported to be present in EF with any consistency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/3\">",
"     3",
"    </a>",
"    ]. The erythrocyte sedimentation rate (ESR) is sometimes elevated (29 percent), and there is often a polyclonal hypergammaglobulinemia (35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ]. Serum levels of creatine kinase (CK) are typically normal, even in patients with myalgia. In one patient, serum aldolase was elevated while the CK was normal [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral blood eosinophilia and other abnormal test values tend to return to normal upon initiation of therapy with glucocorticoids, independent of improvement in the cutaneous involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) may be of value in assessing patients with suspected EF. Increased T2 signal in the subcutaneous and deep fascia and enhancement of these structures on fat-suppressed T1 images after gadolinium administration have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/6,22-27\">",
"     6,22-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In atypical cases (eg, fasciitis without skin changes), MRI may be useful for guiding the skin biopsy and for monitoring the response to therapy. Administration of gadolinium-containing MRI contrast agents should be avoided in patients with moderately to severely impaired renal function (eg, estimated glomerular filtration rate &lt;15 to 30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p>",
"    If gadolinium-based imaging must be performed in a patient with moderate to severely impaired renal function, there may be a role for dialysis to reduce the risk of development of nephrogenic systemic fibrosis (NFS). Causes and approaches to prevention of NFS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in the course of the disease, the deep fascia and lower subcutis are edematous and are infiltrated with lymphocytes, plasma cells, histiocytes, and eosinophils; these features are generally associated with an impressive peripheral eosinophilia. These structures and, eventually, the dermis become thickened and sclerotic as the illness progresses, with disappearance of inflammatory cell infiltrates (",
"    <a class=\"graphic graphic_picture graphicRef68370 \" href=\"UTD.htm?13/48/14084\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/28\">",
"     28",
"    </a>",
"    ]. Peripheral blood mononuclear cells of patients with EF have demonstrated an increased capacity to produce IFN-gamma, IL-5, and IL-10, possibly contributing to eosinophilia and immune globulin overexpression [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infiltrating eosinophils in the fascia degranulate locally, resulting in release and tissue accumulation of cationic granule proteins with toxic and potentially fibrogenic properties (",
"    <a class=\"graphic graphic_picture graphicRef76113 \" href=\"UTD.htm?0/16/259\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/30\">",
"     30",
"    </a>",
"    ]. Mast cells and their degranulation product, histamine, have been found in affected tissue as well, and elevated circulating levels of histamine have been noted in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/31\">",
"     31",
"    </a>",
"    ]. In culture, fascia-derived fibroblasts show increased collagen gene expression compared with fibroblasts derived from adjacent dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic abnormalities are also frequently found in the subjacent muscle. Thickening and inflammation of varying severity occurs in the epimysium, in the perimysium, in the endomysium, and, to a lesser degree, within muscle fibers. This was illustrated in a study of 15 patients with EF who had muscle biopsies that were compared with biopsies from 94 postmortem controls [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/33\">",
"     33",
"    </a>",
"    ]. All 15 had some degree of inflammation of the epi-, peri-, or endomysium or of muscle fibers. With routine histologic studies, the inflammation in EF in or around muscles could not be distinguished from that seen in other idiopathic inflammatory myopathies, such as polymyositis or dermatomyositis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of EF is unknown. The following have been suggested as possibly important causes of EF:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Strenuous exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Initiation of hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Infection with B. burgdorferi [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Radiation therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, most cases are not associated with these factors and are considered idiopathic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EF is suspected when characteristic skin changes occur in an individual with eosinophilia. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical features that are useful in differentiating EF from systemic sclerosis and other scleroderma-like disorders are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raynaud phenomenon &mdash; Patients with EF do not have digital vasospasm triggered by cold or emotions (ie, Raynaud phenomenon), in contrast to those with systemic sclerosis, in whom Raynaud phenomenon is universal.",
"     </li>",
"     <li>",
"      Visceral involvement &mdash; Symptoms suggesting the presence of esophageal reflux or of an esophageal motility disorder, pulmonary fibrosis, or microvascular injury are uncommon in EF. These symptoms are more suggestive of systemic sclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When EF is suspected, the diagnosis should always be confirmed by a skin biopsy. This generally requires an elliptical full thickness incisional biopsy of skin and subcutaneous tissues down to the muscle surface. If there are clinical features suggesting an associated myopathy or myositis, muscle tissue may be obtained during the same procedure.",
"   </p>",
"   <p>",
"    Although there is no pathognomonic finding of EF on biopsy, the finding of compatible changes in the deep dermis and fascia early in the disease or throughout these structures later in the course is helpful in ruling out systemic sclerosis and other scleroderma-like disorders (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Pathology'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359650145\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI may be helpful to confirm fascial inflammation, particularly when the biopsy is nondiagnostic or when a biopsy cannot be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized scleroderma, limited and diffuse cutaneous systemic sclerosis, the eosinophilia-myalgia syndrome and other scleroderma-like disorders are included in the differential diagnosis of EF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Localized scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized forms of scleroderma include morphea and linear scleroderma. These generally have a slowly progressive course, and are not associated with significant eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Systemic sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin changes associated with systemic sclerosis may be difficult to distinguish from those of EF. The various diseases that share skin sclerosis as a hallmark are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief summary of some differences between EF and systemic sclerosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of the Raynaud phenomenon favors a diagnosis of EF, since the overwhelming majority of patients with limited and diffuse cutaneous forms of systemic sclerosis have or develop Raynaud phenomenon at or near the time of the earliest skin changes.",
"     </li>",
"     <li>",
"      Nailfold capillaries are typically normal in EF, while dilated capillary loops and avascular areas observed by capillaroscopy are suggestive of systemic sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to systemic sclerosis, the fingers, feet and face are spared in EF.",
"     </li>",
"     <li>",
"      Internal organ involvement (eg, pulmonary fibrosis, pulmonary hypertension, renal crisis) is frequent in systemic sclerosis, but absent in EF.",
"     </li>",
"     <li>",
"      In contrast to systemic sclerosis, EF is not associated with serum antinuclear antibodies or SSc-specific autoantibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Scleroderma-like disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin thickening and decreased pliability similar to that seen with scleroderma and EF may occur in the following scleroderma-like disorders:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nephrogenic systemic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with advanced renal failure (dialysis-dependent or estimated GFR less than 15",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium and perhaps erythropoietin may be associated with nephrogenic systemic fibrosis (previously called nephrogenic fibrosing dermopathy) that most often occurs in dialysis patients. The clinical manifestations of this apparently novel syndrome resemble EF but are distinguished by frequent involvement of the hands and feet and the absence of eosinophilia and eosinophilic tissue infiltration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Scleromyxedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleromyxedema is an idiopathic disorder that may occur alone or in association with malignancies. Skin thickening is due to the deposition of an amorphous mucinous material in the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/39\">",
"     39",
"    </a>",
"    ]. The presence of waxy yellow-red papules and a serum monoclonal gammopathy are characteristic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H31#H31\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Scleromyxedema and scleredema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Scleredema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse skin induration without evidence of inflammation on biopsy is typical of scleredema. These skin changes may occur in patients with diabetes, typically those with long-standing insulin-treated disease. Scleredema may occur in the absence of associated diabetes mellitus. Associated plasma cell disorder and a monoclonal gammopathy have been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H31#H31\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Scleromyxedema and scleredema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Eosinophilia and skin thickening",
"    </span>",
"    &nbsp;&mdash;&nbsp;When significant peripheral blood eosinophilia and skin or fascial thickening are both present, the differential diagnosis is more limited; among the diseases to be considered are the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Eosinophilia-myalgia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathology of skin and subcutaneous tissue in eosinophilia-myalgia syndrome (EMS) cannot be differentiated from EF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'L-tryptophan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are some features that may be of value in distinguishing the EMS from EF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cases of the EMS resulted from exposure to a contaminant of the dietary supplement L-tryptophan used principally to treat insomnia. The illness occurred in an epidemic form in 1989, and subsequent sporadic cases have been rare [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/40\">",
"       40",
"      </a>",
"      ]. A related supplement, 5-hydroxytryptophan, has also been suggested as a cause.",
"     </li>",
"     <li>",
"      Myalgias, often severe, were commonly seen in the eosinophilia-myalgia syndrome, and remain a criterion for classification, whereas they are infrequent and mild in patients with EF. Nonpitting edema that evolves into induration with a peau d'orange appearance in EMS is similar to that seen with EF [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Visceral involvement, such as pneumonitis and neuropathy, may occur in patients with EMS, whereas these are uncommon in EF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Toxic oil syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adulterated rapeseed oil was associated with an epidemic illness in Spain that was characterized by symptoms of dyspnea, myalgia, and arthralgia; physical findings of limb edema, chronic scleroderma-like skin changes, livedo reticularis, neuropathy, and joint contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Other clinical features included pulmonary infiltrates, prominent eosinophilia, and elevation of serum CK [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used therapy for EF has been glucocorticoids, usually starting at doses equivalent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1 mg",
"    <span class=\"nowrap\">",
"     /kg",
"    </span>",
"    per day, although there is a lack of randomized trials to evaluate therapies for EF. There is often a rapid resolution of the peripheral blood eosinophilia and normalization of the ESR. Doses are reduced as the affected skin softens. If symptoms and signs of EF do not improve and eosinophilia persists, higher dose glucocorticoids may be necessary.",
"   </p>",
"   <p>",
"    Relapses may occur, and many patients do not respond to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5,44\">",
"     5,44",
"    </a>",
"    ]; thus in some patients, other immunosuppressive or immunomodulatory agents are required to obtain a therapeutic response",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as glucocorticoid-sparing agents. In patients with no evidence of a response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at doses of up to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    given for three months, we use low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 to 25 mg once weekly) using the dosing employed in rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other alternative therapies include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , although there are limited published data supporting the use of either agent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"     5",
"    </a>",
"    ]. A three- to six-month trial of one or the other of these agents should be sufficient to assess the clinical response.",
"   </p>",
"   <p>",
"    The usual duration of therapy once remission is achieved is four to six months, depending upon the clinical response.",
"   </p>",
"   <p>",
"    Treatment of glucocorticoid-resistant disease is largely based on anecdotal reports of successful use of the following agents and on retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/5,44-53\">",
"     5,44-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       Hydroxychloroquine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"     </li>",
"     <li>",
"      Intravenous immune globulin",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"     </li>",
"     <li>",
"      D-penicillamine",
"     </li>",
"     <li>",
"      Psoralen-UVA photochemotherapy",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      A",
"     </li>",
"     <li>",
"      Antithymocyte globulin",
"     </li>",
"     <li>",
"      Bone marrow transplantation (in the setting of aplastic anemia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical release of joint contractures in combination with glucocorticoid therapy has been utilized by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/54\">",
"     54",
"    </a>",
"    ]. Others have resorted to surgical fasciectomy in patients resistant to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/55\">",
"     55",
"    </a>",
"    ]. Surgical release may also be necessary for some patients with chronic carpal tunnel syndrome that does not respond to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of the recommended approach to diagnosis and treatment of EF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359650344\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EF is characterized by symmetrical induration of the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. The onset is typically acute and findings include erythema, swelling, and induration of the extremities that is accompanied by eosinophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/10/8360/abstract/4\">",
"       4",
"      </a>",
"      ]. A subacute course may also occur. The thickening and hide-bound quality of the affected skin is similar to that seen with the scleroderma-spectrum disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359650304\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough medical history including questioning about exposures to potentially toxic chemicals, use of food supplements that have been associated with eosinophilia and skin thickening (eg, tryptophan or 5-hydroxytryptophan containing products), review of systems seeking symptoms of Raynaud phenomenon, gastroesophageal reflux, dysphagia, or dyspnea, that suggest visceral involvement (unexpected in most cases of EF and more suggestive of systemic sclerosis or a scleroderma overlap disorder).",
"     </li>",
"     <li>",
"      Physical examination should include a careful assessment of the pattern of skin changes with particular attention to the presence or absence of orange peel-like puckering of the skin (peau d'orange appearance), assessment of the distribution of skin changes (eg, sparing of the digits favors the diagnosis of EF while sclerotic skin changes of the fingers (sclerodactyly) or toes is more suggestive of systemic sclerosis), and nailfold capillary microscopy (normal findings favor EF while dilated loops or vascular drop out favor systemic sclerosis). Affected limbs may be elevated to assess for inward bowing of the skin over peripheral veins (the groove sign) as the distending pressure is reduced.",
"     </li>",
"     <li>",
"      Laboratory findings suggestive of EF include transient peripheral blood eosinophilia, elevation of the ESR, and the presence of polyclonal hypergammaglobulinemia. Antinuclear antibodies are rare, and systemic sclerosis-associated autoantibodies are not seen. Muscle enzymes are typically normal in EF, and marked elevation of CK or aldolase suggests myositis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       scleroderma/myositis",
"      </span>",
"      overlap disorder. A full thickness skin biopsy reveals inflammation and fibrosis of the subcutaneous fascia and the deeper dermis.",
"     </li>",
"     <li>",
"      While there are limited data that bear on the clinical utility of noninvasive imaging techniques, there are anecdotal reports indicating that MRI can demonstrate abnormalities in affected fascia. Both unenhanced T2 and fat-suppressed T1 gadolinium-enhanced images can localize the affected tissue and can potentially be used to follow the course of disease, particularly if deep fascial involvement is not accompanied by classic skin findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359650408\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids are the mainstay of treatment of EF. Doses equivalent to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day may be useful initially for reducing skin edema and producing rapid skin softening. Clinical improvement is generally accompanied by a resolution of the peripheral blood eosinophilia. If there is no improvement in the fasciitis and the eosinophilia persists, a higher dose of glucocorticoids may be needed. If glucocorticoid therapy is successful, skin and fascial thickening generally regress and may resolve completely.",
"     </li>",
"     <li>",
"      Given the uncertainty over the cumulative dose of glucocorticoids that will be necessary, it is appropriate to initiate prophylactic measures to prevent glucocorticoid-induced bone mineral loss (eg, for patients without risk factors for osteoporosis other than glucocorticoid use: calcium and vitamin D); for patients at higher risk for osteoporosis, consider baseline determination of bone mineral density (BMD) and use of antiresorptive agents appropriate for the patient's age and sex. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of glucocorticoid-resistant disease is based on case series and anecdotal reports of successful use of a variety of agents, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , and others. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For disease that shows no evidence of response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at doses of up to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      given for three months, we recommend using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      . A three- to six-month trial of one or the other of these agents should be sufficient to assess the clinical response.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/1\">",
"      Shulman LE. Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 1975; 88:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/2\">",
"      Rodnan GP, DiBartolomeo A, Medsger TA Jr. Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 1975; 18:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/3\">",
"      Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/4\">",
"      Varga J, Griffin R, Newman JH, Jimenez SA. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. J Rheumatol 1991; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/5\">",
"      Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/6\">",
"      Huppke P, Wilken B, Brockmann K, et al. Eosinophilic fasciitis leading to painless contractures. Eur J Pediatr 2002; 161:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/7\">",
"      Bachmeyer C, Monge M, Dh&ocirc;te R, et al. Eosinophilic fasciitis following idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Hashimoto's disease. Dermatology 1999; 199:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/8\">",
"      Farrell AM, Ross JS, Bunker CB. Eosinophilic fasciitis associated with autoimmune thyroid disease and myelodysplasia treated with pulsed methylprednisolone and antihistamines. Br J Dermatol 1999; 140:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/9\">",
"      Imren S, T&uuml;z&uuml;ner N, Yazici H. Eosinophilic fasciitis with thyroid disease. Clin Exp Rheumatol 1988; 6:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/10\">",
"      Boiesen M, Keiding LM, Thomsen K. Eosinophilic fasciitis. Report of a case with features of other autoimmune disease. Dermatologica 1983; 167:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/11\">",
"      Smiley AM, Husain M, Indenbaum S. Eosinophilic fasciitis in association with thyroid disease: a report of three cases. J Rheumatol 1980; 7:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/12\">",
"      Jones HR Jr, Beetham WP Jr, Silverman ML, Margles SW. Eosinophilic fasciitis and the carpal tunnel syndrome. J Neurol Neurosurg Psychiatry 1986; 49:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/13\">",
"      Moriguchi M, Terai C, Kuroki S, et al. Eosinophilic fasciitis complicated with peripheral polyneuropathy. Intern Med 1998; 37:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/14\">",
"      Nassonova VA, Ivanova MM, Akhnazarova VD, et al. Eosinophilic fasciitis. Review and report of six cases. Scand J Rheumatol 1979; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/15\">",
"      Doyle JA, Connolly SM, Hoagland HC. Hematologic disease in scleroderma syndromes. Acta Derm Venereol 1985; 65:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/16\">",
"      Hoffman R, Dainiak N, Sibrack L, et al. Antibody-mediated aplastic anemia and diffuse fasciitis. N Engl J Med 1979; 300:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/17\">",
"      Littlejohn GO, Keystone EC. Eosinophilic fasciitis and aplastic anaemia. J Rheumatol 1980; 7:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/18\">",
"      Chaudhary UB, Eberwine SF, Hege KM. Acquired amegakaryocytic thrombocytopenia purpura and eosinophilic fasciitis: a long relapsing and remitting course. Am J Hematol 2004; 75:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/19\">",
"      Khanna D, Verity A, Grossman JM. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis 2002; 61:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/20\">",
"      Jacob SE, Lodha R, Cohen JJ, et al. Paraneoplastic eosinophilic fasciitis: a case report. Rheumatol Int 2003; 23:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/21\">",
"      Naschitz JE, Misselevich I, Rosner I, et al. Lymph-node-based malignant lymphoma and reactive lymphadenopathy in eosinophilic fasciitis. Am J Med Sci 1999; 318:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/22\">",
"      Nakajima H, Fujiwara S, Shinoda K, Ohsawa N. Magnetic resonance imaging and serum aldolase concentration in eosinophilic fasciitis. Intern Med 1997; 36:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/23\">",
"      al-Shaikh A, Freeman C, Avruch L, McKendry RJ. Use of magnetic resonance imaging in diagnosing eosinophilic fasciitis. Report of two cases. Arthritis Rheum 1994; 37:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/24\">",
"      Baumann F, Br&uuml;hlmann P, Andreisek G, et al. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol 2005; 184:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/25\">",
"      Moulton SJ, Kransdorf MJ, Ginsburg WW, et al. Eosinophilic fasciitis: spectrum of MRI findings. AJR Am J Roentgenol 2005; 184:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/26\">",
"      De Clerck LS, Degryse HR, Wouters E, et al. Magnetic resonance imaging in the evaluation of patients with eosinophilic fasciitis. J Rheumatol 1989; 16:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/27\">",
"      Ronneberger M, Janka R, Schett G, Manger B. Can MRI substitute for biopsy in eosinophilic fasciitis? Ann Rheum Dis 2009; 68:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/28\">",
"      Barnes L, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol 1979; 96:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/29\">",
"      Viallard JF, Taupin JL, Ranchin V, et al. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 2001; 28:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/30\">",
"      Fredens K, Dybdahl H, Dahl R, Baandrup U. Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. APMIS 1988; 96:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/31\">",
"      Falanga V, Soter NA, Kerdel FA. Increased plasma histamine level in eosinophilic fasciitis. Arch Dermatol 1989; 125:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/32\">",
"      Peltonen J, Varga J, Sollberg S, et al. Elevated expression of the genes for transforming growth factor-beta 1 and type VI collagen in diffuse fasciitis associated with the eosinophilia-myalgia syndrome. J Invest Dermatol 1991; 96:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/33\">",
"      Huang KW, Chen XH. Pathology of eosinophilic fasciitis and its relation to polymyositis. Can J Neurol Sci 1987; 14:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/34\">",
"      Florell SR, Egan CA, Gregory MC, et al. Eosinophilic fasciitis occurring four weeks after the onset of dialysis in a renal failure patient. J Cutan Med Surg 2001; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/35\">",
"      Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol 1996; 18:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/36\">",
"      Hashimoto Y, Takahashi H, Matsuo S, et al. Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 1996; 192:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/37\">",
"      Mosconi S, Streit M, Br&ouml;nimann M, Braathen L. Eosinophilic fasciitis (Shulman syndrome). Dermatology 2002; 205:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/38\">",
"      Herson S, Brechignac S, Piette JC, et al. Capillary microscopy during eosinophilic fasciitis in 15 patients: distinction from systemic scleroderma. Am J Med 1990; 88:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/39\">",
"      Mori Y, Kahari VM, Varga J. Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep 2002; 4:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/40\">",
"      Allen JA, Peterson A, Sufit R, et al. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 2011; 63:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/41\">",
"      Alonso-Ruiz A, Zea-Mendoza AC, Salazar-Vallinas JM, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum 1986; 15:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/42\">",
"      Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/43\">",
"      Posada de la Paz M, Philen RM, Borda AI. Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 2001; 23:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/44\">",
"      Lebeaux D, Franc&egrave;s C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 2012; 51:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/45\">",
"      Schiener R, Behrens-Williams SC, Gottl&ouml;ber P, et al. Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy. Br J Dermatol 2000; 142:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/46\">",
"      Pimenta S, Bernardes M, Bernardo A, et al. Intravenous immune globulins to treat eosinophilic fasciitis: a case report. Joint Bone Spine 2009; 76:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/47\">",
"      Bonnotte B, Chauffert B, Caillot D, et al. Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis. Br J Rheumatol 1998; 37:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/48\">",
"      Caspi D, Fishel R, Varon M, et al. Multisystem presentation of eosinophilic fasciitis. Rheumatol Rehabil 1982; 21:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/49\">",
"      Cetkovsk&yacute; P, Koza V, Cetkovsk&aacute; P, Svojgrov&aacute; M. Successful treatment of severe Shulman's syndrome by allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/50\">",
"      Jones AC, Doherty M. Eosinophilic fasciitis with late onset arthritis responsive to sulfasalazine. J Rheumatol 1993; 20:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/51\">",
"      Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol 2008; 47:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/52\">",
"      Khanna D, Agrawal H, Clements PJ. Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford) 2010; 49:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/53\">",
"      Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin Exp Rheumatol 2006; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/54\">",
"      Suzuki G, Itoh Y, Horiuchi Y. Surgical management of eosinophilic fasciitis of the upper extremity. J Hand Surg Br 1997; 22:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8360/abstract/55\">",
"      Neumeister MW, Robertson GA. Therapeutic fasciectomy for eosinophilic fasciitis. Ann Plast Surg 1998; 41:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7547 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8360=[""].join("\n");
var outline_f8_10_8360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cutaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Articular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Endocrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Muscular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hematologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Visceral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359650145\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Localized scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Scleroderma-like disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nephrogenic systemic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Scleromyxedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Scleredema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Eosinophilia and skin thickening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Eosinophilia-myalgia syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Toxic oil syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359650344\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359650304\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359650408\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7547|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/37/27230\" title=\"picture 1\">",
"      Skin in eosinophilic fasciitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/48/14084\" title=\"picture 2\">",
"      Eosinophilic fasciitis biopsy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/16/259\" title=\"picture 3\">",
"      Eosinophilic fasciitis biopsy 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_10_8361="Pathophysiology and treatment of fever in adults";
var content_f8_10_8361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and treatment of fever in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Reuven Porat, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Charles A Dinarello, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/10/8361/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/10/8361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever, an elevation in core body temperature above the daily range for an individual, is a characteristic feature of most infections but is also found in a number of non-infectious diseases such as autoimmune and autoinflammatory diseases. Definitions of normal body temperature, the pathophysiology of fever, the role of cytokines, and the treatment of fever in adults will be reviewed here. Fever of unknown origin in adults, drug fever, and the treatment of fever in infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=see_link\">",
"     \"Approach to the adult with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15431?source=see_link\">",
"     \"Etiologies of fever of unknown origin in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=see_link\">",
"     \"Drug fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=see_link\">",
"     \"Pathophysiology and management of fever in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL BODY TEMPERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal body temperature varies over the course of the day, controlled in the thermoregulatory center located in the anterior hypothalamus. The body is normally able to maintain a fairly steady temperature because the hypothalamic thermoregulatory center balances the excess heat production, derived from metabolic activity in muscle and the liver, with heat dissipation from the skin and lungs. However, faced with environmental extremes, humans cannot maintain the narrow daily variation of body temperature without the aid of clothing and protective environments [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1992, a detailed study of the range of oral temperature readings in 148 healthy men and women aged 18 to 40, was reported using over 700 measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/2\">",
"     2",
"    </a>",
"    ]. Oral temperatures in the cohort ranged from 35.6&ordm;C (96.0&ordm;F) to 38.5&ordm;C (100.8&ordm;F) with a mean of 36.8 &plusmn; 0.4&ordm;C (98.2 &plusmn; 0.7&ordm;F). Low levels occurred at 6 AM and higher levels at 4 to 6 PM. The maximum normal oral temperature at 6 AM is 37.2&ordm;C (98.9&ordm;F), and the maximum level at 4 PM is 37.7&ordm;C (99.9&ordm;F), both values defining the 99th percentile for healthy subjects. From these studies, a morning reading &gt;37.2&ordm;C (98.9&ordm;F) or an afternoon temperature of &gt;37.7&ordm;C (99.9&ordm;F) would be considered a fever. Rectal temperatures are generally 0.6&ordm;C (1.0&ordm;F) higher than oral readings. Oral readings are lower probably because of mouth breathing, which is particularly important in patients with respiratory infections and rapid breathing. Temperature measurements from the lower esophagus reflect core temperature, and tympanic membrane temperature readings are also close to core temperature.",
"   </p>",
"   <p>",
"    The normal daily temperature variation is typically 0.5&ordm;C (0.9&ordm;F). However, in some individuals recovering from a febrile illness, this daily variation can be as high as 1.0&ordm;C. During a febrile illness, daily low and high temperature readings are maintained but at higher levels.",
"   </p>",
"   <p>",
"    In menstruating women, the morning temperature is generally lower during the two weeks prior to ovulation, rising by about 0.6&ordm;C (1.0&ordm;F) with ovulation and remaining at that level until menses occur. Seasonal variation in body temperature has been described, but this may reflect a metabolic change and is not a common observation. Elevation in body temperature occurs during the postprandial state, but this is not fever. Pregnancy and endocrinologic dysfunction also affect body temperature. The daily temperature variation appears to be fixed in early childhood. On the other hand, it is well-established that the ability to develop fever in the elderly is impaired, and that baseline temperature in the elderly is lower than in younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, elderly patients with severe infections may only display a modest fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FEVER, HYPERTHERMIA, AND HYPERPYREXIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever, hyperthermia, and hyperpyrexia are not synonymous terms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is regulated at the level of the hypothalamus. The thermostat device, which regulates the temperature in a home, is comparable to the way the hypothalamus controls core body temperature. The thermostat setting in the hypothalamic thermoregulatory center shifts upwards during a fever, for example, from 37 to 39&ordm;C. In other words, during fever the \"set-point\" in the hypothalamus shifts upwards from the \"normothermia\" setting to febrile levels, similar to the way the home thermostat is reset to a higher level in order to raise the ambient temperature in a room. Elevated levels of PGE2 in the hypothalamus appear to be the trigger for raising the set-point. Once the hypothalamic set-point is raised, this activates neurons in the vasomotor center to commence vasoconstriction and warm-sensing neurons to slow their firing rate and increase heat production in the periphery.",
"   </p>",
"   <p>",
"    The vasoconstriction produces a noticeable cold sensation in the hands and feet. Blood is shunted away from the periphery to the internal organs, essentially decreasing heat loss from the skin, and the patient feels cold. For most fevers, this is sufficient to raise core body temperature 1 or even 2&ordm;C.",
"   </p>",
"   <p>",
"    At the same time, thermogenesis in fat contributes to increasing core temperature. This is termed \"non-shivering thermogenesis.\" At birth, highly thermogenic brown fat is present but rapidly decreases within the neonatal period. It is unclear how much brown fat remains as a source of heat production in the adult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of obesity\", section on 'Brown adipose tissue and body temperature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thermogenesis in either the fat or muscle takes place by uncoupling proteins, which release ATP and heat. The combination of heat conservation and thermogenesis accounts for the majority of fever. There is also increased heat production from the liver.",
"   </p>",
"   <p>",
"    Shivering may be initiated in order to increase heat production from the muscles, but shivering is not required for most fevers. Shivering appears to take place when there is a rapid rise to match the new febrile set-point.",
"   </p>",
"   <p>",
"    In humans, behavioral instincts assist in raising body temperature with reduction of exposed surfaces. Subjects seek warm rooms, add extra clothing, and reduce activity. The processes of heat conservation (vasoconstriction), heat production (shivering, non-shivering thermogenesis, increased metabolic activity) and behavioral changes continue until the temperature of the blood bathing the hypothalamic neurons matches the new setting. When that point is reached, the hypothalamus now maintains the new setting at the febrile level temperature, just as it does at the normothermic level. In fact, studies have shown that the mechanisms of balancing heat loss and heat production in fever are the same as in the afebrile state.",
"   </p>",
"   <p>",
"    When the hypothalamic set-point is reset downwards, the processes of heat loss are accelerated through vasodilation and sweating. The resetting of the set-point downwards can be due to either a reduction in the concentration of pyrogens or the use of antipyretics. Behavioral changes are also triggered at this time and removal of insulating clothing or bedding takes place. Loss of heat by sweating and vasodilation continue until the temperature of the blood supplying the hypothalamus matches the lower setting.",
"   </p>",
"   <p>",
"    In some rare patients the hypothalamic set-point is elevated owing to local trauma, hemorrhage, tumor, or intrinsic hypothalamic malfunction. The term \"hypothalamic fever\" is sometimes used to describe elevated temperature caused by abnormal hypothalamic function. However, the majority of patients with hypothalamic damage have hypo not hyperthermia. These patients do not respond properly to minor environmental temperature changes; in this condition, core temperature falls upon exposure to slight drops in temperature, whereas normal hypothalamic function can maintain core temperature for a few hours. In those very few patients in whom elevated core temperature is suspected to be due to hypothalamic damage, the diagnosis depends upon the demonstration of other abnormal hypothalamic functions, such as production of hypothalamic releasing factors, abnormal response to cold, and absence of circadian temperature and hormonal rhythms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the vast majority of patients with elevated body temperature have fever, there are a few instances in which an elevated temperature represents hyperthermia. These include heat stroke syndromes, certain metabolic diseases, and the effects of pharmacologic agents that interfere with thermoregulation. In contradistinction to fever, the setting of the thermoregulatory center during hyperthermia remains unchanged at normothermic levels, while body temperature increases in an uncontrolled fashion and overrides the ability to lose heat. Exogenous heat exposure and endogenous heat production are two mechanisms by which hyperthermia can result in dangerously high internal temperatures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to make the distinction between fever and hyperthermia. Hyperthermia can be rapidly fatal, and its treatment differs from that of fever. Despite physiologic and behavioral control of body temperature, excessive heat production can easily occur. As an example, overinsulating clothing can result in elevated core temperature. Hyperthermia is most often observed in persons who work or exercise in hot environments and produce heat faster than the peripheral mechanisms can lose it. Hypohydration is a major cause of hyperthermia.",
"   </p>",
"   <p>",
"    Certain metabolic diseases such as hyperthyroidism can result in mild elevations of core temperature. The effects of some pharmacologic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ) that interfere with thermoregulation by blocking sweating or vasodilation can also raise core temperature. These syndromes represent hyperthermia because they take place in the presence of a normal hypothalamic set-point. The recreational drug \"ecstasy\" (3,4-methylenedioxymethamphetamine) produces hyperthermia, which is due to a loss in heat dissipation (vasoconstriction) and heat production via uncoupling protein 3.",
"   </p>",
"   <p>",
"    A diagnosis of hyperthermia is often made because of a preceding history of heat exposure or use of certain drugs that interfere with normal thermoregulation. There is no rapid way to differentiate elevated core temperature due to fever from hyperthermia. The immediate events prior to the onset of hyperthermia usually play an important role in determining its cause. However, physical examination can assist the clinician in some forms of hyperthermia; for example, the skin is hot but dry in heat stroke syndromes and in patients taking drugs that block sweating. Antipyretics do not reduce the elevated temperature in hyperthermia whereas there is usually some decrease in body temperature in patients with fever or even \"hyperpyrexia\" after adequate doses of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Hyperthermia can also occur when certain anesthetics produce a rapid uncoupling of oxidative phosphorylation in susceptible individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/4\">",
"     4",
"    </a>",
"    ]. This is known as malignant hyperthermia and is often fatal. Another form of hyperthermia results in patients taking certain neuroleptic drugs and is called \"neuroleptic malignant syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another possible cause of hyperthermia is the serotonin syndrome, which may result from any combination of drugs that has the net effect of increasing serotonergic neurotransmission (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 1",
"    </a>",
"    ). The syndrome is classically associated with the simultaneous administration of two serotonergic agents, but it can occur after initiation of a single serotonergic drug or increasing the dose of a serotonergic drug in individuals who are particularly sensitive to serotonin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperpyrexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperpyrexia is the term for an extraordinarily high fever (&gt;41.5&ordm;C), which can be observed in patients with severe infections but most commonly occurs in patients with central nervous system (CNS) hemorrhages. Although antipyretics reduce the body temperature in hyperpyrexic fever, cooling blankets and cool water sponging are recommended to accelerate peripheral heat losses. However, peripheral cooling with cooling blankets can be counterproductive in the absence of antipyretics since cold receptors in the skin trigger reactive vasoconstriction, thus reducing heat loss mechanisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PYROGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term pyrogen is used to describe any substance that causes fever. Pyrogens are either exogenous or endogenous. Endogenous pyrogens belong to the class of biologically active proteins called cytokines. Fever-producing cytokines are more precisely termed pyrogenic cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exogenous pyrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous pyrogens, derived from outside the host, are mainly microbes or their products, such as toxins. The classic example of an exogenous pyrogen is the lipopolysaccharide endotoxin produced by all gram-negative bacteria. Endotoxins are potent substances not only as pyrogens but also as inducers of various pathologic changes observed in gram-negative infections [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/7\">",
"     7",
"    </a>",
"    ]. Endotoxins belong to a classification of microbial products termed toll-like receptor (TLR) ligands. TLR evolved with insects and the mammalian homologues on macrophages bind microbial products from several bacteria and fungi and result in activation of the cell. Therefore, TLR recognition of bacteria explains how infections cause fever. As discussed below, the activation of macrophages via the TLR on mammalian cells results in the production of fever-producing cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another group of bacterial substances that are potent pyrogens is produced by gram-positive organisms. The toxic shock syndrome toxin (TSST-1) is associated with strains of Staphylococcus aureus isolated from patients with the toxic shock syndrome (TSS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. TSST-1 and other enterotoxins from S. aureus and exotoxins from group A streptococcus act both as direct toxins but also serve as \"superantigens\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Superantigens appear to play a role in the pathogenesis of severe gram-positive infections by interacting with the major histocompatibility complex (MHC) II and a number of T cell subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] to release pyrogenic cytokines. Like the endotoxins from gram-negative bacteria, the toxins produced by staphylococci and streptococci produce fever in experimental animals when injected intravenously in the",
"    <span class=\"nowrap\">",
"     submicrogram/kg",
"    </span>",
"    range. Of considerable importance is the fact that endotoxin is a highly pyrogenic molecule in humans since 2 to 3",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    produces fever and generalized symptoms of malaise in volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pyrogenic cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyrogenic cytokines are specific cytokines produced upon activation of TLR [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/2\">",
"     2",
"    </a>",
"    ]. Cytokines are small proteins (molecular weight 10 to 20,000 Daltons) that regulate immune, inflammatory, and hematopoietic processes (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    ). As an example, stimulation of lymphocyte proliferation during an immune response to vaccination is the result of various cytokines including interleukin (IL)-2, IL-4 and IL-6. A cytokine called",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) stimulates granulocytopoiesis in the bone marrow (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=see_link\">",
"     \"Introduction to recombinant hematopoietic growth factors\"",
"    </a>",
"    ). Some cytokines cause fever and hence are called pyrogenic cytokines.",
"   </p>",
"   <p>",
"    From a historical point of view, the field of \"cytokine biology\" began with laboratory investigations into the cause of fever by products of activated leukocytes in the 1940s. These fever-producing molecules were called \"endogenous pyrogens\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/16\">",
"     16",
"    </a>",
"    ]. When endogenous pyrogens were purified from activated leukocytes, they were shown to possess a broad range of biological activities, affecting all organ systems. Cytokines can affect organ function during disease, but unless challenged by infection or trauma, cytokines do not seem to play a role in normal physiologic functions, including temperature regulation or endocrine functions.",
"   </p>",
"   <p>",
"    There are several pyrogenic cytokines, namely IL-1, IL-6, tumor necrosis factor (TNF) and ciliary neurotrophic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Others likely exist. Interferon (IFN)-alpha can also be considered a pyrogenic cytokine since it produces fever. In fact, IL-1, IL-6 and TNF have each been injected into humans and have produced fever. IL-1 and TNF are particularly pyrogenic, resulting in fever at doses as low as 10",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    (either subcutaneously or intravenously) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/17\">",
"     17",
"    </a>",
"    ]. IL-6 is also pyrogenic but",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    rather than",
"    <span class=\"nowrap\">",
"     nanogram/kg",
"    </span>",
"    doses of IL-6 are needed to produce fever in humans. Nevertheless, large amounts of IL-6 circulate in nearly all febrile diseases and IL-6 induced by IL-1 or the combination of IL-1 plus TNF likely accounts for the clinical fever most often measured. Mice without the gene for IL-6 do not develop fever during bacterial infection. Thus, in most inflammatory and infectious diseases, low concentrations of IL-1 and TNF induce large amounts of IL-6, and it is the IL-6 that likely triggers the hypothalamic centers for control of body temperature. Thus, in addition to exogenous pyrogens from microbial sources, endogenous pyrogenic cytokines cause fever. Each cytokine is coded by a separate gene and each pyrogenic cytokine has been shown to cause fever not only in laboratory animals but also when injected into humans.",
"   </p>",
"   <p>",
"    A wide spectrum of exogenous pyrogens induces the synthesis and release of pyrogenic cytokines via activation of the TLRs. Most of the exogenous pyrogenic substances can be recognized from their bacterial or fungal sources. Viruses induce pyrogenic cytokines by infecting cells. However, in the absence of microbial infection, fever is often present in a variety of diseases. Inflammation, trauma or antigen-antibody complexes induce the production of IL-1, TNF and IL-6, and each or all three cytokines trigger the hypothalamus to raise the set-point to febrile levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/19\">",
"     19",
"    </a>",
"    ]. The cellular sources of pyrogenic cytokines are primarily monocytes, neutrophils and lymphocytes, although many different cells can synthesize these molecules, when stimulated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ELEVATION OF THE HYPOTHALAMIC SET-POINT BY CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;During fever, hypothalamic tissue and third cerebral ventricle levels of prostaglandin (PG)E2 are elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The highest concentrations of PGE2 are near the circumventricular vascular organs (organ vasculosum lamina terminalis, OVLT) which are networks of enlarged capillaries surrounding the hypothalamic regulatory centers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/23\">",
"     23",
"    </a>",
"    ]. Destruction of these organs reduces the ability of pyrogens to produce fever. However, most studies in animals have not been able to show that pyrogenic cytokines pass from the circulation into the brain substance itself [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, it appears that both exogenous and endogenous pyrogens interact with the endothelium of these capillaries, which is probably the first step in initiating fever.",
"   </p>",
"   <p>",
"    The interaction of pyrogens with the hypothalamic circumventricular vascular endothelium is the first step in raising the set-point to febrile levels. The following algorithm illustrates the key events in the production of fever (",
"    <a class=\"graphic graphic_algorithm graphicRef80455 \" href=\"UTD.htm?29/42/30382\">",
"     algorithm 1",
"    </a>",
"    ). As shown, several cells have the potential to produce pyrogenic cytokines. Pyrogenic cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF) are then released from the cell and enter the systemic circulation. Although the systemic effects of these circulating cytokines initiate fever by their ability to induce the synthesis of PGE2, they also induce PGE2 in peripheral tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/17\">",
"     17",
"    </a>",
"    ]. The increase in PGE2 in the periphery accounts for the non-specific myalgias and arthralgias that often accompany fever. However, it is the induction of PGE2 in the brain which starts the process of raising the hypothalamic set-point for core temperature.",
"   </p>",
"   <p>",
"    There are four receptors for PGE2, and each signals the cell in different ways. Studies in mice demonstrated that the third PGE2 receptor (EP-3) is essential for the production of fever; mice deficient in the gene for this receptor do not develop fever following the injection of IL-1 or endotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/24\">",
"     24",
"    </a>",
"    ]. Deletion of the other PGE2 receptor genes leaves the fever mechanism intact. Although PGE2 is essential for fever, PGE2 is not a neurotransmitter. However, release of PGE2 from the brain side of the hypothalamic endothelium triggers the PGE2 receptor on glial cells, and this results in the rapid release of cyclic AMP (cAMP), which is a neurotransmitter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As shown in the following algorithm, release of cAMP from the glial cells activates neuronal endings from the thermoregulatory center that extend into the area (",
"    <a class=\"graphic graphic_algorithm graphicRef80455 \" href=\"UTD.htm?29/42/30382\">",
"     algorithm 1",
"    </a>",
"    ). The elevation of cAMP is thought to account for changes in the hypothalamic set-point either directly or indirectly by inducing the release of monoamine neurotransmitters. Receptors for endotoxin share many similarities to those of IL-1, and hence, activation of endotoxin receptors on the hypothalamic endothelium also results in PGE2 production and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Production of cytokines in the central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several viral diseases produce active infection in the brain. Glial and possibly neuronal cells synthesize IL-1, TNF, and IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/26\">",
"     26",
"    </a>",
"    ]. CNTF is also synthesized by neural as well as neuronal cells. These cytokines produced within the brain itself appear to play a role in the production of fever. When a cytokine is injected directly into the brain of experimental animals, the dose required to cause fever is several orders of magnitude lower compared to intravenous injection. Thus, it appears that CNS production of these cytokines can raise the hypothalamic set-point, bypassing the circumventricular organs involved in the fever which results from circulating cytokines. Local production of cytokines in the CNS may account for the hyperpyrexia of CNS hemorrhage noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Does anti-cytokine therapy mask infection by preventing fever?",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing number of patients with autoimmune or autoinflammatory diseases are being treated with biologic agents. These are mostly anti-cytokine therapies, such as IL-1 receptor inhibitors, TNF-alpha inhibitors, an IL-6 receptor inhibitor, anti-IL-12 antibodies, or anti-IL-23 antibodies. Anti-cytokine therapy has the distinct drawback of lowering host defense against infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/27\">",
"     27",
"    </a>",
"    ]. In the case of neutralizing antibodies to TNF-alpha by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , opportunistic infections such as Mycobacterium tuberculosis with dissemination have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The soluble receptor for TNF-alpha,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , is also associated with opportunistic infections, but less so compared with the neutralizing antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In nearly all reports of infections associated with the use of anti-cytokine therapies, fever is one of the presenting signs. However, it is likely that fever in these patients is blunted in much the same way as does therapy with high-dose glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability of a patient to present with fever despite being treated with an anti-cytokine agent is due to the other cytokines that can cause fever (eg, IL-1, TNF-alpha, IL-6, interferons, and others) that are not affected by a specific anti-cytokine agent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/31\">",
"     31",
"    </a>",
"    ]. For example, in a patient with staphylococcal skin infection being treated with anti-TNF-alpha for rheumatoid arthritis, the three pyrogenic cytokines, TNF-alpha, IL-1, and IL-6 are produced, but only TNF-alpha is blocked by the anti-TNF-alpha antibody. Thus, the fever may be due to IL-1 and IL-6. Another explanation is that microbial products are capable of inducing brain PGE2 directly via their TLR. In the case of the patient with staphylococcal skin infection being treated with anti-TNF-alpha for rheumatoid arthritis, staphylococcal products may reach the TLRs of the hypothalamic endothelium and trigger COX-2 expression.",
"   </p>",
"   <p>",
"    Anti-cytokine agents dramatically reduce fever in autoimmune and auto-inflammatory diseases. Some autoimmune diseases and most autoinflammatory diseases have recurrent fever as a prominent presenting sign. The auto-inflammatory diseases are diseases in which the monocyte rather than the lymphocyte plays a pathological role. The auto-inflammatory diseases include adult and juvenile Still's disease, familial Mediterranean fever, hyper IgD syndrome, familial cold-induced autoinflammatory syndrome, neonatal onset multisystem auto-inflammatory disease, Blau's syndrome, Schnitzler's syndrome, Muckle-Wells syndrome, and TNF receptor associated periodic syndrome. They are characterized by recurrent fevers, neutrophilia, and serosal inflammation. The fever associated with these diseases is dramatically reduced by blocking IL-1 with the IL-1 receptor antagonist, casapse-1 inhibitors, or anti-IL-1beta neutralizing antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. The febrile course of a patient with spiking daily fevers due to adult onset Still's disease are unaffected by daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    but rapidly falls with a single dose of the IL-1 receptor antagonist (",
"    <a class=\"graphic graphic_figure graphicRef53770 \" href=\"UTD.htm?16/44/17102\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/32\">",
"     32",
"    </a>",
"    ]. Although the fever in auto-inflammatory diseases is mediated by IL-1beta, patients also respond to antipyretics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ANTIPYRETIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synthesis of PGE2 depends upon the constitutively expressed enzyme cyclooxygenase. The substrate for cyclooxygenase is arachidonic acid released from the cell membrane, and this release is the rate limiting step in the synthesis of PGE2. Inhibitors of cyclooxygenases (either COX-1 or COX-2) are potent antipyretics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/38\">",
"     38",
"    </a>",
"    ]. There is a direct correlation between the antipyretic potency of various drugs and their ability to inhibit brain cyclooxygenase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is a poor cyclooxygenase inhibitor in peripheral tissue and does not display noteworthy antiinflammatory activity; however, acetaminophen is oxidized in the brain by the p450 cytochrome system, and the oxidized form inhibits cyclooxygenase activity.",
"   </p>",
"   <p>",
"    There is no difference between oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in reducing fever in humans. Nonsteroidal antiinflammatory agents (NSAIDs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , are also excellent antipyretics and can be used for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There appears to be no role for PGE2 in normal thermoregulation based upon observations that chronic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAIDs in arthritis does not reduce normal core body temperature.",
"   </p>",
"   <p>",
"    Corticosteroids are also effective antipyretics, which act at two levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar to the cyclooxygenase inhibitors, corticosteroids reduce PGE2 synthesis by inhibiting the activity of phospholipase A2 which is needed to release arachidonic acid from the membrane.",
"     </li>",
"     <li>",
"      Corticosteroids block the transcription of the mRNA for the pyrogenic cytokines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drugs that interfere with vasoconstriction (eg, phenothiazines) can also act as antipyretics as can drugs that block muscle contractions. However, these are not true antipyretics since they can also reduce core temperature independently of hypothalamic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT OF FEVER AND HYPERTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated core temperature, whether fever or hyperthermia, increases the demand for oxygen and can aggravate preexisting cardiac or pulmonary insufficiency. For every increase of one degree above 37&ordm;C, there is a 13 percent increase in O2 consumption. In addition, elevated temperature can induce mental changes in patients with organic brain disease. Although a rapid reduction in elevated core temperature due to hyperthermia is mandatory, treatment of fever is often a debated issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Decision to treat fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of fevers are associated with self-limited infections, most commonly of a viral origin, where the cause of the fever is easily identified. The decision to reduce fever with antipyretics assumes that there is no diagnostic benefit of allowing the fever to persist. However, there are rare clinical situations in which observation of the pattern of fever can be helpful diagnostically. As an example, the daily highs and lows of normal temperature are exaggerated in most fevers, but these fluctuations may be reversed in typhoid fever and disseminated tuberculosis. Temperature-pulse dissociation (relative bradycardia) is seen in typhoid fever, brucellosis, leptospirosis, some drug-induced fevers and factitious fever. In healthy subjects, the temperature-pulse relationship is linear with an increase in heart rate of 4.4",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    for each 1&ordm;C (2.44",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    for each 1&ordm;F) rise in core temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/31\">",
"     31",
"    </a>",
"    ]. Fever may not be present during infection in newborns, the elderly, patients with chronic renal failure, and in patients taking corticosteroids; hypothermia, in fact, can occur. Hypothermia can also be observed in patients with septic shock.",
"   </p>",
"   <p>",
"    Some febrile diseases have characteristic patterns. Among these are malaria and cyclic neutropenia. However, most of the febrile illnesses that are thought to exhibit a specific time-related pattern (eg, Hodgkin lymphoma) are in fact, upon close examination, not reliable indicators or are of no diagnostic value. As an example, there is no periodicity of fever in patients with familial Mediterranean fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are many reports on the beneficial effect of elevated temperature (febrile range) in animals during infectious challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?8/10/8361/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition, in vitro cultures of animal or human cells at elevated temperature are supportive of a heightened immune response as well as increased bactericidal killing. However, there are no studies that fever itself facilitates the recovery from infection or acts as an adjuvant to the immune system. In fact, peripheral PGE2 production is a potent immunosuppressant and during influenza vaccination, treatment with NSAID increases the anti-influenzal antibody level. Hence, treating fever and its symptoms does no harm and does not slow the resolution of common viral and bacterial infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treating fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing fever with antipyretics also reduces systemic symptoms of headache, myalgias, and arthralgias.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and NSAIDs are excellent oral agents but cause unwanted side effects on platelets and the gastrointestinal tract. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is generally the preferred antipyretic. The combination of aspirin and acetaminophen is more effective than either alone.",
"   </p>",
"   <p>",
"    In cases of hyperpyrexia, the use of cooling blankets facilitates the reduction of temperature, but cooling blankets should not be used without antipyretics. The objectives in treating fever are to first reduce the elevated set-point of the hypothalamus and then to facilitate heat loss. If the patient cannot take oral antipyretics, parenteral preparations of NSAIDs or rectal suppositories of various antipyretics can be used. Since hyperpyrexia may occur in patients with CNS disease or trauma, reducing core temperature helps to reduce the ill effect of high temperature on the brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treating hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of hyperthermia is primarily targeted at rapid reduction of body temperature by physical means. It is also crucial to identify the underlying cause of the hyperthermia, since management varies depending on the etiology. Antipyretics are of no use in reducing body temperature due to hyperthermia. Rapid reduction in body temperature can be accomplished by cool or tepid (20&ordm;C), not cold, bathing, preferably using damp sponges. Submersion should be avoided, so that body heat loss by evaporation can occur. Alcohol adds nothing to tepid or cool water sponging. Cooling blankets are of potential danger because of excess vasoconstriction preventing heat loss from the skin&rsquo;s surface. Intravenous fluids should be administered for dehydration, but if cool fluids are used, avoid a central line close to the heart.",
"   </p>",
"   <p>",
"    The management of hyperthermia, depending on the underlying cause, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"     \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"     \"MDMA (ecstasy) intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/31/36338?source=see_link\">",
"       \"Patient information: When to worry about a fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1710419\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever, an elevation in core body temperature above the daily range for an individual, is a characteristic feature of most infections but is also found in a number of non-infectious diseases such as autoimmune and autoinflammatory diseases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal body temperature is low in the early morning and high in evening, varying 0.5&ordm;C (0.9&ordm;F) over the course of the day, controlled in the thermoregulatory center located in the anterior hypothalamus. However, in some individuals recovering from a febrile illness, this daily variation can be as high as 1.0&ordm;C. During a febrile illness, daily low and high temperature readings are maintained but at higher levels. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal body temperature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability to develop fever in the elderly is impaired, and baseline temperature in the elderly is lower than in younger adults. Thus, elderly patients with severe infections may only display a modest fever. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal body temperature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the vast majority of patients with elevated body temperature have fever, there are a few instances in which an elevated temperature represents hyperthermia. These include heat stroke syndromes, certain metabolic diseases, and the effects of pharmacologic agents that interfere with thermoregulation. It is important to make the distinction between fever and hyperthermia. Hyperthermia can be rapidly fatal, and its treatment differs from that of fever. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hyperthermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperpyrexia is the term for an extraordinarily high fever (&gt;41.5&ordm;C), which can be observed in patients with severe infections but most commonly occurs in patients with central nervous system hemorrhages. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hyperpyrexia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with autoimmune diseases being treated with biologic agents, such as tumor necrosis factor-alpha inhibitors, are at increased risk for routine as well as opportunistic infections. In these patients, a low-grade fever may serve as an early warning sign of a serious infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Does anti-cytokine therapy mask infection by preventing fever?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhibitors of cyclooxygenases, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and nonsteroidal antiinflammatory agents (NSAIDs), are potent antipyretics. Although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      is a poor cyclooxygenase inhibitor in peripheral tissue and does not display noteworthy antiinflammatory activity, acetaminophen is an excellent antipyretic. Acetaminophen is oxidized in the brain by the p450 cytochrome system, and the oxidized form inhibits cyclooxygenase activity. There is no difference between aspirin and acetaminophen in reducing fever. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mechanisms of antipyretic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reducing fever with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or NSAIDs also reduces systemic and local symptoms of headache, myalgias, and arthralgias but causes unwanted side effects on platelets and the gastrointestinal tract. Thus,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      is generally the preferred antipyretic. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treating fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated core temperature, whether fever or hyperthermia, increases the demand for oxygen and can aggravate preexisting cardiac or pulmonary insufficiency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment of fever and hyperthermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of fevers are associated with self-limited infections, most commonly of a viral origin, where the cause of the fever is easily identified. The decision to reduce fever with antipyretics assumes that there is no diagnostic benefit of allowing the fever to persist. However, there are rare clinical situations in which observation of the pattern of fever can be helpful diagnostically. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Decision to treat fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treating of hyperthermia is primarily to rapidly reduce body temperature by physical means. It is also crucial to identify the underlying cause of the hyperthermia, since management varies depending on the etiology. Antipyretics are of no use for hyperthermia. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treating hyperthermia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/1\">",
"      Lee-Chiong TL Jr, Stitt JT. Disorders of temperature regulation. Compr Ther 1995; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/2\">",
"      Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 1992; 268:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/3\">",
"      Roghmann MC, Warner J, Mackowiak PA. The relationship between age and fever magnitude. Am J Med Sci 2001; 322:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/4\">",
"      Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/5\">",
"      Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999; 33:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/6\">",
"      Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999; 156:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/7\">",
"      Bone RC. Gram-negative sepsis: a dilemma of modern medicine. Clin Microbiol Rev 1993; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/8\">",
"      Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 2004; 10:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/9\">",
"      Schlievert PM, Shands KN, Dan BB, et al. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 1981; 143:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/10\">",
"      Parsonnet J, Gillis ZA, Pier GB. Induction of interleukin-1 by strains of Staphylococcus aureus from patients with nonmenstrual toxic shock syndrome. J Infect Dis 1986; 154:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/11\">",
"      Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/12\">",
"      Proft T, Moffatt SL, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med 1999; 189:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/13\">",
"      Kum WW, Laupland KB, Chow AW. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 2000; 46:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/14\">",
"      Bannan J, Visvanathan K, Zabriskie JB. Structure and function of streptococcal and staphylococcal superantigens in septic shock. Infect Dis Clin North Am 1999; 13:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/15\">",
"      Wolff, SM. Biological effects of bacterial endotoxins in man. J Infect Dis 1973; 128:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/16\">",
"      ATKINS E. Pathogenesis of fever. Physiol Rev 1960; 40:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/17\">",
"      Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis 1999; 179 Suppl 2:S294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/18\">",
"      Shapiro L, Zhang XX, Rupp RG, et al. Ciliary neurotrophic factor is an endogenous pyrogen. Proc Natl Acad Sci U S A 1993; 90:8614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/19\">",
"      Dinarello CA. Thermoregulation and the pathogenesis of fever. Infect Dis Clin North Am 1996; 10:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/20\">",
"      Coceani F, Bishai I, Lees J, Sirko S. Prostaglandin E2 and fever: a continuing debate. Yale J Biol Med 1986; 59:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/21\">",
"      Dinarello CA, Gatti S, Bartfai T. Fever: links with an ancient receptor. Curr Biol 1999; 9:R147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/22\">",
"      Coceani F, Akarsu ES. Prostaglandin E2 in the pathogenesis of fever. An update. Ann N Y Acad Sci 1998; 856:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/23\">",
"      Stitt JT. Evidence for the involvement of the organum vasculosum laminae terminalis in the febrile response of rabbits and rats. J Physiol 1985; 368:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/24\">",
"      Ushikubi F, Segi E, Sugimoto Y, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/25\">",
"      Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/26\">",
"      Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/27\">",
"      Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 2005; 74:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/28\">",
"      Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/29\">",
"      Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/30\">",
"      Wallis, RS, Saliu, OY, Sofer, C, et al. Differential effects of TNF blockers on TB immunity. Ann Rheumat Dis 2005; 64:132.",
"     </a>",
"    </li>",
"    <li>",
"     Dinarello, CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res 10:202.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/32\">",
"      Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/33\">",
"      Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/34\">",
"      Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/35\">",
"      Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/36\">",
"      Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117:208.",
"     </a>",
"    </li>",
"    <li>",
"     De Koning, HD, Bodar, EJ, Simon, A, et al. Beneficial response to anakinra and thalidomide in Schnitzler's syndrome. Ann Rheum Dis 2005;.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/38\">",
"      Vane, JR. Inhibition of prostaglandin synthesis as a mechanisms of action for the aspirin-like drugs. Nature 1971; 231:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/39\">",
"      Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/40\">",
"      Bailey JM. New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 1991; 3:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/41\">",
"      Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 1987; 139:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/10/8361/abstract/42\">",
"      Greisman LA, Mackowiak PA. Fever: beneficial and detrimental effects of antipyretics. Curr Opin Infect Dis 2002; 15:241.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2734 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-A67B6C3D87-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8361=[""].join("\n");
var outline_f8_10_8361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1710419\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL BODY TEMPERATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FEVER, HYPERTHERMIA, AND HYPERPYREXIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperpyrexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PYROGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exogenous pyrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pyrogenic cytokines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ELEVATION OF THE HYPOTHALAMIC SET-POINT BY CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Production of cytokines in the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Does anti-cytokine therapy mask infection by preventing fever?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MECHANISMS OF ANTIPYRETIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT OF FEVER AND HYPERTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Decision to treat fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treating fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treating hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1710419\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2734\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2734|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/42/30382\" title=\"algorithm 1\">",
"      Pathways of fever production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2734|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/44/17102\" title=\"figure 1\">",
"      Temperature after IL-1 antagonist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2734|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/19/43324\" title=\"table 1\">",
"      Serotonin syndrome drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31927?source=related_link\">",
"      Approach to the adult with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/25/2456?source=related_link\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15431?source=related_link\">",
"      Etiologies of fever of unknown origin in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/31/36338?source=related_link\">",
"      Patient information: When to worry about a fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_10_8362="Infections after allogeneic HCT";
var content_f8_10_8362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 652px\">",
"   <div class=\"ttl\">",
"    Phases of opportunistic infections among allogeneic hematopoietic cell transplant recipients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 632px; height: 533px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIVAngDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiuau/H3g6zuprW88WeH4LmB2jlil1GFHjdTgqylsggggg0AdLRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRXK/8ACx/A/wD0OXhv/wAGkH/xVH/Cx/A//Q5eG/8AwaQf/FUAdVRWVp/iTQ9R0q51PT9Z0270223efdwXSSQxbVDNucHC4UgnJ4BzWV/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1VFZWoeJND07SrbU9Q1nTbTTbnb5F3PdJHDLuUsu1ycNlQSMHkDNZX/Cx/A/8A0OXhv/waQf8AxVAHVUVyv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVQB1VFcr/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFUAdVRXK/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVAHVUVyv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVQB1VFcr/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFUAdVRXK/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVAHVUVyv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVQB1VFcr/wsfwP/wBDl4b/APBpB/8AFUf8LH8D/wDQ5eG//BpB/wDFUAdVRXK/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVAHVUVyv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVQB1VFcr/wsfwP/wBDl4b/APBpB/8AFVLaePvB15dQ2tn4s8Pz3M7rHFFFqMLvI7HAVVDZJJIAAoA6WiiigAooooAKKKKACiiigArlfhp/yLl5/wBhrVv/AE43FdVXK/DT/kXLz/sNat/6cbigDqq5XUPH/hzT9autLvL2eK5tZYoLhzZTmCF5FVkV5wnlrkMvVh1rqq8guPBur+I/GPxCsrm6/s/w5qV3ZecGsWMt5GtrCGEUxcKoypUnYxHPINAHpmha1b61HetapKgtLuWyk8wAZeNtrEYJ4z0/lWnXiw8JtDctrMOiyrrf/CZCQXYt284WjXGHIbGREUZs4+Ujk+tZltDqM/xI0fVYPCqaTdpq90t79h0GaKVoDHON815kRTCRgjYCn5ip3A8EA98or5u0vw3q0WiavZ+G9LnWaTSxHNqc+jXGn3r4uI2eKYNIFupGj8z94hByMZG6vQ/g/pQ0/U9dktVa3sJY7ZUtofD8+kWwkXzNzxxzOzFyCoYgAcL1OcAHZ6f4p0rUPEl/oNrJdNqdige4jeynREVj8p8xkCHdg4wxzg4zg426800dt3xR8fm503VWs7nT7ONHNjMkdx5QnEqJIVCsf3igYbnPGcHHYeCYrODwjpEWl6deaXYpbIIbK8VlmgTHCOGJIYd8k0AUNH+IHhvWNRt7KxvZzPcySxW7TWU8Mc7xEiRY5HQI5Uq2QpPQ11VeLeB/BOsXvhPTX16doLTS7/UL600sWLwzmZprhUaSRnO4YkZlCouQwzu6nKk8DCx8A+AHh0S3t4xawPrkc2iy37yyi2+T7RBGyyyhXLDadwQkfKAOAD36ivOfh7pOv2XhSyg0nU7a2tEuZ28rUtDniYRtKSqRRtcBokAJCh9xxjgYxXGz+HtTPj+e41DzV1RtfS4t7yDw9czzC0EqlEF8JREkPl5VkI4+b5ScZAPeKK8S8LeEZNJ/4QrU7DRZLTWpNWvlv7k27CQQOl1tEpxkR7hCQDxnbjk85vhizsrbV/CNo2h3tr4sFjenVrq4sHjkup/IxITMVHngucgqWADAZGQKAPf6wtb8Rx6ZrGnaVDp99qOoXqySrFaCP93EhQPI5kdQFBkQcEk54BryJPDVrovgHwPZjwTpkk97YQnU7y98Py6lJbzJCmFkhjAkLEtIoLMAmCOOBU3w+8HrqOp+DpfFPhtblbbQr2Bm1HT8+Uy3kXkIfMDFWCFyoJJALYJ5NAHs+iarZ65pFnqmlzefY3cSzQy7WXehGQcMAR+Iq7Xz/wCEPB2nXOi/DnSbrwnJE9ndsNcjm0l4UkkWznAeRygWVS+0bssp3AZ5wdLw94MTSJdIv7DQpbXUIPFl3GJ0t2EiafvuERc4yINmzA+5yCOuaAPbqr6heQadYXN7eSeXbW0TTSvgnaigknA5PAPSvn3w94a1aC8t/tyTjxAkd9/aEtt4duY3uy0Mo2zXrSmOZCxQoFBOQgAXnGrB4EFppmm2mleHzCdR8HXcGoL9nIE11ttzEsxYY8wMZNu7kcgcDgA9wtbiO7tYbi3bfDMgkRsEZUjIOD7VLXKfDCDTLbwfZxaRpD6QqqouLd9Oaybz9i72KMq7j0G8ZBxwTiuroA8q8Tf8id8bf+3j/wBM9rXqteVeJv8AkTvjb/28f+me1r1WgDl9f8e+HdA1Oew1S7uIri3hS4nKWM8scEbkhXkkRCiKSp5YjpWlo2v2er6jq9nZiQvpk0cMshxskLwpMpQgnI2yLycc5+teea/4Y13XPiX4phsroaXpeoaJa2c13JYNN5oLzB1ifeqq4Dc5D43Dgd8XWPAsUH/Cb3dpoc8uo2l5py6Rc+QzzBIre1XdC2M8FWDFeu0g9MUAe50V4R4qt9QvPiHb3Vp4Yhsr228QWa/arbQZ2uZ7YSIJJnvlIj8soWBQhiAOcYyKiaDqo1TWB4Z0ud9XuYNTZdSvdJmsr21kdW8sNdlvKuQWIVcfdG09qAPoKufuvF+kW3iKXQpGvm1SK3N20MenXEgMQGSwdYyregwSS3yj5uK4D4QaMNO8TSy2sUtrb/2aIZoYvDlzpcUkgdSHkaaVvNmA3DcoOQxyx4rYurs23xvlu5LHVWs4vD5t2uY9OuJIjIJfNKB1Qqx2dACcn5R83FAHYeFvEWm+KdJXU9ElmmsmdkWSW2lg3EdcCRVJGeMgYyCOxqbxDrVh4e0e51XV5zBY24BkkEbSEZYKPlUFjyQOBXmHgC2tf+FWeFLTXvD2uTz2mrx7bf7HNDJbT/aGeOd1bYfKXcrFuVxnIOCK6j42WV5qPwx1q10y3mubyQQ+XFFE0jEiZDwq8nABP0FAG/4e8TaV4he7j0yaYz2bKtxBcW0ttNEWGV3RyqrAEcg4wccVs1434x8GX0Wq2mu+IHfxDBdX9uur2thYOsf2SKOYRqLcNI8iiWRXYZYn+7gYrBvtCLaTbebpV/Fow1O+m0vTbvw/PqNtHbskYVZrVCskWX8xo+BtDHIHSgD3W31SyuNXvNLhm3X1nFFNPFtYbEkLhDnGDny36HjHOMirteKeDdBSy8XLe6l4Ui03V73RNPXT7htNkvorK5jSZHDyjlCFMIO51LKoG7itT4laN4gvLTQBrM+n6nYwXkkl4sGg3FzAR5WIvMtEnZ5AG3dCQCykrhSaAPV6K8M8H+CINQ1/QoNe0ubUtFg07UzEt9pcltBEXuoDHGIZGcqoXfsVzuAUHA2jFGCxMPh/Q5PH2h6nqNhb+GhFbxTafLci2u1dt5kXafLfy/KxI+0AK3zCgD6Bqrqt/b6Vpd5qN8/l2lpC9xM+M7URSzHH0Brx3wj4bju7vStT1Hw8up/YvBel/Y1uYcxm5QztsUsNokGU56ruHTPPKxaJfX9r4lW28LxWdve+Eb4SWVh4cnsIheBo2hjIkyJply211UZ5xnHAB7v4d8TwazMttJZXum37W63YtLxU8wwMcLJmNnUAkEYLbhjkCt+vJbLwroei/ETRLiXwnAlqdKhhtJrfSPMS2u1mLEkoh8lvnB3ttHXniuf8D/DjTUsvhuuo+FkBfTJ/7WWezPzybIyi3II+Yhs7VfpjgDFAHvVFfPE/hzUm0zwzHrdk0mj2lld20dtfaDdaqsUguGCZghdWU+SF2SEEAA4IJGZ4vA73uj+J5NW0u+1O+tvClnFpt1e2bLMbhUujlFy2JlPldGLjI5+Y5APc7bVLO51O90+CbdeWaxtPHtI2CQEpyRg52noT0q7XlfhbSLO1+J15f6x4ff8AtO+srKS01I6W0m2URSLNmdUIifoDuKk5A5r1SgDyrwz/AMid8Ev+3f8A9M91XqteVeGf+RO+CX/bv/6Z7qvVaACiiigDldQ8f+HNP1q60u8vZ4rm1liguHNlOYIXkVWRXnCeWuQy9WHWtfQtat9ajvWtUlQWl3LZSeYAMvG21iME8Z6fyrzO48G6v4j8Y/EKyubr+z/DmpXdl5waxYy3ka2sIYRTFwqjKlSdjEc8g1VHhNobltZh0WVdb/4TISC7Fu3nC0a4w5DYyIijNnHykcn1oA9porwDSrfUZviFo+oxeF/7Gdri/XUI9M0Ga2lWMwTbDLdkiKcs6oylVxuI+YZwc6z8Naovh7VbHQNJdFNlbpc6idEudPup0FyhmhljMg+1SGIOS8ZBblQRuBoA+kK5k+OdCF7rVp5l+bjRk8y+UaZcnyl7EER4fI5G3OQCwyATXOfB7TP7Pudfe3VoLGZ4DHbRaDNpFsjhWDNFFM7MSRt3EBRlR1JNZ0dxJH4r+KcradrHlXNrAtu40u5KzmOFo2EZEeH+ZhjbnI5GQCaAOug+IXh2f+wvKnv2Guc6cf7LusTjk5H7vgbQWy2Bt+b7vNdZXiOiyTxQ/BRJNL1tW023MV7nSrkfZm+xNb/vP3fy/vDjJ4x833ea9L8Kw6fFq3iRtP0i/wBPnkvt11NcoypeSeWg82IliCmMLkADKnigDUtdYsbrWb/Srefff2CRSXEWxhsWXdsOSMHOxuhOMc44q/XmcGojw98V/F13qVhrJtL6z09bea00q6ukkMYn3jdFGwBG9evrXHWVreal8RtF1FfCcGlSvq10l+tv4fnidrdopgXuLs4jmWQ7GwFPJBLA8EA9w0bVLPWtMt9R02bzrOdd0cm0ruGcdCAR07irtfO9n4Y8jwToNhZ6B/Z5sb3/AIn8Uvh6edLnaswiZ449hu0DEH5GcDcpIwCK9U+EunvpvhWS3LzmD7XM8CSafJYLFGxyEjgkdnSMHO0MR9AMUAdhczLb28szglY0LkDrgDNU/D2qwa9oGmavaJKltqFrFdxLKAHVJEDAMASM4IzgmvBvCOk215b6BN4c0O8i1uG/v5NS1MWUkaPbH7QvlmYgLKGYxAIpbBGcAg1seGPDM3hfS/BV5o/hmQ3z+F7ldUgEBQ3U4ggZIbgkfeLh1AfpyBwMUAe40V856XpVzM+viLRbvSdOvtCCTx6H4buLALN5y4Xy5GHnuqs2SoXcuQAe0z6DqM2loltolna+H4tWWW5EPh27jhvEFsQrPphkEhVZCoIXhjhiCFNAH0NRXF/CXT303wrJbl5zB9rmeBJNPksFijY5CRwSOzpGDnaGI+gGK7SgArlfiX/yLln/ANhrSf8A0429dVXK/Ev/AJFyz/7DWk/+nG3oA6qiiigAooooAKKKKACiiigArzrwl4ktdBsL+w1Ow8QJcpq2pSfutCvZkKSXs8iMrpEVYFWUggnrXotFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFZWk6z4M0e7uLrSPDWpWF1cf66a18JXsTy85+ZltwTzzzXf0UAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHK/8J5pH/Pn4k/8JzUf/jFH/CeaR/z5+JP/AAnNR/8AjFdVRQByv/CeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wAJzUf/AIxXVUUAcr/wnmkf8+fiT/wnNR/+MUf8J5pH/Pn4k/8ACc1H/wCMV1VFAHlV6lxrPgb4tTWNhqX/ABMvtH2OKexmgmn/AOJZbxfLFIqucujKOOSOK6v/AITzSP8Anz8Sf+E5qP8A8YrqqKAOV/4TzSP+fPxJ/wCE5qP/AMYo/wCE80j/AJ8/En/hOaj/APGK6qigDlf+E80j/nz8Sf8AhOaj/wDGKP8AhPNI/wCfPxJ/4Tmo/wDxiuqooA5X/hPNI/58/En/AITmo/8Axij/AITzSP8Anz8Sf+E5qP8A8YrqqKAOV/4TzSP+fPxJ/wCE5qP/AMYo/wCE80j/AJ8/En/hOaj/APGK6qigDlf+E80j/nz8Sf8AhOaj/wDGKP8AhPNI/wCfPxJ/4Tmo/wDxiuqooA5X/hPNI/58/En/AITmo/8Axij/AITzSP8Anz8Sf+E5qP8A8YrqqKAOV/4TzSP+fPxJ/wCE5qP/AMYrK1nWfBmuTQS634a1LUZbfPkvd+Er2Yx5wTtLW5x0HT0rv6KAOUHjvSAMCz8SY/7FvUf/AIxS/wDCeaR/z5+JP/Cc1H/4xXVUUAcr/wAJ5pH/AD5+JP8AwnNR/wDjFH/CeaR/z5+JP/Cc1H/4xXVVBFd20t3PaxXEL3MCq0sKuC8YbO0svUA4OM9cGgDnP+E80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGK6qigDlf+E80j/nz8Sf+E5qP/xij/hPNI/58/En/hOaj/8AGK6J760jvorJ7qBbyVGkjgMgEjopAZgvUgEjJ7ZFWKAPKrJLjRvA3wlmvrDUv+Jb9n+2RQWM080H/EsuIvmijVnGHdVPHBPNdX/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHK/wDCeaR/z5+JP/Cc1H/4xR/wnmkf8+fiT/wnNR/+MV1VFAHHWfjHQLK3WCy0zX7eBSSI4vDOoIoJJJOBBjkkn6mp/wDhPNI/58/En/hOaj/8YrqqKAOV/wCE80j/AJ8/En/hOaj/APGKP+E80j/nz8Sf+E5qP/xiuqooA5X/AITzSP8Anz8Sf+E5qP8A8Yo/4TzSP+fPxJ/4Tmo//GK6qigDlf8AhPNI/wCfPxJ/4Tmo/wDxisTxb4ktdesLCw0yw8QPcvq2myfvdCvYUCR3sEjszvEFUBVYkkjpXotFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXNeIfEV5a67aaJoWmR6jqk0DXTie5NvBBCrBdzuEc5LHAUKc4OcAZoA6WiuUHjBdMjt4fFlodM1O4aX7PaWpkvjcLHs3NH5ce5vvj5Sobrxwar658Q9I02y1UhNQF7ZWdxdpb3OnXMHniEZby2eMBwCVyVzgHPTmgDs6K838E/EObUtZs9H1e3nkvLqxjvluLfSLu3jXe7r5bJIrFQNh/esyq2eAO/bXeuadZ6l/Z91dLFd/ZXvQjqQDChAdg2McFlyM5GRxzQBpUVyp8f8AhwfZT9tn8u4SFxKLKcxxCXHl+a+zbCW3LgSFTyPWkf4g+G1WVlvLmVYpntiYbC4kBmWQxmJdqHdJuU/IMsQNwBXmgDq6K5+z8Y6HeQtJDePhbSS+ZZLeWNlhRyjsVZQQQykFSN3HSoYvHXh+XU7ewhvJ5LifygrJZztGplQPGryBNiMykEKxB5HHNAHTUVynxA8Ut4Vj0KcorW97qaWc+IZJnCNHI37tE+YvlFAABznpTZfiL4Yjsra6+3zyJcedtiisZ5Jl8ptspeJULxhDwxZQB3oA62iuak8c+H0vre0S9lnknETI9taTTRDzRmLdIiFFLgjaGIzkY6034feL4PGWhJqMFneWjZIeOe3lRR8zAbXdFD/d525xnB5oA6eiuH8TeP7Sw1ex0rSma5vX1S3sLom0meGISEbl84ARiQKQdpbPPSpLX4g6Hb2dkNQ1X7XcTx+aZbPTLkRiMytGHdQH8pdyldzsASpPToAdpRXOp4z0J9YGmJdytctK8CMLWbyXlQEvGs23y2cbWygYt8pGODVdfH/h7yL6We5vLX7HHHLNFeafc28u132IVjkjV3y/yjaDzx1oA6qiuUb4g+HVtkm+0XxLNIvkLpl01wnl43loRH5iqNy5ZlA5HPNall4k0m+1CysbO9Sa5vLI6jbhFYrJb5VfMDY24y68Zzz0oA16K4/4j+Nh4MtbGRdPfUJJ3d5Y0k2GG2jQvNP0OQgxx3LDkVf1bxnoOlX8dld3jm4dElIgtpZ1jR22o8jRqyxqxzguQDg+lAHQ0VzN5430SHSIr+G5edbgXQtkSGTdM9usjSKAFJBHlP25xxnIznaR8StEvfDumandR6jbS3sAn+yLp11LIo2IzsFEW5413geaF2Hse1AHb0VBYXlvqFjb3tlMk9rcRrLFKhyrowyCPYg1PQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5R4sbw5/wsa+HxK+wf2R9gh/sn+1tv2PdmTz9u/5PO/1fX5tuMcZrlr26k0i68Y654J1a4stO0zSdNngtxCrpcqDNhXMylwuAw+UqfmzngV6D4p8LeO9R166utB+Iv9jabJt8qx/sOC48rCgN+8Y5bLAtz0zjtWT/AMIT8T/+iuf+W1a//FUAVtY8QeI47PxVqMWtTQW2m66mnKEtYnS2tn+z+ZM+ULN5ayO45AHJbcMAU7TxPrmp39hpmk+KZrrTJ/EBsYdcit7ZnuYBZSTOi/u/KYrIu3eq44xg4OdX/hCfif8A9Fc/8tq1/wDiqa3g34lo6I/xfVXc4RT4btQWOM8fNzwDQBit468VW+mqIbr7bd29hre4m1UmaS0vI4Y5SiAchCxKrgE546Y9D+Hmp2+pQXxs/F3/AAlMMbp/pHlQjyiUBKb4VVG9cYyucEmuY/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9Voryr/hCfif/wBFc/8ALatf/iqP+EJ+J/8A0Vz/AMtq1/8AiqAPVaK8q/4Qn4n/APRXP/Latf8A4qj/AIQn4n/9Fc/8tq1/+KoA9VrM8TXl7p/h/UL3SrRb29t4WmitmYr5xUZ2AgHBIBAODyRXnv8AwhPxP/6K5/5bVr/8VTJ/B/xKt4JJp/jAscUal3dvDdqAqgZJPzdKAIfAX7QPgnxV5cF1eHRNQbjyNQIRCf8AZl+6R9SpPpXriOsiK8bBkYZVlOQR6ivzGXTr/wAReI7mDRLe51W5nndkFva4aQFid3lrkKD1wOBX1B8CfhZ8T/Drw3F94kOg6XkM2mMRdlx1IKE7I8/3gd3tQB9N0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAVynivwpPquqQ6npl9b2l6LWSxuI7u0+1211buQTHJFuQnBBwQw+8wOQcV1dFAHnvg74bJ4b1LTbyO9tv9Elvpjb2tkLeHNz5WVjXedir5XAy3Xrxzh2/wbMc11JJq9k0k1lfWZul0zF1N9pXbvnmMpMpTtwo7ACvXqKAOOfwbJ/bttereWctm2lppN/Z3dkZluYVLH5TvAXO9gQyuCDjFVPF3wz0nWdJ07T9IEGg29rOxdLC2VFlgkXbPDtXAAkXGW7EA4OK7yigDzbWfhba3vi291q2/sQfbWgaVb7RY7uWExIqDyJGYCMFUUYKsARkYq5eeAJJfCEmiRahZsX1OfUS93YedGwlnkl2FN6sCPMADq6tlQRjJFd7RQB5kPhtqsFhBFZ+JwLk6dPplzNdWTT74pJC48sGUFNmSq7mf5QAckZqW0+Gtzb+I9M1JdagRLIW4JgsTFcSLFGqeW0qyhWRtvIdGbBwGxjHpFFAHJXPgPR430j+wrLT9GisdSTUZI7OzSMTlY5E2nbtwf3n3uemMc1jx/DzUdP1O51PQfEENpf3Et6ZGnsPPTyriYS7QvmLh0YcNkg85WvRaKAPMbX4VtYatos2m6xHbWemJaxJstCt20cKgGMzpIoZHwdwdGwGYAgEY2dC8A2cOiro/iSHSNf022meSxS601S0AZmYhi7OGb5sblVOB0rtaKAPPrjwDqD6uGg12GPRv7ZXWzaNY7pjKGDMnneYBsLZP3MjPUgYrLn+FFy0Olwwa9BD9ij8tbhbArcp++aQtFKkqlfvYw4kXjIAyc+q0UAeW23wlgtNUvJ7O50qGKee5uVuRo8Z1GJpt5IW7LZwrOSp2bgABuxVbTPhA9hb6iseoaKkt5ZQ2beVogWOTy5N5kmVpWMrt0Lbg3cEECvW6KAPIn+Dm4Wc0uo6VfXduJ0EWqaT9ttEjkKkLFFJMWj2lcg+YfvNng4HoGjaNe6XLpkUepR/2XZ6cLRrKOyjiWSYFMTArjYAFYeWo2/N7Ct2igDxD4k+J/hvB8Qr2Hxx4mvILu0sVsRYWq30HlLJ+8kLSQYEgdTF8vQbBnJ6ctofxG8FaA8J0j4nRputbezumuPD9zK8iQFhGUPARvLbaSwcHGcA19MUUAfMVj46+HkGoacs3xEil0bT576a3tV0K6WbF0soYPLgg7fNOCEHTkHqKFx4q+HN1aaGt9430HULnSLM6dB9v8JXNxA1vtQIWiY/60FCd6sAQ2NtfVlFAHjuh/HP4X6Vothp6+KI2FrAkO6PSriFTtUDIRYtqjj7o4HQVd/4aD+GH/Qzf+SF1/8AG69VooA8q/4aD+GH/Qzf+SF1/wDG6P8AhoP4Yf8AQzf+SF1/8br1WigDyr/hoP4Yf9DN/wCSF1/8bo/4aD+GH/Qzf+SF1/8AG69VooA8q/4aD+GH/Qzf+SF1/wDG6P8AhoP4Yf8AQzf+SF1/8br1WigDyr/hoP4Yf9DN/wCSF1/8bo/4aD+GH/Qzf+SF1/8AG69VooA8q/4aD+GH/Qzf+SF1/wDG6P8AhoP4Yf8AQzf+SF1/8br1WigDyr/hoP4Yf9DN/wCSF1/8bo/4aD+GH/Qzf+SF1/8AG69VooA8q/4aD+GH/Qzf+SF1/wDG6P8AhoP4Yf8AQzf+SF1/8br1WigDyr/hoP4Yf9DN/wCSF1/8briPjN8Vfhr40+H2o6bY+JyuqRgXVg62VyjLcJyuG8sYzyuewY19GVwvxpt/EGo+Ab7SPCNoZ9U1TFnvLhFhiYHzHZj0G0FfXLDGaAPkzwF+0V408M+XBqcya/YLx5d6T5wHtKPmz7tur6a+F/xv8L/EC5isLUXdjrDgn7HPEWzgZJV1ypH12n2rzrwF+yxptp5dz421R9QlHJs7ImOEH0Mh+Zh9AlfQXhvw3ovhiwFn4f0y00+27rBGF3H1Y9WPucmgDWooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKoa9pNtrujXml6gJDZ3cZhmWNyhZD95cjkAjIOOcGr9FAGT4b8N6L4YsBZ+H9MtNPtu6wRhdx9WPVj7nJrWoooAKKKKACiiigAooooAKKKKACiiuK07xF4q1dbu40rw/ojWUV7dWcb3OsyxSP5E7wliq2rBcmMnG48Ec0AdrRXK/bvHH/AEL3hv8A8H0//wAh0fbvHH/QveG//B9P/wDIdAHVUVyv27xx/wBC94b/APB9P/8AIdH27xx/0L3hv/wfT/8AyHQB1VFcr9u8cf8AQveG/wDwfT//ACHR9u8cf9C94b/8H0//AMh0AdVRXK/bvHH/AEL3hv8A8H0//wAh0fbvHH/QveG//B9P/wDIdAHVUVyv27xx/wBC94b/APB9P/8AIdH27xx/0L3hv/wfT/8AyHQB1VFcr9u8cf8AQveG/wDwfT//ACHR9u8cf9C94b/8H0//AMh0AdVRXK/bvHH/AEL3hv8A8H0//wAh0fbvHH/QveG//B9P/wDIdAHVUVyv27xx/wBC94b/APB9P/8AIdH27xv/ANC94b/8H0//AMh0AdVUVxcRW0TS3EiRxryWc4Ari9a8R+LdG02a+v8AQ/DUVvEuWP8Ab0+foP8AQ68R8VeN9Z8UkpqEkcNnnctvCTtH1JALfkPpXZg8FUxcrQ2W7NaVGVV2R6v4s+M3h/QxItuXvHQ4yn3M/WvNNR/aQvJG22WmRQKD98nfuFeIazPJfavKjEiCM7UXsPwq3FpcZhBIHSuh4anGbjFXt3PSo5eqmx7toPx41C6DZtLS7brhWMZUfTvXf+HPi5oupSLDqCSafMeMyDKE+xr42uy2mTrc27lGU8Y7+1adx4mv7gKbeJI1xyCM5rX2OEnBqacZeWpnPCRT5GtT77triK5hWW3kSWNuQyHINS18afDr4ra1oF0lqpjMRbP2eViI3OOmcEr9QD9DX0hofiXxXrenRXunaH4algk6H+3Z8g+h/wBD4NeZVoOnqnddzgqUnTdmd3RXK/bvHH/QveG//B9P/wDIdH27xx/0L3hv/wAH0/8A8h1iZnVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8cf9C94b/8AB9P/APIdAHVUVyv27xx/0L3hv/wfT/8AyHR9u8b/APQveG//AAfT/wDyHQB1LMFUsxAAGSTXPXPiZXkaHSbWW+lXgsgwgPuaxbW81/X9RubHVrPT7Gyt8CU2F89z5jf3SzRR4/I11MUcUEIigRY41GAqjGKaQm7GQ934nYgrDp0f+yXJxQmr69akfa9MhuU9bWT5vyNaztx1qGVxkYzTsRzMk0nXrPUnaJC0Vyv3oZRtYf41rVympWdvegeeCJRykqHDKfY1lLr3iex1OLS4LDSNQR13Q3N5qElqzf7JCwSAnpzkfSk1YamnoegUVyv27xv/ANC94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHSLOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6AOqorlft3jj/oXvDf/AIPp/wD5DqObU/GkMLyy6B4aWNAWZjr0+AB/250AdRdXMNrA81zKkUSDLO5wAK8q8W/HPw9o8jQaYsmp3AOMxfcB+teO/Ej4i6340vJNNY21rp8TlTFZztKshHcuUQkf8BFZOheGvMABjO0+3SvoMJk8PZqrina/RbibPSk/aEvWuCf7BQQYwB5h3Zro/Dvx70O9mjg1e0uNPduDIwzGDXng8G/L908DisTV/C3lrkJyOcHvXU8vwFT3Y3XzFc+utO1C11K0jurGeOe3kGVdDkGrWa+Qfh94zvvAWtoZnll0djtmt88L/tCvrPS76DUrCC8tHDwToHRh3BrwsdgZ4Odnqnsyi3RRRXEAUUUUAFFFFABXK/DT/kXLz/sNat/6cbiuqrlfhp/yLl5/2GtW/wDTjcUAdVRXK/EnxVP4P8OpqNnpTatdS3cFpFaJN5RkeVwigNtPOSOMVT034j6Rez38hPl6Zb2VjeRXILSPMblpVWMRKpbeDEBtGSS2MAjkA7aiuf0rxjoeq3Fvb2d3L9pnllgWCa2lhkV41Duro6goQrKfmAyCMZrGj+Jejy+I4NPgjvZrOaxN6l9FZ3DoMSGMhgIyFA2kliQB07igDuaK5H/hYvho2lrcx3d5NFdgG28nTrmRrgFN5MarGS4VfvFQQp4bB4pL74keFbJYXk1KSVJrNdQV7aznnVbYkjzWMaMEUFSCWxjvigDr6K5ybxtoEOqpp7XrtM8scHmx20rwCVwCiNOqmNWbcuFLAncPUVQi+Ivhy++0QafqbJcLHcGOaewuBCWhB8wBiqrIUwSUVtxA49aAOyormP8AhM9JtRpsWoXFzvvEg2Xa6bcpayNLgJ+9KlE3EgBWfIJAPNdPQAUVwfgr4hWWtXL6dqT/AGfVTqN7ZwqtpMkMghmkVVWVgUaTy0DFQ2epwBwNIeP/AA6IbyS4ubyzFpEs8y32nXNq4jZtgcLJGrMu4gEgEDvQB1VFcuvjnQ5rxLGG5u/t0qLJHE2nXG4ozsgk27AfL3Kfn4XHOQCDVSD4haDbaRp9zqGqi58+zivHubTTrgQrE4+WWQAP5CHnHmMOh54NAHZ0HpWLpvifSdT1W406wnlnurZ3im2W0uyJ1xlWk27AeeATzzjODV/V7pbHS7u5kztiiZzj2FAHgPxl8USavr0mlwsRYWRwwB4eTvn6V5dFcTRXDyXpEVuAcH37Yq/NcG4lnupnJeV3kYk9cmqwKTXFpfQoLmO3fLQf36+1w9D6vh4qHxJXt3PZpwUIJI5bWtNdrmTUdMzcQyHLoo5Q/SqKasI1CMpBHGCDmu91eWSd9R1K0tRZmdQFgT+HHU/WlXTNKgvbE6ZOL7zYt9yXGdjf41xVMLzVI2vFy6WNYVJwdo6XPMtQaea4hklidIT90sMAmt7TYYjCMgGuy8R6Qmq6f5G4JKnzRsB0PpXnt2t/o5KXsLIAcBh0b6VlisFLBzu9Yvqa05qlNufUTWkETo0Yw6kFSPWvfPgn4ol0jWreyvJCtpfKqlSeEl7Y+tfPNtdrJexzXsTyQKdxUdTXoOnalDdRR3dnIVMTqwxwykGpw1KGIpVIt6vZenU5q/LW5rH2sOlFUtEuftmj2Vxg/vIlbnr0q7Xzx4pU1fUbbSNMudQvjKtrbIZJWjheVgo6nagLHHsDTdF1S11rSrXUtPaV7O5QSRNJC8TMp6Ha4DAHqMjkc9DVTxlFcz+E9YgsbWW7uprSWKKCNkVnZlKjl2VR17kV5Hqfw71DXdGnfUfDqtfweDY9OsVuZIWeG/j83GwhyFbJQh84AbqPmFAHulFeB+NvCH/CPabqYtdFVNFvG0FDa27Ioublb3EwwWHzspjBdsbsjLHBImvvBGry20sNv4UjtvD13qb3S6RHBp889iogRFZFnLW6b3EjMF3EBhgZJwAe3efJ9v8As/2SfyvK8z7TlPL3Zxsxu37sc/dxjvnirFeFR+BPE7+E7WynsZGuk8Pxaewa6jLCVbtX2bg2OEGcjjjA9Kn+IHw1mufEEp07SLy40RrFY7WDSjYRm2ud7mSRjcoSjPuQ+dEfMyvOcDAB63rutW+ix2TXSSuLu7iso/LAOHkbapOSOM9f5Vp14nL4M1Y+Jree58MNe6iuvwXx8QST27stmu393uLCXKgbSoQKcEjk4rr/AIlaHcarqug3MuhHxHo1qLlbrSt8XzyOqCKXbMyxts2uOTkeZkZIoA72uX8O+NtN1/ULazs4LxJbi3ublTKigBYLjyHBwx5Lcj264PFeXj4f6u/iaC8utI1ZVWWxksDZ3diyadFHHEGgaaZDcAKyPnyiRIDzgsxLpvh94kn0G6tBYqkz6Lqlqu6dMGWW/E0SZBP3kGc9B0JFAHsXiDW7bQ4bKS7SZ1u7yGxTygCQ8rhFJyR8uTz39jWpXj93oXiPXPE99q0ugXGnwzajosqRXFzAz+XbyyNKx2SMBgMDjJJHTnIHNr4D8UTX+q3Z0L7Je3umapbXRt1sLe2nllTEQTysSuCRndMcgnOFyaAPoSisDw/oqaD4ZEGlWNrbag0AeQEcS3GwDdIw5Y5ABYknA614np3w78R/YtYhTQJLJL/SooZ4FXT7aGS5FxG5EaWxHyBN+GkJbHHHQgH0XWNpuu2+rWOpzWqyxiyuZrN/NAGXjOGIwTxnp39q811rwFdWl/qMWk+H4pvDJ1SyvH0i3eKOO8iWB0lURsypnzPKch9obZzmuq+Geh3Oj+F9UtbnSF0hZ7+6ngsVaMiKJ2yi/uyVHHYHigC34LH/ABT0MrD95M7SOx6kljzW0SDmsPwW2PDkEbHEkTOjqTyDuNbLsCcZOD3q0ZtmX4j13TvD+lyX2qTiG2T8ST6Ad68c1f49R/aAui6K08I/jmbBb8K4r4u67ceJvHF1Y+YwtbN/KSMH5eO9TaN4aikiBZeMV6lDB0+RTq9egJHoXhj4zaRqlzHbavbSaZdSEKGY7oyfr2rvtStxf2TRxyAPw8Minow5BBr5s8UeHUSF8Lggda9Q+Bevzap4Xlsbos8umv5Yc87lPT8qzxOGjCKnDYzmrao9p8K6n/aujQ3DcSDMcg/2l4NN0TxNpmt6lqlhp0ly11pkohulltJoRG5GQAzoFbjB+Ungg9CCcf4fsUutbt8/KlwGUD7oBHauK1PwlrGt6n4khvfD866ffeJbC+BnngKTWsSxRynCyEjiNmwQCQRxnIHmM3i7q57NRXj+nfDc6Xqkd7pmhW1rcQeJhc28sJjRotPKYZUwfljJZ/3Yx1+70rl/B/hzVb3w/Zah4X8NQWl9FZ6ks19dmAx6q0m9Y4WVXLOobB/ehQNmBwTQM+gL64ktoVeG0nu2LqhjhKBgCQCx3sowByec4HAJ4qxXgfh7wFr9pDrMVvo1zZ2lxfaJcxQTfYYPmgui9y4jtiI1AUKecswA5J4GnqPw71GTwZdCHTgNXl1q5uLlY2gae5sWvJJBCrSho9pDI/lv8hI+YAk0Ae01l+FtbtvEnhzTtasUmjtb+BLiJJgA4VhkBgCRn6E15Bp3ge9sTppu/CV/rWhxPeY0a/nsCYZZPJ8qby02W6qAko2ruK7yRnJA6zS/DWuQ/Aa18ORr9k15NIW12eeF2yBMFPMQnGeRuB4zmgD0euX8ReNtN0DULmzvILx5be3trljEikFZ7jyEAyw5Dcn26ZPFeaa74IudQt7H+yvBV1omjx3Re90m2k093uiYtqyiKUyWx2Nx8xDHO7ggUN4D18aZ5Ntp15s/s2wt0W7u4JJVaPUmmZGZNqfLEQRtAUDCgkigD3Osvwvrdt4k8P2GsWKTR215GJY1mADgH1AJGfxrzaHQPEUevWNj/YcxsoPFVxrL6j9pg8owSCUqAu/zNwMoBBUdOMiuJ1/4e+Lrrwjpunf8I/vvbLRo4rKa1WwMsN0HdmEk8xLoo+Qr5Pcn5hQB9J0VxXgzwstj4g8SatqenQi9n1WWayuH2u6wNDEpKHJ2birAjgnaM9BXFfEHwl4i1fx42o2ei7jb3thJY31qlimIUeNpvOlk/wBI3D94AqFV29S2SpAPaqy5dbto/FFtoTJN9ruLOW9VwB5YSN40YE5znMq44xgHn18u034e6jY3Om6jYabDZa22t6pNd3yugk+yzC68oswOWXc0B2DODzgEGpfhh4SvdH8X6VeSeExoq22hS2V9eGW3dr27aWBt5Mbs758t23uAeTkDjIB7BXnHx81t9F+H10IX8uW7YW6tnpmvR68c/aiieTwFbMikhLxCxHYV04OMZ14Rls2vzA8I8J6asxUlMHse1ex6emn6Po/27V5Fht48fvCOvsPevL/BEiiSLJ6eppnxP1eXUtbi0mKRxZwKMxdix719PmLnOappknQat8W3aVk0PSYfJQ4Dy5JYevtVBfiWl2oTWtKCRnrLD1B+lQ+G9BgkhUhBnHXtU2v+HoVgZwBwMYFcKhTi7K/qBR8Sw2t3bLPaSLJFKuVZfT3969j/AGZtZlvvCt3p1xJuNhNsjBOTtPP5V856fcNYX01huJt5VLAHs3tXtn7LdpM11rt7tAgysOc/xda2zC08FeW6Y0fQlFFFfLjCiiigAooooAK5X4af8i5ef9hrVv8A043FdVXmDf8AJFPG/wDv+If/AEru6AOy8YeH/wDhIrXTYftX2b7HqVrqGfL37/JlWTZ1GM7cZ7Z6GuGvfg3ZTT+J2i1FRbatc2t3b2s9os0Nq8MkkrKUJxJG7zOSmFwCRn0or418S+H7O106caLf3BttKkheGKWJYluLlYGjky7EnByrjGcE7O1Wdc8ceMdP1/UNLsrDT79tIjgkvJhHFbxzCUkggy3amFQuF3bZcsD06UAadh8ObzTVsLjSdQ0PTtRtLua4X7HoawWuyWJYynkpKGJG0MHLk54ORgBdK+HV9pUWnrZ67AWi0+XTbtprAt58bymTcgEo8tgWI53D2rNtviDqt542s9PjihuPD2pXV9Yw3JsxAweCORjtY3DtIAYypPlIpzkHsec+HnxBv7X4VW7WVvaQro+nadZJb3qussks3lRrcNggC3G/IIyW2tyuMUAeiSeCb22sfCh0bWIbbVNAsW09Li4szNFNG0cavmMSKQcxIww/GMHINc2nw51u11Z7DSdTittJk0FNOub+e1E0kztPM8uxRIvlt+8yCVZRuAwcVSsNb1zSfHOuact5pE2r6rq1rZG+NrIltDiyaTmLzSxYiPaF8wZY5yOlTXHxM8QRWdrHFZ6XcX9493plnJGH8m4v4rlIkI+bPlMrM5GSV8t/mOM0Aalr8JbOw8S/2hYNoxtTdQXWLzRo7m7jMYQbIrhmGxTsHVSVJJUg9Lp+G+dG0mw/tX/jwk1CTf8AZvv/AGpZlxjfxt873zt7Z4wdM+JGv+I49Kl0ODTbSDUtVTTYnvbeSQx7bJp5yyrIuSsqtGBkfcPrkdp4Q8RX2q+CrnUr6G3Oo2st5byLbqwjkeCWSPKgkkBvLzjJIzjJoA5HUfg+17qEFw+r2UgiawdZLnTPOuIfs3l/JBKZB5SP5eSAucsckjiu/wDDCayH1eXXZSRJfy/YocJ+5tlwqcr13bS/JJG8A4xivPPDV9qmleE/h9aeHpdO+3+Jg13fXt9C82+V7c3EkuEdCzEjHJ6YHGKNK8feKfsGn3upx6LJFf2moNHFbQSq0U1qDglmkO5WKt8uFI45NAGxZfDq+SWKC819H0u21G71S2htrMwzpPOZSC0pkYME898YVckAnpisbTfgybWK7VtV05HnsEsWktNJ8l5CsyS+dMxlYySHZgkkdcgDobetfEq+sLSGWGHT5Wl0S0v/AJiwWOaeeOIMxBOIl8zce+FPNWrrxH4oh12Hw8NT8L/2i0d1ctftbS+SscSwERND52VlJm3H94QEAbBzgAHWN4fz4vu9c+1f8fGmx6f5Hl/d2ySPv3Z5z5mMY7da8+PwXhjhsVivNGuZYdMttNll1TQ470/uVKiWHe/7piDyDvXgcHFMtPibrd62iX32bT7HR7qKyM8jwPcgSTPtZWdJAYc5Tyy0bB94OQMkVfCerazqXirSBp8ulaZpb6bqMk+mx2TmCXy9Q2OVQSqokZcfOQ2Czkg7sAA9S8MaENCGqBZxML6/lvQBHs8vfj5OpzjHXj6VY8SWz3egahbxY3yQOoz0zivJtB8f6xFpvhd4bPRdM0Kaz04y/Z7N5Io3nwGj/dyZtgNyBA0bhtw5ABI9itry0v0uBaXMFyIZGgm8qQP5ci/eRsdGGeQeRQB8YTSqg+yeRNPJhgyxDJABwTUGiW1jcWWq3Nzqc1vewtm1h6eZjtiu48Z6bqHgv4hX9xpyRhZ1LRiRcqUb09xXHSRmNoiWjUu5aWfZu2E88CvrYOeJgqj0ilo1uevB86Ui1pd5dyzBLiJVTaM8cjjrVi9fyDa29qI7eS7l8vzcABc96q/2gYNLe5mG8qcAj+LnANWLq1vYjZ2+uW0Pl3kfmwlD0H+Nei6qUFT5vels35nQpWja+5deCXTtTutOuZ47n7Oobz0PDAivN9bvX1vV2HPkxnai54xXf/Z4orSaKBQvmKRknJz7mvMbFjaXLxSDEiMQc964MydWnSp0pu/djS1jGb0NI6YqxZxUPh4tBrvlJ92RSpH41YutSUQ4B7V1fwW8Jz+IfGFu8sZECkSNuH8APf615KahLnj01KxsqcY+6fYPhqJ4PD+nRSDDrAgI/CtKmxqEjVUGFUAAe1Orxj50K4jxr4k1LRPGfhi0sbO91C2vYL1prOzSIySNGIirbpGUKF3N/EM5xycCu3rLvdEtrzxBpesSvMLnT454olUjYwl2btwxkkeWMYI79aAOftfiNo11ps99bxXrwQ6KNdb92oJgO/5AC3+sBjYY6dOao6p8U9PsJ7xf7D165t7N7WOe5ghhaNHuFRolwZAxJMirwpwTzxglLj4U6W+lQafa6vrVlAumHSZmt5Id1zb7mYK5aM4ILNyu37xByK1JfAGlyWuowNcXuy+uLK5lIdMhrXyvLC/L0PkruznOTjHGACunxFtHTyU0bWTrH25tO/soJD9oEqxCUnd5vlbfLYNu8zHOOvFP074hWOqXlpaaZperXV3PE0rQrHGpt9kxhkWQs4Csjq2Rk5x8u7IBbrng3SIrm71iXWL3SbuTUVv1vkmiQwStCltsXzEKFWVVG1g2WPHOMO8N+DNAtfOfTrya8xbT6ZcsbhZDIzzNJM0jKM+aXZs8jGcYFAHMa98WLa+8M+KI9B82w13TLE3S75rS524cKT+5llUEE8q+Dz0r0DxRqUem/wBk+bcXkP2rUIbZfsyRtvZs4V94OEOOSuG6YNctF8KNLFhcWdxrGs3MEmmf2TGsjQKILfcrAIEiUbsqPmbJPfNdjrmi2+s/2f8AanmT7FeR3sflkDLpnAOQeOe2D70Acfa/FK3vJbJLPwx4kna/ExstsduBceUQJMEzDbjP8e3PbJ4pLz4s6TDZxXdrpOt31qdJXWpZbeGIC3tiWBLh5FO5SjZVQTxxnmt7SPBmnaU+htbzXbHSEuEg3sp3CYgtvwozjHGMfjWba/DTR7bR7rTUudQMFxop0J2MibhATIdw+TG/963OMcDj1ACD4kacVnF3per2M8UlkvkXEcYd0u5fKhkG2QjbuzkEhhg5XPFS6p8QbGx1CWwh0zVb69TUxpKw2yRZkmNsLjILyKAuw4ySMHPbmpdX8A6Zqkl7JNc30U1zb2duJInQGI2srSxSJlSNwdsnOQcDjrmLS/h9Y2OoRX82p6rfXqamdWaa5eLMkxtjb4ISNQF2HOABg47cUAc94l+JkcPh+bV9Gj1IXselajdJp9xFCIlktZEjkE/zb9yO3RHwVDdTtrfm+IVnYWt22taXqenXdtYLqH2aUQu8yGQxhYzHIyli+wYLD/WJ6nGTrXhXwVpZez13XUtDd2mqR+Td3sUJeK7kE1wwBAPyleCPujOc9au6h4GfU9Y8H3F3qD6nZ6K8ty11dMgnmJCmJMRIiFAyq5OM5jTryaAOtsNUN3qt7Ytp9/btaxQyGeaICGXzA3yo4JDMu35gOm5eua0TWHpOm6hB4l13Ub69aS1uTDFZWqysUhjRPmYqeA7Oz5xnhU57DcPSgDgte1C18Hajc3d/II9LvP3gI5Il7jHvUfhDxjp3i4XbaUk/k2xAdpF25J7Vzfj3wJrXiXxJ5U85urKQbi7NsW2A6BB3avPU1u48OzvpHhm6W3t4JWaaZx8zkHBL/wCFQqklJ8y0/MKdCdeTjBHLeP8AT5dA+It+twhWGaTzocdCp966rRdYhMC5YYxnjtXX21tafFbwWzaqkcV7DIyRzwjDKR0OPQ+lefS/CvxdZTtHaS2lxbD7shfaT9RXt0MTCdNRm7NGblytxluhnizVYXjkXOTj1rqPgBp8lpouqardAx29zJ+6Y8ZVepxWXoXwovmuVufGF7BBaI27yEb/AFg9Ca9i0XSk1aGO0sovs2jRAKSF27wP4V9ves8ViIOPJBkSfP7sTZ+HdtIunXV9KpQ3sxlC+i9B+Yp/xR1a80P4e69qelymG9tbZpIpAittYY7MCD+IrpbeJIIkjjUKijaoHYVn+KNEtvEnh+/0e+eaO2vIzFI0JAcA+hIIz+FeXubpW0Oet/iHYtNJb3ulatp95HeWlm1tcpFvH2k4ik+SRhtJBzzuG05Wi++Idlb3/wBhttK1a/vTqUmlpDbJFl5Y4VmYgvIoC7W6kjkHOBzVrXPA2nave6leSXV9b3d41nIJYHQGCS2ZmieMMpGcsc7gwPpUOifD+w0vULa+Oo6ne3kN/NqRluXjJkmlgELbgqKNu0ZAAGD7cUAUdM+KWk3cMVzdadq+m2Mttc3Md3eRRiNhbjMy4R2YMvPVQDtOCcU9vibp1vAW1LR9b0+Yi1kit54Y2kmjnlWJJFCSNwGYblJDjP3ckCrn/CvdGbTrCwna6ntLRLyIRyOuJUutwlD4UdnIGMfjWRZeDPD15PFFP4mvdXvswi3ea7gaVI7K4RzGoRACBKqrISC2cAsDigC1qnxN07RtW07T9b029064vZI4kWa6si6M77FzElw0hGSCSqsADk9DjR8D6teappmuy6hcNI1tq19axMqKCkUcrKgGBg4AHJznvmqmtfDjT9V1m+v21PVbZL+5tbu6tYGiEU0tuUMZYtGXwPLX5QwXvgHmuh0TQbXRrW/t7WSZ0vbue8kMhBIeZyzAYA4BPHX6mgDhovitptjotvcHT/EWp28WkW+r3N6YbYNFby7grygOg3fIxKxqfYHnGnN8S7K3t7s3eh67Be29xa25sHihM7m5OImULIVwSCMFgwIOQKdF8MdGj0G90hbrUfs13o0GhuxkTeIIRIFYHZjefNbJxjgcDvpan4J03Udan1Oae8W4muLK5ZUdQoa1dmjAyucEud3PPGMUAZum/Ei0vNQhtZtC1yxD350uSa4jh8uG6wSI2KSsTkAYZQy/MORmrS/EDSjpmm3wt77yb+G6miGxNyrbqS+75up2nGM++KtHwZpxkZvOu8tq41o/Mv8ArgoXb937mB06+9ZNv8MtOhljB1bWZLSCO6itrR5IvLt1uAwkC4jDH7xwWZiOO3FAFe5+I9ldaRePLZ+INGdbOC/ikMVuZZYJJAgeMFnXrgEOAQDnHQ0aR8RJ/P1L+3NEvbayg1o6VHfJ5JhXLqkZk/elx8zAFtuPmHvjU1H4f6Vf26QzXF8qrp0WmAq6A+VHIrqfu/eyoyemO1VvEHgaSbRPFlrpF9Kza4krCzvGUW0M8gAMqssfmgjbuxuIz0x1ABq2fi62vkiksdP1O5t5NUk0sTQwh0DIG3TEhuIQyMm4/wAWOMEGukrhbHTLXyvB+j+HNdt107S2aeeO3u/313HCrRY+UncvmsC+TjcuDya7qgArA8d6BH4m8LX+lydZoyEPo3at+imm4u6A+H7P7VoOqz2GoxmK4t5CjKfbvS+NTvv7XVomxGUEch64PY19M/FD4ZWXjKIXVuwtNWjHyzAcP7NXzt4h8M+IvDEslvq+mSSWx43opdG9+K+soYyjjoq75Zrvs/QloueG/EEUUOCwBx68Grmua9DLaFdyknuDXnM1oEk/0V5rd25ETKT+VS2mhavf+WscV1IjzxWwYRlV3ySLGoJPqzqPxpVMOoe9JpL1QEIaXUNbH2WNpZSdiKg+8x7Cvsn4SeFv+EU8H2trKuLuUebP/vHt+Fct8KPhFa+GUt9Q1cLPqicqoOUi+nqfevXR1rxswxkaqVGn8K692UhaKKK8wAooooAKKKKACuQ+H1vDd+FNRt7qKOa3m1fV45IpFDK6nULkFSDwQRxg119cr8NP+RcvP+w1q3/pxuKANGw8LeH9OtXttP0LSrW2klSd4oLONEaRCGRyAMFlIBB6ggVJqvhzQ9XvILvVtG02+u7fiGa5tUlePnPyswJHPPFeWaifEP2nxEbf/hK/+EvE9/8A2dsE39m+R5T/AGbOf9H+7sx/H5vXjNZlnZ+JZdFvorXVfFUwuLnTFdTYX1o8GbpROUkuJpJD+7J37P3YAz60Aeuf2F4Wsdeivf7K0S31q7kdo5/s8SXEz7G3kNjczbC+e+Cc8Zq2fDuitFHEdH04xR2xs0Q2qYSA4zEBjhOB8vTgcV47q2hXcHie2OrJ4sudA0rXZ1gmgnvprhLeWwQgq8RMzp5xZd2WxllzgkVo6na65FoGsXsyeIbi7m125tY/9IvttrZmdisqQW7rJIoAXG3nDYBC5oA7uTRPB1i8HhxtE0eJNTV5lsV09PKnEW3cWAXb8u9cZ9eK24dG0uGCxhh02yjhsG3WkawKFtzgrmMY+Q4JHGOCa8n+H1rr8niDwxNrEeqTx2kmsRLc3dtPGViZ4fK3eazOAQDt3uzYHU4rd+I0XiaHxBFb+HW1J7TxBbrp00sDMV0x1kBNyP8AnmTE8oyMZdI+/NAHeQ6PpkIgEOnWcYgme5iCQKPLlfdukXjhjvfLDk7j6mp7O0trKJorO3ht42dpCkSBAXZizNgdyxJJ7kk147pFv4oHxFZtR1HW4fK1aRYrdNPvJbeWx5Ee6Yz/AGYDYVyTH5u4d+pzLbT/ABrp/hbRbnTJ/E8us3+iXv25bueaUpOvlGLCykrFJjeF4XPfPNAHr3h3wrpug2dva2yGaG0mlmshcKjmzEmcxxNtBVQGYDJJwcZxgVow6Tp0P2cQ6fZxi33mHbCo8rf9/bxxuyc4655ryES61b/arrQF8XN4ctrzS5it+t294+JT9qCJL++ePZ5eVwQTu2gjNUtcvvEF/aX90g8WQ2kutXL28H2S/jMkH2eERg+RieJd28r8pXO4MAaAPXbDwl4c0+O4jsPD+kWqXCGKZYLKNBKh6qwC8g+hqNvBfhZtLXTT4a0Q6cshmW1NhF5QkIwWCbcbscZxmsHxJdavF8J7SSHTNRfUpLe1SaAzzPcwbigkZmt9srsgyT5eC2D2JrhNDbxGukJFrUviqbQItfmSWW2t76G7e1NqjRFVZ3uvK85mzhi3Y4AIAB7DN4Z0GfU7fUZtE0uTULYKILp7SMyxbfu7XxlcdsHilm8M6DP9j87RNMk+xSma132kZ8iQtuLpkfKxb5iRg55rzOxNz/bUQ1P/AIT/AOyhLT+x/LFxu27v3n2nb8m7P3vP52Yx82a5vSIvGZsruXU9X8UQazJZ3EV7Da6PeSLHKSAHjeScwtg8r9nVSQTwDjAB7WvhLw4t5Z3a+H9IF1ZqqW0wso98CqMKEbblQOwGMVP4d0S10DTns7HzGV55rmSSQgvJJLI0jsxAHdj26YrxCaTxEdBVfL8VxQrfSldv9qyLcr5KYG7i8hUMWxuDIWDdAQB7f4Xe5fwxpL30Fxb3ZtIjLFcyCSVH2DKu4A3MD1OBk0AY3xD8IweK9HaI/JeRAtBKOob0PtXzRqdhdabey2V7E0FymVZSMfiPavsTtXOeLfCOmeJ7UR38IEq8pMnDKfrXp5fmMsI+V6xZ00MQ6Wj2PkXyktLKYXS74mwnlryXbsfrVq38+O5jj1JbpLhIh5K3BzhP9mvQfFnwh1+3DjTWW+hDB0dSFdSOmRXMarpPiSW5W71ywvJJoE8lWWE7VFe3SxdGdSPs2rLvuvv/AAO6Nam2rMw7O7uJ7khsLHzlSuNuDxz3qpq2hWWpSGZt0Ux6uh6/WuktdC1e92/ZdLvZNxwG8ogZ9M11mifCrxFf3cIvoksLVv8AWMWDMB7Ct62LwsYctaal+P5FSrU4r3pXPIl8OWljHcXUi3F2LaJ7hkAzhUUsxP4A19d/DbwdF4V0hVkVH1CUZmlA/JR7CvPf+EXstB8B/GGGEvNJaw3MEcspywQ6ZDIQPT5pGP41654n8QWnh2yhnuo7ieW4mW2tra2QNLcStnCICQM4BOSQAASSAK+ZxmMjW9ylHlj+fqedWr+00WiNiiuLvfHjWKWyXfhbxDFe3N4ljBaMttukdopJAVfzvKKhYmz8+QcDHNPf4gafHp8ssmn6pHqMd5FYNpbxItz58n3F5fy8EZIffswD83FcBzlL47W0V58L9Utrhd8M09nG65xlTdRAj8jXlWuyahbf8Jpomoh5L3RfD8VnFPLwLqEXJaGTPclCoY/3lavdtB8Rx63pF7eWun30dxZyy281jMI1mE0fWMHeYyTxgh9vI561neHvGcuta5eaWvhjXLOSylWG7muHtPLgdollUHZOzNlXX7ob73OOcAGb8Ovk1zWI/EioPGx+e5YtlXtSx8s2xIB8gdMdQ+d3JBOLqHi3UI/FGuQN4iFrqtndNFp3hz7NG32+MQB0blfNO9ifnVgq7cEda9H1PX9G0q8trTVNW0+yuro7YIbm5SN5TnGEViC3PHFZuueM9H0+x11rTUNPvtT0i0muptPiu084eWhYqyjLL0xkjjNAHijeKdZ1/wALXqan4g0rU4nTT7iS1t7lZprab7dbgqwW2iEQ5YbHZ3BA5PJqxqXiq+8O2+orZa7HpkJ1nWJZY0eCO4mYXHyeWZ0aOTHzZjBV2JXBxmvZfCnif+37/Vrb7J9n+wG3G7zd/mebAkvTAxjfjvnGeOlXLfxNoNzrB0m31vS5dUBYGzju42mBUkMNgO7jBzxxg0AYXjnWdSsfBOnX2mXBtr64vNOhMktuCQs1xEjhoznGVcgjORngg81wXjHxR4o0PxVcaSviaxs0tI4HtZNWnihfUd5Jc+Wloxlwfk2xNGRgE5JzXrz+INGjtIrqTV9OW1mhe4jma5QI8SAF3DZwVUEZI4GeaoReOfCU0kaQ+KNCkeSXyEVdQhJaTj5AN3LcjjrzQB5te+NtWjtdduY/EgTxJbPfonhn7JHJ5UcTOI5doXzT8gWXcW2tu2gcinReM9UtY9U1DS/EreJPDmjNZ3d1qAhgPmRP5i3MIaJApMaeXN8oDD7pJziu+0PxxpWo69qmjXN3Y2ep2l89nDayXaedchY0fzFQ4bHzkYGfunn01B4n0E3t7ZjW9LN3ZI0l1B9rj326qMs0i5yoA6k4xQB4/r3jPxZDaaHLc6vZ6FbavBc6glzfTRWixKXBgtjI9vMpYRMCVKhmOcNxiuv8A6nr+v63cf2lrY+z2drYTNDZ26LHO8tvufmRN4Qn5gMKw45HIrqbnxn4XtRm58SaLCPNMGZL+Jf3gAJTlvvAMpx15HrWjql8bMWZRrMCe4SE/abnychs/c+U7344TjPqKAPJvHU2paX4y+IGuabq93bXOm+FoZ4IhFA8ZP8Ape0HdGWwGXeMEZJ5yuFE+teIPEAs/Gl9H4lXTotJv4La2WSCIRBZLe2ZvMcxuRzI5VjgKxy5KDA9J03xNoOqXslnpmt6XeXkal3gt7uOSRVBwSVUkgZ71DbeMPDV1FJLbeItGmjik8qR472Jgj7WbaSG4OEY49FJ7GgDxzTNck1XxH4N1TVfFd5aQJNqNmt9KbEJI37grGsqx+VKH5XcoUnaQACCT7ho+sWGtR3b6bP56WtzJZytsZQJYztdRkDODxkZGQearReKvD017aWcWvaS93dosttAt5GZJkYZVkXOWBHII61S8Oax4St7a7sNB1jSHjsTLPcxw3ySmHLs0jyfMSPmLElu9AHSkccda8e1j4KWt34ou9Wtb0QpdPueFlJA9SPevQoPFelX7WMukatol7YzSSRyTpqKEgpGXIjChg7DALDcu1ctzjBn03xT4f1VLptM13SrxbVPNuDb3kcghTBO59pO0YB5PpSaT3LhOUHeLsZFp8PtFtbWKK3SaEp954pCpc+pxSnwY+5iNb1HBPA3Dgelbmh+ING19JX0LV9O1NIiBI1ncpMEznGdpOM4P5Vp007bGbSk7s8X0LRre80j4TarqBku7zUZop7hpmyrM+l3MhO3oPmANeypGEUKgCqBgADAFeW+Gf8AkTvgl/27/wDpnuq9VoHawCisi48TaDbaumlXOt6XDqjuI1s5LuNZmYgEKEJ3EkMDjHcetWhq2mtsxqFmd9w1ouJl+adc5iHP3xtbK9eD6UAfPAGn23jG7vre68Oza7D4tcpp0FsF1aZTPsIMyuW8oKxcqYwuFwWxXrnxJ1ufSbvQoJNaHh/SbyaVbvVdsX7oqmY490qtGm855YH7uBya0z4+8HBZGPizw/tjwXP9pQ4XPTPzcZqtN490a08Xz6JqV9p9kv2S2ura4uLxEF0ZnlUIinGceWDkE53DgdwDzK68c+JG8QrbW/ijSobWFbJrSS9YWx1aN1RnkW3+zO8mSXXEcibSASPXQ+G//I9aP/3Mv/pzir1iTX9Gj1pdHk1bT11ZhuWya5QTkYzkR53Yx7VTm8aeFoYHmm8S6JHCgQtI9/EFUOCUJO7+IKceuDjpQB5B8Z5LdfiEbuf7P9p0+0spba1nyLq8KzvIfsDdpMhFdVyXU7fkwGPeazrOpa78FJtU0yQvqtxpytP/AGbuDJJgeesQOWDr+8AB+YEAda7eTU7CPTP7SkvbVNO8sS/amlURbDyG35xj3zWdP4v8NW5QXHiHR4jJM1uge9iXdKpwyDLcsCQCOoNAHkXiz/hWZ8D69/whv9jfbv7KPnfYuvk+YmftGP484/1vz/e/2q04Lqys/EdxP8GrGw1CFNOm+3W2mSIli85aIW+CCIvMAMpIUglQQSCVr1OfxBo1vq8elXGr6dFqkg3JZvcoszDBOQhO4jAPbtUNh4q8PahG0lhruk3UazJbM0N5G4ErnCRkg/eY8Bep7UAef/BZLu18T+N7W9stWjnN1bzT3GoSQM7ytbxlt3lSOATncAvyquBkYxU83gzwu3xigVvDeilW0eW6YGwiwZvtCfvD8v3+T83Xmu81PxJoWlpcNqetaZZrbyLFMbi6jjEbsu5VbcRglSCAeo5p0viLRIXt1m1jTY2uBG0Ia6QGUSEiMrzzuIIXHUg4oA5b4la9PpOq6Daza6PDmj3YuWudV2xfJIiqYot0qtGu/c55GT5eBgmuEHjjxLL4mgt08SaTBbxy2K2yXji3fVYZI4maZbf7M8jlyz42SoEIww+Uk+y6x4g0bRZLePWdW0/T5Lg7YVu7lIjIfRQxGeo6Vk2fjbSxa6nc63dWWj21lqMunCW7u0jSRkxzlsAE5+7z0oA89+Ef/I1aN/2C9X/9Ogr2us59d0hI5JH1SwVI1id2NwgCrKcREnPAc8Kf4j0zWPq3jTTdN8Q2GnS3Fn9mljumubtrpVS0aAREq/YEiUdSMcdc0AdTRVdb21e+azW5ga8WMTNAJB5gjJIDleu0kEZ6cGrFABTJYo5UKyorqeoYZFPooAoNo2mM6u2n2hdehMK5H6Vz/wARLeG38N2iwRRxr/bWknCKB/zEbeuvrlfiX/yLln/2GtJ/9ONvQB1VFFFABRRRQAUUUUAFFFFABXK/DT/kXLz/ALDWrf8ApxuK6quV+Gn/ACLl5/2GtW/9ONxQB1VFFFABRRRQBW1O/tdL0+5vtQnjt7O2jaWaWQ4VFAySa4nSfiPY3mueIVuDLb6Pp9tYyQvNYXENxJJO0y7RG6h3z5aBQqZJJ69uo8W6JH4j8NajpE0zwLdwmPzUAJQ9Q2D1wQDjvXD6p8Mb3Xf7am8Ra5ZXl5f/AGEx7NKCwRm1eRl3xPI/mK3mkMpI74I4wAddpPjPQtWvIbSzu5BdSmVVhntZYHDRBC6ssiqVYLIjbWwSDkAgE1nQePtDc3F8dat20sWlvcxxiymEpE0jpGwb/lpvKEKipu4zyGFYd38Kxc+E5NLiv9O0q+N6buK60bSUs0hVo/KdFjDkndGXG5mJywPRQK0NY+HMd1qEt3pmoDT3jt9PiskFv5iW7WkkjoSNw3qRJtK/KcDg88AGm/xB8OpbJMbm9OfM3Qrpty00QQgO0kQj3xqCR8zqBz1qaHxvoFzqkenWl881xKyRpLHayvBveMSKpmC+WGKEMFLA4I9RXLeIPhnea/f2+qavqWhahqyQyWzm/wBBS4thGW3J5cTS5RlJPzF2znkHjE9j8OLmz8T2OrR6taxx2pjJSz04Ws0yJEEETvHII2j4HBjJAAAYADAB0ngjXLrWLXUoNUSBNU0u+ksbnyARGxAV0dQSSA0bo2CTgkjJxXR1yvgHS76zi1rUdWt/st9q+oyXr25dXMKBEijUlSVLbIlJwSMkjJxXVUAFFFFABRRRQAUUUUAFIyhhhgCPQilooARVVBhVAHoBiloooA8q8Tf8id8bf+3j/wBM9rXX+ONCvtWTSb3RZraLVtJu/tlsLoHypcxvG6ORkgFJG+YAkHBwa5DxN/yJ3xt/7eP/AEz2tdN8Wry6sPh7q91p8ssV1GIzG8UhjbPmoMBh0znH40AZuv6X4z1iTR7ySy8PR3Gl6ol7FaLqE210FvNEwabyM7syqQBHjAPJrP1bwPrurR3uo6h/Y0+pXt9azXGmM8hspraAOEt3kKFm+Zy5bZgkAbcZzpx+PbyDVG0rV9Ght9SS/tLN1t70zRbLhWKSBzGpJGxgVKjp1wQaz73xpr954y0qw0Kxsvs4v7+xuIrm7MYm8lEIbcIXK/eJwO4wTjkAHSfDnQLzw5olza35t0868luYrW2leWK1jcgiJXcBmGctkgcscADFWfDuiXOm+I/FWoTvC0Oq3kNxAEJLKqW0URDZAwd0bHjPGPpTPFPiG80rVtH0zTdMjvrvU/OEfm3PkJGY1DZY7WOOewJHYGuU074o3eoas8Np4V1K5sFmuLb7RbRXDnzId4JyYBDsLxlQRKWyRlRyAAaur+HNZTxfqWp6Xa6HfWmqwW0E41J3VrcRMx+VVRhICHztJTDDOTnjjrb4U6tBYXenstjOEttQgtb+fWL12zcRyKp+zHMUR/efMV3Z5IANWJviTr+rWunNo1hpdtdnVbS2mt31FixSUOTHKr24eI5UAnYe+0nBFa+v+Nb9rHxGlxoS/ZNGuYra8lg1eSB2d44ZB5TJGG4aXByU4GeclQAdB4J8N3mhanrlxdyW7pfG1MYiYkjyraOJt2QP4kJGM8Y6dKxbbwJewyWcm+xEkPim41x2BbJhkEwC52/fxIoI6cHnpUXiPxt4gm8P+KL7w9o1uthpy39uuoS3wWWOa3Rw0nkGMgp5iFR8xJOCVCnNQXvxH1jSbfSrK48Pi/1uewF/LHZvczp5WQqkNFasQ7HPysqqMffoAw7n4Z+Krrw9a6JLJoaWun6NqGlW063MrPM06qqO6+UAgwoyAWxzgmuh8SfDu61EeL/sY02JtW0iy0+0LZXymhMpbdheF+aPGM/d6DArO8XeN9X1bQ7mTRdNl0+ytNT0u2u7qe7e3uo5JJraRohCEORtmVG3Ov3mGDjnpvjBNqum+B9X1vRNbvdMudNs5Z0SCKCRJmAyN4ljc4GP4SvU+2ADIk8Ea3NrWoxSJpKaVd+IIdb+2JO5ulEXlFYhH5YUEmLG7zOFduKw7b4U6tBYXenstjOEttQgtb+fWL12zcRyKp+zHMUR/efMV3Z5IANemyzHwn4X1PUNX1TUNWhsYZbyWa4jhEojRNxVREkanhTjIzk9emOV1X4g6zo1hZyat4XSO51KSOPT4rW8luxIWjkkcSCKAyKUWPnYkg+YYJAYgAq+MfAms31tpkegJplvPbaYdP8AtBupISmcbg0flPHNFlVPlsq5xjcASK6/xPod1qsGgJBLBusNRt7uVnygdYwd20AHk54HT3ry3xt4x1jUNLlvo4tV0Gf/AIRnWpWtmaaErLE8ASVQyo3QkqxVWAY8DmvUfFHiGTw9o2mXKWbX0t1d21kIxKEOZXCbskY4znBxn1FAHGn4ZXsvhzRtLe5s7d7a01O1uJ4dxYG6RlDJ8oyRkE5x071aXwhr2ovoA1fT/DVrHpV3Zyn7HJJI00cMU6HJaJcYMilE5C/P8xyKS9+JepWniCbSB4XnvLmxkgh1D7B9quBG8oV/3TLbbGCo6sfMaI9QAeCZbX4k3QmhudS0OO20SfUrvTI7qK982XzIDN8xi8sYVhA/RiQeoxzQBRufh1qDeNL2/Mdpe6fdarBqYkn1a9hMBTy8j7LH+6kYGPKsxGMjIIGKxh8MvFV5cibXJtN1OX+zrqyne71W8lF40skTBvL2qtuuIyMRdDtOWxxq2XxcvLjSrrUpPCV/HZLaJeW8pW4jSQNIihGeWBEDkSBhsaRTtPzdCbd/4y8R6T4w1M6rYWMei2GhDVLq3jvS7xKsk2XQ+SN7lY1BQsFBHDHqQCpYeAPEjz2txqd5ZO0V1dTbGuGnkVJLIwKGm8lDKd5zllG1cAE4AqDWvhzexeGbOMSWaCw8MDTZVhikl82dJIZeI0Qs8bGJwcAsd/CkmtHV/Hd3Fp09v4i0E2lw0NnewR2WrP8APHJcxxYaVURkZWZSVGVYZG4gmpdR+Jd5Z2l5djQA9tHqkujQbbmSSSe4SUqD5ccLsEKqzEgMwIwFbrQBP8Ln1XUvEHinXNV0z+zYrw2sNvH5cybhFG2SBNFE5GXxkoo4IGQMn0Suf8Ea/c+I9Iku77SbrSp452hMU8cqB8AEOnmxxuUOepReQRjiugoA8q8M/wDInfBL/t3/APTPdV6rXlXhn/kTvgl/27/+me6r0bX9Sj0jRL7UJnt0S2haXNxKYo8gcBmCsQCcDIVj6AnigDiPEHgS91KXxdJC9iJNXv8ATrq3dy2US38ncGO3g/u324z1HTJqrH4L8RR67aRqdJOi2/iKbXPPNxJ9ocSCT935fl7QQZDzvOQB06Uyy+Kl7dwSxR+HR/aa31rZJC9xNDG4nVij7prdHwNhz+7x3BNaFp4/1K9ubTS7PQbY6/LdXlvLBLqBW2jW2KB3EwiLMD5seB5YPzHOMUAVPDHw6udLXwaLpdNc6Npd7ZXOwE75JzFhkyoyMLJknB+bocmsSH4a+JLbRn0uNdBnjvPDNn4fubia4k3W5iEoeSNPKPmD94CAWTlRnFdT4L1+6svgrB4g1Dzb66tdNmvJBLMS0pQO20uQTztxnB+lUNX+JmqafPa2q+F3uL24tf7QSCCW4uCLc4C7jDbSbZC24bT8mB9/nFAFWx+GuoWPilpyLfUNOOqpqa3FzrF6jxkBePsq/uXcFeHJHGMqcU7/AIV9q9n4H8K6XZRaa2o6SHLzxX01myyMpUtHKkbZyGYMGjOQexGavaj8Sb61/tK5Xw4RpmmQWlxetcXZhuI1nUMQIfLOXQE5UsvTjniorX4pzXmrzxWfhu/n0qOe5t/tqxXGA0O8FmPkeSIy0ZXIlZhkZUcgAGvq/hTU9Q+EUnhiS5spNVk09bVphH5MBkAGSFRflXjsv4DpWJ45+Hd5q3iK7vtPhtLqyvNMj057OfVbuwjiCM5HFvxKhEmDG2OnDDJpq+MvFupap4Kn07SNMtrDWreS5+zz6kd0i+Sr/ORbts2liRtJ3cZ28gTt8RZrmxjnvNE8nR9UgvDp88WoMJ5fJjd8OqoDDvRHIZXYjHODigCG78B601t4i0a3j0NtK1qRpWv5XkN1alrcRYSPaQxUqCrmQEA4wccg8AatrFrqQ1xdI0+VtGi0q0XTZHkUPG3mRzsWRdu1wpVAG288nNWE+IklnpmoXK6MTpejadb3t1PJfs8nlvB5gVQUJkftliAeSWB4Oz4D8X3/AIku7231Dw/eaX5EaSxzPFcrFKGJBXM8EJ3jAyAGGCMMaAOSn+G2ttBomozXFtd67FPeXWpRw6ldafHPJcbOUnhHmARiNEUFSCo5wea6HwT4Im0HX7W+kh0+KCDRo9OjigkllMTiaWRtrSZYrh1GSckg8AYrL8TeK9X1DU7FNMtFtdHtvElvp0t4L5kmmZZAJF8kJgxkkry/OPu4pNP+JVtpegRy3Gl3EcMmnTXtiJb57iS6lScxtb73GdxZosEk/wCsxgBeQC58SvCGu69rEV34fbT7eQ2n2Vrma5kRlBfdh4fLeOePodjBTkH5sHiufBOvWGvJrenf2Te3UV/qE6W13NJFG0dysYDbxGxWRfKxjaQQ7DIzUo+Jd7J4oOlW/hi9uYYLyKwu54EuJPKlYIXYFYDEUTeMlpUbAJ29Msl+JGrL4atNcXw1EthdTGBJHvpCsWC4MkvlwOUjygAYAkswBCjkgGRcfB2a7tdCsbq+tvsCac9pqiRqy+a6l3t/KHZY5JnIyQRtTHfGn4f+Hd/bpoTeIZ7O+kSDU/7YKs5+0SXbITsG0ZXCleccAYzWF4v8Z32qaXcrokBt767h0fzJodbkMQjubx4isTIpVT8hBlUBsPnqgU6cHj4+H7eTTbfRby41b+0ZLLyWv7zUEzFbwvI/mCGWUL86gAR8nLHaWY0AbPwW0O+03w2+oa2bhtTvyi5uYjHKltCvl26Op5DbBvYHndI1ehV5fffFG9tV0dpvDT2K3sIlkOqXElmEbzTGY1LQkFgF3/vDHlWX149QoAKKKKACuV+Jf/IuWf8A2GtJ/wDTjb11Vcr8S/8AkXLP/sNaT/6cbegDqqKKKACiiigAoorjdQ8d/Z9b1PTbPw3reotp8qwTT2zWqx72ijlwPMnRj8sq87cZoA7KiuI/4Ty7/wChK8Sf9/bD/wCSqP8AhPLv/oSvEn/f2w/+SqdmB29cr8NP+RcvP+w1q3/pxuKpf8J5d/8AQleJP+/th/8AJVc34A8aXVtoV0i+EPEE4Oq6lJujkssDdfTsV+a4Byudp7ZBwSMElmB63RXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgdvRXEf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgYPib/AJE742/9vH/pnta9G13SLLXdJuNM1SEzWVwAJEEjISAQR8ykEcgdDXiHiDxbcyeFvi3EfC+toLzz9ztJabbfOl26fvMTknAXd8gbgjvlR6P/AMJ5d/8AQleJP+/th/8AJVFmBoDwJ4f/ALNnsmtbmRJ7hLqSeS+uHuTKmNj+eXMoK7RjDcduppkXw/8ADkNrbwQWt1CILl7yOWLULhJhK42u3miTedw6gnB7iqX/AAnl3/0JXiT/AL+2H/yVR/wnl3/0JXiT/v7Yf/JVFmB1V1pdndalY39xDvu7LzPs8m4jZvG1uAcHI9c1hy+AfDct9cXL2MpNw8kssIu5hbtJIpV38kP5e9gxy23PJ5qj/wAJ5d/9CV4k/wC/th/8lUf8J5d/9CV4k/7+2H/yVRZgWYvh14ajs5rcWt4wlaFzNJqNy86mEkxbJmkMiBctgKwAyfU1oHwjorWGo2b2jyQajJHLdiS4lZpnRERWLFt2dsSd+cZOSTnG/wCE8u/+hK8Sf9/bD/5Ko/4Ty7/6ErxJ/wB/bD/5KoswNGbwJ4dm1O4v5LGQy3DSvLF9qmEDvJGY5H8nf5e5kYgttycnmoJfh54dltbSB4NQ/wBFjeGKUapdCYRtjdGZRJvaPgfIWKjHSqv/AAnl3/0JXiT/AL+2H/yVR/wnl3/0JXiT/v7Yf/JVFmBZuvhz4XurtLiXT5gytA/lx3k8cTPBtETNGrhGZQigMwJwAM4rodb0qz1zSLzS9Uh8+xu4mhmi3Mu9CMEZUgj8DXK/8J5d/wDQleJP+/th/wDJVH/CeXf/AEJXiT/v7Yf/ACVRZgdndQQ3VtLb3MaSwSoY5I3GVdSMEEdwRXKRfDjwxHatAtndsu6Jkd9RuXkhMQYR+VIZC0QUO4AQqAGNV/8AhPLv/oSvEn/f2w/+SqP+E8u/+hK8Sf8Af2w/+SqLMC+/gHw3JZG1lsJJYmtbmzYyXUzu8VwVaYM5csxYop3EluOCK2dS0ix1OC1hvoPNjtZ4rmEb2XbJGwZG4IzggcHg965f/hPLv/oSvEn/AH9sP/kqj/hPLv8A6ErxJ/39sP8A5KoswNXVPBehanq0mpXdrN9rlCCYw3c0KT7PueaiOFkx23g1m+F/h5pWi3Ul5ctNqF8bu7uo3mllMUXnyOxCQs7RqQr7CygFhn1Ipn/CeXf/AEJXiT/v7Yf/ACVR/wAJ5d/9CV4k/wC/th/8lUWYFm1+HHhe1glgisJzbyQ/ZxC99cPHFHvV9kas5Ea7kU4QAfKK1NV8L6Tquqx6jfW8r3awG2YpcSxpLEckxyIrBZF5PDgjk1hf8J5d/wDQleJP+/th/wDJVH/CeXf/AEJXiT/v7Yf/ACVRZgXLT4e+GbW0uLaOwleOcQK5nvJ5mCwuHiRWdyyorAEIpC+1XbnwhodzpV1p01jm0ubtr6QCZ1YTs+8yK4bcjbuQVIx2xWN/wnl3/wBCV4k/7+2H/wAlUf8ACeXf/QleJP8Av7Yf/JVFmB0ug6JY6DZvbaakwjkkaZ2nuJJ5Hc4yzPIzMTwOp7VpVxH/AAnl3/0JXiT/AL+2H/yVR/wnl3/0JXiT/v7Yf/JVFmBg+Gf+RO+CX/bv/wCme6r0nWNMs9Z0y507U4FuLK5QxyxMSNwPuOR9RyK8N8P+LbmPwt8JIh4X1txZ+RtdZLTbcY0u4T93mcEZDbvnC8A98KfR/wDhPLv/AKErxJ/39sP/AJKoswNCw8B+HrG4eeK0uZLh7iG6ea5vp55GliDCNi0jsTgMRgnH5CnX3gfQL0lpbOaOU3Mt351vdzQyCSQASEOjhgGAGVB2nA4rN/4Ty7/6ErxJ/wB/bD/5Ko/4Ty7/AOhK8Sf9/bD/AOSqLMDoLbw3pNt4XPh2C126Mbd7U2/mOf3TAhl3E7uQTznNVNZ8GaHrAtDeW06yWkJtopba7mtpBEcZjLxurMpwPlJIrK/4Ty7/AOhK8Sf9/bD/AOSqP+E8u/8AoSvEn/f2w/8AkqizAIvhvo58QXeo3Znmt5BaiGyE80cMYgUBN6B9kvIBG9TjFaB8CeHv7SmvRZzLJLLJO8S3kywGVwVeTyQ/lhyCcsFzz1rP/wCE8u/+hK8Sf9/bD/5Ko/4Ty7/6ErxJ/wB/bD/5KoswNi68IaNc2GkWbW88UOkqq2TW93NBJCoTZgSI4YjbwQSc981Wt/APhu3vLi5i0998yTRlGuZmijWb/W+VGW2Rbu5QKaof8J5d/wDQleJP+/th/wDJVH/CeXf/AEJXiT/v7Yf/ACVRZgbtr4X0a2gvoI7BDDfQR2tzHIzOssSJ5aqQxPG3j375pvh3wrpPh6SWTTIroSSRrEWuLya4KoudqL5rttUZOFXArE/4Ty7/AOhK8Sf9/bD/AOSqP+E8u/8AoSvEn/f2w/8AkqizA0LjwH4euNbGrS2c32sXS3wVbydYftCgAS+SH8vfgD5tuT3zmpX8FeHpLXR7aTTUeHSLn7XYq0jnyZck7sk5PLE4ORnHHAxlf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVRZgalx4J0G411tXe0mW9eaO5k8u7mjilljxsd4lcRuw2jBZSeB6Us/gvQ5tLsdPFvcwW9i7SWxtr2eCSJmzuxIjh+dx4z3rK/wCE8u/+hK8Sf9/bD/5Ko/4Ty7/6ErxJ/wB/bD/5KoswNGLwH4bhjSOLTFRFS1QATSdLaUyw/wAXVXZmz1bPzZp194J0C+80zWcqSyXh1AzQXU0MqzlAhdJEYMmVUAhSAR2rM/4Ty7/6ErxJ/wB/bD/5Ko/4Ty7/AOhK8Sf9/bD/AOSqLMCzJ8OfDEiwI1lc+XFEITGL+4CSoHLhZV8zEo3Mx+fd1NddXEf8J5d/9CV4k/7+2H/yVR/wnl3/ANCV4k/7+2H/AMlUWYHb0VxH/CeXf/QleJP+/th/8lUf8J5d/wDQleJP+/th/wDJVFmB29cr8S/+Rcs/+w1pP/pxt6pf8J5d/wDQleJP+/th/wDJVYXjHxbc6nYabaS+F9bsEk1nSs3FzJaGNMX8B5Ec7NzjHCnkjoOaLMD1SiiikAUUUUAFea6b/wAjf44/7C0X/pvtK9KrzXTf+Rv8cf8AYWi/9N9pVR3A2KK57xffa7p9ulxokGjvbxq73UupXTwLGBgggqrDH3sk46CuZ8BePrnxHr32Ca68MSp5TSbdOvpJpeMfwtGoxzzzWlwPR65v4f8A/ICuv+wtqf8A6XT10lc38P8A/kBXX/YW1P8A9Lp6AA2moa1411Kwi17UdMtLPT7SdY7OO3O55ZLlWLGWJz0iTGMDrWn/AMIbf/8AQ6eIv+/Vh/8AI1R+G/8Ako/iH/sE6d/6Ova7OqSPNr1ZxqNJnIf8Ibf/APQ6eIv+/Vh/8jUf8Ibf/wDQ6eIv+/Vh/wDI1dfRRZGXt6nc5D/hDb//AKHTxF/36sP/AJGo/wCENv8A/odPEX/fqw/+Rq6+vHdR1Bbiz8W61rFz4knm0q+nie10fUvsx0+2iBKSmIyxq+5FD/MHJ3YAwMUOxUatSX2js/8AhDb/AP6HTxF/36sP/kaj/hDb/wD6HTxF/wB+rD/5GrCn8Z6nEPEM6XVlbaTo626pLPZyXNxOZreNkBVZUG7fIOnXOOPvVnWvjzxXO/8AZslrp1pq39swacZLm2IVY5Ld5dxijuJMMCvTzTkdQp6LQfPV/mOu/wCENv8A/odPEX/fqw/+RqP+ENv/APodPEX/AH6sP/kaue8PeMvE0mpaYNXXSJrS61a90Zo7O3kjk8y3WYiUM0hGGMJGwjjIO49K1te8T68H0G207Sv7Hu9S1E2Z/tdI59qCCWUuqwTkHmPGCw79OtPQHUqp25i3/wAIbf8A/Q6eIv8Av1Yf/I1H/CG3/wD0OniL/v1Yf/I1cc3xE8T3S6dp+mabaTau4vjO6Ro0bm2uDCdiS3EWAcbj87FQeh6iW48f+IpNPvdQhTRbKPTv7PjntpVa5aeS4SJ2McqSqoUCXCkB9xU9qWg+ar/MdZ/wht//ANDp4i/79WH/AMjUf8Ibf/8AQ6eIv+/Vh/8AI1cxH491m78XW2n2awSaPqNxe2VrdtZeUUlgjkbIP2ktKA0ZUny4wc8MOlZnhbV/EZ8O+CWLaRq2tXuh3NzZ3VzaOZo2WKAiNpDKSxdmw7DbnA4GOTQOer/Md1/wht//ANDp4i/79WH/AMjUf8Ibf/8AQ6eIv+/Vh/8AI1cpc/FG+vdLk1Pw/YwzWMs1np9uXUFhdTLvl3bpI1IQNGm0smXJG4YxXY+D9V1fVdAv28QWkNrfW80kBWJo/mUKCGZUllCN82CpckYz3FNWJdSqldsh/wCENv8A/odPEX/fqw/+RqP+ENv/APodPEX/AH6sP/kavP8AwR4u1Lwz4H8Nwarc6Y1hN4bN5byQWkjSWnlLEqeavmfvQxkUceXyCPcadj8QPEb3M2kX1pZWurNqNrYxz3FuI0iWaKSTdJClxJz+6IC+aCS65291oU5Vf5jrf+ENv/8AodPEX/fqw/8Akaj/AIQ2/wD+h08Rf9+rD/5GrgvG+qXVzFqFnqKaJcXsdtYPJf6fEQZMaqUEe4sxCjZkpk7XL8mtLwReiHxfDZmzs5DcatrrC4kizNDsnTiNv4Q275h32r6UaBz1LX5jq/8AhDb/AP6HTxF/36sP/kaj/hDb/wD6HTxF/wB+rD/5Grr6KdkZ+3qdzz24+GS3Frq9tN4s8RNDq277au2yHm7oliPP2fK/Iij5cdM9ea0/+ENv/wDodPEX/fqw/wDkauvoosg9vU7nn+kx32neMdW0m61e91O2isLO6ia7jgV0aSS5VgDFGgIxEnUHvXRVz97oFlrnxO1j7c9+nk6Pp+37JqFxa9Zr3O7ynXd0GM5xzjqa0/8AhANE/wCe+v8A/g/v/wD49SsdUcVGKSle5doql/wgGif899f/APB/f/8Ax6j/AIQDRP8Anvr/AP4P7/8A+PUWZX1yHZl2iqX/AAgGif8APfX/APwf3/8A8eo/4QDRP+e+v/8Ag/v/AP49RZh9ch2Zdoql/wAIBon/AD31/wD8H9//APHqP+EA0T/nvr//AIP7/wD+PUWYfXIdmXaKpf8ACAaJ/wA99f8A/B/f/wDx6j/hANE/576//wCD+/8A/j1FmH1yHZl2iqX/AAgGif8APfX/APwf3/8A8eo/4QDRP+e+v/8Ag/v/AP49RZh9ch2Zdoql/wAIBon/AD31/wD8H9//APHqP+EA0T/nvr//AIP7/wD+PUWYfXIdmXaKpf8ACAaJ/wA99f8A/B/f/wDx6j/hANE/576//wCD+/8A/j1FmH1yHZl2iqX/AAgGif8APfX/APwf3/8A8eo/4QDRP+e+v/8Ag/v/AP49RZh9ch2Zdoql/wAIBon/AD31/wD8H9//APHqP+EA0T/nvr//AIP7/wD+PUWYfXIdmXaKpf8ACAaJ/wA99f8A/B/f/wDx6j/hANE/576//wCD+/8A/j1FmH1yHZnB+Hv+RV+EX/bD/wBNdxXpNZEfwx8MxRWcUcerpHZ4+zIut3wEGEKDYPO+X5WK8Y4JHSs7XdAtPD+u+FJdMudXBudSe3mS41a6uEkT7HcvgpJIy/eRTnGeKLNFQxUJtRSZ1FFFFB0hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWD4z/wCQdp3/AGGtK/8AS+3rerB8Z/8AIO07/sNaV/6X29J7AeoUUUViAUUUUAFea6b/AMjf44/7C0X/AKb7SvSq8103/kb/ABx/2Fov/TfaVUdwMz4lGKfwxd6dKt6DdxPtktrN7kJsG/5lXscYxkZziuL8Ah7jx5m3jv4NMha8ubdbjSJ7d8zurvG8jfLtDZKgcnj0rvfiJFbzeBtbivblbW3e1dXmaIybMjg7QQWOcYAPXFcp8PvEes6hqdmus6uJYrn7TCltJpP2aQSwlQ4ZhK20jJOMc4PTFW9wPTa5v4f/APICuv8AsLan/wCl09dJXN/D/wD5AV1/2FtT/wDS6emAyPWINB8favcahbambe60yyjiltdNuLpWZJbsupMSMAQJEODj7wra/wCE/wBE/wCeGv8A/ggv/wD4zWQbTUNa8a6lYRa9qOmWlnp9pOsdnHbnc8slyrFjLE56RJjGB1rT/wCENv8A/odPEX/fqw/+RqaucFZUud8zdyT/AIT/AET/AJ4a/wD+CC//APjNH/Cf6J/zw1//AMEF/wD/ABmo/wDhDb//AKHTxF/36sP/AJGo/wCENv8A/odPEX/fqw/+Rqeplah3ZJ/wn+if88Nf/wDBBf8A/wAZrH1TWPA2rXsd5qvh27vbuPASe58K3cjrjkYZrckVqf8ACG3/AP0OniL/AL9WH/yNR/wht/8A9Dp4i/79WH/yNRqNKgtmyrJ4o8JyRXccmk6m8d4AtyreGb0icBQoDjyPmwoA57DFVrDWvBGnJGmn+H7y1WOQTIsHhW7QLIFKhxi34YAkA9cEitP/AIQ2/wD+h08Rf9+rD/5Go/4Q2/8A+h08Rf8Afqw/+RqNQ/cd2Vk8VeFI2jZNK1RWine5jI8NXo2TPu3yD9xw7b2y3U7jnqamn8aeHLiW3kuLHWpZLd/Mhd/Dt8xjbaV3KTBwcMwyOxI70/8A4Q2//wCh08Rf9+rD/wCRqP8AhDb/AP6HTxF/36sP/kajUVqHdmXf6x4G1C1W2v8Aw7d3VssjzLFP4Vu3QSOSzOAbfG4kkk9SSc1ia9D4M1zWrK/vYfEIS0ESx20fhaZVCxtuVfM+yecFyB8qyAY4xgkHr/8AhDb/AP6HTxF/36sP/kaj/hDb/wD6HTxF/wB+rD/5GpalJ0Vs2ZkGteB7fVm1SDw9eRamzmRrxPCt2sxYggsXFvuyQzDOehPrTtO1zwVpk/naboF7ZzbnfzLfwteRtufG45EA5O1c+uB6Vo/8Ibf/APQ6eIv+/Vh/8jUf8Ibf/wDQ6eIv+/Vh/wDI1PUX7nuykfEfg86ZNpx0XUf7PnZmltf+EYvPKkLHcxZPIwSTycjk1JpfirwppNkLPStJ1SytASRBbeGr2NMnr8qwAVZ/4Q2//wCh08Rf9+rD/wCRqP8AhDb/AP6HTxF/36sP/kajULUO7MnTtV8B6bDdQ6d4bubSK6Ty50g8KXcazL/dcC3+Ycng02HUvANvp9xYweGbiOxuNvnW6eE7sRy7TkblFvg4ycZrY/4Q2/8A+h08Rf8Afqw/+RqP+ENv/wDodPEX/fqw/wDkalqH7nuzNh1vwTBbrBD4fvY4FRYxGnha8ChFfeqgeRjAclgOxOetWYfFXhSG4W4h0rVI51aR1kTw1ehg0hBkIIgzliAWPfHNWf8AhDb/AP6HTxF/36sP/kaj/hDb/wD6HTxF/wB+rD/5Gp6h+47sk/4T/RP+eGv/APggv/8A4zR/wn+if88Nf/8ABBf/APxmo/8AhDb/AP6HTxF/36sP/kaj/hDb/wD6HTxF/wB+rD/5Go1Fah3ZDJ8TvDMUV5LJJq6R2eftLtol8BBhA53nyfl+Vg3OOCD0q1/wn+if88Nf/wDBBf8A/wAZrIuPhktxa6vbTeLPETQ6tu+2rtsh5u6JYjz9nyvyIo+XHTPXmtP/AIQ2/wD+h08Rf9+rD/5Go1C1DuzmXsdD8Z+O9U1G+0L7bZxabZ28MmraS8eHEt0zhBPGD0aPJAxyK0/+ED8If9CpoH/guh/+JrT/AOENv/8AodPEX/fqw/8Akaj/AIQ2/wD+h08Rf9+rD/5GpWOmGIpQioozP+ED8If9CpoH/guh/wDiaP8AhA/CH/QqaB/4Lof/AImtP/hDb/8A6HTxF/36sP8A5Go/4Q2//wCh08Rf9+rD/wCRqLFfW6Zmf8IH4Q/6FTQP/BdD/wDE0f8ACB+EP+hU0D/wXQ//ABNaf/CG3/8A0OniL/v1Yf8AyNR/wht//wBDp4i/79WH/wAjUWD63TMz/hA/CH/QqaB/4Lof/iaP+ED8If8AQqaB/wCC6H/4mtP/AIQ2/wD+h08Rf9+rD/5Go/4Q2/8A+h08Rf8Afqw/+RqLB9bpmZ/wgfhD/oVNA/8ABdD/APE0f8IH4Q/6FTQP/BdD/wDE1p/8Ibf/APQ6eIv+/Vh/8jUf8Ibf/wDQ6eIv+/Vh/wDI1Fg+t0zM/wCED8If9CpoH/guh/8AiaP+ED8If9CpoH/guh/+JrT/AOENv/8AodPEX/fqw/8Akaj/AIQ2/wD+h08Rf9+rD/5GosH1umZn/CB+EP8AoVNA/wDBdD/8TR/wgfhD/oVNA/8ABdD/APE1Y8D31xqfgrw/f30nm3d1p9vPNJtC7naNWY4GAMknpW5SsdJzf/CB+EP+hU0D/wAF0P8A8TR/wgfhD/oVNA/8F0P/AMTXSUUWA5v/AIQPwh/0Kmgf+C6H/wCJo/4QPwh/0Kmgf+C6H/4mukoosBzf/CB+EP8AoVNA/wDBdD/8TR/wgfhD/oVNA/8ABdD/APE10lFFgOb/AOED8If9CpoH/guh/wDiaP8AhA/CH/QqaB/4Lof/AImukrmI9Hg17x9q9vqFzqYt7XTLKSKK11K4tVVnluw7EROoJIjQZOfuiixE5qEeZnBaH4S8OS+G/hdLJ4f0h5bzyftLtZRkz502dzvO35vmUNz3APWvSNO8JeHNMvY7zTfD+kWd3HnZPb2UcbrkEHDBQRkEj8alj+GPhmKKzijj1dI7PH2ZF1u+AgwhQbB53y/KxXjHBI6Va/4QDRP+e+v/APg/v/8A49T5Wc/1yHZl2iqX/CAaJ/z31/8A8H9//wDHqP8AhANE/wCe+v8A/g/v/wD49RZh9ch2Zdoql/wgGif899f/APB/f/8Ax6j/AIQDRP8Anvr/AP4P7/8A+PUWYfXIdmXaKpf8IBon/PfX/wDwf3//AMeo/wCEA0T/AJ76/wD+D+//APj1FmH1yHZl2iqX/CAaJ/z31/8A8H9//wDHqP8AhANE/wCe+v8A/g/v/wD49RZh9ch2ZdorLtvBXh26837Nfa1N5Uhik8vxFfNscdVOJ+CPSp/+EA0T/nvr/wD4P7//AOPUWYfXIdmXaKpf8IBon/PfX/8Awf3/AP8AHqgt/Bfhy5edLa+1qZ7eTyplj8RXzGN8BtrYn4OGU4POCD3osw+uQ7M1KKy7PwX4cvYBPZ32tXEBLKJIvEV86kqSrDInxkEEH3Bqf/hANE/576//AOD+/wD/AI9RZh9ch2Zdoql/wgGif899f/8AB/f/APx6j/hANE/576//AOD+/wD/AI9RZh9ch2ZdorK/4Q3w39v+xfb9Z+2+X532f/hI77zPLzjft8/O3PGemasf8IBon/PfX/8Awf3/AP8AHqLMPrkOzLtFUv8AhANE/wCe+v8A/g/v/wD49R/wgGif899f/wDB/f8A/wAeosw+uQ7Mu1g+M/8AkHad/wBhrSv/AEvt60f+EA0T/nvr/wD4P7//AOPVFN8OtAnVVnbXJFV0kUPr18QHVgysMzdQwBB7EA0NNh9ch2Z6JRXCeDLT+zPHfiHToLzUprNdNsLhI72/nu9jvLeKxUyuxXIjTIBx8oru6xas7HTCSnFSQUUUUigrzXTf+Rv8cf8AYWi/9N9pXpVea6b/AMjf44/7C0X/AKb7SqjuBj/FTWNE0nwdfL4hl2wXMbRpEsojkkYDICN2YYyPpXG/D19CHjS2TT/Es3ie5k+13CsgRUsy5DSSMFHLOSFzkAdAOa9C8faXc6z4P1WwsVR7qaEiNWbbuPXbu/hJGRntmsXRr3VNa8Vadcw6Jqmi6fZQSrdi9ZUE7Pt2qqqzb9pUnecY7dat7gd1XN/D/wD5AV1/2FtT/wDS6eukrm/h/wD8gK6/7C2p/wDpdPTAv+G/+Sj+If8AsE6d/wCjr2uzrzqPWINB8favcahbambe60yyjiltdNuLpWZJbsupMSMAQJEODj7wra/4T/RP+eGv/wDggv8A/wCM1SaseZiKcnUbSOrorlP+E/0T/nhr/wD4IL//AOM0f8J/on/PDX//AAQX/wD8Zp3Rj7Kf8r+46uiuU/4T/RP+eGv/APggv/8A4zR/wn+if88Nf/8ABBf/APxmi6D2U/5X9x1dFcp/wn+if88Nf/8ABBf/APxmj/hP9E/54a//AOCC/wD/AIzRdB7Kf8r+46uuO+J9/NZaXpUSX0mnWl7qUNpeXsbhGghYMSQ5+4WZUTd238YODU3/AAn+if8APDX/APwQX/8A8ZqG78beHry2kt7uy1qe3lUq8Uvh2+ZXB7EGDBFK6HGnNO/K/uOVv/EH/CJ3WvW+lW+vLqNslo62+t35u7aSOW6EAljbzZJFJw3BIxgEr2Mnifxx4i0HUpIIzY6ktjLbR6h5WnGGOLzpAFUSvdZ3bGH3Y5ORk4BwNKx1TwHp9tLbWHhu5treVleSKHwpdojspBUkC3wSCAR6ECpNQ1rwRqN+t9qHh+8u71AFW4n8K3kkgAOQAxgzgHml8zTld9Yv7jKfxf4um1GEWj6BHaXXiC50OFZbSZnjEYlYSsRKAxxERtAXJI+Yduj8K+KtV1HR7SW50S4vbk3dzZ3M2ntCkEbQztEXKyyhwDt3YG8jkc8ZiXxV4UUoV0rVAUuGukI8NXvyzMCGkH7jhyGbLdTuPrU1p408OWcRjtLHWoI2dpCkXh2+UFmYszYEHUsSSe5JNNepLhJrSP4HMj4ga9aJFqV7Fpl1p02pahYJY2sMi3WLfzysm8uQeIMMNoxuBz2obx14ktrUo/8AYV/e3elRanaG2Vo0i3zJGY23y/vCRJlMMm8oy4HFWvDd54J8PXNzd2GlawdQuJp5pL1/DV557ebI0jKZBbglQWwAewHWrEGp+AoLW8tYPDVxHbXhBuYk8J3YSfHI3gW+G6980vmU4P8Alf3HL674u1O/0eXcNOGsRafrCi8Wwlt7izaKKJgqBpC0bEOM4dhwhzxitZ9c13SwJzb6Rqmq2+gJqDXKWbxzSwiVS8QJlYk7NxHOC+DjtWzaa/4MsoYIrPQr+3igV0iSLwveKsavjeFAg4DYGQOuBmjStf8ABmkDGlaFf2I2GPFt4XvIvlJyV+WAcE849aPmHLL+V/cY9/8AEfVbpYJfDdnb3VpqepPY6ZPsVzIscRaR8PNErZdXVRvXhSfm6V1GneJdSj+HF5r+sWES6jZW91NLa28qOrmEvwCjuATs5Xc20kjJIrPm17wXPo8ekz6DfSaVHjZZv4WvDCuOmEMG0flVux8YeGdPsY7Ow07WLWzjXakEPhy+SNB6BRBgCn8yXBtWUWc3eePPEOm+Vb3B0LULu5i0+5hktY5I4o1uLlIWR8uxPD5VxjOCdvGDL4k8X+J9Jj18pdaDnQo4DOZbKUG6eY5Gwed+7UAheS+5g3TpWhZax4GsIJIbHw7d20MsqTyRw+FbtFeRDuVyBb8sCAQeoI4rH8WDwf4p1m21DVU8Rt5ARREvheY7grbsea1oZlBPBCyKCPqcr5lKDvrF/cXrjx3qqeOLWytYobrQpdUOlPKbQRGOUIxYLIbgs5Vl5xCFwcbsjnGj8da/ceFobzXLbQru11fQdQvo7VLWQKjQIp2SbpGEiOGORhcdMnrW3L4q+Hiaje6zLpUq39o2+6vm8NXQlhZUDZeTyMqQjA5J4Ug9DV4+IvBxtobc6JqHkQxPBHH/AMIxebUjcAOijyMBWAAI6HHNHzDlf8j+4yrXxtq8ev2dq8Om2ujSPFbQmO2eRXYwByolSQiJw2QI3jHyrndyKz9I8Z+N9RtNIkE3huN9S0KTW1/0GciIJ5Y8sjzvmLeavPG3B4bjPQJrXgiPUxqSeHrxdRC7RdL4VuxKFxjG/wCz5xjjr0qxD4n8JQLCsOkanGsFubWIJ4ZvQI4TjMa/uOEO1flHHyj0o+Ycr/kf3GLB8QdXuNT0WRorC00i9SwLsYHuDvuFUmNpEkzC2XUKHjIbIOQM49UrztdX8Crf218vhy6F7aoscFwPCl35kKqMKqN9nyoA4AHStn/hP9E/54a//wCCC/8A/jNNMiVOT2i/uOrorlP+E/0T/nhr/wD4IL//AOM0f8J/on/PDX//AAQX/wD8Zp3RPsp/yv7jq6K5T/hP9E/54a//AOCC/wD/AIzR/wAJ/on/ADw1/wD8EF//APGaLoPZT/lf3HV0Vyn/AAn+if8APDX/APwQX/8A8Zo/4T/RP+eGv/8Aggv/AP4zRdB7Kf8AK/uOrorlP+E/0T/nhr//AIIL/wD+M0f8J/on/PDX/wDwQX//AMZoug9lP+V/cZHw0/5Jx4U/7BNp/wCiVrpK5/4e281r4B8NW91FJDcQ6ZbRyRSKVZGESgqQeQQeCDXQVCPZCiiimAUUUUAFFFFABWV4b/5KP4h/7BOnf+jr2tWubN3qGi+NdSv4tB1HU7S80+0gWSzktxteKS5ZgwllQ9JUxjI60GOIi5U2kehUV57b/E1bi10i5h8J+Imh1bb9ibdZDzd0TSjj7RlfkRj82OmOvFaf/CZX/wD0JfiL/v7Yf/JNO6PO9hU7HX0VyH/CZX//AEJfiL/v7Yf/ACTR/wAJlf8A/Ql+Iv8Av7Yf/JNF0HsKnY474rxaXN8RtBXWrzwxaW/9lXZV/ENotxblvOt8BVaSMB8ZwcngNxzkVNU1vWNPs/EE+g+ILSLTNB0uxurW30yygWzuC+/dgEOwjITACvkZ4b17z/hMr/8A6EvxF/39sP8A5Jo/4TK//wChL8Rf9/bD/wCSaWhooVEkuU5e98YTW2s64+o+I57W7sLi4SHw9b2sTy3FukLOrqChkLMBuD52DhSK5O2+IeufYNXH/CTWrQR/2XKl+s9tdG1We6Mcqu6QRR5CDkbW2nPznt6p/wAJlf8A/Ql+Iv8Av7Yf/JNUtW159WtUt9Q8C+IpoUmiuFX7RZLh43V0ORdDoyg46HHPFHzGqcusDi9S8aatBYT/AGXxZBLpiam0Vtq0r21u97CIFZljlaI2+UlbGSo3BSF5HL5fiPeW2hakbnWGg1GWz06fTY7u3ihnlEgHmuIuQckNnG4L2IGK77/hMr//AKEvxF/39sP/AJJo/wCEyv8A/oS/EX/f2w/+SaPmL2cv5DzzUvEdxorajaWWpNpc15r2oMLqS5ht4BsEfyO8sE2WO75VVdxwfSqum+ItRm1Ky8STaq0Ws3vhCG5tbECFU1G5Uyt5KhkLHLFThCG+brjAr03/AITK/wD+hL8Rf9/bD/5Jo/4TK/8A+hL8Rf8Af2w/+SaB8k/5DzXTvHHiE6VNPJ4p0ue1l+yefcwSpdSaYryhZJGxbRJGApxtk3lSMnIzXafBqeG5XxjLbao2rwtrr7b5jGfOH2W2G7Maqh9MqADitb/hMr//AKEvxF/39sP/AJJo/wCEyv8A/oS/EX/f2w/+SaEKVObVlE828CeJJ9MgsIdO1uXUgLnVHv8ARoI4XezhR53WQYXzFYuEADkhvMGBUOk/EHxA8WpeVrUF5aG2s5zdCWC8ewjkuPLlkfyYIk3JGdxQhwpXJYjIr0//AITK/wD+hL8Rf9/bD/5Jo/4TK/8A+hL8Rf8Af2w/+SaPmPkm3fkOBk1GB/Hfh7UI/Hct9afZ762t77FpGk8oktmFtv8AK2OW5GUAJ2gDBDE5enePfFUvh7WNQm17S/tqaJdXb6fHKss9jcIoK5i+zJ5QU5BWV5M8YJwSfUv+Eyv/APoS/EX/AH9sP/kmj/hMr/8A6EvxF/39sP8A5JoDkn1gcx4o8R6t4auNRW71a+u4f7JS8Bjit4jBK9wseVYxlVjUHJMm/C5JJxWp8IPEOoa7Br8Wp6jban9gvlhhureZJldGhjf/AFiRRK+Cx5CL+OMnT/4TK/8A+hL8Rf8Af2w/+SaP+Eyv/wDoS/EX/f2w/wDkmmS6U2rcp19Fch/wmV//ANCX4i/7+2H/AMk0f8Jlf/8AQl+Iv+/th/8AJNF0R7Cp2OvorkP+Eyv/APoS/EX/AH9sP/kmq9749uLKOOS58HeIkSSaK3U+ZYnMksixoOLnuzqM9BnJwKLoPYVOxs6D/wAlO8R/9gfTf/R19XZVxfg+LVLjxjrmrahot7pNtPYWVrCt3LA7yNHJdM5AikcAATJ1I7+ldpWEtWenRTjBJhRRRSNArzXTf+Rv8cf9haL/ANN9pXpVea6b/wAjf44/7C0X/pvtKqO4EXjmLUZvCWpxaKZBqDxbYvKkEb8kZCsSAGxnByOcV5r8OdMbT/iJcWdoL+Y6fJdpdzy6iZ4fKdwbddpkJEgHykEDoc5PNdV8UtFvdXk0U2+itrdnbySvPaC5WEbim2N8sRkqSSPSsL4c+H9c0/V/DjXvhpdJFhp0ttfXi3MLm8kbyyCwQ7j8ys2TnrVvcD1qub+H/wDyArr/ALC2p/8ApdPXSVzfw/8A+QFdf9hbU/8A0unpgBtNQ1rxrqVhFr2o6ZaWen2k6x2cdudzyyXKsWMsTnpEmMYHWtP/AIQ2/wD+h08Rf9+rD/5GqPw3/wAlH8Q/9gnTv/R17XZ1SR5terONRpM5D/hDb/8A6HTxF/36sP8A5Go/4Q2//wCh08Rf9+rD/wCRqxtakk1XxtrljezaxKun2tvJZaVpd+bKS5WQtvm3CSPfgjbguFG08EkVzGofEy80zwvFeeFvteo2tjYC+u01S2WSZUaV1HmXH2hFBOwgBUkPAODS0Ep1XtI9A/4Q2/8A+h08Rf8Afqw/+RqP+ENv/wDodPEX/fqw/wDkauU8R+MteGpa1pwmsbK2ZLy3spVtpJWkeOB3BWeOXaJAVYmNlQrtPJOM3tC1rxQT4U0gX+kTz6lpMl817LaSnYE+zhcr5xLsRK2TuXJIPGCGNBc9X+Y3f+ENv/8AodPEX/fqw/8Akaj/AIQ2/wD+h08Rf9+rD/5GrjNQ8e6tJoBvL620S707VbPUjDp5gdng8iKRgs5LkSKQhRwFTBYDnNWpvGviC1bUbi1i0ZNI0qbTYGtvs8nmyLcLBu2uJNqbfNOPlbIAHGMk0Hz1e51P/CG3/wD0OniL/v1Yf/I1H/CG3/8A0OniL/v1Yf8AyNXEW3irxPomlX8png1Sa88S3GlWkbW53QHzJCCTJcKrJhNqpuTG4fMeht6h468W2mmQNcWOnWt1D9qa9bylumiSMrsZoIbgtGpBbcQ8mwrjB3CjQOar/MdZ/wAIbf8A/Q6eIv8Av1Yf/I1H/CG3/wD0OniL/v1Yf/I1cKdc1drbxlf3lzpWq6XHqtikVjdWkkqqJVsyrIWkwqjzCwGwfON3H3a27bxrryarFcX39k/2LJr1zo3lRwSLOixiUrKZC5U/6sZXZ75HSjQHOr/Mb/8Awht//wBDp4i/79WH/wAjUf8ACG3/AP0OniL/AL9WH/yNXmHiXxzq2u+GNf0+/gibTr3QZdTsrkWgtWdFljQHZ9olYqRICCwQ8dD29d8efbn8NT22jahb2Gq3TpDavNMIt7bgWjVsHDsiuAQCQeccU9BOpVVryKP/AAht/wD9Dp4i/wC/Vh/8jUf8Ibf/APQ6eIv+/Vh/8jVwVxeXTRrpWg6lqula1PrNrp9zb31/LqSW4CtOTHIZN3zJHhhv6ZXC5DVr3/jXxNY6fqepEaRdWtrqK6Rb28Vs0cl3cErEW3vNsiUTFjg5+UbSwPzUtB89X+Y6b/hDb/8A6HTxF/36sP8A5Go/4Q2//wCh08Rf9+rD/wCRq5qz8XeMZrq20qe20qz1G4v3hFxcRKUjgjt/MkZ4YrmTa4YoADIMhgSBWfbeK/Ees6lo9wl/ZWsNha6jqF2YrWV4ryKKbyY2VPOB2upZ1DE4Kg/Nxg0Dnq/zHa/8Ibf/APQ6eIv+/Vh/8jUf8Ibf/wDQ6eIv+/Vh/wDI1cnL8R9a063t7zUItIuor7SjqUVta70azLywxwrNKWYMrGblgq42MQCBWpc+I/EttrltoUmoeGWvblZZjeLDII7VIVQyo8Rlyz/vY8fOvy5YgcAmguer/MbH/CG3/wD0OniL/v1Yf/I1H/CG3/8A0OniL/v1Yf8AyNXNeH/HWv8AiW0DWD6Dp0lrbQS3El8shjuXmZhEI8ODGjBQQx3nLgBTjNMvPHmvHwq/iSzl8PrZ3MbtZWEyyG45kEMTswcBsyOgZQq7d2NxNGgc9W9rmrcfDJbi11e2m8WeImh1bd9tXbZDzd0SxHn7PlfkRR8uOmevNaf/AAht/wD9Dp4i/wC/Vh/8jVm614s15tQ16Dw5ZW99FpklrbO6RGZ0kcM0zbBIu/Ypi+QEHLHJ4xWjF4kvJPhq2vWM1jqN+0DPAzRGxhkk3FVUrJISpzhcF+SOCMjD0F7Sr3F/4Q2//wCh08Rf9+rD/wCRqP8AhDb/AP6HTxF/36sP/kauXsPG3iO/v9O0mGfSotTuNRltJmudMniMCrbeeN0Jm+8evEhBBHQ5AqN8R/E17HY2ukaXaS6gba5uJ5VRGhlENw8OYxJcQ7UOzdu3OVDLwetLQrmq/wAx2f8Awht//wBDp4i/79WH/wAjUf8ACG3/AP0OniL/AL9WH/yNWRpHivWtcnupAdCsLKzmt7a5s7omWWZpYI5CUlVwmP3u1flYPtPIzXK6d8Q/EJ0bT4vDmg6ZHHa6LaajPCixQwASqTtUvcR+TGNpG4LJjuBjk0BTqv7R6D/wht//ANDp4i/79WH/AMjUf8Ibf/8AQ6eIv+/Vh/8AI1ZWheMNZu/HR0zUVsbfT5p7mG2VIHcyiLJBW4WRkL4BLIUQrgjJI59Ep6ESq1Y7s89FpqGi+NdNsJde1HU7S80+7naO8jtxteKS2VSpiiQ9JXznI6V0lZXiT/ko/h7/ALBOo/8Ao6yrVpHoUJOVNNhRRRQbBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHm3h7/kVfhF/2w/9NdxXpNebeHv+RV+EX/bD/wBNdxXpNJAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArB8Z/8AIO07/sNaV/6X29b1YPjP/kHad/2GtK/9L7ek9gPUKKKKxAKKKKACvNdN/wCRv8cf9haL/wBN9pXpVcJfeD9dXxBrWoaPrumW9vqVwly0N1pUk7RssEUOA63CAgiIH7vc9acXZgWaKqf8Iv4v/wChk0D/AMEU3/yXR/wi/i//AKGTQP8AwRTf/Jdac6At1zfw/wD+QFdf9hbU/wD0unrZ/wCEX8X/APQyaB/4Ipv/AJLrnPAXhzxTNod01v4g0SJBqupIVk0aVyWW+nDHIuhwWBIGOAQMnGSuZATx6xBoPj7V7jULbUzb3WmWUcUtrptxdKzJLdl1JiRgCBIhwcfeFbX/AAn+if8APDX/APwQX/8A8Zp3/CL+L/8AoZNA/wDBFN/8l0f8Iv4v/wChk0D/AMEU3/yXTU7HPPDRnLmbMnWtf8Ga6sS63oV/qSxEmMXnhe8mCZ643QHFVrzUPAF6IBe+GJ7jyIzDF5vhK6fy0OcqubfheTwOOTW//wAIv4v/AOhk0D/wRTf/ACXR/wAIv4v/AOhk0D/wRTf/ACXRzon6pFdWZEWueCYdWl1SLQL2PU5gRJdr4WvBM4Iwdz+RuOfc0ul694L0lkOlaDfWJQOENt4WvItofbvxtgGN2xc+u0Z6Ctb/AIRfxf8A9DJoH/gim/8Akuj/AIRfxf8A9DJoH/gim/8AkujnD6pHuzGTWvBCXd7dJ4fvFub5Gjuph4Vuw9wrfeWRvs+WB7g5zU7eJvCLRzRto+plJ2jaVT4ZvcSFMbCw8jkrtXGem0Y6Vpf8Iv4v/wChk0D/AMEU3/yXR/wi/i//AKGTQP8AwRTf/JdHOH1SHdmLPq/ga4lvpJ/Dt3LJfAC7Z/Cl2xuMdPMJt/mxjvmoZb74fTWttbS+FppLa2JMETeEropET12j7PhfwroP+EX8X/8AQyaB/wCCKb/5Lo/4Rfxf/wBDJoH/AIIpv/kujnQfVY92Y9zrfgm6vnvbnw/ezXjqqNcSeFrxpGVSCoLGDOAVUgdiB6VZHirwoNmNK1QbLg3a48NXvExzmUfuPvnc2W68n1q//wAIv4v/AOhk0D/wRTf/ACXR/wAIv4v/AOhk0D/wRTf/ACXRzh9Uh3ZgW1/8P7X7R9l8LzQ/aEaOby/CV0vmKxBZWxb8glVJB64HpWhqnivwrq9qbbVdK1W+t858q58NXsqZxjo0BHc1f/4Rfxf/ANDJoH/gim/+S6P+EX8X/wDQyaB/4Ipv/kujnD6pDuzDk1TwHJpUemSeGrltNjfzUtD4TuzCr/3gn2fAPJ5xVuTxP4Sk02bT5NI1N7CYs0ts3hm9MTlmLMWTyMHLEk5HJOa0f+EX8X/9DJoH/gim/wDkuj/hF/F//QyaB/4Ipv8A5Lo50H1SPdnIXEfw8uLyzkm8PX72lpDLFDp58K3X2VDIyM0gj+zY3/u1GfTPrW3ceIfBtxd2d1caJqEtzZrttpX8L3jPAPRGMGVH0xWp/wAIv4v/AOhk0D/wRTf/ACXR/wAIv4v/AOhk0D/wRTf/ACXRzof1WPdmNZaz4HsbS7tLLw9eW1rd/wDHxDD4Vu0Sb/fUW+G/GoWv/h+1hBYt4XmNlBIZYrc+Erry43PVlX7PgE+orf8A+EX8X/8AQyaB/wCCKb/5Lo/4Rfxf/wBDJoH/AIIpv/kujnQvqse7Mm617wXdahbX91oN9NfWwAguJPC140kQHQKxgyuPaoF1PwGv27b4auR9uGLvHhO7/wBIGc/vP9H+bnnnPNbv/CL+L/8AoZNA/wDBFN/8l0f8Iv4v/wChk0D/AMEU3/yXRzoPqke7OVn1v4YrpVzaz+H0Gm2MhmuIX8LXPk27iNSWdTBhW8sqcnB247Yrdl8XeF5tOOny6bqz2BQRm2bw3emLYOi7fIxj2rhtf0HxGnhf4svJrekNFb+f9pVdJkUzY0y3Y7D9oPl/KQvIfkE8g7R6N/wi/i//AKGTQP8AwRTf/JdHOH1SHdnJXy/D28XTYX0DUI7CwmkuEsY/C10LaR3QoS8f2fB65HTkD0rU1DWvBGpWdraaj4evLu1tRi3hn8K3ciQjGPkU2+F4AHFbP/CL+L/+hk0D/wAEU3/yXR/wi/i//oZNA/8ABFN/8l0c6H9Vj3Zjy654Jm1C3v5dAvZL63UJDcN4WvDJEoGAFbyMgD0FR3WqeA7xLNbvw1czrZII7US+FLthAo6Kmbf5QMdBitz/AIRfxf8A9DJoH/gim/8Akuj/AIRfxf8A9DJoH/gim/8AkujnQvqke7Mm01/wXZ6pNqdnoV9b6jNnzbqLwteJLJnrucQZP4mtT/hP9E/54a//AOCC/wD/AIzTv+EX8X/9DJoH/gim/wDkuj/hF/F//QyaB/4Ipv8A5Lo5w+pwfVmHJrEGvePtIuNPttTFva6Zexyy3Wm3Fqqs8toUUGVFBJEbnAz90109VP8AhF/F/wD0Mmgf+CKb/wCS6P8AhF/F/wD0Mmgf+CKb/wCS6OdG8IKEeVFuiqn/AAi/i/8A6GTQP/BFN/8AJdH/AAi/i/8A6GTQP/BFN/8AJdHOiy3RVT/hF/F//QyaB/4Ipv8A5Lo/4Rfxf/0Mmgf+CKb/AOS6OdAW6Kqf8Iv4v/6GTQP/AARTf/JdH/CL+L/+hk0D/wAEU3/yXRzoC3RVT/hF/F//AEMmgf8Agim/+S6P+EX8X/8AQyaB/wCCKb/5Lo50Bboqp/wi/i//AKGTQP8AwRTf/JdH/CL+L/8AoZNA/wDBFN/8l0c6At0VU/4Rfxf/ANDJoH/gim/+S6P+EX8X/wDQyaB/4Ipv/kujnQFuiqn/AAi/i/8A6GTQP/BFN/8AJdH/AAi/i/8A6GTQP/BFN/8AJdHOgOB8Pf8AIq/CL/th/wCmu4r0mvLtA0HxG/hf4TPHrekLFceR9mVtJkYw50y4Ybz9oHmfKCvATkg8AbT6N/wi/i//AKGTQP8AwRTf/JdJSQFuiqn/AAi/i/8A6GTQP/BFN/8AJdH/AAi/i/8A6GTQP/BFN/8AJdPnQFuiqn/CL+L/APoZNA/8EU3/AMl0f8Iv4v8A+hk0D/wRTf8AyXRzoC3RVT/hF/F//QyaB/4Ipv8A5Lo/4Rfxf/0Mmgf+CKb/AOS6OdAW6Kqf8Iv4v/6GTQP/AARTf/JdH/CL+L/+hk0D/wAEU3/yXRzoC3RVT/hF/F//AEMmgf8Agim/+S6P+EX8X/8AQyaB/wCCKb/5Lo50Bboqp/wi/i//AKGTQP8AwRTf/JdH/CL+L/8AoZNA/wDBFN/8l0c6At0VU/4Rfxf/ANDJoH/gim/+S6P+EX8X/wDQyaB/4Ipv/kujnQFuiqn/AAi/i/8A6GTQP/BFN/8AJdH/AAi/i/8A6GTQP/BFN/8AJdHOgLdFVP8AhF/F/wD0Mmgf+CKb/wCS6P8AhF/F/wD0Mmgf+CKb/wCS6OdAW6Kqf8Iv4v8A+hk0D/wRTf8AyXR/wi/i/wD6GTQP/BFN/wDJdHOgLdYPjP8A5B2nf9hrSv8A0vt60/8AhF/F/wD0Mmgf+CKb/wCS6xPFuheI7Ky0y41LW9IurRNZ0vfDb6TJA7Zv4AMObhwOSD905Axx1CclYD1iiiiswCiiigArjdQ8d/Z9b1PTbPw3reotp8qwTT2zWqx72ijlwPMnRj8sq87cZrsq8103/kb/ABx/2Fov/TfaU0rsDT/4Ty7/AOhK8Sf9/bD/AOSqP+E8u/8AoSvEn/f2w/8AkqpaKvkQEX/CeXf/AEJXiT/v7Yf/ACVXN+APGl1baFdIvhDxBODqupSbo5LLA3X07FfmuAcrnae2QcEjBPU1zfw//wCQFdf9hbU//S6ejkQG/wD8J5d/9CV4k/7+2H/yVR/wnl3/ANCV4k/7+2H/AMlVzmhL4p160ub211bRLS3F9d20cMmlSysFhuJIgS4uVBJEeeFHWtH+xfF//Qw6B/4JJv8A5LrndelF2bM3VitLml/wnl3/ANCV4k/7+2H/AMlUf8J5d/8AQleJP+/th/8AJVZv9i+L/wDoYdA/8Ek3/wAl0f2L4v8A+hh0D/wSTf8AyXS+sUe4e1h3NL/hPLv/AKErxJ/39sP/AJKo/wCE8u/+hK8Sf9/bD/5KrN/sXxf/ANDDoH/gkm/+S6P7F8X/APQw6B/4JJv/AJLo+sUe4e1h3NL/AITy7/6ErxJ/39sP/kqj/hPLv/oSvEn/AH9sP/kqs3+xfF//AEMOgf8Agkm/+S6P7F8X/wDQw6B/4JJv/kuj6xR7h7WHc0v+E8u/+hK8Sf8Af2w/+SqP+E8u/wDoSvEn/f2w/wDkqs3+xfF//Qw6B/4JJv8A5Lo/sXxf/wBDDoH/AIJJv/kuj6xR7h7WHc0v+E8u/wDoSvEn/f2w/wDkqj/hPLv/AKErxJ/39sP/AJKrN/sXxf8A9DDoH/gkm/8Akuj+xfF//Qw6B/4JJv8A5Lo+sUe4e1h3NL/hPLv/AKErxJ/39sP/AJKo/wCE8u/+hK8Sf9/bD/5KrN/sXxf/ANDDoH/gkm/+S6P7F8X/APQw6B/4JJv/AJLo+sUe4e1h3NL/AITy7/6ErxJ/39sP/kqj/hPLv/oSvEn/AH9sP/kqs3+xfF//AEMOgf8Agkm/+S6P7F8X/wDQw6B/4JJv/kuj6xR7h7WHc0v+E8u/+hK8Sf8Af2w/+SqP+E8u/wDoSvEn/f2w/wDkqs3+xfF//Qw6B/4JJv8A5Lo/sXxf/wBDDoH/AIJJv/kuj6xR7h7WHc0v+E8u/wDoSvEn/f2w/wDkqj/hPLv/AKErxJ/39sP/AJKrN/sXxf8A9DDoH/gkm/8Akuj+xfF//Qw6B/4JJv8A5Lo+sUe4e1h3NL/hPLv/AKErxJ/39sP/AJKo/wCE8u/+hK8Sf9/bD/5KrN/sXxf/ANDDoH/gkm/+S6P7F8X/APQw6B/4JJv/AJLo+sUe4e1h3OK8QeLbmTwt8W4j4X1tBeefudpLTbb50u3T95ick4C7vkDcEd8qPR/+E8u/+hK8Sf8Af2w/+Sq5K88AeI7vT/EdnJ4l0gR67v8AtJXRpMput0gOz/SuPljB5zzntxW3/Yvi/wD6GHQP/BJN/wDJdH1ij3D2sO5pf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVWb/Yvi//AKGHQP8AwSTf/JdH9i+L/wDoYdA/8Ek3/wAl0fWKPcPaw7ml/wAJ5d/9CV4k/wC/th/8lUf8J5d/9CV4k/7+2H/yVWb/AGL4v/6GHQP/AASTf/JdH9i+L/8AoYdA/wDBJN/8l0fWKPcPaw7ml/wnl3/0JXiT/v7Yf/JVH/CeXf8A0JXiT/v7Yf8AyVWb/Yvi/wD6GHQP/BJN/wDJdH9i+L/+hh0D/wAEk3/yXR9Yo9w9rDuaX/CeXf8A0JXiT/v7Yf8AyVR/wnl3/wBCV4k/7+2H/wAlVm/2L4v/AOhh0D/wSTf/ACXR/Yvi/wD6GHQP/BJN/wDJdH1ij3D2sO5pf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVWb/Yvi//AKGHQP8AwSTf/JdH9i+L/wDoYdA/8Ek3/wAl0fWKPcPaw7ml/wAJ5d/9CV4k/wC/th/8lUf8J5d/9CV4k/7+2H/yVWb/AGL4v/6GHQP/AASTf/JdH9i+L/8AoYdA/wDBJN/8l0fWKPcPaw7ml/wnl3/0JXiT/v7Yf/JVH/CeXf8A0JXiT/v7Yf8AyVWb/Yvi/wD6GHQP/BJN/wDJdH9i+L/+hh0D/wAEk3/yXR9Yo9w9rDuaX/CeXf8A0JXiT/v7Yf8AyVR/wnl3/wBCV4k/7+2H/wAlVm/2L4v/AOhh0D/wSTf/ACXR/Yvi/wD6GHQP/BJN/wDJdH1ij3D2sO5pf8J5d/8AQleJP+/th/8AJVH/AAnl3/0JXiT/AL+2H/yVWb/Yvi//AKGHQP8AwSTf/JdH9i+L/wDoYdA/8Ek3/wAl0fWKPcPaw7ml/wAJ5d/9CV4k/wC/th/8lUf8J5d/9CV4k/7+2H/yVWb/AGL4v/6GHQP/AASTf/JdH9i+L/8AoYdA/wDBJN/8l0fWKPcPaw7ml/wnl3/0JXiT/v7Yf/JVH/CeXf8A0JXiT/v7Yf8AyVWb/Yvi/wD6GHQP/BJN/wDJdH9i+L/+hh0D/wAEk3/yXR9Yo9w9rDucV4f8W3Mfhb4SRDwvrbiz8ja6yWm24xpdwn7vM4IyG3fOF4B74U+j/wDCeXf/AEJXiT/v7Yf/ACVXJWfgDxHaaf4cs4/EukGPQtn2Yto0mX227wDf/pXPyyE8Y5x24rb/ALF8X/8AQw6B/wCCSb/5Lo+sUe4e1h3NL/hPLv8A6ErxJ/39sP8A5Ko/4Ty7/wChK8Sf9/bD/wCSqzf7F8X/APQw6B/4JJv/AJLo/sXxf/0MOgf+CSb/AOS6PrFHuHtYdzS/4Ty7/wChK8Sf9/bD/wCSqP8AhPLv/oSvEn/f2w/+Sqzf7F8X/wDQw6B/4JJv/kuj+xfF/wD0MOgf+CSb/wCS6PrFHuHtYdzS/wCE8u/+hK8Sf9/bD/5Ko/4Ty7/6ErxJ/wB/bD/5KrN/sXxf/wBDDoH/AIJJv/kuj+xfF/8A0MOgf+CSb/5Lo+sUe4e1h3NL/hPLv/oSvEn/AH9sP/kqj/hPLv8A6ErxJ/39sP8A5KrN/sXxf/0MOgf+CSb/AOS6P7F8X/8AQw6B/wCCSb/5Lo+sUe4e1h3NL/hPLv8A6ErxJ/39sP8A5Ko/4Ty7/wChK8Sf9/bD/wCSqzf7F8X/APQw6B/4JJv/AJLo/sXxf/0MOgf+CSb/AOS6PrFHuHtYdzS/4Ty7/wChK8Sf9/bD/wCSqP8AhPLv/oSvEn/f2w/+Sqzf7F8X/wDQw6B/4JJv/kuj+xfF/wD0MOgf+CSb/wCS6PrFHuHtYdzS/wCE8u/+hK8Sf9/bD/5Ko/4Ty7/6ErxJ/wB/bD/5KrN/sXxf/wBDDoH/AIJJv/kuj+xfF/8A0MOgf+CSb/5Lo+sUe4e1h3NL/hPLv/oSvEn/AH9sP/kqj/hPLv8A6ErxJ/39sP8A5KrN/sXxf/0MOgf+CSb/AOS6P7F8X/8AQw6B/wCCSb/5Lo+sUe4e1h3NL/hPLv8A6ErxJ/39sP8A5Ko/4Ty7/wChK8Sf9/bD/wCSqzf7F8X/APQw6B/4JJv/AJLo/sXxf/0MOgf+CSb/AOS6PrFHuHtYdzS/4Ty7/wChK8Sf9/bD/wCSqP8AhPLv/oSvEn/f2w/+Sqzf7F8X/wDQw6B/4JJv/kuj+xfF/wD0MOgf+CSb/wCS6PrFHuHtYdzS/wCE8u/+hK8Sf9/bD/5KrC8Y+LbnU7DTbSXwvrdgkms6Vm4uZLQxpi/gPIjnZucY4U8kdBzVv+xfF/8A0MOgf+CSb/5LqnqfhXxVqMMEU3iLQ1WG6t7tdmiygl4ZklUHN10LIAfbPTrR9Yo9w9rDueq0VyHhLVdcl8T6xpGvXGm3X2WztLuKays3tv8AWvcKysGlkzjyAQQR1NdfWkZKSui07q6CiiimMK8103/kb/HH/YWi/wDTfaV6VXmum/8AI3+OP+wtF/6b7SqjuBsUUUVqAVzfw/8A+QFdf9hbU/8A0unrpK5v4f8A/ICuv+wtqf8A6XT0gKFtZCwn1e007xjrdlHaSSX1xbRwWrrB57yTHBe3ZiCS5xuYjp6VfsbHU76yt7u18ca/JbzxrLG/2exG5WGQcG2yOD3rE1fwhLqmv+Kby4W/RLm0hjtDbajLbrKyo4IZY5FB5K/fGOfrXJah4G1qa5smvbLUrry9PsorZrKayU2UkaASKXmVnj+Ybt0JOe/QVk6UHq4onlj2PTv7H1r/AKHXX/8AvxYf/I1H9j61/wBDrr//AH4sP/kavOvFPhpdP8KatdahpSTXt14hQpgo0ktvJqEbLGrE4UNwdpIGeTiotQ8EarPHvt9Hns9BfUXn/sG2Nm7xoYUQPsl3W/31ZtmeN+Qc5o9lT/lQckex6V/Y+tf9Drr/AP34sP8A5Go/sfWv+h11/wD78WH/AMjV5jf+CtWaPRRBoV1cy2tssUf9oz2twkJ89nwxBRoiAR88OeAFx8uT2nxS0S41u002O302fUFhmaRo4xbyIDsKjfDOVSQfMcfMCpAIz0o9jT/lQckexqR6brr3U0TeLPEqRxhSs7Q6bskJzkKBblsjAzkDqMZ5xN/Y+tf9Drr/AP34sP8A5GrzweCdYu4Uh1HSbcQSHRlmgimBjCQM/nKNzFsKGHUknsTV6x8BHTtRS70/R7e2nh8QCeCSIopjsimGVcH5UJZv3Y9enSj2NP8AlQckex1OsW+q6TpF9qNz4z8RNBaQPcSLHb6eWKopYgZtgM4HrU9pp+r3VpDcR+NPEISVFkUNBYZAIzz/AKNXlXh7wzeat4ZSXRtCazmNhqUU96XhX+0TIrpHGMOWIDEHMgULt461qTeCdXfxMt3fWmpXLLNaSWlxazWSraoiRhkZ5FMyYZWJERKuG5xkknsqf8qDkj2PRv7H1r/oddf/AO/Fh/8AI1H9j61/0Ouv/wDfiw/+Rq5Lwz4a1Ky8cPqVzpWzRpJZzZWn2hG/s1zjdLtzt/e4Y4XJTOP4mxb8eeGtU1HW420dB9i1eBdO1hvMCFIFcMHAz8zFDNHxk/vAego9jT/lQckexuW2m67M04k8WeJYBHIUUyQ6aRKMA7122545I+bB4PGMEzf2PrX/AEOuv/8Afiw/+Rq45PBl1P4kjN7psb6T/bV1cuhdNht3s1iXK55UsNu3HTqMUn9hazbagmn2uhv9hj8QLqaXSTQrCINowoXdvBHTG3HHBNHsaf8AKg5I9jsv7H1r/oddf/78WH/yNR/Y+tf9Drr/AP34sP8A5Grj/hZ4Z1DQ9ZupbnRzY2722xppzC08km/OC8THzRjJ3yKr9PU16dTVGn/Kg5I9jB/sfWv+h11//vxYf/I1H9j61/0Ouv8A/fiw/wDkat6ij2NP+VByR7GD/Y+tf9Drr/8A34sP/kaj+x9a/wCh11//AL8WH/yNW9RR7Gn/ACoOSPYwf7H1r/oddf8A+/Fh/wDI1cxpd/4q1XTLPUbCXx9LZ3cKXEMm3Ql3o6hlOCARkEcEZr0WuR8BeLtO0rwL4c0+/s9fivLTTba3mj/sK+bY6RKrDIhIOCDyDiufERUEuSCfyM6it8KMC4/4WX9l1f7N/wAJd9p+b+zfM/sTZ/ql2+djn/W787f4dvfNaX/FZ/8AU/f+UGuhk+JnhqKK8lkk1dIrPP2l20S9Agwoc7z5Py/KwbnHBB6Va/4T3Rf+eGv/APggv/8A4zXNzT/59r7jO8v5fwOU/wCKz/6n7/yg0f8AFZ/9T9/5Qa6v/hPdF/54a/8A+CC//wDjNH/Ce6L/AM8Nf/8ABBf/APxmjmn/AM+19wXl/L+Byn/FZ/8AU/f+UGj/AIrP/qfv/KDXV/8ACe6L/wA8Nf8A/BBf/wDxmj/hPdF/54a//wCCC/8A/jNHNP8A59r7gvL+X8DlP+Kz/wCp+/8AKDR/xWf/AFP3/lBrq/8AhPdF/wCeGv8A/ggv/wD4zR/wnui/88Nf/wDBBf8A/wAZo5p/8+19wXl/L+Byn/FZ/wDU/f8AlBo/4rP/AKn7/wAoNdX/AMJ7ov8Azw1//wAEF/8A/GaP+E90X/nhr/8A4IL/AP8AjNHNP/n2vuC8v5fwOU/4rP8A6n7/AMoNH/FZ/wDU/f8AlBrq/wDhPdF/54a//wCCC/8A/jNH/Ce6L/zw1/8A8EF//wDGaOaf/PtfcF5fy/gcp/xWf/U/f+UGj/is/wDqfv8Ayg11f/Ce6L/zw1//AMEF/wD/ABmj/hPdF/54a/8A+CC//wDjNHNP/n2vuC8v5fwOU/4rP/qfv/KDR/xWf/U/f+UGur/4T3Rf+eGv/wDggv8A/wCM0f8ACe6L/wA8Nf8A/BBf/wDxmjmn/wA+19wXl/L+Byn/ABWf/U/f+UGj/is/+p+/8oNdX/wnui/88Nf/APBBf/8Axmj/AIT3Rf8Anhr/AP4IL/8A+M0c0/8An2vuC8v5fwOU/wCKz/6n7/yg0f8AFZ/9T9/5Qa6v/hPdF/54a/8A+CC//wDjNH/Ce6L/AM8Nf/8ABBf/APxmjmn/AM+19wXl/L+Byn/FZ/8AU/f+UGj/AIrP/qfv/KDXV/8ACe6L/wA8Nf8A/BBf/wDxmj/hPdF/54a//wCCC/8A/jNHNP8A59r7gvL+X8DlP+Kz/wCp+/8AKDR/xWf/AFP3/lBrq/8AhPdF/wCeGv8A/ggv/wD4zR/wnui/88Nf/wDBBf8A/wAZo5p/8+19wXl/L+BwVv8A8LL+y6R9p/4S77T8v9peX/Ymz/VNu8nPP+t2Y3fw7u+K0v8Ais/+p+/8oNdDH8TPDUsVnLHJq7xXmPszrol6RPlS42Hyfm+VS3GeAT0q1/wnui/88Nf/APBBf/8Axmjmn/z7X3BeX8v4HKf8Vn/1P3/lBo/4rP8A6n7/AMoNdX/wnui/88Nf/wDBBf8A/wAZo/4T3Rf+eGv/APggv/8A4zRzT/59r7gvL+X8DlP+Kz/6n7/yg0f8Vn/1P3/lBrq/+E90X/nhr/8A4IL/AP8AjNH/AAnui/8APDX/APwQX/8A8Zo5p/8APtfcF5fy/gcp/wAVn/1P3/lBo/4rP/qfv/KDXV/8J7ov/PDX/wDwQX//AMZo/wCE90X/AJ4a/wD+CC//APjNHNP/AJ9r7gvL+X8DlP8Ais/+p+/8oNH/ABWf/U/f+UGur/4T3Rf+eGv/APggv/8A4zR/wnui/wDPDX//AAQX/wD8Zo5p/wDPtfcF5fy/gcp/xWf/AFP3/lBo/wCKz/6n7/yg11f/AAnui/8APDX/APwQX/8A8Zo/4T3Rf+eGv/8Aggv/AP4zRzT/AOfa+4Ly/l/A5T/is/8Aqfv/ACg0f8Vn/wBT9/5Qa6v/AIT3Rf8Anhr/AP4IL/8A+M0f8J7ov/PDX/8AwQX/AP8AGaOaf/PtfcF5fy/gcp/xWf8A1P3/AJQaP+Kz/wCp+/8AKDXV/wDCe6L/AM8Nf/8ABBf/APxmj/hPdF/54a//AOCC/wD/AIzRzT/59r7gvL+X8DlP+Kz/AOp+/wDKDR/xWf8A1P3/AJQa6v8A4T3Rf+eGv/8Aggv/AP4zR/wnui/88Nf/APBBf/8Axmjmn/z7X3BeX8v4HKf8Vn/1P3/lBo/4rP8A6n7/AMoNdX/wnui/88Nf/wDBBf8A/wAZo/4T3Rf+eGv/APggv/8A4zRzT/59r7gvL+X8DlP+Kz/6n7/yg0f8Vn/1P3/lBrq/+E90X/nhr/8A4IL/AP8AjNH/AAnui/8APDX/APwQX/8A8Zo5p/8APtfcF5fy/gcp/wAVn/1P3/lBqve/8J75cf2L/hOPM86Lf539hY8rzF83GP4vL37e27GeM12f/Ce6L/zw1/8A8EF//wDGajm+IegwKrTprkas6RqX0G+ALswVVGYepYgAdyQKOaf/AD7X3BeX8v4Dvhrj/hJ9f+2/8JJ/bH2Oy83+2vsP+o33PleX9k+X73nZ3c9K9Erg/BV1/afjrxDqMNnqUFm2m2Fukl7YT2m90lvGYKJUUtgSJkgY+YV3ldlO/Krqx0Q2QUUUVZQV5rpv/I3+OP8AsLRf+m+0r0qvNdN/5G/xx/2Fov8A032lVHcDYormPHdn5mn/ANoTeI9T0O0skd5nstnzjj7wZGJIxwB6965L4c61Z3viNIYfEPi2/d4pdsOqWixQtsYK5yI1+ZTwRng8GtLgeqVzfw//AOQFdf8AYW1P/wBLp66Sub+H/wDyArr/ALC2p/8ApdPQB0lFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA828Q/8AIq/F3/tv/wCmu3rYvLjVNa8Y6hpFlq02kWunWsMrNbRRPNO8pfBPmo6hFCdhkknnisfxD/yKvxd/7b/+mu3rr9a8M6XrN3FdXsM63caGJbi1upbaTYTnYXiZSVzzgnFSBg3ni260GeXR9Qg+36uq2ws3DeUNQMr7CcBSE2EEt1wuD3wM3SPGGvxxXQvbCzvJrjXJ9LsALwpyryHa+IflRUjb5huY46ZNdIvhCxTX9Ev4hGlvo1vLDaW/l5KPJtBfeST90EY/2iSTUlx4M0O4e7aS2uP9JnF04S8nQJMDnzIwHAjfP8SbScnJ5o1Awx451O4u7LTrHQYJNVllu4J4Zb/y4ont9mcSCMlgwkUg7QfUDnFOz+J7jSotS1XRDa2dzpcmq2vk3XnSOiMilGXYu1iZFxgtwecHiuw03wxo+myWUllaeXJZ+d5LmV2bMpBkLEkl2YqMlsn3qJPB+grZ2tp/Z6NbWtlJp8UbuzKLd9u5Dk852LycnjrRqBzdr8QNRmCwS+Gp4b+e6htbQTGeCCZnWRzmSaBGG1YmJwjdVxnNMvPiJd21gWOlWbamlzc272SXc8rN5BAZ4/LtnZl56sqgcZPpq6h4D086XNb6UWhuXeJ1uLy4urlo/Lzs2N56yJgMwG1xjceOah0j4caTa6VDb6g093dK87vcxXE1uX85tzodsm5kOF+V2bOOSTk0agY0PjWY63LqNrDPcx6jpekvZWEk+xFluZJ8EnkLxt3MATheh4Fa8fj4W1+bXXbCOwEE81rdzLcmWKGVIVnTDbF3K8ZY5IUgrjHOa128F+H2s/sp0/8Ac/ZbezAE0gKxQEmEK27KspYkMCG96JvBXh+fQ5dIuLDz7CWcXMqzTSSPLKCDveQsXY8AZJORweOKNQOZHjmSCR7yXRblLuW102Q2xv2IAup3jVQhGxXUDJIAyTgnABrSv/Gt1ptp4jbUNKhW60a1huXjhuy6S+YXwoYxqRgIOdvf2yd6+8N6Tf3kt1d2nmTy/Z97eY4z5Ehki4Bx8rkn36HI4qrr/gzQtfuZZ9UtJZJJYlhlEd1LEsqKSVDqjAPgkkbgcdqNQKFn4xmn8avoUunw2yCR40ee5KTSBV3B0jMYV0PQFXJ6kgAHHY1hW/hPR7fWv7Vit5vtgledd11K0aSOCGdYi2xWIJBIUHk+prdpoAooopgFFFFABRRRQAUUUUAFFFFAHm3h7/kVfhF/2w/9NdxXSWbeI9Z1jXotN1LSLK0068S0RLjTZLh3zbwyliwnQdZSMbe1c34e/wCRV+EX/bD/ANNdxXa+BP8AkL+NP+wwn/pBaVzYicoU7xM6knGN0M/sXxf/ANDDoH/gkm/+S6P7F8X/APQw6B/4JJv/AJLrsaK8/wCtVe5z+1n3OO/sXxf/ANDDoH/gkm/+S6P7F8X/APQw6B/4JJv/AJLrsaxPGsmpw+FtRuNBfbqVvH58K7Q3m7CGMfIP3wCue27PHWhYqq3bmD2s+5k/2L4v/wChh0D/AMEk3/yXR/Yvi/8A6GHQP/BJN/8AJdYl54/kfULnUtKntpdGt7O1WOGdmQXV1c4kVVMcUkhZYgpCqpyZOnGRNpPxEvtXOmW1joC/2jePexNFcXTwxxPbMgJJaIPtYPnmMMMYK+l+2r9/yK56hq/2L4v/AOhh0D/wSTf/ACXR/Yvi/wD6GHQP/BJN/wDJdZWkeMbu4b+z/DuiG7vjLfyul7qjhVSC5aHIkZHbLN91MBVHGQAKfZ/EW5vPEo0638OX8lql4LCe4SOdzFJwHYlYTDsVjgnzQeCdvTK9vX7/AJBz1DS/sXxf/wBDDoH/AIJJv/kuj+xfF/8A0MOgf+CSb/5LrgvBvi6906xtb/UdQa5C+HLSbZfXcoSSZ7qVMkqsjbz8oyFYnAFej+APFL+KtOv5p7B7C5srxrOaFvM+8ERwR5kcbgFZF+8inr7EuVetHqDnNdSr/Yvi/wD6GHQP/BJN/wDJdH9i+L/+hh0D/wAEk3/yXWTcfEHVbKfWVvNAspYNNEULT2OpNKjXUsiRx25LwoA3zqWIyFBGeTin6n8QdQ0yK8hvdAiXUrO6ign8u7kktYo5I2dJWlWEuFO0r/qvvEdjml7av3/IOeoaf9i+L/8AoYdA/wDBJN/8l0f2L4v/AOhh0D/wSTf/ACXXMwfEPVY9V1fUrm1sZPDtnolvqUkcF6JXj3GfcYyseJCxjC4LqAFB6kgXLf4lagY/9L8K3kLvdWtvCSJ4o5PPk2YDTwRfOvBIAI5HzdcP21fv+Qc9Q2v7F8X/APQw6B/4JJv/AJLo/sXxf/0MOgf+CSb/AOS60td1u90PwlPrF9p0Uk9qglube2uGdUjDDzGVygLbUy2CozjHHWsC48ZQXuuWUcFnLLZrqz6fb3cV88ayulrJLIxRRh1BUphiRuyf4RlLEVn1/ISqTfUu/wBi+L/+hh0D/wAEk3/yXR/Yvi//AKGHQP8AwSTf/JdVvDHji91hvDMl1o0Vna69bm4t2F75kiARB23L5YGMkAENyOSFPFZc/wAUJ0i0mZdEhjgvo/MM11etDGD5zRmNH8oqXAXcQ5QYYcmj29fa/wCQ+eobv9i+L/8AoYdA/wDBJN/8l0f2L4v/AOhh0D/wSTf/ACXXY0VP1qr3J9rPucd/Yvi//oYdA/8ABJN/8l1T1Pwr4q1GGCKbxFoarDdW92uzRZQS8MySqDm66FkAPtnp1rvaKX1qr3D2s+5keEtV1yXxPrGka9cabdfZbO0u4prKze2/1r3CsrBpZM48gEEEdTXX1xnh7/kpviP/ALA+m/8Ao6+rs676UnKCbOqDvFNhRRRWhQV5rpv/ACN/jj/sLRf+m+0r0qvNdN/5G/xx/wBhaL/032lVHcDP+J9rNefD/XYbRZGufsxaIRRmRi6kMuFAJJyBXKeCUsbzxs11at4lihBuLqGzvtLe3hhkmIMp8wqM5OSFJwMnFdP8QP7WS1tZdIh1WZFLrOumTwpKqsuAwWRSHIPIAI59aw/h/eWk2uNE3ivxDc6gsTFtK1iJIHA4y2zy1Jx6qSOavqB6RXN/D/8A5AV1/wBhbU//AEunrpK5v4f/APICuv8AsLan/wCl09MDz/x9qN7B4p10QzaxAYvsEdtexXzR2dg0hYF5ow+CpxyTGw7EjOa25vGmvy+K7u2sNNtm0iy1GKwneVolOH2Zfe06sD8/yqIm3YwDk8dBNqS3Gp63a2HhG/1TynWzvZ4RZqkxMKSBG82ZWYBJgORjkiqn2JPtlvef8KwvPtduqpDNs0zfEFGFCt9oyAB0x0rN1IJ2ckS5RXU5dfiD4hj0y9muY9LjvRFDLbQNbyBCr3CRFhKsjLMmHHzLt5x8pFaL+I9QHiW00vVrfR7+5tdV+zreRWzKFDWUk2UVnYpICu0ncflbtmrGoeH4LvSrzT4vhtqdlDePG9wbMaZE0uyQOA37/DAlec9ia1LOJ7K3ggs/hrqFvBbyGWGOIaaixuQVLKBcYBIYgkdiaXtofzIOePc52Pxl4im8PeH7tH046lrNmLyGzg08yBI1jVpGZ5LmJQMup5IxnHzdapaf4u1u7vG8QpNCtkvheLVZdN8t3DsDKWWM+YArErjcVPGBjjNdZd232yztbS7+Gd9Pa2mPs8Mq6ayQ4GBsU3GFwOOKX7P89k//AArO+32K7LVtum5t19I/9I+UewxR7WH8yDnj3MG98ba7plrOtwdGvrprSzvYXtkkSNBNOkRRwXYnhsq4Izg/Lxzd1XxTr2jax/Yd4unXOq6h5R0mSK3eOJ8uRMHUyEny1w5IIyD0FWQbHRbYRzfDy50vTry7t4pnEVh5RleZEjZ1jmJOHZedpI61a1aUN46he10XWdWv9NsQ4W1ktkhhWd2Xd+9kQlz5DDjIA+tV7SNua+g+ZWvcteONbudItbGLTCG1O9uPIt4vsv2gyEKzEbTLEBwpO4uAMVxul+OPEutWlgbFNItJ20+9u7g3EDygvb3BhwoSXADYz95sZ4LY563VXudYtfs2rfDvVL62DB/KuTp0qbh0OGuCM8mmWqzWiKtp8ONSgVY3iURf2coCO251GLjozckdzyan21P+ZC549ziPF3ijUvEfg7VmhbTrGxi0+ynnimjaSWVp1V8I29QgGQoJVskHpXd/EHxBeeH9NsDplqLi8vr1LKLcFYIWVm3ENJGD9zABdeWHPY0rvT4rx7d7v4XXc7W0YhgMsemMYkHRVzccKPQcVoahdX+pWklrqPgDWLu1k+/DO+nyI31U3ODR7an/ADIOePc5m28UeLry+sdMEOkWF+8N7LO1xF5w/cvEE+SKchCRLypdiOuT0OVZ+MtbefUvEYlhNjH4as9VbTDG7ZLLOSEbeAp3Ly+w5UKMfLk9nZLLYLCLH4b6lbCFGjiEP9nJsViCyri44BKrkDrgelUtVnttKsf7Vv8A4cX0UGkWrsk/l6cxtoEUlgmJyQAuflX8qPawf2kHPHuZKeNPFNvYzSX+nWCyPLYi2ZzGgdZ51jbKR3ExxhsrJkAn+HjmxceINS0rVdUtDFo39qy3llZ/b1tWiQmVGIeVd5ZgoG0DcMkgZGeNq8tdF0O/t9L0fwfHeXN8r3ph0+2tYh+4eP538x0BIaVCOpzzxipLprm8juo7v4d6pOl2FFwsp05hMF+6HBuPmx2z0pyqRi7Njckt2XEuNabwzfvDNpV5rcImWJoEYQPIpO1WXeSp4AI3HBzya47/AITY+IY7S9tLGwn0cahptsn2qEyOtxIytIQcgBow8YBxkOG9MV1OnXV9ptpHaad4A1e0tY87IYH0+NF+ii5wKjiNxFbrBF8OtTSBZvtCxqdOCiXdu3gfaMbt3OeueaXtqf8AMhc8e5j6d4s1ubTdJ1K5/sxba+1X+zvJSF9wAnkj37y+ASEA24PPOecCnq/jnWwLn+y4rBkhvbyB5BA1wyxQhNreUsqswyx3OpIXA+XmuimE0+mtp0/w51KTT2JZrV/7OMRJbcSUNxj7xJ6deaqS6XbS20VtL8K7h7eJy8cTRaYURjjJA+0YB4HPtR7aH8yDnj3MWHx7r9/qsn9ladaT6Zay2sVxKTGiyCVI3Lh5J0ZBiT5R5T7sYyCSBreCvFep6tr8lnq32KFZIJLi3ihgb5kWRV3JMHeOVcMMkBCCRx1xbubc3V9Be3Pw0v5r2AARXEi6a0keOm1jcZGPaoNI1DRrRtKu/C/hKSS816xbUQLCC1gl8oeUSZWeRATmdOAW5z9aaqReqY+ZPqZ3iH/kVfi7/wBt/wD0129XtYbzvGOvyz3P2WXTdDR7KYxmTyDKZvMmVedx/dRjA5wuP4qz9Us/E13ovjqzj8HauJNd8z7MWubLCbrKKAb/APSOPmjJ4zxjvxXQzTX8uqW+ov4F8QfbYI3iSRbqyX5GwSpAusMMqDg5wRkYpe2p/wAyFzx7nnmmeLZdH0zU7vSpW1u5trKJ2mt9Zl1G1JaVELyCXaYXAJfYGA2g5IxkF98WNVttB+0eZpH23fceUVWCSK5RFQgblvdsb5cgoHlcjDBe1en/ANsa1/0JWv8A/f8AsP8A5Jo/tjWv+hK1/wD7/wBh/wDJNHtaf8yDnj3OGk+JGpJq00SJp9wPsLXVvYWirPPIwtvN2Oyzb4juyOYSuMANlhRZ+PNavZorTTr3QL9prm0gXULa3lNuhmSUvGV83LOnlqeGHDgEKenc/wBsa1/0JWv/APf+w/8Akmj+2Na/6ErX/wDv/Yf/ACTR7Wn/ADIOePc848R/FLVNK0CKfdpy6pH9tEkb24EU/wBnmaPKM9whUnbnYvmtzwDjmfTLj+2rnWNHRQP7Z14S3C9dttHZ2skoPqD8kf8A20ruI/Fq3UGhvpWj6nqMmr2LajDDAYEaOECLJcySquf3yDAJ7+lPN/qZuluT4E1s3KoYxL5un7whIJXP2nOMgHHsKcqkIuzY3JLdnFJ4u177Vf2ulnTovI/te6ZrtJrgsLa6EaqMygrkN64H8IAAWs0+OtZ02fxRffbLKd2azng06VSXgilht8zLumUeUhdt33QWySyZOPTP7Y1r/oStf/7/ANh/8k0f2xrX/Qla/wD9/wCw/wDkml7Wn/Mhc8e5yHhvxpr2uXmjWcX9jobz7Yz3K7Z1KwmDaVWGd1UnzWBUyHBAOexzoPGvi+eyhuVk0BRNpF1qyqbKY7RA6r5ZPnclt4O7jHPBr0D+2Na/6ErX/wDv/Yf/ACTR/bGtf9CVr/8A3/sP/kmj2tP+ZBzx7nm+qeKdSfxRaTx6paaNYpqkcc0t20skGJNMWRRIDKqgbmIAG0FtrckHdTtPH2uaJo0cE2p6be3J1C8hnknRQ1jtmlKJL5t1GPnGNgLLhVwA/WvVP7Y1r/oStf8A+/8AYf8AyTUTeKon0XQNQsdNv7063s+yW0PlLL80Dz/NvkVBhEbPzdeBmmpxd2mNST2Zxw8deIXt5L7ydIjtrWPTnngAMzSm5cK2yZJNgAzkHDZ/Ws20v7y5+Hmqz6jq9re6xpGpvJAiIwuLWUXkgRX3SMcOPlVcL8h2/N1r0j+2Na/6ErX/APv/AGH/AMk1T1Ga/wBS+zfbfAuvyrbzLcRqbmyCiRfukgXWGweRnIBAPUA0va0/5kLnj3OqorB/tjWv+hK1/wD7/wBh/wDJNH9sa1/0JWv/APf+w/8Akmn7an/Mg549zeorB/tjWv8AoStf/wC/9h/8k0f2xrX/AEJWv/8Af+w/+SaPbU/5kHPHub1Fc5/wlUX/AAjf9r/2bf7vtn2D7F+68/z/ALT9m2Z8zy/9Z334xzmpf7Y1r/oStf8A+/8AYf8AyTVOpCO7G5Jbs3qKwf7Y1r/oStf/AO/9h/8AJNH9sa1/0JWv/wDf+w/+San21P8AmQuePc5Tw9/yKvwi/wC2H/pruK3PDvinw/ofiDxjba1ruladcvqscixXd5HC5U2NqAwDEHGQRn2NYOl2fia00XwLZyeDtXMmheX9pK3Nlh9tlLAdn+kc/NIDzjjPfiut/tjWv+hK1/8A7/2H/wAk1lVdOrHlckTNxkrXNH/hYXgv/obvDv8A4M4f/iqP+FheC/8AobvDv/gzh/8Aiqzv7Y1r/oStf/7/ANh/8k1XbxasenahcT6PqcN1ZX0GnPYsYDM003k+WFIlMeD9oj5LjHOelcywtOW0zNUovZmz/wALC8F/9Dd4d/8ABnD/APFUf8LC8F/9Dd4d/wDBnD/8VWd/bGtf9CVr/wD3/sP/AJJo/tjWv+hK1/8A7/2H/wAk0vq9L+cXs4fzGRby/Ci20X+yrTXvD1vZfavtqiDW1jdJv76yLIHU44GCMDjpxVnSNT+GGkT201h4j0BJrZp3jd9aWRg0xUyElpDuLFV656cY5q9/bGtf9CVr/wD3/sP/AJJo/tjWv+hK1/8A7/2H/wAk1Xsaf/PwfJH+Yybub4VXUSRv4i0OPY88ge317yZP37l5QXSUMVZjkqTt6ccCnx3fwsi1NL+HxFoUUyyJNsi10JCZEACu0Ql8tmAA+YqTwK0/7Y1r/oStf/7/ANh/8k0f2xrX/Qla/wD9/wCw/wDkmj2NP/n4HJH+YxzJ8JzZpajXfD6xR28VtGV1sK0aRSGSPawl3KVckhgQ3PWtPw94i+HXh6C6i0rxToUa3U5uZ2l1pZnklKqpdmkkZiSEXv2z1JoXxVEmi6/qF9pt/ZHRN/2u2m8ppflgSf5dkjIco64+brwcVL/bGtf9CVr/AP3/ALD/AOSabw0EvenuDprrIw7MfCizsbmxi8S6U1jcK6yWs3iV5YTubcWEbzFQ27ncACDyDUgl+FiwbF8TaUsnnm5NyviNhctIV2ZM4m8w/LxgtjHFbH9sa1/0JWv/APf+w/8Akmj+2Na/6ErX/wDv/Yf/ACTS9jT/AOfgckf5jKW4+FSmHZr/AIfRIrX7D5aa2Fjlg+b5JUEu2UfO5+cNyxPWktLj4WWuwp4l0aQxyQyxmfxAZihhbdGFLynaqnkKPl9q1v7Y1r/oStf/AO/9h/8AJNH9sa1/0JWv/wDf+w/+SaPY0/8An4HJH+YvTePfBE8LxTeLPDjxyKVZW1KAhgeCD81Yen6l8LtO03SbCy1/w3FaaVI0tnGurp+7dldWOfMyxIkf72fvZ64q9/bGtf8AQla//wB/7D/5JqvJ4tW1g1x9V0fU9Ok0ixXUZoZzA7SQkS4KGOVlz+5cYJHb1ojhqb0jMFSi9Eyvcah8MJ9J0vTj4k0OO10tQln5GuiKSFQmzAkSUPgrwQSc981T2/CURW8K6/oaQQxCAQpr5WOSMOXCyKJcSAMzHDg9a3P7Y1r/AKErX/8Av/Yf/JNH9sa1/wBCVr//AH/sP/kmj2NP/n4HJH+Y0f8AhYXgv/obvDv/AIM4f/iqP+FheC/+hu8O/wDgzh/+KrO/tjWv+hK1/wD7/wBh/wDJNH9sa1/0JWv/APf+w/8Akmp+r0v5xezh/MaP/CwvBf8A0N3h3/wZw/8AxVH/AAsLwX/0N3h3/wAGcP8A8VWd/bGtf9CVr/8A3/sP/kmszxBc69qNpaRQeDNcVodQsrtt9xYgbIbmKVgMXPUqhA98dOtH1el/OHs4fzHQ+BtZ0zXPiJ4ludF1Gy1G2XStNjaW0nWZAwmvSVJUkZwQce4r0Kud8NeKP7b1O/0+bR9S0q8s4Ybh470wNvSVpFUqYpHHWF8gkHp610VdVNKMUkbxSSsgoooqygrzXTf+Rv8AHH/YWi/9N9pXpVea6b/yN/jj/sLRf+m+0qo7gN8S6Rd6zDDBa61e6VCGJmNmEEko4wA7A7PqOag8PeDtD0G6e8sbPdqEg2yXtw7TXD+uZHJPPoMCuhorSwBXN/D/AP5AV1/2FtT/APS6eukrm/h//wAgK6/7C2p/+l09AEj+HrqPUtRu9N8R6vpov5luJoLeO1dN4iSLI8yF2GVjXjOKd/Y+tf8AQ66//wB+LD/5GreoqHSg3dpE8sX0MH+x9a/6HXX/APvxYf8AyNR/Y+tf9Drr/wD34sP/AJGreopexp/yoOSPYwf7H1r/AKHXX/8AvxYf/I1H9j61/wBDrr//AH4sP/kat6ij2NP+VByR7HN3Xhu9vhBHqXirW7y2iuIbkwSR2aq7RSLIgJSBWxuRehFT3+gzza3Nqmn67qel3E9vFbSrapburrG0jISJYnIIMr9CO1btQrdW73Ulqs8TXMaLI8IcF1ViQrEdQCVbB74PpVezgly20Hyq1rGP/Y+tf9Drr/8A34sP/kaj+x9a/wCh11//AL8WH/yNW9RU+xp/yoXJHsYP9j61/wBDrr//AH4sP/kaj+x9a/6HXX/+/Fh/8jVtTzR28Mk08iRQxqXd3YKqqBkkk9AKIJo7iGOaCRJYZFDo6MGVlIyCCOoNHsaf8qDkj2MX+x9a/wCh11//AL8WH/yNVXVPDGo6rpl5p9/4x1+Wzu4Xt5o/KsV3o6lWGRbAjIJ5BzXUUUexp/yoOSPYxtY0SS/1Oz1C01a/0y8tYZbdZLRYW3JI0bMGEsbjrEmCAD1qL+x9a/6HXX/+/Fh/8jVvUVUqcJO7Q3FPdGD/AGPrX/Q66/8A9+LD/wCRqP7H1r/oddf/AO/Fh/8AI1b1FT7Gn/Khckexg/2PrX/Q66//AN+LD/5Go/sfWv8Aoddf/wC/Fh/8jVia7pFrJ41vL/VvBX/CS2kun2sEEnlWcvkuklw0gxPIpGRJH0znHtTf7N8N/wDRHf8AyS0r/wCP1hNRi7KnchpJ/Cbv9j61/wBDrr//AH4sP/kaq8fhJbWDQ00rWNT06TSLFtOhmgEDtJCRFkOJImXP7lDkAd/Wsr+zfDf/AER3/wAktK/+P0f2b4b/AOiO/wDklpX/AMfpKVlZUwvb7Jn6peeJrTRfHV5H4x1cyaF5n2YNbWWH22UU43/6Pz80hHGOMd+a63+x9a/6HXX/APvxYf8AyNXH3F14Kt7TV7mb4S7YdJ3fbW/s7TD5W2JZTx52W+R1Py56468Vp/2b4b/6I7/5JaV/8fpXX/PoWn8pu/2PrX/Q66//AN+LD/5Go/sfWv8Aoddf/wC/Fh/8jVhf2b4b/wCiO/8AklpX/wAfo/s3w3/0R3/yS0r/AOP0XX/PoNP5Td/sfWv+h11//vxYf/I1H9j61/0Ouv8A/fiw/wDkasL+zfDf/RHf/JLSv/j9H9m+G/8Aojv/AJJaV/8AH6Lr/n0Gn8pqx+EltYNDTStY1PTpNIsW06GaAQO0kJEWQ4kiZc/uUOQB39asf2PrX/Q66/8A9+LD/wCRqwv7N8N/9Ed/8ktK/wDj9H9m+G/+iO/+SWlf/H6blzO7pjbvvE3f7H1r/oddf/78WH/yNR/Y+tf9Drr/AP34sP8A5GrC/s3w3/0R3/yS0r/4/R/Zvhv/AKI7/wCSWlf/AB+ldf8APoWn8pu/2PrX/Q66/wD9+LD/AORqP7H1r/oddf8A+/Fh/wDI1YX9m+G/+iO/+SWlf/H6P7N8N/8ARHf/ACS0r/4/Rdf8+g0/lN3+x9a/6HXX/wDvxYf/ACNUTeFYk0XQNPsdSv7I6Js+yXMPlNL8sDwfNvjZDlHbPy9eRisf+zfDf/RHf/JLSv8A4/R/Zvhv/ojv/klpX/x+qU7KypjTttE3f7H1r/oddf8A+/Fh/wDI1H9j61/0Ouv/APfiw/8AkasL+zfDf/RHf/JLSv8A4/R/Zvhv/ojv/klpX/x+puv+fQtP5Td/sfWv+h11/wD78WH/AMjUf2PrX/Q66/8A9+LD/wCRqwv7N8N/9Ed/8ktK/wDj9H9m+G/+iO/+SWlf/H6Lr/n0Gn8pu/2PrX/Q66//AN+LD/5Go/sfWv8Aoddf/wC/Fh/8jVhf2b4b/wCiO/8AklpX/wAfo/s3w3/0R3/yS0r/AOP0XX/PoNP5TY/4RWL/AIRv+yP7Sv8Ad9s+3/bf3Xn+f9p+078eX5f+s7bMY4xUv9j61/0Ouv8A/fiw/wDkasL+zfDf/RHf/JLSv/j9H9m+G/8Aojv/AJJaV/8AH6pz5t6Y277xN3+x9a/6HXX/APvxYf8AyNR/Y+tf9Drr/wD34sP/AJGrC/s3w3/0R3/yS0r/AOP0f2b4b/6I7/5JaV/8fqbr/n0LT+Uz9LvPE13ovgW8k8Y6uJNd8v7SFtrLCbrKWc7P9H4+aMDnPGe/Ndb/AGPrX/Q66/8A9+LD/wCRq4+3uvBVxaaRcw/CXdDq237E39naYPN3RNKOPOyvyIx+bHTHXitP+zfDf/RHf/JLSv8A4/Rdf8+g0/lN3+x9a/6HXX/+/Fh/8jVXbwksmnahbz6xqc11e30GovfMIBMs0Pk+WVAiEeB9nj4KHPOetZX9m+G/+iO/+SWlf/H6P7N8N/8ARHf/ACS0r/4/TUuXamNO20Td/sfWv+h11/8A78WH/wAjUf2PrX/Q66//AN+LD/5GrC/s3w3/ANEd/wDJLSv/AI/R/Zvhv/ojv/klpX/x+ldf8+hafym7/Y+tf9Drr/8A34sP/kaj+x9a/wCh11//AL8WH/yNWF/Zvhv/AKI7/wCSWlf/AB+j+zfDf/RHf/JLSv8A4/Rdf8+g0/lN3+x9a/6HXX/+/Fh/8jUf2PrX/Q66/wD9+LD/AORqwv7N8N/9Ed/8ktK/+P0f2b4b/wCiO/8AklpX/wAfouv+fQafymwvhWJ9F1/T77Ur+9Ot7/tdzN5Sy/NAkHy7I1QYRFx8vXk5qX+x9a/6HXX/APvxYf8AyNWF/Zvhv/ojv/klpX/x+j+zfDf/AER3/wAktK/+P1TndJOmNu/2Td/sfWv+h11//vxYf/I1H9j61/0Ouv8A/fiw/wDkasL+zfDf/RHf/JLSv/j9H9m+G/8Aojv/AJJaV/8AH6m6/wCfQtP5Td/sfWv+h11//vxYf/I1H9j61/0Ouv8A/fiw/wDkasL+zfDf/RHf/JLSv/j9H9m+G/8Aojv/AJJaV/8AH6Lr/n0Gn8pu/wBj61/0Ouv/APfiw/8Akaq8nhJbqDXE1XWNT1GTV7FdOmmnECNHCBLgII4lXP75zkg9vSsr+zfDf/RHf/JLSv8A4/R/Zvhv/ojv/klpX/x+nGXK7qmNO20Td/sfWv8Aoddf/wC/Fh/8jUf2PrX/AEOuv/8Afiw/+Rqwv7N8N/8ARHf/ACS0r/4/R/Zvhv8A6I7/AOSWlf8Ax+ldf8+hafym7/Y+tf8AQ66//wB+LD/5Go/sfWv+h11//vxYf/I1YX9m+G/+iO/+SWlf/H6P7N8N/wDRHf8AyS0r/wCP0XX/AD6DT+U3f7H1r/oddf8A+/Fh/wDI1ZniC217TrS0lg8Z64zTahZWjb7exI2TXMUTEYtuoVyR7469Kq/2b4b/AOiO/wDklpX/AMfrD1bSLWPxJoV/pPgr/hGrSK5tIJ5PKs4vOd9U09oxiCRicCOTk4xn3qoqMnZ07DSTfwns/hrwv/Ymp3+oTaxqWq3l5DDbvJeiBdiRNIyhRFGg6zPkkE9PSuioorRJLRGqVgooopgFea6b/wAjf44/7C0X/pvtK9KrzXTf+Rv8cf8AYWi/9N9pVR3A2KKKK1AK5v4f/wDICuv+wtqf/pdPXSVzfw//AOQFdf8AYW1P/wBLp6QHSUUUUwCiiigArkvih5v/AAi3H2j7D9rt/wC0Ps+7f9k8xfN+782Nuc4525rraKAPCfF8OkT6f4iTwA0CaONEka/OlhTb+askZjxtBTzNgm3YGdvXBwat6pe3cGoeKNc8PeKpbwWGgQXS3apbTLeFJbohXKxhdo2svyBT75Bz7XRU2A8iuPFmvyePHs/7W03T4o9Qgt49PuJgr3EDhMssXkM7k7mw6yqqkfMAASex+HNxqWpaDBqmq6nLdSXAdRD5UaRoFkYAjau4sQOcnHTgck9ZRTsB5d/wkniBtR1bSDculzoUV3dXd15KYnjZCbQY24yQxJxjmE9iRSJrPiLULbXZLXVZ45LDRLW9gigt4maWd4JWIO5DkFlU4AzkDBAyD6lRRYDx/UviBNd/av7F8RWCwRaXZSPcEoY453mYSfvNjKjFBgFgUVsZA5rOufHGuSWWmLDrkNlaSi6J1PUJ7eBZZI3UKgmWCWJxgkgqiF8cYwQfcaKLAeP6f4v1eTxZpFrea7DKJ/sitaWKR/MXiVnZopY1mKliW3o2FXgjIIrd+KGv6tpWpaTa2N/aaVZXMUzy39zcJboJF2bY/MeGVRkMxwVGccEYwfQ6KLAeJat411eLS7mW98TwafqEFlayWdvawx7NRZx88iiaMuy5yMKF24yetev2Gq2d/d39tZzeZNYSiG4ARgEcqH25IwTtYHgnGeaq6t4c07VryO41BbqUx7CIftkywMVbcpaEOI2IODyp6D0FXbDT7Ww+0/ZIhH9oma4lO4kvI2Mk5+g+mKFcDyLxBDqzeGfH8lte2EemjVJPMgks3eVuIs4kEoA7dUP41F4sh1Z/DHxVezvbGLT1u5vOgls3klc/ZIM7ZBKoXjA5Rsdec4HttFFgPJ/E6y23iHUvB0Qk8nxRcRXMRBOEiORejPb5Y8/Wb8Kz7K7+x/ECeW7TRbzVzrIs4bGa1Y3tvaH5UlhcvhIxGdx2oAfmy2a9ooosB5t4h/5FX4u/9t//AE129ek15t4h/wCRV+Lv/bf/ANNdvXpNCAKKKKYBRRRQAUUUUAFFFFAGBdanrU3iS60rQ9M065+y2kF1LLeX72/+teZQqhYZM48kkkkdRUuPGn/QE8O/+Dqb/wCRKxfGkWm2+t2MzWOvXWq6in2VF0nUpLQukQeQB8TxKQN7kE5PJrG1CWysZIoJNL8dvdtayXsluniKXdDEjbSWJvApzwQFLcH1yK55qrf3WrENSvozs8eNP+gJ4d/8HU3/AMiUY8af9ATw7/4Opv8A5ErmNLHh7UBdMt94pgW3s4dQYz65fpuglQsrgefnjawOQMFSKdcwaPbeDh4jmfxctqbdbn7OddvBNtbBAI+0bQ3I4zU8tf8AmQrT7nS48af9ATw7/wCDqb/5Eox40/6Anh3/AMHU3/yJXA6jqml6fa6lNdaX49VtMTzb6IeIJS1vGV3K5/0zDBgGxsLHKkEDjOzptrp91rEOl3cHjLTr2a3lulS58Q3Lfu42jUnMd045MowPY5xxk5a/8yC0+50uPGn/AEBPDv8A4Opv/kSjHjT/AKAnh3/wdTf/ACJXGahcaTZ6jqtv9l8cz22lOiXl5Brl08ce6NZM7ftXmMArjOEPf0rqYPC+mTwxzQ6j4gkikUOjr4gvyGBGQR++o5a/8yC0+5ax40/6Anh3/wAHU3/yJRjxp/0BPDv/AIOpv/kSoP8AhErD/n+8Rf8AhQX/AP8AHqP+ESsP+f7xF/4UF/8A/HqfJX/mQWn3J8eNP+gJ4d/8HU3/AMiUY8af9ATw7/4Opv8A5EqD/hErD/n+8Rf+FBf/APx6j/hErD/n+8Rf+FBf/wDx6jkr/wAyC0+5Pjxp/wBATw7/AODqb/5Eox40/wCgJ4d/8HU3/wAiVB/wiVh/z/eIv/Cgv/8A49R/wiVh/wA/3iL/AMKC/wD/AI9RyV/5kFp9zB0/wt40s9K8I2X2Dw6/9gbPn/taYefttZLfp9m+XPmbu/THfNdLjxp/0BPDv/g6m/8AkSuC0fTWuNA+HVzNq3iJptW8r7a39uXo83dYTSnjzcL86Kflx0x04rtv+ESsP+f7xF/4UF//APHqSjX/AJkFp9yfHjT/AKAnh3/wdTf/ACJRjxp/0BPDv/g6m/8AkSoP+ESsP+f7xF/4UF//APHqP+ESsP8An+8Rf+FBf/8Ax6nyV/5kFp9yfHjT/oCeHf8AwdTf/IlGPGn/AEBPDv8A4Opv/kSoP+ESsP8An+8Rf+FBf/8Ax6j/AIRKw/5/vEX/AIUF/wD/AB6jkr/zILT7k+PGn/QE8O/+Dqb/AORKMeNP+gJ4d/8AB1N/8iVB/wAIlYf8/wB4i/8ACgv/AP49R/wiVh/z/eIv/Cgv/wD49RyV/wCZBafcnx40/wCgJ4d/8HU3/wAiUY8af9ATw7/4Opv/AJEqD/hErD/n+8Rf+FBf/wDx6j/hErD/AJ/vEX/hQX//AMeo5K/8yC0+4z/hJ/8Ai3H/AAlf2P8A5hP9qfZfN/6Y+Zs34/DOPfHarWPGn/QE8O/+Dqb/AORKn/sPTv8AhHP7B+z/APEp+yfYfI3t/qdmzbuzu+7xnOfeqP8AwiVh/wA/3iL/AMKC/wD/AI9WlRVHbkdipKXQnx40/wCgJ4d/8HU3/wAiUY8af9ATw7/4Opv/AJEqD/hErD/n+8Rf+FBf/wDx6j/hErD/AJ/vEX/hQX//AMerPkr/AMyJtPuT48af9ATw7/4Opv8A5Eox40/6Anh3/wAHU3/yJUH/AAiVh/z/AHiL/wAKC/8A/j1H/CJWH/P94i/8KC//APj1HJX/AJkFp9yfHjT/AKAnh3/wdTf/ACJWXfeJ9T0mDxL/AG1pVlHc6Ppa6oqWl80yTKwnwpZokKnMB7H7w+lXf+ESsP8An+8Rf+FBf/8Ax6nReEtJjt9UhdL25TU7cWl013f3Fw8kIDgIGkdmUfvH+6R941UI1U/easOKlfVkuPGn/QE8O/8Ag6m/+RKMeNP+gJ4d/wDB1N/8iVB/wiVh/wA/3iL/AMKC/wD/AI9R/wAIlYf8/wB4i/8ACgv/AP49U8lf+ZCtPuT48af9ATw7/wCDqb/5Eox40/6Anh3/AMHU3/yJUH/CJWH/AD/eIv8AwoL/AP8Aj1H/AAiVh/z/AHiL/wAKC/8A/j1HJX/mQWn3J8eNP+gJ4d/8HU3/AMiVQ1nTfGmpW1tF/ZPh2Lyb21vM/wBsTNnyLiObb/x6/wAXl4z2znB6VY/4RKw/5/vEX/hQX/8A8erJ8TeHbeysrKS21HxEjyanYW7H+3r45jlu4Y3HM3dXYZ6jORg0nGv/ADILT7noPhbxDqeo67qmla1pdlY3NnbW10rWl81ykizNMoBLRRkEGA9j94V1FYfh7wtpfh+6u7nTlvWuLpI45pbu/nu3ZYy5RQZXYgAyOcDH3jW5VRvbUtXtqFFFFMYV4/J4m0HRvHHja31jW9MsLhtThkWK6u44mKmwtAGAYg4yCM+xr2CimnYDyn/hPPCH/Q16B/4MYf8A4qj/AITzwh/0Negf+DGH/wCKr1aiq5wPKf8AhPPCH/Q16B/4MYf/AIquf8D+NfC1totylx4l0SJzqeoSBZL+JSVa8mZWwW6FSCD3BBr3auV+Gn/IuXn/AGGtW/8ATjcUc4HJ/wDCeeEP+hr0D/wYw/8AxVH/AAnnhD/oa9A/8GMP/wAVXq1FHOB5T/wnnhD/AKGvQP8AwYw//FUf8J54Q/6GvQP/AAYw/wDxVerUUc4HlP8AwnnhD/oa9A/8GMP/AMVR/wAJ54Q/6GvQP/BjD/8AFV6tRRzgeU/8J54Q/wChr0D/AMGMP/xVH/CeeEP+hr0D/wAGMP8A8VXq1FHOB5T/AMJ54Q/6GvQP/BjD/wDFUf8ACeeEP+hr0D/wYw//ABVerUUc4HlP/CeeEP8Aoa9A/wDBjD/8VR/wnnhD/oa9A/8ABjD/APFV6tRRzgeU/wDCeeEP+hr0D/wYw/8AxVH/AAnnhD/oa9A/8GMP/wAVXq1FHOB5T/wnnhD/AKGvQP8AwYw//FUf8J54Q/6GvQP/AAYw/wDxVerUUc4HlP8AwnnhD/oa9A/8GMP/AMVR/wAJ54Q/6GvQP/BjD/8AFV6tRRzgeU/8J54Q/wChr0D/AMGMP/xVH/CeeEP+hr0D/wAGMP8A8VXq1FHOB5T/AMJ54Q/6GvQP/BjD/wDFUf8ACeeEP+hr0D/wYw//ABVerUUc4HzTrni3w5L4b+KMUfiDSHlvPO+zIt7GTPnTYEGwbvm+ZSvHcEda9A/4Tzwh/wBDXoH/AIMYf/iqXxN/yJ3xt/7eP/TPa16rRzAeU/8ACeeEP+hr0D/wYw//ABVH/CeeEP8Aoa9A/wDBjD/8VXq1FHOB5T/wnnhD/oa9A/8ABjD/APFUf8J54Q/6GvQP/BjD/wDFV6tRRzgeU/8ACeeEP+hr0D/wYw//ABVH/CeeEP8Aoa9A/wDBjD/8VXq1FHOB5T/wnnhD/oa9A/8ABjD/APFUf8J54Q/6GvQP/BjD/wDFV6tRRzgfPPj7WfC+vXeizxaz4K1SGxlleWz1PVYkjkDRlQfuycgnPK9qwtRm8MXF5ptwo+GUtvb2Utt/Zs2rxCCB2l3h4z5JzkZz8qnLHr1P1HRS5gPl3U49En0jQ7OHx54aZ0tjpuqySamn7+0Z1dkT5iSRtKLkjhzk9q67xt4j8K674S1HSbPxb4ciluYhGhfU4lVeR3U5HTtXulFHMB8869ceCJPBviHSdE8U6BHearA8bT3mtCZncrtUvI7s5AHHfHYVLr3irSR4vsNb0bxH4PulhsZ7OSG71xLc5kkicMCqSZx5ZGMDrX0DRRzAfNL+Io1vfEbWviXwLCmttE7TPrgka2Ito4nAj2ASYKNgllzxkDpXaaR4t8F6VpNlp9v4r0Iw2kCQRltShJ2ooUZ+b0FexUUcwHlP/CeeEP8Aoa9A/wDBjD/8VR/wnnhD/oa9A/8ABjD/APFV6tRT5wPKf+E88If9DXoH/gxh/wDiqP8AhPPCH/Q16B/4MYf/AIqvVqKOcDyn/hPPCH/Q16B/4MYf/iqP+E88If8AQ16B/wCDGH/4qvVqKOcD5p0Pxb4ci8N/C6KTxBpCS2fk/aUa9jBgxps6HeN3y/MwXnuQOtegf8J54Q/6GvQP/BjD/wDFUvhn/kTvgl/27/8Apnuq9Vo5wPKf+E88If8AQ16B/wCDGH/4qj/hPPCH/Q16B/4MYf8A4qvVqKOcDyn/AITzwh/0Negf+DGH/wCKo/4Tzwh/0Negf+DGH/4qvVqKOcDyn/hPPCH/AENegf8Agxh/+Ko/4Tzwh/0Negf+DGH/AOKr1aijnA8p/wCE88If9DXoH/gxh/8AiqP+E88If9DXoH/gxh/+Kr1aijnA8p/4Tzwh/wBDXoH/AIMYf/iqP+E88If9DXoH/gxh/wDiq9Woo5wPKf8AhPPCH/Q16B/4MYf/AIqj/hPPCH/Q16B/4MYf/iq9Woo5wPKf+E88If8AQ16B/wCDGH/4qj/hPPCH/Q16B/4MYf8A4qvVqKOcDyn/AITzwh/0Negf+DGH/wCKo/4Tzwh/0Negf+DGH/4qvVqKOcDyn/hPPCH/AENegf8Agxh/+Ko/4Tzwh/0Negf+DGH/AOKr1aijnA8p/wCE88If9DXoH/gxh/8AiqP+E88If9DXoH/gxh/+Kr1aijnA8p/4Tzwh/wBDXoH/AIMYf/iqyvEPi3w5qcek2em+INIvLuTWdL2QW97HI7YvoCcKGJOACfwr2uuV+Jf/ACLln/2GtJ/9ONvQ5AdVRRRUAFFFFABXlE+n/wBseMvF7Xmo62q22oRQQx22r3VvHGn2K2fASORVHzOxzjqa9XrzXTf+Rv8AHH/YWi/9N9pVR3Ah/wCEWtP+gj4k/wDChv8A/wCPUf8ACLWn/QR8Sf8AhQ3/AP8AHq3qK0sgMH/hFrT/AKCPiT/wob//AOPVz3gbw5azaLcs1/4gUjU9RTEeu3qDC3swBwsoGTjJPUnJJJJNd/XN/D//AJAV1/2FtT/9Lp6LICb/AIRa0/6CPiT/AMKG/wD/AI9R/wAItaf9BHxJ/wCFDf8A/wAereoosgMH/hFrT/oI+JP/AAob/wD+PUf8Itaf9BHxJ/4UN/8A/Hq3qKLIDB/4Ra0/6CPiT/wob/8A+PUf8Itaf9BHxJ/4UN//APHq3qKLIDB/4Ra0/wCgj4k/8KG//wDj1H/CLWn/AEEfEn/hQ3//AMereoosgMH/AIRa0/6CPiT/AMKG/wD/AI9VHXNJ07RtE1DVLq/8UPb2VvJcyLH4gvixVFLEAGcDOB3IrrK5v4l/8k48V/8AYJu//RLUNIDL/snUv+ha+If/AIVP/wB8KP7J1L/oWviH/wCFT/8AfCvYaK8X6/U7I05UePf2TqX/AELXxD/8Kn/74Uf2TqX/AELXxD/8Kn/74V13xL8cx+CtPglSwfUbqTfKbdJRH5dvGAZZmbBwqgqOnJZR3rZl8T6XHrh0hXu5r5WRJFt7KeZIWYAqJJEQpHkEH5iOCD0qvrtW1+VC5Uecf2TqX/QtfEP/AMKn/wC+FH9k6l/0LXxD/wDCp/8AvhXaaf8AEXwvfuRBqTpH5Ms6zT2s0MMkcZAkZJHQI4XIztJpzfEHw2lne3M17cQJZvDHMk9jcRSAzNtiIjZA7BiDggEcHng0fXK38q+4OVHE/wBk6l/0LXxD/wDCp/8AvhR/ZOpf9C18Q/8Awqf/AL4V2Nx8R/DVuwWe41CNt0aSBtKuwYWkbbGsv7r90WJGA+0kEEcEE0NY8fG21NIbRLOS1hu7tLqQO7MsNtbl5eCqhXEhReC64zzngNYyt/KvuDlRzv8AZOpf9C18Q/8Awqf/AL4Uf2TqX/QtfEP/AMKn/wC+FdnoXjO0bwwt5r9xDb6haW9q+pRwwybIJZ0VlRepbJcAYJPIrT0zxPpeqanLY6e93PJEzo0y2U/2fch2son2eWSCCMBs5BHak8bVX2V9wcqPOf7J1L/oWviH/wCFT/8AfCj+ydS/6Fr4h/8AhU//AHwr0K48X6Lb6+NFkuJzf+YkLBLSZ40kddyI8oQorEYIDMDyPUVS0n4ieF9VG611Jli+zyXazXNrNbxPFHjzHR5EVXC5+baTjvij67W/lX3Byo8k1Hwd4guNJ8YW8Xhrxn52q+Z9k8zxEpTm1jiHng3pD/OjZ3B/k2jkAKOm/snUv+ha+If/AIVP/wB8K7hfH3h0291K95cQm38vdFPYzxTP5hIj8uJkDybiCBsByQcVHD430eW5ln/tWOOxitGmkt5rGaKdGWXyySWwQd3yeXs3lsY64o+uVv5V9zDlRxf9k6l/0LXxD/8ACp/++FH9k6l/0LXxD/8ACp/++FdsfiB4dEW43F6JvO+z/ZP7OuftW/Z5mPs/l+bjZ82duMc5rotNvrfU9Otr6yk821uY1lifaV3KwyDg4I47Gk8dVW8V9wcqPJ/7J1L/AKFr4h/+FT/98KfpOnw3uqXmnXsXjTS7y1hhuGju/Edy26ORpFUqYrpx1ifIJB6etevV5vrMetyfFHV/7CstNusaNp/m/bL17bb+/vdu3bDJu75zjGB1zxrQxrlK1SyQOIv/AAi1p/0EfEn/AIUN/wD/AB6j/hFrT/oI+JP/AAob/wD+PVZ+zeNv+gL4c/8AB3P/APIlH2bxt/0BfDn/AIO5/wD5Ers+s0f5kTZlb/hFrT/oI+JP/Chv/wD49R/wi1p/0EfEn/hQ3/8A8eqz9m8bf9AXw5/4O5//AJEo+zeNv+gL4c/8Hc//AMiUfWaP8yCzK3/CLWn/AEEfEn/hQ3//AMeo/wCEWtP+gj4k/wDChv8A/wCPVZ+zeNv+gL4c/wDB3P8A/IlH2bxt/wBAXw5/4O5//kSj6zR/mQWZW/4Ra0/6CPiT/wAKG/8A/j1H/CLWn/QR8Sf+FDf/APx6rP2bxt/0BfDn/g7n/wDkSj7N42/6Avhz/wAHc/8A8iUfWaP8yCzK3/CLWn/QR8Sf+FDf/wDx6ub0qC41bS7PUdP8PfEOayvIUuIJP+EnK743UMpwb8EZBHBGa637N42/6Avhz/wdz/8AyJWr8Kf+SXeDv+wNZ/8AohK58Ri1FJ0rMaj3OH/snUv+ha+If/hU/wD3wo/snUv+ha+If/hU/wD3wr2GiuX6/U7IrlR49/ZOpf8AQtfEP/wqf/vhR/ZOpf8AQtfEP/wqf/vhXsNFH1+p2QcqPHv7J1L/AKFr4h/+FT/98KP7J1L/AKFr4h/+FT/98K9hrjfH3jlPClzpttFp8moT3EsZuFSTYLW3aRYzMxwc4Z1AXjPPIwaqOOqydkkLlRyH9k6l/wBC18Q//Cp/++FH9k6l/wBC18Q//Cp/++Feif8ACV6SdXm02OS6luIHMc0kVlPJBCwXcVedUMaEAgkFgRkeorO0z4jeFtSgkmttRkSJLb7YHubSe3EkO4LvQyIu8bmVflzyQOpFH12t/KvuDlR5Np3g7xBb6T4Pt5fDXjPztK8v7X5fiJQnFrJEfIAvQE+d1xtCfJuHAJU9N/ZOpf8AQtfEP/wqf/vhXbnx/wCHUs5LiW7uoQl0lm0M1hcRziZ13InktGJOV5Hy4NMHxE8N/bILU3N8Jpp47UZ0y6CpNIQEjdvLxG5yPlcgjOSBR9crfyr7mHKji/7J1L/oWviH/wCFT/8AfCj+ydS/6Fr4h/8AhU//AHwrW134kvaiafTo7Oe0t7bVLqR1Mj7ktCsagZCYZpm24G4HacMetdRZeK7BNNL6ndRpeW1zBp14sUMm1byQR4jUYJPMqdCQM8ng4bxlZfZQcqOB/snUv+ha+If/AIVP/wB8KP7J1L/oWviH/wCFT/8AfCvR9E8T6Zrd3JBpjXkwQM3nmxnS3cK207JmQRvyf4WPQ+hqtL410KLV5tNe6m+0xO0UjLaTNCsix+YyeaE8veEGdu7PtS+u1duVfcHKjgf7J1L/AKFr4h/+FT/98KP7J1L/AKFr4h/+FT/98K7bTPiD4Z1K3mnt9RdIYrUXpe5tZrcPBkDzE8xF3rkgZXPJA6kU8ePPD/2aWV7q6jeOVIDbS2FxHcmRwSqrAyCRiQrEYU5Ck9jR9drfyr7g5UcN/ZOpf9C18Q//AAqf/vhR/ZOpf9C18Q//AAqf/vhXZweONHea6uW1WM2MdvBKLf7BOlwpkkkjXOeWZmjZRGEDgqc5yKWX4ieG47dZWurws0kkZt1065a4Ro1Vn3QiPzFCh0JLKBhh6in9crfyr7mHKji/7J1L/oWviH/4VP8A98KP7J1L/oWviH/4VP8A98K9ctZ4ru1huLd98MqCRGH8SkZB/Kpaj6/U7IfKjx7+ydS/6Fr4h/8AhU//AHwo/snUv+ha+If/AIVP/wB8K9hoo+v1OyDlR49/ZOpf9C18Q/8Awqf/AL4Uf2TqX/QtfEP/AMKn/wC+Few0UfX6nZByo8n0DS7HWNO+1rceLLUiaa3kguPEN7vjkilaJwdlwyn5kbkEitH/AIRa0/6CPiT/AMKG/wD/AI9Wd4Ug8UPZ6k2laZok9kdZ1Ty5LnVJYZD/AKdPnKLbuBzn+I8c8dBtfZvG3/QF8Of+Duf/AORK9FYmlbVq5FmVv+EWtP8AoI+JP/Chv/8A49R/wi1p/wBBHxJ/4UN//wDHqs/ZvG3/AEBfDn/g7n/+RKPs3jb/AKAvhz/wdz//ACJT+s0f5kFmVv8AhFrT/oI+JP8Awob/AP8Aj1H/AAi1p/0EfEn/AIUN/wD/AB6rP2bxt/0BfDn/AIO5/wD5Eo+zeNv+gL4c/wDB3P8A/IlH1mj/ADILMrf8Itaf9BHxJ/4UN/8A/HqyfEmg21lBpVxHe63K6azpeEudZu7iM5voBykkrKevcHB56it/7N42/wCgL4c/8Hc//wAiVQ1nRvG2pW1tF/ZXhyLyb21vM/2zO2fIuI5tv/Hp38vGe2c4PSk8TR/mQWZ6tRXM+Gde1S+17U9I1vTLKxubO2trpWtL57lJEmeZQCWijIIMB7H7wrpqqMlJXQgooopgFea6b/yN/jj/ALC0X/pvtK9KrzXTf+Rv8cf9haL/ANN9pVR3A0Lq8trTb9quYYN2dvmOFzjrjNNt9QsrmTy7a7t5nxnbHKrHH0BrmPilaaX/AMIreapqWj6bqU9jETB9ugEixliASc8hehOMcCvP/hfGmnePI7SVPDS3mb22lh0/TEt7iLynAVyQxIR1w3TuBz1rS4HuNc38P/8AkBXX/YW1P/0unrpK5v4f/wDICuv+wtqf/pdPQB0lFFZGrazLZapZ6dZaRf6peXUM1wsdo0K7I42jVixlkQdZUwASetDkoq7A16Kxf7S13/oSNf8A/Aiw/wDkmj+0td/6EjX/APwIsP8A5JrL6xS/mX3jszaorF/tLXf+hI1//wACLD/5Jo/tLXf+hI1//wACLD/5Jo+sUv5l94WZtUVi/wBpa7/0JGv/APgRYf8AyTR/aWu/9CRr/wD4EWH/AMk0fWKX8y+8LM2q5v4l/wDJOPFf/YJu/wD0S1Wv7S13/oSNf/8AAiw/+SaranJqup6bd2F94E1+W0uongmj+1WK7kYFWGRdAjIJ5FDr0v5l94WZ6ZRXjv8AY+of9Cx8Qv8AwqP/AL4Uf2PqH/QsfEL/AMKj/wC+FeR9Vj/z8RfN5HSeJfhraeJbjX7rV9RvWvNRtms7dreeaCO1g2YCGNJAJRvLOd/DE4wAKzvEHgbWBdXGuWF5ayarbWrCBLC2a0uL2RYSkaTzNOUdckE5QfdXkYrM/sfUP+hY+IX/AIVH/wB8KP7H1D/oWPiF/wCFR/8AfCtFSt/y8Qr+Rd/4VTcaj4YtNK17WbeUWOnJYWK2tj5cUABjZmdWd/NZvKRTyoK7hgbia09H+HCWMtnIZNFthFqEd9LFpOjJZRyiON1jTAdm4d9+5mbpgBc1z/8AY+of9Cx8Qv8AwqP/AL4Uf2PqH/QsfEL/AMKj/wC+FHsr6e0QX8iceF/EN54ykthBLb+GW1wazcSXUUIaVowuxUdJ3ZlLojAPGhAHJyAKvyfCtZNOuLaTV9zz2d3aySfZjlmurkTTvjf/ABABMdgOp6Vk/wBj6h/0LHxC/wDCo/8AvhR/Y+of9Cx8Qv8AwqP/AL4Uey7VEF/I6C4+H17Nrd1L/bcI0a61eDV5rI2OZHaJYwkRl8zGwGFCBs4xjmrvhbwVcaP4pu9bnv7MNcRuslrptpJaQyuzK3mSI00gZxg4IC/fcnJNcl/Y+of9Cx8Qv/Co/wDvhR/Y+of9Cx8Qv/Co/wDvhS9jdW9ogv5HUX/gW5u/HcfiBdVgt0WaOUrDZmO4ZUUDymmWQK6HHO+Njg4BAxjm/DPwy1HUfBmm6b4yvo40t9MnsYrO1gCPbmYbWZ5PMcSMAOMBRycg1H/Y+of9Cx8Qv/Co/wDvhR/Y+of9Cx8Qv/Co/wDvhTVKyt7RBfyNOx+Fz2cIe2u9Csr+CWCe1n07QY7VfMiLfNMquTLuDEEBkA6gA1a174cXPiWC8/4SHW47q4ubMWpaKwVI1ZbkToQhZsoCqqVYnIBy3NcPeeHvFr6f4jS10Xx2l3Pv/sl28TjFv+4RV3/6ac4mDt0bgj6Db/sfUP8AoWPiF/4VH/3wo9lrf2iC/kaEvwskbT/s8U3he3zN5pitvDqwQZC7QQEmEgfk/MJOhIxg4r0Lw7p0mkaFYafPe3F/LbQJE91cHMkxAwWY+p+p+p615b/Y+of9Cx8Qv/Co/wDvhR/Y+of9Cx8Qv/Co/wDvhUyoKWjqIL+R7FXmmu21/cfFHVv7P1u/0rbo2n7/ALJHbv5n7+9xu82J+nOMY6nOeMZH9j6h/wBCx8Qv/Co/++FWtIs9Q0m6ubm28FeLJbm4SOOSW81a2unKIXKqDLeMQAZHOBj7xrShRpwleU00DbZq/wBm67/0O+v/APgPYf8AyNR/Zuu/9Dvr/wD4D2H/AMjUf2lrv/Qka/8A+BFh/wDJNH9pa7/0JGv/APgRYf8AyTXZ/sv938CdQ/s3Xf8Aod9f/wDAew/+RqP7N13/AKHfX/8AwHsP/kaj+0td/wChI1//AMCLD/5Jo/tLXf8AoSNf/wDAiw/+SaP9l/u/gGof2brv/Q76/wD+A9h/8jUf2brv/Q76/wD+A9h/8jUf2lrv/Qka/wD+BFh/8k0f2lrv/Qka/wD+BFh/8k0f7L/d/ANQ/s3Xf+h31/8A8B7D/wCRqP7N13/od9f/APAew/8Akaj+0td/6EjX/wDwIsP/AJJo/tLXf+hI1/8A8CLD/wCSaP8AZf7v4BqH9m67/wBDvr//AID2H/yNW18Kf+SXeDv+wNZ/+iErF/tLXf8AoSNf/wDAiw/+Sa5u08PXVnaw21p4S8fQW0KCOKKLxMFSNAMBVAv8AAAAAVz4inRqJKEkhps9norx3+x9Q/6Fj4hf+FR/98KP7H1D/oWPiF/4VH/3wrl+qx/5+Irm8j2KivHf7H1D/oWPiF/4VH/3wpLOwjfWodL1Kx8b6VcT28tzC114kndXWNo1cAxXbkEGVOoHeqjhFJ2jNMOY9jrzrxB8L7fXV1+6vdVvRrGpkCO6ilmjigjQ/uYzAsoSQJyfm6szHjOAz/hFbL/oIeI//Chv/wD49R/witl/0EPEf/hQ3/8A8erWOAqR1UhcyKfi/wAA6xPPrmraTdWY1C6t7iCK30+2e0M5lQxhrh2mZJCikNnapJQHsBUupfC2bWbBU1rWLS5ureCC2sgmmhbWGKKRJNjwtIxkDmNNwLjIUYxU/wDwitl/0EPEf/hQ3/8A8eo/4RWy/wCgh4j/APChv/8A49V/U6v8yFzIt6B8PItMvNKuGk0qL7Fey3zQabpSWUMjtCYUG1WJ+UO5yxYkt1AAFYGheF/Ecviy3juIprTw3Z6rdawv2uGESyzSGTYu6OeQuoaUsNyxkBVHJ6c7o9hJcaB8OrmbWPEbTat5X21v7dvR5u6wmlPHm4X50U/LjpjpxXbf8IrZf9BDxH/4UN//APHqSwdT+ZBzIjtvhYsWmRWcmr+Yq2dpZyN9mxvEdybi4b7/AB5xIB/ugfxVah8A6imtCeTXoZNLTV5tZW0NgRI0rq2xXl8z5lQspACjhQD6iH/hFbL/AKCHiP8A8KG//wDj1H/CK2X/AEEPEf8A4UN//wDHqPqVX+ZD5kavgnwXL4c1e/1CW9tCbpAhtNOtXtbYHcWLmNpZBv5xkFRjtWXqvw/vZvEd9rUGpwI0nnP5NtaGCa43RMixSyCTY6AlTlo93yLlvlFJ/wAIrZf9BDxH/wCFDf8A/wAeo/4RWy/6CHiP/wAKG/8A/j1H1Gre/Mg5kZ+m/DG91fwjY2fi7UIftEWiR6XBBbWoUWv+qdt+ZHWZg0MYJG1SFPHzVd074Zz6e8F3YXmg6fqlrdJc2z6doSW0HEUkTCSNZN0m5ZW53jB6Y5y//hFbL/oIeI//AAob/wD+PUf8IrZf9BDxH/4UN/8A/Hqf1Or/ADIXMhNc+Gc2vreza1rMF3fXENmu9tPUw+ZbzSyAtEWIZCJdhQnOF+8Sc1UuvhVNNpkdrDeeHrQrPLNttNAFvGhdUUGMRzK6sNmdxkbOeQQqgXP+EVsv+gh4j/8AChv/AP49R/witl/0EPEf/hQ3/wD8eoWDqr7SDmR3+mWzWWnWlrJcS3LwRJE08xy8pUAbmPcnGTVmvN/+EVsv+gh4j/8AChv/AP49R/witl/0EPEf/hQ3/wD8erP+zp/zIfMekUV5v/witl/0EPEf/hQ3/wD8eo/4RWy/6CHiP/wob/8A+PUf2dP+ZBzHpFFeb/8ACK2X/QQ8R/8AhQ3/AP8AHqP+EVsv+gh4j/8AChv/AP49R/Z0/wCZBzGX4XstWmtdTktPFOr2EB1nVNtvbw2bIn+nT5wZIGbk5PLHr2GBWz/Zuu/9Dvr/AP4D2H/yNV3R9MtdHsFs7FZFgV5JP3szyuzu5d2Z3JZiWZiSSetXa9COHp21ivuJuzF/s3Xf+h31/wD8B7D/AORqP7N13/od9f8A/Aew/wDkatqin9Xpfyr7guzF/s3Xf+h31/8A8B7D/wCRqP7N13/od9f/APAew/8Akatqij6vS/lX3BdmL/Zuu/8AQ76//wCA9h/8jVmeIE8RadaWksHjXXGabULK0bfbWBASa5iiYjFt1CuSPfHXpXW1g+M/+Qdp3/Ya0r/0vt6HQpW+FfcF2df4c8MnR9Uv9RuNY1LVby8hht3kvRAuyOJpWUKIoox1mfJIJ6eldDRRUpJKyEFFFFMArzXTf+Rv8cf9haL/ANN9pXpVea6b/wAjf44/7C0X/pvtKqO4EHjy/u9M8H6te6cCbuGAsh8vzNvqxXuAMkj0FeWXvibVNK1hb7SfE+i+JP8ARGubr7Jp8YcorxqsbOjkru3kLnuoGD29U8earcaH4P1bU7IwrcW0BkVphlV9WIyM4GTjvjFcd8N9TsZtde3sfGmi6t5sbSPZ2Wmx2zsRj5yysScZ9O9WwPT65v4f/wDICuv+wtqf/pdPXSVzfw//AOQFdf8AYW1P/wBLp6YHSVlWn/JUdF/7A2o/+j7KtWsq0/5Kjov/AGBtR/8AR9lWGL/gyGtzvqKKK+fNQooooAKKKKACiiigAooooAKKKKACiiigDjrjxRrF7d6inhXQINTtdPla3lnub/7KJZl+/HCBG+4qflJbYNwIzwTWhD4v0s6tHpV2buz1B1chLmznijYou5wkzII3wMn5WPAzWbY+Ftc0u5uodH8RQW2kXF9LfGF9OEtxGZXMkiJKZNu0szHmNiM4z0xy2mfB+a1lluJdasn1AabdWMd9Hpe24eSYBftE0hlZpXADcZVfm4A762pvd/mLU7DSviH4Y1O1lubbUmS3jtTemS5tprdWgBAMimRF3qCQMrnk461jD4kRXXiK4tdOiH2KKOziBv7a5tJHurmZkRMNGWA2KWzsIORllGSJ/EHw6XUyxt9SFt5NjZ2dkrW/mLD5E4mJcbhvDlIwV+XhOvPEUXw8urnUTfa3ri3dzJqX9ozG3tDADttTBFGg8xioQszg5JJIz6kSp7hqWbr4gWl34j0TSfDxa6a7u5UuJ3s5/J8iKNzI0UuAkhDqi/KWxu6Vv6F4o0vXLy5s7F7tLy3RJZILuyntZAjFgrBZUUlSVYZAIyK4mD4Y6mdMhs7rxNERZaO2j6e1tp5h8hWMeZG/eksxESqcFcgnG3mtv4eeA4vCF/q975mnNPqAhQrY2H2SONYw3be5YksxLMST3JxRJU7aPUNTQuvHXh61vLy2nvJ1a0EpmkFnO0KmJDJIolCbCyqCSoJbjpTLPx94bu7a6njv5I0to45XE9pNCzpI22No1dA0gZuFKA5OAMkiuT8U/DfUrq48RalY6lC0t5a3qpaW1r9mkuWlgdEimkEvluoLAgmMNlVy3HMtx8M7nX9HdfFGp281+1pa28AhsQsNuIZBKA8bSOJcsAGyQCBgAdafLTtuGp1H/Ce+Hvsvnfarrf8AaPsv2X7BcfavN279v2fZ5v3SG+7056VFbeN9HYXl0dVjnsx9n8mGCxmM4MqFlXAy0rMASFRAVAOQetYun/Dm60yS1vdJvtC07VLaeSSP7FoawWhjeMIyNCsoZidqncZMgjHTio9b+F7a2k0uq6rb3189xaXYa605JIGlhieM+ZDuAdGEjfKCuOMHIzStT7/19wam9P8AEXwzDbxzNe3LBllZo47C4eWFY2CyGWNYy8QUkAlwuK6xWDKGU5BGQa8rv/hTcXFjBb22paLYNGJNr2OiC2NuznO+3MUytGwwv3mcEqpIJAr1KFPLiRC7PtULuc5LY7n3qZqC+Fgh9FFFQMKKKKACiiigAooooAKKKKACiiigArhvFf8AyUfw5/2CdS/9HWVdzXDeK/8Ako/hz/sE6l/6Osq6cH/Gj/XQmWxoUUUV75mFFFFAHm3h7/kVfhF/2w/9NdxXpNebeHv+RV+EX/bD/wBNdxXpNJAFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArB8Z/8AIO07/sNaV/6X29b1YPjP/kHad/2GtK/9L7ek9gPUKKKKxAKKKKACvNdN/wCRv8cf9haL/wBN9pXpVea6b/yN/jj/ALC0X/pvtKqO4EviYoPD9+ZJL6NPJbc1ghecD/YABy34GvO/Aryt4xtP7Mn8YXNh5EwuzrUBijQ/L5ZXKLk5DDHPXPbnp/HEOspq2h6joemPqX2U3CywpcJCRvQKpy5AODUHw5uPEtvpel6T4g8Pz232WzSKS/kvopvMdVA+6pLc881fUDt65v4f/wDICuv+wtqf/pdPXSVzfw//AOQFdf8AYW1P/wBLp6YHSVkato0t7qlnqNlq9/pd5awzW6yWiwtvjkaNmDCWNx1iTBAB61r0UOKkrMDF/s3Xf+h31/8A8B7D/wCRqP7N13/od9f/APAew/8Akatqisvq9L+VfcO7MX+zdd/6HfX/APwHsP8A5Go/s3Xf+h31/wD8B7D/AORq2qKPq9L+VfcF2Yv9m67/ANDvr/8A4D2H/wAjUf2brv8A0O+v/wDgPYf/ACNW1RR9Xpfyr7guzF/s3Xf+h31//wAB7D/5Go/s3Xf+h31//wAB7D/5Graoo+r0v5V9wXZi/wBm67/0O+v/APgPYf8AyNR/Zuu/9Dvr/wD4D2H/AMjVtUUfV6X8q+4Lsxf7N13/AKHfX/8AwHsP/kaj+zdd/wCh31//AMB7D/5Graoo+r0v5V9wXZi/2brv/Q76/wD+A9h/8jUf2brv/Q76/wD+A9h/8jVtUUfV6X8q+4Lsxf7N13/od9f/APAew/8Akaj+zdd/6HfX/wDwHsP/AJGraoo+r0v5V9wXZi/2brv/AEO+v/8AgPYf/I1H9m67/wBDvr//AID2H/yNW1RR9Xpfyr7guzF/s3Xf+h31/wD8B7D/AORqP7N13/od9f8A/Aew/wDkatqij6vS/lX3BdnnGqal4ptNF8dXkfjLVzLoXmfZg1rY4fbZRTjf/o/PzSEcY4A7811v9m67/wBDvr//AID2H/yNXIeIf+RV+Lv/AG3/APTXb16TQqFL+VfcF2Yv9m67/wBDvr//AID2H/yNR/Zuu/8AQ76//wCA9h/8jVtUUfV6X8q+4Lsxf7N13/od9f8A/Aew/wDkaj+zdd/6HfX/APwHsP8A5Graoo+r0v5V9wXZi/2brv8A0O+v/wDgPYf/ACNR/Zuu/wDQ76//AOA9h/8AI1bVFH1el/KvuC7OM1HUb6w1JrCTxn4xnu0iSd47PRYLrYjllUsYrJgMlHwD/dNQ/wBsah/0M/xC/wDCX/8AvfXU+FP+Sj+I/wDsE6b/AOjr2u5rzq9aFKo4KC0KSujx3+2NQ/6Gf4hf+Ev/APe+j+2NQ/6Gf4hf+Ev/APe+vYqKx+tR/wCfaHy+Z47/AGxqH/Qz/EL/AMJf/wC99H9sah/0M/xC/wDCX/8AvfXsVFH1qP8Az7QcvmeO/wBsah/0M/xC/wDCX/8AvfR/bGof9DP8Qv8Awl//AL317FRR9aj/AM+0HL5njv8AbGof9DP8Qv8Awl//AL30f2xqH/Qz/EL/AMJf/wC99exUUfWo/wDPtBy+Z47/AGxqH/Qz/EL/AMJf/wC99JZ38aa1DqmpX3jfVbiC3ltoVuvDc6KiyNGzkCK0QkkxJ1J717HRVRxai7xgkHKeb/8ACVWX/QP8R/8AhPX/AP8AGaP+Eqsv+gf4j/8ACev/AP4zXpFFaf2jP+VC5Tzf/hKrL/oH+I//AAnr/wD+M0f8JVZf9A/xH/4T1/8A/Ga9IqC+uorGxuLu5bbBbxtLI3oqjJP5Cj+0Z/yoOU8I0e/kt9A+HVtNo/iNZtJ8r7av9hXp8rbYTRHnysN87qPlz1z05rtv+Eqsv+gf4j/8J6//APjNamk/EXSrplGr2134eWS0jvYn1Z4I0lidtqkMkjAHJA2sQ3I4rdl8T6BFo6atLrmlppTttW9a7jELH0D52k/jT+v1F9kOVHHf8JVZf9A/xH/4T1//APGaP+Eqsv8AoH+I/wDwnr//AOM13UWsaZKqtFqNm6tb/awVnUgw/wDPXr9z/a6VRm8X+GoLpLWfxDo8dzIodInvYg7KVDAgFskFSDn0INH9oVP5Q5Ucn/wlVl/0D/Ef/hPX/wD8Zo/4Sqy/6B/iP/wnr/8A+M11w8V+Hf7HOr/29pP9lb/L+2/bI/I3/wB3fnbn2zUl74l0KxtbO6vda0y3trzH2aWa7jRJ89NhJw3UdM0f2hU/lDlRxv8AwlVl/wBA/wAR/wDhPX//AMZo/wCEqsv+gf4j/wDCev8A/wCM13P9taX5Mc39pWXlSTm1R/PTa0wJBjBzy4KsNvXIPpXP6v8AEjwlpulzX51/TLqCG4htpBa3kUhR5X2qG+bA6MxyR8qOf4TQsfUe0Q5UY3/CVWX/AED/ABH/AOE9f/8Axmj/AISqy/6B/iP/AMJ6/wD/AIzXTHxnoEcdzPc6tp1tYQmJVvZb6AQymRBIoUh8j5WU/MBkMCMg5rdtLiC8tYbm0mjntpkEkUsTBkkQjIZSOCCCCCKTzCa3iHKeef8ACVWX/QP8R/8AhPX/AP8AGaP+Eqsv+gf4j/8ACev/AP4zXpFFH9oz/lQcp5v/AMJVZf8AQP8AEf8A4T1//wDGaP8AhKrL/oH+I/8Awnr/AP8AjNekUUf2jP8AlQcp5v8A8JVZf9A/xH/4T1//APGaP+Eqsv8AoH+I/wDwnr//AOM16RRR/aM/5UHKeb/8JVZf9A/xH/4T1/8A/GaP+Eqsv+gf4j/8J6//APjNekUUf2jP+VBynm//AAlVl/0D/Ef/AIT1/wD/ABmj/hKrL/oH+I//AAnr/wD+M16RRR/aM/5UHKeb/wDCVWX/AED/ABH/AOE9f/8Axmj/AISqy/6B/iP/AMJ6/wD/AIzXpFFH9oz/AJUHKeb/APCVWX/QP8R/+E9f/wDxmsjxNr8N7ZWUdtpniN3j1OwuGH9gXwxHFdwyOeYeyoxx1OMDJr1+il/aM+yDlM3w/wCKNM166u7awN6lzaJHJNFeWE9o6pIXCMBMikgmNxkZ+6a265HSP+So+Iv+wNpn/o+/rrq7aU+eCl3JasFFFFaCCvNdN/5G/wAcf9haL/032lelV5rpv/I3+OP+wtF/6b7SqjuBsUUUVqAVzfw//wCQFdf9hbU//S6eukrm/h//AMgK6/7C2p/+l09IDpKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5t4h/5FX4u/9t//AE129ek15t4h/wCRV+Lv/bf/ANNdvXpNJAFFFFMAooooAKKKKAM/wp/yUfxH/wBgnTf/AEde13Ned3miXL61Pqmm69qelXE9vFbTLapbusixtIyEiWJyCDK/QjtS/wBm67/0O+v/APgPYf8AyNXl4jB1KlRzTWpalZHodFeef2brv/Q76/8A+A9h/wDI1H9m67/0O+v/APgPYf8AyNWP9n1e6/r5D5keh0V55/Zuu/8AQ76//wCA9h/8jUf2brv/AEO+v/8AgPYf/I1H9n1e6/r5BzI9Dorzz+zdd/6HfX//AAHsP/kaj+zdd/6HfX//AAHsP/kaj+z6vdf18g5keh0V55/Zuu/9Dvr/AP4D2H/yNR/Zuu/9Dvr/AP4D2H/yNR/Z9Xuv6+QcyPQ6K88/s3Xf+h31/wD8B7D/AORqP7N13/od9f8A/Aew/wDkaj+z6vdf18g5keh0V55/Zuu/9Dvr/wD4D2H/AMjUf2brv/Q76/8A+A9h/wDI1H9n1e6/r5BzI9DrB8d6Rda/4R1TSLGSOKW+i+zs8jFQI2IEnIBOdhbHHXHTrXNf2brv/Q76/wD+A9h/8jUf2brv/Q76/wD+A9h/8jU1l9VO91/XyFzImvfhzp41DRW0+FTawXi3F897czXU0scccgiiVpS52h3DbcgDHHNc7efDjWzfWupLJaXV0LjULiW3TVbrT1je4lDI6SwLvJWNVQqQAeeaztL1LxTd6L4FvJPGWriXXfL+0hbWxwm6ylnOz/R+PmjA5zwT35rrf7N13/od9f8A/Aew/wDkarWEr91+IcyMO++HniGC2v8AT9DGjRWN/o1vpBke6nD2iKZDOIwVcvu81iCzgjAznFax+H08gkSZNOMV14gj1K5HJzawKFgiHy8keXFlTwMvgnvN/Zuu/wDQ76//AOA9h/8AI1H9m67/ANDvr/8A4D2H/wAjUfU6/dBdFH/hCfENlrsGt2I0a7vBf6hdPbXU8kcSGcosMissbEukcSqQVGd7YI6lmieAda8P3YW0TQ9WtrjTorGd9Q3p5H7yR5xHEEYMjmQ/IWX7qgkgCtH+zdd/6HfX/wDwHsP/AJGo/s3Xf+h31/8A8B7D/wCRqPqdba6C6Mnwx4Ouby/8Tard2QksZLq7XR9Mvd9qqiUbZpXIUsnmEMFO0kISQPnNOtfBni220/TIxcWNxFYanDdwabdajJIkcUcLoEFz5AY/OyMAY+NmM85rU/s3Xf8Aod9f/wDAew/+RqP7N13/AKHfX/8AwHsP/kan9TreQcyMvUvAeuutxcWK2SaxPqV5fpqEepy2723mYSMBRC4lHlJGGDbeVwDjmvUbGOaKyt47qb7RcJGqyTbAvmMBy2BwMnnFcF/Zuu/9Dvr/AP4D2H/yNR/Zuu/9Dvr/AP4D2H/yNUSwNaW7QcyPQ6K88/s3Xf8Aod9f/wDAew/+RqP7N13/AKHfX/8AwHsP/kap/s+r3X9fIfMj0OivPP7N13/od9f/APAew/8Akaj+zdd/6HfX/wDwHsP/AJGo/s+r3X9fIOZHodFeef2brv8A0O+v/wDgPYf/ACNR/Zuu/wDQ76//AOA9h/8AI1H9n1e6/r5BzI9Dorzz+zdd/wCh31//AMB7D/5Go/s3Xf8Aod9f/wDAew/+RqP7Pq91/XyDmR6HRXnn9m67/wBDvr//AID2H/yNR/Zuu/8AQ76//wCA9h/8jUf2fV7r+vkHMj0OivPP7N13/od9f/8AAew/+RqP7N13/od9f/8AAew/+RqP7Pq91/XyDmR6HRXnn9m67/0O+v8A/gPYf/I1ZniBPEWnWlpLB411xmm1CytG321gQEmuYomIxbdQrkj3x16Uf2fV7r+vkHMjsdI/5Kj4i/7A2mf+j7+uurnvDnhk6Pql/qNxrGpareXkMNu8l6IF2RxNKyhRFFGOsz5JBPT0roa76UHCCi+hDd2FFFFaCCvOrvQfFVp4m8Q3elWWiXdlqV3HdRtc6lLBImLaGEqVW3cdYic7uhr0WimnYDzz7F44/wCgN4b/APB3P/8AIlH2Lxx/0BvDf/g7n/8AkSvQ6KfMwPPPsXjj/oDeG/8Awdz/APyJXO+A7Pxi2iXJtdJ8PvH/AGpqQJk1eZDvF7PvGBangNkA55ABwM4Hstcq3gLRPOuJIpNbt/PmkuHjttcvoY/Mkcu5CJMFXLMxwABkmjmYGN9i8cf9Abw3/wCDuf8A+RKPsXjj/oDeG/8Awdz/APyJWz/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0czAxvsXjj/oDeG//B3P/wDIlH2Lxx/0BvDf/g7n/wDkStn/AIQPSP8An88Sf+FHqP8A8fo/4QPSP+fzxJ/4Ueo//H6OZgY32Lxx/wBAbw3/AODuf/5Eo+xeOP8AoDeG/wDwdz//ACJWz/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9HMwMb7F44/6A3hv/wAHc/8A8iUfYvHH/QG8N/8Ag7n/APkStn/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+jmYGN9i8cf9Abw3/4O5//AJEo+xeOP+gN4b/8Hc//AMiVs/8ACB6R/wA/niT/AMKPUf8A4/R/wgekf8/niT/wo9R/+P0czAxvsXjj/oDeG/8Awdz/APyJR9i8cf8AQG8N/wDg7n/+RK2f+ED0j/n88Sf+FHqP/wAfo/4QPSP+fzxJ/wCFHqP/AMfo5mBjfYvHH/QG8N/+Duf/AORKPsXjj/oDeG//AAdz/wDyJWz/AMIHpH/P54k/8KPUf/j9H/CB6R/z+eJP/Cj1H/4/RzMDG+xeOP8AoDeG/wDwdz//ACJR9i8cf9Abw3/4O5//AJErZ/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6OZgY32Lxx/0BvDf/AIO5/wD5Eo+xeOP+gN4b/wDB3P8A/IlbP/CB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wAKPUf/AI/RzMDG+xeOP+gN4b/8Hc//AMiUfYvHH/QG8N/+Duf/AORK2f8AhA9I/wCfzxJ/4Ueo/wDx+j/hA9I/5/PEn/hR6j/8fo5mBjfYvHH/AEBvDf8A4O5//kSj7F44/wCgN4b/APB3P/8AIlbP/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP0czA8h1+18VDwx8VzLpmiLEnn/a2XVJS0f/EstyfLH2cb/k2nkpySOANx9F+xeOP+gN4b/wDB3P8A/IldHaeD9GttE1bSVguZrLVt/wBtFzezzyT74libMkjl/uKq8NwBxiqv/CB6R/z+eJP/AAo9R/8Aj9HMwMb7F44/6A3hv/wdz/8AyJR9i8cf9Abw3/4O5/8A5ErZ/wCED0j/AJ/PEn/hR6j/APH6P+ED0j/n88Sf+FHqP/x+jmYGN9i8cf8AQG8N/wDg7n/+RKPsXjj/AKA3hv8A8Hc//wAiVs/8IHpH/P54k/8ACj1H/wCP0f8ACB6R/wA/niT/AMKPUf8A4/RzMDG+xeOP+gN4b/8AB3P/APIlH2Lxx/0BvDf/AIO5/wD5ErZ/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfo5mBjfYvHH/QG8N/+Duf/wCRKPsXjj/oDeG//B3P/wDIlbP/AAgekf8AP54k/wDCj1H/AOP0f8IHpH/P54k/8KPUf/j9HMwMb7F44/6A3hv/AMHc/wD8iUfYvHH/AEBvDf8A4O5//kStn/hA9I/5/PEn/hR6j/8AH6P+ED0j/n88Sf8AhR6j/wDH6OZgY32Lxx/0BvDf/g7n/wDkSj7F44/6A3hv/wAHc/8A8iVs/wDCB6R/z+eJP/Cj1H/4/R/wgekf8/niT/wo9R/+P0czAxvsXjj/AKA3hv8A8Hc//wAiUfYvHH/QG8N/+Duf/wCRK2f+ED0j/n88Sf8AhR6j/wDH6P8AhA9I/wCfzxJ/4Ueo/wDx+jmYGN9i8cf9Abw3/wCDuf8A+RKPsXjj/oDeG/8Awdz/APyJWz/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0czAxvsXjj/oDeG//B3P/wDIlH2Lxx/0BvDf/g7n/wDkStn/AIQPSP8An88Sf+FHqP8A8fo/4QPSP+fzxJ/4Ueo//H6OZgY32Lxx/wBAbw3/AODuf/5Eo+xeOP8AoDeG/wDwdz//ACJWz/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9HMwMb7F44/6A3hv/wAHc/8A8iUfYvHH/QG8N/8Ag7n/APkStn/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+jmYHkOgWvio+GPhQYtM0Ron8j7IzapKGk/wCJZcEeYPs52fJuPBfkAcg7h6L9i8cf9Abw3/4O5/8A5Ero7vwfo1zomk6S0FzDZaTs+xC2vZ4JINkTRLiSNw/3GZeW5BOc1V/4QPSP+fzxJ/4Ueo//AB+lzMDG+xeOP+gN4b/8Hc//AMiUfYvHH/QG8N/+Duf/AORK2f8AhA9I/wCfzxJ/4Ueo/wDx+j/hA9I/5/PEn/hR6j/8fp8zAxvsXjj/AKA3hv8A8Hc//wAiUfYvHH/QG8N/+Duf/wCRK2f+ED0j/n88Sf8AhR6j/wDH6P8AhA9I/wCfzxJ/4Ueo/wDx+jmYGN9i8cf9Abw3/wCDuf8A+RKPsXjj/oDeG/8Awdz/APyJWz/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0czAxvsXjj/oDeG//B3P/wDIlH2Lxx/0BvDf/g7n/wDkStn/AIQPSP8An88Sf+FHqP8A8fo/4QPSP+fzxJ/4Ueo//H6OZgY32Lxx/wBAbw3/AODuf/5Eo+xeOP8AoDeG/wDwdz//ACJWz/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9HMwMb7F44/6A3hv/wAHc/8A8iUfYvHH/QG8N/8Ag7n/APkStn/hA9I/5/PEn/hR6j/8fo/4QPSP+fzxJ/4Ueo//AB+jmYGN9i8cf9Abw3/4O5//AJEo+xeOP+gN4b/8Hc//AMiVs/8ACB6R/wA/niT/AMKPUf8A4/R/wgekf8/niT/wo9R/+P0czAxvsXjj/oDeG/8Awdz/APyJR9i8cf8AQG8N/wDg7n/+RK2f+ED0j/n88Sf+FHqP/wAfo/4QPSP+fzxJ/wCFHqP/AMfo5mBjfYvHH/QG8N/+Duf/AORKPsXjj/oDeG//AAdz/wDyJWz/AMIHpH/P54k/8KPUf/j9H/CB6R/z+eJP/Cj1H/4/RzMDG+xeOP8AoDeG/wDwdz//ACJR9i8cf9Abw3/4O5//AJErZ/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH6OZgY32Lxx/0BvDf/AIO5/wD5ErF8VWviqO00x9V0zRILIazpfmSW2qSzSD/T4MYRrdAecfxDjnnoez/4QPSP+fzxJ/4Ueo//AB+hfAWiedbySya3ceRNHcJHc65fTR+ZG4dCUeYq2GVTggjIFLmYHVUUUUgCiiigAooooAK8q1e2ivPEPj271PxBq2lRaWLc29xDqc0MNqDbqxbyt3lNluSGU5zXqtYt94T8O3+qjU77QNJudSGD9rms43m4GB85XPA6c0AeX3XxM8R21hpdylnDK8VtpzaxbvZbBby3GzK+c1wpBIfIVYZCO/Xjp9I8Zate+Mx4Wkt7NdStLq4e/dY32CyCgwSIN3DP5sa8kjKS8ccdZqPhnQdT1BL/AFLRNLu75FCrcT2kckigHIAYgnAPNLp2hW1jr2raukk0t7qPlLI0hBEaRqQqJgDC5Zm5ycseegAByHjkm/8AGUem3uq3+m6dDotzfo1neSWxaVXRS5ZCCwjUg7Tlfn5B4rqPAd9d6p4H8PX+pZ+3XWnW88+Rj940aluO3JPFXNZ0LSNcSFNb0uw1FIW3xrd26TBG9V3A4PuK0AAoAUAAcADtQAtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4joEtxp3hPwXrlvrWrTa5qV9DBJaXWpTXCXqPLtlAikZguyMs+UC42c8cV7dWLpPhPw7o9615pGgaTYXbZDT2tnHE5z1yygGgDzmw+IHibU9b+yaTBY3NpqNreTaTcz2P2dZHhxsyBcu7qclSxSLsRkcV1nw88YTeNJL2+tIY4tFhjgiQsrea1yU3zKTnGE3ImMfeD88YrcsvDGg6fqEl/p+i6ZaX8hZmuoLSNJSW+8SwGST3z1p/hfQrXw3olvpdi8skURd2lmIMkruxd3cgAFmZiTgAc9KAOcke9h+NFnCdUvZbC50O6mFizKIInSe2UMoVQScM3LFiNxAwDiua0B7vR/HFs2qST6uNYv9Rk025svEVzPGEXzJFie0crCoVPkyCwVwvQ4Nei3Hhbw/c60usXGhaVLqysrrevZxtOGUAKRIRuyABjnjFP0/w5omnalPqOn6PptrqE+fOuYLVI5ZMnJ3OBk5PPJoA47xr4r1ddIt7aHRPEGizX0kkct39i+2vaxIqlnAtTMA7btqbiMEMxGFAbj7C51XX/AAH4H1aHUJ7lbHQ5Z9TtLnW7vSZ7ptkOJ96LukClJPmY7TvyG5zXupAYEMAQeCD3rGvfCfh2/trO3vtA0m5t7JQlrFNZxusCjGAgIwo4HAx0oAl8KXkOoeFtGvbRLmO3ubKGaNLmRpJVVkBAdmJZmweSSSTnJNatIAFACgADgAdqWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4XxvbnUfG/hLTJrvUYLKeO9eWOyvprUyFFj27midScZPGe9d1WXrnh7RdfSFNe0jTtTWEkxi9tkmCE9du4HGcDp6UAeXWXi/VrC0udK0TUH1eddWntdNnntlvXureOKN5MuZ4F/du7IXZ+dmOTk0+H4oa1/YmkXM2n2P2zX9OjOkxqGKtf+aI3jc7jlPnSQYIIVZOTjNemXnhrQr7T7awvdF0y4sbZt0FvLaxvHER3VSMKee1QSeFtMOpaJdRRfZ4tHEv2S0gVUgRnXaX2gdQpYDBAG9uDxgAseIYLmfw3exRX89ldeQT9qtFQOrAZJUOHAzjHIOAeDnBrzqwu7vVvC3wnsdQ1LUI7fVrKJ7yeK7khmuZFs96oZlYPlmyxwwJ2c969Q1PTrLVbGWy1Sztr2zlwJILmJZI3wQRlWBB5AP4Vmr4R8Nro7aSvh7RxpTSea1kLKPyS/94pt254HOKAPKdEv7nXksbLWNe1SCwttM1O4guoL2S3kuPJu2iSZ3QgvtiCNgkg78kGvVfAd9d6p4H8PX+pZ+3XWnW88+Rj940aluO3JPFT3/hrQtRs7Sz1DRdMurS0x9nhntI3SHAwNikYXjjitUAKAFAAHAA7UALRRRQAUUUUAFFFFAHjWp82/xF1268Q6tp95pGpuljIupSiCPbaQOkfkFvKcM7n5ShJ3YHOKnvviPrkHiDToobSGSwN/Y6ZqCNZeX9muLgR7kEzXALMvmA4WFgAMEjrXoknhPw7JrP8Aa8mgaS+rbxJ9tazjM+4DAbzMbs475p1z4Y0C61cardaHpc2qKyMLyS0jaYFCCp3kbsgqCOeMDHSgDlPCXjPVta8TroE9taR3+mfaP7bZEYKmG223lZYkeap8znOFUjrzVH40JLFpOo6tpmr3cF3ptqsk8cGsSWxtIwzN5y26fLPI3ICSkK20AHrnvNH0K20rUdXvonmlutUnE88kzAkbUCKi4AwqheB15JJOaNR8OaHqeoQX+paNpt3fQY8m5uLVJJI8HI2sQSOeeKAPLL7xJqQ8Y6xq2pRTTaNpOqWunxQRaxLaSRCVYSrm2RQs5Zpc4kboMBeDm9pjXWk+PrWTVZpdSt9X1a7isbmz8RXUiw7VdxFJZ8RBUCMpILbWxkdK9HufD+jXWrwardaTp82qQYEV5JbI00eOm1yNw6noabZ+HNEsdVn1Oy0bTbfUp8+bdw2qJNJnk7nAyc+5oA5P4n+L9U0CaK28OiKe+Sznv54JLITAQpgbzI1xCsag5B++TkYXjnDufiD4jkttQ1Wyi0iPTLC3065ktpoZHmlFyqM6iQSAKVDHBKtnjI716VrPh/RdcaFta0jTtRMBJiN3bJN5ZPXbuBx07U4aHpIt5YBpliIJVjSSP7Om11QYQEYwQoAwO2OKAPLtY1zVNe17RJ5ptNh0u28Wtp8VmsLm5LQiVDI0hk24JBO0J0ZTurc+IA1I/EfwYNGurG1uvsupHzr2Bpo1UCAn5FdCT/wIY5POMV17eGdBbWP7WbRNMOq7g3202kfnZAwDvxuyB70/XPDui6+sK67o+namIc+WL22SbZnGdu4HGcDp6CgDyJfir4r1K3STRNFsWe10yG/u/MeIRSby4JWSW4iMcfyEh9svXkcc9K3jzVo/E0/h57K2bVbS4nurhVRsf2asW9JF+Y/OzOkWc43BzjAxXaal4Y0DVJLV9T0PS7x7UBbdri0jkMIHQIWB2j6U6z0G1tfEeo65vmlvr2KKAmRgViij3FUQAcAszMc5yW9MAAHl118SvEWn+Hvt9x/YV5Ne6C+t2i2kUgW22tEBHLmQ7wfNADjZkowx6al3408S6dqV9od6dFk1UXdhb294lvLHbxi5EhO+MyFmKmJgMOu4sv3a7q28K+HrWO+jttB0mGO+/wCPtY7ONRcc5/eAD5uSeuetWb/Q9J1BLtL/AEuxukvFRLkTW6OJ1QkoHyPmCknGemeKAOS+EhuDD4r+23Ftc3I164WSW2jMcbMI4gcKWYr9Cx+td7VLSNJ03RbT7Lo+n2en227d5NrCsSZwBnaoAzgAfhV2gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuf1Txr4V0i/lsdV8S6JY3sWPMt7m/iikTIBGVZgRkEH6EV0FcBDq/8Awj8HxU1nyPtH9nXrXnk79nmeXpdo+3dg4zjGcHHpQBq/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVVv7a8af9C54d/8Hs3/AMh0f2140/6Fzw7/AOD2b/5DrL21PuR7SPcs/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVO8LeIdT1HXdU0rWtLsrG5s7a2ula0vmuUkWZplAJaKMggwHsfvCuorRNNXRSd9Ucr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VXVUUxnK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAHK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVdVRQByv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVXVUUAcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV1VFAGVoXiPQ/EHn/2DrOm6n5G3zfsV0k3l7s7d20nGcHGeuDWrXK6b/wAlT8Q/9gXTP/R9/XVUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V4m/5E742/9vH/AKZ7WvVa8q8Tf8id8bf+3j/0z2tAHe0UUV4p55ieHv8AkpviP/sD6b/6OvqofGDW/EGjQeHP+EVkX7XcaiwlgaNW+0xR280zQ/MDtLeUACMEZ61f8Pf8lN8R/wDYH03/ANHX1dNqGlWeoXWn3N5D5k2nzG4tm3MPLkKNGTgHB+V2GDkc+uK9Wh/DR20/hR5Ho3xP1OfXtZv2je60a8t7B9CsGRYWYz3MlsjO+CQHZA+TnCkcZ69K3xC1CLUItIm0CEa62p/2a8Ed/uhUtavcRyiUxglSFwRsDDnhsAN1Or+FdF1i4vJ9SsVnlu7eK1mYyOMxxu0kYGCNpV3Zgww2cc8DEGneC9B042rW1nIZbe8a/Saa5llladozEZHd2LOdjFfmJwMY6DGpZzFj8Sb278Trpcfhq7lgjvRp1zc26XMqxTDAdg32cRGJWONxkVsDOwdK6DxJ4j1Gz1220bQdIh1LUZLWS9cXF59mjSNGVcBgjksWYADAHByRU0ngrQn106v9lmS8adbpxHdzJC8ygASNCHEbPgD5ipPAqfxH4U0fxHLBLqlvMZ4UeNJre6ltpAj43oXiZSVOBlSSDgcUAc3H8QLw6hG0uhLFo39qJo0lybwGdLliE/1QTBQSEJu3577cVn6b8RfEOpy6Qln4UsSNXFw1m0msFRiBgHMmIDtznjbuz3x1rqofAnh2HWItTi09kuIpFmRBcS+SJVTYJPJ3eXvC8b9u73q7p/hjSNPbTDaWflnTVlW1/eufLEpy/U85I75x2xQBwNx8WL2TS11HSvDcdxbRaCuv3Xn6h5LRR7pA0agRtvYeWxByoPtxm83xH1C3a6s77w9HHq/+gmzt4r/fHMLt3SPfIYx5ZUxtuwrYxwWrpIPAvhyDT57GLTttrNp39kyJ58h3WuXPl53Z/wCWj/N97nr0qXUvBug6kbo3th5jXMEFvIwmkVgkLM8W0hgUZWdiGXDZPXgUAcyvxB1WXVodDt/D1o2vfbJrOeF9SKwRlIY5g4lEJLKySL/ACDkYrrfBuuDxL4Y0/VxbNatcoWaBnD+WwJVl3Drgg88ZqHSvB+h6VNazWVm6z20ss6TSXEksjSSgLI7u7EuxAAyxJwBitLR9Ls9G02Gw02HybSHOyPcWxkljyST1JoAu0UUUAYfjPWpvD+gtfWlpHeXDXNtaxwyzGFGaaeOEFnCsQAZMnCnpWR/bXjT/AKFzw7/4PZv/AJDro9f0ey1/S5NP1OOSS2d45CIpnhcNG6yIyuhDKQyqQQR0rC/4V9on/Px4i/8ACi1D/wCP1nNTfwsmSl0If7a8af8AQueHf/B7N/8AIdaPg3Xb3WxrEWqWFtY3mm3os5Et7priN8wRTBgzRoekwGNvUdaqf8K+0T/n48Rf+FFqH/x+tfw74e0/w9BdRaWlwBdTfaJnubqW5kkk2KmS8rM33UQYzjAFEFNP3mKKl1M3V9VvLf4i+GtLhm22N5Y3808W1TveNrYIc4yMeY/Q855zgVg6l8SpofF1zpGm+Hb/AFG3s7uKzuriCG4cq7qjErsgaIhVkUnfKh4OAeM9V4h8LaXr93ZXeoreLdWayJBNaX09o6LJt3jdE6kg7E4OelUm8A+HmvUu2trwzgxGQnUbnE7R48tph5mJmGB80gY8DmtCzl4vijeumsk+HR9osIjItkLt/teBKseZITCCqgNvLR+aAo9SAep8JeLF1vwvc6xdRWsKW7yhxZ3X2lMIM5BKIwOP4WVSPToarR/DXwskciCxuSrp5a7tQuW8hfMWTEJMn7kb1Vv3e3lR6Ct7RNB07RLGW00+FxDNI0sxmmed5XYAFneQszEgAZJPAAoA49PHeuf2Rp19L4YgRdXMCaWo1MHzGlywWc+X+6IQFjt8wdgSaYnxB1W4vLXS7Pw/avrbX1zYXEMmpFIInhjSTcsoiJZWSRSPkB5wR1rWh+G/haG1ktksLjyWCKitfXDfZwjb0EJL5hAbkeXtxWlpXhHRNKeyeys2WWzkmlikeeSRy8vEjuzMS7N6sSaAOJsvipfPpUWo6h4bS1trrSbzU7MJqHmO5tlUvHIPLATO7hgW6cgdKZe/E7X7GPUJLzwlZqlhpcetT7NXLEWrlxhf3IzKPLf5eF4+/wAiu0fwT4efT7WxbT82tra3FlCnnSfLDOAJVzuydwA5PI7EVNeeEdEvY71Lmy3pe6eulTjzXG+2XfiPhuP9Y/IweevAoA54+P5zqgZdHQ6B/aqaN9tN3ibz2IQN5OzHl+YQmd+e+3FN8J+Pr/WdR0aO+0OGystXW5+yTR33nPuhPIdPLUKCMkEM3TkCtweCPD411dXFi4vFmFwB9ol8nzgmwS+Tu8sybeN+3d71bsfDGj2H9l/ZLPy/7M837J+9c+X5n3+p5znvnHbFAGdpv/JU/EP/AGBdM/8AR9/XVVyum/8AJU/EP/YF0z/0ff11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef/wDEx07WvGFvc+D9S1nTdWvVmV4JLMwyxGzt4WRlmnQ/eicEFcEeua9AooA8q/sDw9/0RL/yS0f/AOSKP7A8Pf8AREv/ACS0f/5Ir1WigDgNCli8P+f/AGD8K9S0zz9vm/Yk0uHzNudu7bcjOMnGemTWr/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcf4XGpXnjTXNXv8ARL7SbafT7K0iW8lgd5HikumcgQySAACZOpHf0rsKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EBV: Epstein-Barr virus; HHV6: human herpesvirus 6; PTLD: posttransplant lymphoproliferative disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Tomblyn M, Chiller T, Hermann E, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant 2009; 15:1143. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8362=[""].join("\n");
var outline_f8_10_8362=null;
var title_f8_10_8363="Mech opioids may red dys";
var content_f8_10_8363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mechanisms by which opioids may reduce dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Decreased metabolic rate and ventilatory requirements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduced medullary sensitivity to hypercarbia or hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunted medullary response to hypercarbia or hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alteration of neurotransmission within medullary respiratory centre",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortical sedation (suppression of respiratory awareness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Analgesia  -  reduction of pain-induced respiratory drive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiolytic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunted afferent transmission from pulmonary mechanoreceptor to the CNS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasodilation (improved cardiac function)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8363=[""].join("\n");
var outline_f8_10_8363=null;
var title_f8_10_8364="Differential diagnosis of metabolic alkalosis";
var content_f8_10_8364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F85833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F85833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of metabolic alkalosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Low urinary [CL] (&lt;20 meq/L) chloride responsive",
"       </td>",
"       <td class=\"subtitle1\">",
"        High urinary [CL] (&gt;20 meq/L) chloride unresponsive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Diuretics (remote)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Diuretics (recent)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vomiting/nasogastric tube suction",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         High blood pressure",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Status post chronic hypercarbia",
"        </strong>",
"       </td>",
"       <td class=\"indent1\">",
"        Primary hyperaldosteronism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Chloridorrhea",
"        </strong>",
"       </td>",
"       <td class=\"indent1\">",
"        Cushing's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cystic fibrosis",
"        </strong>",
"       </td>",
"       <td class=\"indent1\">",
"        Ectopic ACTH production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"       </td>",
"       <td class=\"indent1\">",
"        Exogenous mineralocorticoid production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mineralocorticoid-like substances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liddle's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Low blood pressure",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bartter's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gitelman's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <strong>",
"         Severe potassium depletion",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Emmett M. Diagnosis of Simple and Mixed Disorders. In: Acid-Base and Electrolyte Disorders: A Companion to Brenner &amp; Rector's The Kidney, DuBose TD Jr, Hamm LL (Eds), Saunders, Philadelphia 2002. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8364=[""].join("\n");
var outline_f8_10_8364=null;
var title_f8_10_8365="Hungry bone syndrome after PTX";
var content_f8_10_8365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing the time course of development of hypocalcemia following parathyroidectomy for primary hyperparathyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 246px; background-image: url(data:image/gif;base64,R0lGODlhZAH2ANUAAP///4CAgAAAAEBAQMDAwP+AgP+goDAwMBAQEKCgoHBwcP8AANDQ0GBgYODg4PDw8CAgIFBQULCwsJCQkP9AQP/AwP+wsP+QkP9gYP8wMP8QEP/g4P/Q0P8gIP9wcP/w8P9QUIAwMN8AAK9AQJ8AAL+AgIBwcJ+AgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAfYAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vQAEDEMOEwETD77ImwwBAgNDAwLRB8nUl9DNQxIPDxACBNXgkwTYRd0ORQQB6uolFeHvguPORBMCCkbp6wEjIPD+fvKIKBDQoMkJDf8S5mFQ7wCBYxEEQFD3TUkAERwUaqRzLdq3aCADLAlAosDGk4gChKCAsiWhACYWuJwJSF0GCzRz7lHnwYPO/5931FXIALToHHUAFmwwytQNUgoGmkpVg/QChqlYzSDl0CGrVzFIAWjI+LVoggRkwmK4ULbogHlf8g0QCcBAv7Y/34aRS3cDQrwo862DADdMWAAd3AHeyAxktMJgDnswuVij4HVoxxy2QLSy5yeHPyz48Pnf29Nv72mmK+RmaX+OQUL+chhAAZ+v/UGo2IC1Yd8VuuaGJ2CCEAWzvdQWu3R4OGgDDhBM6xsAiKjOwT2IKCDCsdVFrGYvCgxdMCbLOfwd70vClGXkAMBPbmQ5YrLseUkMcO7JNbj/NWHfWvn1IgF3EWTWREBDMIiOPgHMZYQBLBXYiwMBdIOAAv0p4f/gL/ERcVmE1QGwgUwWIkNAAx4t8eGHSdgHQAaKpejLAxOchwRDAjh0DI8+jlQiAD3ZuFFH3gCAZEUxDsmZkbkg2d13kQ2ZFGlQ2hLdWwhIZ6UWMgJAAU5Z1rLbcQ00QB+YVhZwVZm0TLfdXGtmESZXcNLCYkgNRADWlxo0lycsD0Q4gHEMdEjblxRQNihTYda1AHaPtkJABKep9qcSBkxaaSsIOFYnm0t0SumnqGyIRqRDmIpqKgkMQMCsOv7WhKuvmrLnY3upI+GtnuZKSo+Y9UriE7gKG8oAmpbB6oTBKvtJAwhkSl0UyUrLCZKj2vllEtlqC86zSIQrbjLklhv/7bnoflvquuz2ki648Mary7z0nmqvJCsyaesV5u7rCAOP1aqcu04ELHAj6Si4qBYKL2wIA7OWt6CODyQQQAJUNrlFxBILwh2vS8w3hHTQTCMkFyCH/Aex6jiMRIAASNAdABG5ZxHC2NbrciDMRsEgMyIR/aA+v7Ls888AVZvaguQYbbSIECattL5M+xGqbFDPU889Axm3MxgtZ22Hqk8A+ZADEhFgzspkL232HchVbPARSwKQQDcQyHwEvlOUPXcc3F4rhuCDu6FxseCNgXjilQBexeOQo1F442RQXnkZyL1lj+FlaL65GQfwfIXkAMs9+hrcdIsF6qljvXoaSBaE//kZos++RecDNNBxlWvkrrsgsGch/PBT8Ld4zKCrcTzyUHhzeVy+mh637NBz8RDFdhtrdfCqZ2+nnw4MoPOmbzwv/hIIZKZm822ovz4SSQIQIfzxhz+/FAccIIEEaENfHOS3v2yABAGKAt4cCFhAAGBoAglU4AL118AkVOyCdzuYHRiYvdiQTIB04CDyIMS824WQghWEQ/FCh8IUDiEBWwuRBO8gQt1BoBsDQIDtopCxAJxvbHqo4eoEYDMAKGCHT3iAdKTTLCSsEHctrKA3SocpKXwNAG8D4h6EWLkD9CYaTRTQ56Dhr19UzXrpW8AFBOVCJUxAbFFgWzNCVcYRff8viBRYQAY8UKM2DiEA5DPfezbWDfSgUQ4W8EAHNIABA2Cpje0TwvukkIBLfQ5ug9jABfKYgQvgp4H1u58UojERAR3yDh+wAAY00AEMWOCR6+vf/wL4L0VwoAAZWAAI1rg+m0UDgfhLxAfswkoPkAl5D4zgwyRRAQ9kQAPXYaMfrfBEQGgSBHoswCenKYVqDkKVi2wkLLlpyk5wYJMLoIAnyVnOTwxzla085sJgyDUTfuKWudylNM91wzkicYaj2AAx99hHbRFRAEb85zJTkchFXmecr5oiIF13ulNy4prZ3GalvNiYMG6BL7FIJQbC+cpcvVEMIKXFOXOpzn1CiXv/FgMhLd5ZTHnaaGQyXGgumpnPAhigAhWA6HBgtrFg4kKgBQABBfK4gHRSAAMFKIAFgPqZoJ3Bm6/YAFAvENWl5nIBGlgqVKVaAY2Sx2lWlelJtFoBrnpgqR1oageWOpkCANWsGolhTjU4FQ4ANapvpUBcFzDXRhXgAkB1aTJoadSvANUCUcXAUjXQ1AwsNaqIDSov6karxr7msVFVKlOdCoKomva0qE2talfL2ta6NqoFdcP0agmnDwDVAK/NrW53m9vYtmF5RbUnOweRKGdZdLhy6J0vM8iEHhrDkMglBBEHAAEvSkGJzRAAAn5Xn+NG9w3e0KEooTCOaZARk9/9/8MBujGBSUIBu+tVqB29m142EKBLDkAAHJNIrW4c4HfzrS8m6iGSiLgLqwI2AwMw9bQoJKBHBJCO34qA4ASTQTr1jIICQlVK9Fo4DwJ4MAB649kPy8Ebu0FOiU0Mh4nsyU/CZfEcGMCA7XhnxTK+RIVzvAUP7rULO+ZxFlBjrRgLGRNBPvIVJDCACJRRrUpmA8FAokydRrkNAUDALOkLhSRfuZvzuGMXUvplLHuQolMgc5nX0BhR4XjNjPAynPMg5zkHhct2/kOd80yHPfNZDn7+swrxLGg9BLrQWCY0ou+86D484IIP8XCj7zAOxzyZwoqedBgeTYAHC6DKf8y0pv/FwCL5Vm0uJEy1qlfN6la7+tWwjrWsZ03rWtv61ri+9aUNIccI2hHVuT51sFP9lmGTsNjGXgeyk+0rYCd72cyG9rNFHYdSt5MLXs42te23bW7zFcjdPvQZKg1qIiRZ21b2VrpfF+52MwIaHv3btme1bizQG9xx2TU1u31vfHNC3Or2A8DZXZNuC9zg9Wb0wQveiX7zweF7gLgeJD5xfY/64hjPuMY3znHk9pBjeRhGMTpGsXK3oeRCcC533cDpih1D5M+tQw9/2EOE1wFlPcpDR1Qmn1DZnAoM8DkAsAuN7c6h0iD5xs5lvsRLBr0ZEKiEzfyUMzxogxv1w/DPp6D/dRCZt35x4LSnz3H1blhcDVd8WzeY+wipCWDrV3hblgcC9y5v6O1DXyIEFFrt6RAhi4AeozcI1k8YT8LtdafCFQkmganJgfFGe0B/e7RyN/SaHpecgxxz6I3yRjjElLhi2PIwENu1ORqJR09sioF3A9fB2kMo/R2WsTeEEswZjo8E23YD+DpEZCIBIIADZlVqk6Nh+CsiiAMe7BAJ04HcQ/g9RepQyYiophsSkM7ZFVH7voHYMazJ/VHwbkQOp74J8CbC6utAStYwQDqR7Lj850//+tv//vjPv/73r5B7D9/4WCB5aeUGDDAAEwYFKkYEscJ2gxMNQiB+X8AiCqAx/2B3VUkyDlymMRRWgTHCgfbigPaDdw+AHA1wHsFVVBuzDPKhJglCBA6gJszyaN0QfNDQAGhRKE3mHunAAJVkbgkwAb8SKzloRjwofDCoAA9QPgRRSfaAHCKxDN+wgzvYgwdyKEKggfLBYEnygr1zHgmAKQpQgEu4gjH4gBpjgAvmHYWCFhjyQxaCehGCdweAAAEwh+dADtigXdHANqXTJyIyF6VGTwboX/cwh3UoAPAhdEOgXQoQEcYRAQqQIZ/GDD5HAIBIEAxAiJXGeQnANlQ3iXroQ90xEPcADQ6EAHRIRvlVOqgYghGQIRNAiKuYZSojDRwmHQUBAQgAAPVwgP/j4UEBQDD3YDPGgYfOkHPyIREKEHMvpCbYYIoh+A23FwAsog5EZATY8ADYgCHU5Q3McD4J4Iy4d4F4ZzMiAQ2eGII6ExHHMIdKglC9GI310BtkhABRN3SFkiT14B4DEQzYwAwfMY7Zt4tQAoJEg4EgIhLGCADxwWShwnNGZA8BAY0ACSLAlg4eaIyrGI7eWD+kGBAViZAIyXzXWJHvKASmaIoVCZDM0BvqwDaFsZJJUpH/mCTb2COZZyMGiXf2aEnBECpHlIfzsCIScF8EiZJE9GDOQJFv9w2oWEkTQIFPBmEsMgHj4GRkZJLQIAFKGYLBJ5IiGCoEaZIENnUneZWwljh4PVKUYeiIl4KRwUcwTqaLQlCTAYmUiJglO/mE0uF9eoOKA3GM8+AAGHYAtfJ00HGSDtQNfrJgpNR4GYmKl8QiXdKRFYGY28iYYEkXEviAYLdhU6KYA1GZ35B90uAAksdhDuAAjKk3/nUedsmQ88B8H/ZjXCAdAPgGA+GLw2WbWnB7fYCKlcd/xFmcxnmcyJmcyrmczNmczvmc0Bmd0jmd1Fmd1nmd2Jmd2ukPQQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time course of development of hypocalcemia in 25 patients with hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism. Most of the fall in the plasma calcium concentration occurred in the first 24 hours after surgery. To convert plasma calcium concentration from mg/dl to mmol/L, divide by 4.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Brasier, AR, Nussbaum, SR, Am J Med 1988; 84:654.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8365=[""].join("\n");
var outline_f8_10_8365=null;
var title_f8_10_8366="Travel sx Australia NZ Oceania";
var content_f8_10_8366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious causes of symptoms in travelers to Australia, New Zealand, or Oceania",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition or pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Temperate Australia or New Zealand",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tropical Australia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Papua New Guinea (PNG) and Oceania",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Acute fever",
"       </td>",
"       <td>",
"        Malaria",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric fever",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoebic liver abscess",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leptospirosis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Q fever*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scrub typhus and tick typhus*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        + (PNG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melioidosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Acute diarrhea",
"       </td>",
"       <td>",
"        Enteropathogenic E. coli",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotavirus, Norwalk, other viruses",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Campylobacter",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella, Shigella",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoebiasis (E. histolytica)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciguatera poisoning",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Rash",
"       </td>",
"       <td>",
"        Ross River virus*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barmah forest virus*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dengue",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tick typhus*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        + (PNG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scrub typhus*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Pneumonia",
"       </td>",
"       <td>",
"        S. pneumoniae and other common respiratory pathogens",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psittacosis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Q fever*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Neurologic problems",
"       </td>",
"       <td>",
"        Bacterial meningitis due to common pathogens",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic meningitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Murray Valley encephalitis*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Japanese B encephalitis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        + (PNG)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcosis",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciguatera fish poisoning",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tick paralysis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Acute polyarthritis",
"       </td>",
"       <td>",
"        Ross River virus*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barmah forest virus*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Jaundice",
"       </td>",
"       <td>",
"        Hepatitis A or B",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaria",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Skin ulcer",
"       </td>",
"       <td>",
"        Tropical ulcer infected with S. pyogenes or S. aureus",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infected coral injury",
"       </td>",
"       <td>",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M. ulcerans*",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melioidosis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous diphtheria",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These infections are not present in New Zealand.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8366=[""].join("\n");
var outline_f8_10_8366=null;
var title_f8_10_8367="Rx strep endocarditis I";
var content_f8_10_8367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73007%7EID%2F53990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73007%7EID%2F53990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to penicillin-susceptible viridans streptococci and Streptococcus bovis (Minimum Inhibitory Concentration &le;0.12 &micro;g/mL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        British Society for Antimicrobial Chemotherapy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        4 week regimens*:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4 week regimens:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4 to 6 week regimens:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        4 week regimens",
"        <sup>",
"         &bull;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Aqueous penicillin G 12-18 million units per 24 h IV either continuously or in 4 or 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 2 g per 24 h IV or IM in 1 dose",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g per 24 h unless concentrations in serum are inappropriately low",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Aqueous penicillin G 200,000 units/kg per 24 h IV in 4 or 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 100 mg/kg per 24 h IV or IM in 1 dose",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         40 mg/kg per 24 h IV in 2 or 3 equally divided doses",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Benzylpenicillin",
"         <sup>",
"          &yen;",
"         </sup>",
"         1.2 g every 4 h IV",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 2 g per 24 h IV/IM",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Aqueous penicillin G* 12-18 million units per 24 h IV in 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 100-200 mg/kg per 24 h IV in 4-6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 h (or 100-200 mg/kg per 24 h) IV in 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone",
"         <sup>",
"          *",
"         </sup>",
"         2g per 24 h IV or IM in 1 dose",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         30 mg/kg per 24 h IV in 2 equally divided doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        2 week regimens",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2 week regimens",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2 week regimens",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        2 week regimen",
"        <sup>",
"         &bull;&loz;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 12-18 million units per 24 h IV either continuously or in 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 2 g per 24 h IV or IM in 1 dose",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &sect;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose or in 2 to 3 equally divided doses",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 200,000 units/kg per 24 h IV in 4 or 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 100 mg/kg per 24 h IV or IM in 1 dose",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &sect;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose or in 3 equally divided doses",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         benzylpenicillin",
"         <sup>",
"          &yen;",
"         </sup>",
"         1.2 g every 4 h IV",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Cefriaxone 2 g per 24 h IV/IM",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &sect;",
"         </sup>",
"         1 mg/kg every 12 h IV",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Aqueous penicillin G 12-18 million units per 24 h IV in 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 100-200 mg/kg per 24 h IV in 4-6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g (or 100-200 mg/kg) per 24 h IV in 6 equally divided doses",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone",
"         <sup>",
"          *",
"         </sup>",
"         2g per 24 h IV or IM in 1 dose",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &sect;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     h: hours; IV: intravenously; IM: intramuscularly.",
"     <br>",
"      * Preferred in most patients &gt;65 y or with impairment of 8th nerve or renal function.",
"      <br>",
"       &bull; Pediatric doses (should not exceed adult doses): amoxicillin 300 mg/kg per 24 h IV in 4 or 6 divided doses; aqueous penicillin G, ceftriaxone, vancomycin and gentamicin dosing recommendations are same as American Heart Association, pediatric.",
"       <br>",
"        &Delta; Vancomycin therapy only recommended for patients allergic to penicillin and cephalosporins.",
"        <br>",
"         &loz; &nbsp;For non-complicated infective endocarditis. Not intended for patients with known cardiac or extracardiac abscess or for creatinine clearance &lt;20 mL/min, impaired 8th nerve function.",
"         <br>",
"          &sect; Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentrations 3-4 &micro;g/mL,trough &lt;1 &micro;g/mL when 2-3 divided doses used; when given in a single daily dose pre-dose (trough) concentrations should be &lt;1 &micro;g/mL and post-dose (peak, one hour after injection) serum concentrations should be approximately 10-12 &micro;g/mL.",
"          <br>",
"           &yen; Amoxicillin 2 g every 4 to 6 h may be used in place of benzylpenicillin 1.2 to 2.4 g every 4 h.",
"           <br>",
"            &Dagger; Preferred for outpatient therapy.",
"            <br>",
"             &dagger; Netilmicin (4-5 mg/kg/day IV in 1 dose) is an alternative.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2012; 67:269; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested regimens for therapy of native valve endocarditis due to strains of viridans streptococci and Streptococcus bovis relatively resistant to penicillin G (Minimum Inhibitory Concentration &gt;0.12 &micro;g/mL and &le;0.5 &micro;g/mL)*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        American Heart Association",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        British Society for Antimicrobial Chemotherapy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        European Society of Cardiology",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Adult (for patients with normal renal function)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pediatric (not to exceed dose of normal adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 24 million units per 24 h IV either continuously or in 4 or 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 2 g per 24 h IV or IM in 1 dose for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         3 mg/kg per 24 h IV or IM in 1 dose or in 2 to 3 equally divided doses for 2 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          Monotherapy with",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         30 mg/kg per 24 h IV in 2 equally divided doses for 4 wks; not to exceed 2 g per 24 h unless concentrations in serum are inappropriately low",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 300,000 units/kg per 24 h IV in 4 or 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ceftriaxone 100 mg/kg per 24 h IV or IM in 1 dose for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &nbsp;3 mg/kg per 24 h IV or IM in 1 dose or in 3 equally divided doses for 2 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         <strong>",
"          Monotherapy with",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         &nbsp;40 mg/kg per 24 h IV in 2 or 3 equally divided doses for 4 wks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Benzylpenicillin",
"         <sup>",
"          &sect;",
"         </sup>",
"         2.4 g every 4 h IV for 4 to 6 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin 1 mg/kg every 12 h IV for 2 wks",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Either",
"         </strong>",
"         aqueous penicillin G 24 million units per 24 h IV in 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Amoxicillin 200 mg/kg per 24 h IV in 4 or 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Ampicillin 12 g per 24 h (200 mg/kg per 24 h) in 6 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin",
"         <sup>",
"          &loz;",
"         </sup>",
"         &nbsp;30 mg/kg per 24 h IV in 2 equally divided doses for 4 wks",
"        </p>",
"        <p>",
"         <strong>",
"          plus",
"         </strong>",
"        </p>",
"        <p>",
"         Gentamicin",
"         <sup>",
"          &Delta;",
"         </sup>",
"         &nbsp;3 mg/kg per 24 h IV or IM in 1 dose for first 2 wks",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     h: hours; IV: intravenously; IM: intramuscularly; wks: weeks.",
"     <br>",
"      * Patients with endocarditis caused by penicillin-resistant (MIC &gt;0.5 &micro;g/mL) strains should be treated with a regimen recommended for enterococcal endocarditis. European society of cardiology (ESC) guideline recommendations are applicable to strains having penicillin MIC 0.125 &micro;g/mL up to 2 &micro;g/mL.",
"      <br>",
"       &bull; Pediatric doses (should not exceed adult doses): aqueous penicillin G 200,000 units/kg per 24 h IV in 4 or 6 divided doses; amoxicillin 300 mg/kg per 24 h IV in 4 or 6 divided doses; ceftriaxone, vancomycin and gentamicin dosing recommendations are same as American Heart Association, pediatric.",
"       <br>",
"        &Delta; Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3-4 &micro;g/mL, trough &lt;1 &micro;g/mL when 2-3 divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 &micro;g/mL and post-dose (peak, one hour after injection) serum concentrations should be approximately 10-12 &micro;g/mL.",
"        <br>",
"         &loz; Vancomycin therapy only recommended for patients allergic to penicillins and cephalosporins; dose adjusted for peak serum concentrations (1 h after infusion completed) of 30-45 &micro;g/mL and pre-dose (trough) concentration of 10-15 &micro;g/mL.",
"         <br>",
"          &sect;Amoxicillin 2 g every 4 to 6 h may be used in place of benzylpenicillin 1.2 to 2.4 g every 4 h.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Circulation 2005; 111:3167; J Antimicrob Chemother 2012; 67:269; Eur Heart J 2009; 30:2369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_10_8367=[""].join("\n");
var outline_f8_10_8367=null;
